[COMPANY_001] Confidential Page 2
Amended Protocol Version 11            Protocol No. CDRB436X2201
Table of contents
Table of contents ....................................................................................................... 2
AMENDMENT 11 (04- Jun- 2020)................................ ................................ ............ [ADDRESS_923106] OF ABBREVIATIONS................................................................................. 35
1INTRODUCTION .................................................................................................. 40
1.1 Background ................................................................................................. 40
1.2 Dabrafenib ([COMPANY_004]2118436) .......................................................................... 40
1.3 Trametinib ([COMPANY_004]1120212) .......................................................................... 41
1.4 Risk Assessment forDabrafenib +Trametinib Combination Therapy .......41
1.4.1 Benefit Assessment .................................................................... 45
1.4.2 Overall Benefit: Risk Conclusion ............................................... 46
1.5 Histology -Specific Background ................................................................... 46
1.5.1 Cohort 1: 
Anaplastic Thyroid Cancer (ATC) ............................. 46
1.5.2 Cohort 2: Biliary Tract Cancer (BTC) ........................................ 47
1.5.3 Cohort 3: Gastrointestinal Stromal Tumors (GIST)................... 48
1.5.4 Cohort 4: WHO Grade 1 and 2 Glioma ...................................... 49
1.5.5 Cohort 5: WHO 
Grade 3 and 4 Glioma ...................................... 50
1.5.6 Cohort 6: 
Non-Seminomatous/Non -Germinomatous Germ Cell
Tumors (NSGCT/NGGCT) ........................................................ 51
1.5.7 Cohort 7: 
Adenocarcinoma of the Small I ntestine (ASI)
including Periampullary andAmpullary .................................... 52
1.5.8 Cohort 8: Hairy Cell Leukemia (HCL) ................................ .......53
1.5.9 Cohort 9: Multiple My eloma (MM) ........................................... [ADDRESS_923107] SEL ECTION ......................................................................................... 62
5.1 Primary analy siscohort ............................................................................... 62
5.2 Expansion cohorts ....................................................................................... 62
5.3 Number of
Subjects ..................................................................................... 62
5.4 Eligibility .................................................................................................... 62
5.4.1 Inclusion Criteria
........................................................................ 63
5.4.2 Exclusion Criteria ....................................................................... 67
[COMPANY_001] Confidential Page 3
Amended Protocol Version 11            Protocol No. CDRB436X2201
6STUDY TREATMENTS ................................ ................................ ........................ 70
6.1 Treatment Assignment ................................................................................. 70
6.2
Blinding....................................................................................................... 70
6.3 Investigational Products .............................................................................. 70
6.3.1
Dabrafenib ([COMPANY_004]2118436) Capsule........................................... 70
6.3.2 Trametinib ([COMPANY_004]1120212) Tablet ............................................. 71
6.4 Handling/Accountability ofInvestigational Products .................................. 72
6.5 Treatment Compliance ................................................................................ 72
6.6 Treatment ofOverdose ................................................................................ 73
6.6.1 Dabrafenib .................................................................................. 73
6.6.2 Trametinib .................................................................................. 73
6.7 Continuation ofTreatment ........................................................................... 73
7
STUDY ASSESSMENTS AND PROCEDURES .................................................. 74
7.1 Time andEvent Table ................................................................................. 75
7.2 Demographic/Medical History Assessments ............................................... 84
7.3 Critical Baseline Assessments ..................................................................... 84
7.3.1
Baseline Confirmation of BRAF -Mutation Status ..................... 84
7.3.2 Baseline Documentation of Target and Non -Target Lesions for
Solid Tumor Histologies............................................................. 85
7.4 Safety .......................................................................................................... 85
7.4.1 Physical Examinations ................................................................ 85
7.4.2
Dermatological Examinations .................................................... 85
7.4.3
Ophthalmic Examinations .......................................................... 86
7.4.4 Vital Signs ................................ ................................ .................. 86
7.4.5 Performance Status ..................................................................... 86
7.4.6 Electrocardiogram ................................ ................................ ......87
7.4.7 Echocardiogram .......................................................................... 87
7.4.8 Clinical L aboratory Assessments ............................................... 87
7.4.9 Monitoring for Non -Cutaneous Secondary
/Recurrent 
Malignancy ................................ ................................ ................. [ADDRESS_923108] ....................................................................................................... 104
8.2.1 Dermatological Events ............................................................. 104
8.2.2 Malignancies ............................................................................. 107
8.2.3 Pyrexia ...................................................................................... 108
8.2.4 Pneumonitis .............................................................................. 109
8.2.5 Diarrhea .................................................................................... 110
8.2.6 Renal Insufficiency ................................................................... 111
8.2.7 Visual Changes ......................................................................... 112
9LIFESTYLE AND/OR DIETARY RESTRI CTIONS .......................................... 114
9.1 Contraception Requirements ..................................................................... 114
9.1.1 Female Subjects ........................................................................ 114
9.1.2 Male Subjects ........................................................................... 115
9.2 Lactation .................................................................................................... 115
9.3 Caffeine andAlcohol ................................................................................. 115
9.4 Activity ...................................................................................................... 115
10CONCOMI TANT MEDICATIONS AND NON
-DRUG THERAPI [INVESTIGATOR_5165]............. 115
10.1 Permitted Medications andNon-Drug Therapi[INVESTIGATOR_014] ...................................... 116
10.2 Prohibited Medications andNon-Drug Therapie
s ..................................... 116
10.3 Medications tobeused with Caution ................................ ......................... 117
11ADVERSE EVENTS AND SERI OUS ADVERSE EVENTS............................. 119
11.1 Definition of Adverse Event ...................................................................... 119
11.2
Definition of Serious Adverse Event ......................................................... 120
11.3 Laboratory andOther Safety Assessment Abnormalities Reported asAEs
andSAEs ................................................................................................... 121
11.4 Cardiovascular Events ............................................................................... 121
11.5 Death Events ............................................................................................. 122
11.6 Disease -Related Events and/or Disease -Related Outcomes NotQualifying
asSAEs ..................................................................................................... [ADDRESS_923109] CONSIDERATIONS .......................................................... 148
19.1 Posting ofInformation onPublicly Available Clinical Trial Registers .....148
19.2 Regulatory andEthical Considerations, Including theInformed Consent
Process ...................................................................................................... 148
19.3 Data Monitoring Committee
...................................................................... 149
19.4 Quality Control (Study Monitoring) .......................................................... 149
19.5 Quality Assurance ..................................................................................... 150
19.6 Study andSiteClosure .............................................................................. 150
19.7 Records Retention ..................................................................................... 150
19.8 Provision ofStudy Results toInvestigators, Posting ofInformation on
Publicly Available Clinical Trials Registers andPublication .................... 151
20REFERENCES ..................................................................................................... 152
21APPENDI CES ...................................................................................................... 160
21.1 Appendix 1:
ECOG Performance Status .................................................... 160
21.2 Appendix 2:NYHA Functional
Classification System .............................. 160
21.3 Appendix 3:Cockcroft -Gault Formula forCreatinine Clearance ............. 161
161
166
21.6 Appendix 6:Details ofBayesian Hierarchical Model ............................... 167
21.7 Appendix 7:Supporting Simulation Results .............................................. 169
21.8 Appendix 8:Hypothetical Example Trial Results ................................ .....170
21.9 Appendix 9: Country -Specific Requirements ........................................... 183
21.10 Appendix 10:RECI ST,version 1.1................................ .......................... 185
21.11 Appendix 11:Response Criteria forNSGCT/NGGCT with Elevated Tumor
Markers (AFP and-HCG) atBaseline................................ ..................... 190
21.12 Appendix 12:Response Criteria forHCL ................................................. 191
21.13 Appendix 13:RANO Response Criteria: Response Assessment Criteria for
WHO Grade 1or2Glioma ................................ ................................ ........ 194
21.14 Appendix 14:RANO Response Criteria: Updated Response Assessment
Criteria forWHO Grade 3and4Glioma .................................................. 197
21.15 Appendix 15:Consensus Recommendations fortheUniform Reporting of
Clinical Trials ............................................................................................ 200
21.16 Appendix 16:Imaging Guidelines forWHO Grade I
orIIGlioma ........... 203
21.17 Appendix 17:Volumes ofCollected Blood Samples ................................ 205
21.18 Appendix 18:Liver Safety Drug Restart orRechallenge Guidelines .......206
21.19 Appendix 19:Protocol Amendment Changes ........................................... 210

[COMPANY_001] Confidential Page 7
Amended Protocol Version 11            Protocol No. CDRB436X2201
Amendment 11 (04- Jun-2020 )
Amendment Rationale
Asof the end of enrollment on 29 -Jun-2018 ,the study  had enrolled a total of 206 subjects.  
As of 06-Apr- 2020, 55 subjects continued on study  treatment ([ADDRESS_923110] Cancer ) and 23 were in follow up (7 Hairy Cell Leukemia (HCL ), 5 A naplastic 
Thyroid Cancer (ATC) , [ADDRESS_923111] Cancer (BTC) , 3 WHO Grade I or II Glioma, 2 
Multiple Myeloma (MM) , 1 WHO Grade III or IV Glioma).
The main purposes ofthis amendment are to extend the study  by [CONTACT_681824] V600E 
population to the I TT population.
The study  is being extended to obtain more mature estimates for duration of response, 
progression free survival and overall survival. The new study  completion and the timing of 
the final anal ysis will now be the date that represents a minimum follow up of approximately 
3 years for all subjects enrolled.
The primary  analysis population for the final efficacy  analysis is changed from the BRAF 
V600E (centrally  confirmed) population to the ITT population.  It is considered that including 
all enrolled subjects gives a better reflection of outcomes in the patient population likely  to 
be treated in a real -world setting. This also provides consistency with previous interim stud y 
reports.  Of the 206 subjects in the ITT population, 20 were excluded from the BRAF V600 E 
population (mutation status not centrall y confirmed 5 HCL, 3 WHO Grade III or IV Glioma, 
5 WHO Grade I or II Glioma, 4 BTC, 3 ATC).
To reduce burden on patients, collections for blood and tissue samples for  
pharmacod ynamic biomarker research as well as PK sampling at follow up are being 
discontinued as the majority of the planned biomarker anal yses have been completed and the 
PK profile of the regimen is now well characterized.  (NOTE: PK samples collected in 
response toliver and ocular toxicity  per Section 8 “Dose Modifications and Stoppi[INVESTIGATOR_2121] ” 
continue to be required).
Disease assessment intervals after the first 48 weeks of study  treatment for sub
jects in the 
HCL cohort are being extended from “at least every  8 weeks” to “at least every  12 weeks”.  
This change is based on the indolent nature of the disease coupled with I nterim Analysis #15 
data which observed durable responses in HCL subjects treated with dabrafenib and 
trametinib without compromise to patient safety  or data integrit y.  Safety  assessment intervals 
are not affected by [CONTACT_681825]  4 weeks.  (Efficac y 
assessments for other cohorts remain unchanged. )
Changes to the Protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red f ont for deletions and red underline for insertions.
Section 4.1.[ADDRESS_923112] and Companion Diagnostic
Removal of sentence “
The primary analysis to determine theefficacy of dabrafenib 
+ trametinib therapy for the rare cancers will bebased on the BRAF V600E mutation 
status determined by [CONTACT_681826] ” to align with change made 
to the primary  anal ysis population.

[COMPANY_001] Confidential Page 8
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 7.1 Time and Event Table (Table 4)
Assessments of “Blood sample for CBC”, “Peripheral Blood Sample Staining for 
Hairy Cell count” and “Flow cytometry: peripheral blood sample” under the heading 
of “Disease Assessment: HCL Cohort ONLY” changed from being indicated “Every 
8 weeks (+/-3 days)” to “Every 12 weeks (+/-3 days)” .  Footnote 31 was also changed 
according ly.
Footnotes 45, 48, 49, 50, 52, and 53 updated to indicate that corresponding sampling 
is no longer requested as of Protocol Amendment 11 .
Section 7.4.6 Electrocardiogram
Instructions updated regarding discontinuing transmission of ECGs to a central 
storage facility .  Copi[INVESTIGATOR_681694] . 
Section [IP_ADDRESS] L aboratory  and Disease Assessments: HCL
Language under “Post -Baseline Assessments” updated to align with the 
aforementioned change in interval between response assessments.
The following sections were updated with a note indicating that samples are no longer 
collected as of Protocol Amendment 11.
Section 12.2.1 Blood Sample Collection
Section 13.2.1 Peripheral Blood Sample Collection and Anal ysis
Section 16.5 Study  Completion
Updated language to align with study  extension of one additional y ear
Language updated to clarify  that safet y will be followed as part of the rollover study
in the event a subject is transitioned.
Section 16.[ADDRESS_923113] Withdrawal Procedures
Clarified that “withdrawal from study ”in this context refers to “withdrawal from 
study treatment ”.
Section 18.3.1 Analy sis Populations
Updated to reflect the aforementioned change in the primary  anal ysis population.
Section 18.3.3 Final Analy ses
Updated language to align with study  extension of one additional y ear
Formatting and ty pographical errors corrected throughout the document

[COMPANY_001] Confidential Page 9
Amended Protocol Version 11            Protocol No. CDRB436X2201
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Boards 
(IRB)/Independent Ethics Committees (IECs), Research Ethics Boards (REBs) and Health 
Authorities.
The changes described in this amended protocol require IRB/IEC/REB approval prior to its 
implementation.
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into accoun t the changes described in this 
amended protocol.
Amendment 10 (09-Jan -2020 )
Amendment Rationale
As of the end of enrollment on 29- Jun- 2018 the study  had enrolled a total of 206 subjects.  
As of 18 -Nov-2019, 62 subjects continued on treatment and 34 were in follow up .
The primary  purpose of amendment 10is to align the dose modification section of the 
protocol related to severe cutaneous adverse r eactions (SCAR ), as updated in the dabrafenib 
and trametinib investigator’s brochure sedition 11.
In addition ,baseline results of IDH Mutation Status and MGMT Meth ylation Status will now 
be collected as part of disease characteristics forsubjects in the WHO Grade 1/2Glioma or 
WHO Grade 3/4Glioma cohorts only.  Assessment of IDH1 and IDH2 mutations is in 
accord ance with the 2016 WHO classification of Central Nervous Sy stem Tumors (Louis et 
al 2016) which was established after study  start. Further, MGMT methylation status is a 
predictive marker for the activity  of alkylating agents (i.e. temozolomide), which are
considered standard of care for the studied population.  The collection of these additional data 
points are important for the interpretation of the study results.  Data are collected onl y where 
available as part of medical records; retro spective testing i s not requested or required.
References to the use of oral (hormonal) contraceptives being “permitted” or “used with 
caution” were removed from the relevant section sin alignment with changes made at protocol 
amendment #9 to update female contraception requirements.  These sections were 
inadvertentl y not updated at the previous amendment.
Changes to the Protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
List of Abbreviations section updated to include acron yms of DRESS, IDH, and SCAR 
used within the document.
Section 
1.4 Risk Assessment for Dabrafenib + Trametinib Combination Therap y was 
updated to include added SCAR risk.
[COMPANY_001] Confidential Page 10
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 7.1 Time and Event (Table 4)
Footnote #3 “Disease Characteristics” updated to include the collection of baseline 
IDH Mutation Anal ysis status and MGMT M ethylation Analy sis status if available .
Footnote #58 “Extended Follow -Up” part “e ” was co rrected to indicate that subjects 
may have CT and/or MRI  scans of the chest and abdomen for up to6 months to 
monitor for secondary  or recurrent malignancy .  Previously , listed as every 6 months
Section [IP_ADDRESS] SCARs (Severe Cutaneous Adverse Reactions)
Section added in the dose modification section to include the following language
Cases of severe cutaneous adverse reactions (SCARs), including Stevens
-Johnson 
syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS), 
which can be life-threatening or fatal, have been reported during treatment with 
dabrafenib in combination with trametinib. Before initiating treatment, patients 
should be advised of the signs and symptoms and monitored closely for skin reactions. 
If signs and symptoms sugge stive of SCARs appear, dabrafenib and trametinib should 
be permanently discontinued.
Section 10.1 Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
Listing of “oral (hormonal) contraceptives:” and associated information removed as 
no longer permitted as of pro tocol amendment #9
Section 10.2 Prohibited Medication and Non -Drug Therapi[INVESTIGATOR_014]
“Oral hormonal contraceptives” added to the list in this section per updates made to 
female contraception requirements at protocol amendment #9
Section 10.3 Medications to be Used with Caution
The reference to “hormonal contraceptives” in this section has been removed as no 
longer permitted as of protocol amendment #9  
Section 18.3 Data Anal ysis Considerations
Correction made to indicate that the reporting standard to be used to list and 
summarize data is the [COMPANY_004] Int egrated Data Standard Library  (IDSL).  Previously  this 
was listed incorrectly  as a [COMPANY_001] reporting standard
Section [IP_ADDRESS] Efficacy Analy sis
Updated to reflect that ORR estimates along with 95% exact confidence interval (CI) 
will be provided, rather than on a confidence interval based on normal approximation
as previousl y stated
Section 20 References
Added citation [Louis, DN 2016] 
Formatting and t ypographical errors corrected throughout the document
[COMPANY_001] Confidential Page 11
Amended Protocol Version 11            Protocol No. CDRB436X2201
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Boards 
(IRB)/Independent Ethics Committees (IECs), Research Ethics Boards (REBs) and Health 
Authorities.
The changes described in this amended protocol require IRB/IEC/REB approval prior to its 
implementation.
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
amended protocol.
AMENDMENT 09 ( 12-
Feb-2019 )
Amendment Rationale
As of the end of enrollment on 29- Jun- 2018 the study  had enrolled a total of 206 subjects.  
As of 04 -Feb-2019, 85 patients were ongoing.
The primary  purpose of amendment 9 is to revise femal e contraception requirements as 
follows,
1.Double barrier contraception methods are no longer allowed in the stud y as they are not 
classified as highl
y effective methods per the Clinical Trial Facilitation Group (CTFG) 
and [COMPANY_001] internal guidelines .
2. For subjects taking trametinib, contraception using oral contraceptives are not allowed 
while the drug interaction study  between trametinib and oral contraceptives is still 
ongoing and [COMPANY_001] would like to take a conservative approach and restrict oral 
contraceptives until the results are available from the interaction stud y.
Throughout the document where contraception requirements after discontinuation of study  
treatments are discussed, language is clarifi ed as follows,
“Women of childbearing potential should use effective methods of contraception during 
therapy and for 16 weeks following discontinuation of trametinib when taken in combination 
with dabrafenib, or for 2 weeks following discontinuation of dab rafenib monotherapy .”
The Study  Completion (Section 16.5) and Data Analy sis and Statistical Considerations 
(Section 18) sections have been amended as they relate to study  completion and data analysis.
A new end of study  definition is implemented.
Justification
At the time of I nterim Analy sis #14, 54 of 178 subjects had died, representing a death rate of 
approximately  30%.  As a result, a new end of study  definition is implemented with this 
protocol amendment to accommodate the better than expected outcome in this study .  A 
minimum follow -up period of approximately  2 years for all patients is sufficient for collection 
and maturity  of data for the analy sis of the secondary  endpoints, and will be the new end of 
study  definition.
Details of the specific changes made in each section of the protocol are described below in 
the Changes to the Protocol section below.
[COMPANY_001] Confidential Page 12
Amended Protocol Version 11            Protocol No. CDRB436X2201
Changes to the Protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Section 9.1.1. Contraception Requirements for Female S ubjects.  
Updated per change to contraception requirement s(see above) .
Section 16.5. Study  Completion .  
Updated definition for study  completion.  Study  will be considered complete 
at a 
date that would represent a minimum follow up of approximately  [ADDRESS_923114] s enrolled. ” 
Updated language clarifying the possible options for alternative suppl y of study 
treatment for those subjects which continue to derive clinical benefit at study  
completion . 
Section 18.3.1. Analy sis Populations.
Clarified the anal ysis population for supportive final efficacy  anal ysis
Section 18.3.3. Final Analy ses.  
Updated date of final analy ses as t he date represe nting a minimum follow up of 
approximately  2 years for all subjects enrolled.
Section [IP_ADDRESS] Efficacy Analy sis
Removed reference to pooled ORR calculations across histologies.
Changes to Medical Lead Contact, Clinical Trial Head Contact [CONTACT_1629] d Signatory .
Formatting and Ty pographical errors corrected throughout the document.
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Boards 
(IRB)/Independent Ethics Committees (IECs), Research Ethics Boards (REBs) and Health 
Authorities.
The changes described in this amended protocol require IRB/IEC/REB approval prior to its 
implementation.
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
amended protocol. 
AMENDMENT 08 ( 14-Dec-2017 )
Amendment Rationale
As of 20 -Nov-2017:
One hundred fift y five patients have been enrolled in 35 sites located in 13 countries 
(Austria, Belgium, C anada, Denmark, [LOCATION_009], [LOCATION_013] , Italy, Korea, Netherlands, 
Norway , Spain, Sweden and the [LOCATION_002]).  
[COMPANY_001] Confidential Page 13
Amended Protocol Version 11            Protocol No. CDRB436X2201
Eight y patients have discontinued the study  treatments (60 due to disease progression, 
12 due to adverse events, 7 due to patient or investigator de cision and 1 due to a 
protocol deviation).  
Forty-seven patient deaths have been reported of which three occurred during study  
treatment with the reason noted as sepsis for all the deaths.
The primary  purpose of amendment [ADDRESS_923115] from 
the Food and Drug Administration (FDA) to administrat ively  split Study   CDRB436X2201 
from IND#113557 and to file this study  under a new IND (137160) and, other minor changes 
or clarifications to the study  procedures.
Details of the specific changes made in each section of the protocol are described below in 
the Changes to the Protocol section below.
Changes to the Protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Sponsor I nformation Page.  Updated the US IND # to 137160 (Previously  113557).
List of Abbreviations.  Added alloSCT (allogenic stem cell transplantation) and 
autoSCT (autologous stem cell transplantation) and removed ASCT (allogenic stem cell 
transplantation) to avo id ambiguit y.
Section 7.1 Time and Event Table.  Added the following changes:
Table headings.  Added “All Cohorts” or “Cohorts” to the applicable Assessment 
Headings for clarit y,
Pregnancy19Under “Every  12 weeks (+/ -3 day s)” heading, added “X21serum or 
urine” to align with footnote 21instructing every  12 week testing requirement after 
week 48,
TSH, Free T4. Added (ATC only ) to clarify  these tests are onl y required for 
patients enrolled to the ATC cohort,
Blood sample for CBC.  Under “every  4 weeks (+/ -3 day s)” and “every  8 weeks 
(+/-3 day s)” headings, added 31and X31respectively  to clarify  and align with 
footnote 31,
Peripheral Blood Sample Staining for Hairy  Cell Count.  Under “every  4 weeks (+/ -
3 day s)” and “every  8 weeks (+/ -3 day s)” headings, added footnote 31and X31
respectivel y, to clarify  and align with the text noted in footnote 31,
Flow Cy tometry : peripheral blood sample33. Under “every  4 weeks (+/ -3 day s)” 
heading, added 31to clarify  and align with the text noted in footnote 31,
Footnote 31.  Modified the instruction for HCL patients who are tolerating study 
drug treatment bey ond week 48.  These patients may  reduce the frequency  of 
response assessment evaluation from every  4 weeks (+/ -3 day s) to every  8 weeks 
(+/-3 day s) if appropriate in the judgement of the treating investigator.
Footnote 58. Modified the instruction for extended follow
-up as follows:
[COMPANY_001] Confidential Page 14
Amended Protocol Version 11            Protocol No. CDRB436X2201
58EXTENDED FOLLOW -UP: The following evaluations will be performed for all patients 
in all coh orts
a.Dermatologic exam.  Exams will be performed every  4 weeks (+/ -7 day s) for the first [ADDRESS_923116] disease assessments every  12 
weeks (+/ -14 day s) until disease progression or initiation of new anti -cancer treatment, 
or death, whichever comes first.
c.Subjects will be followed every  12 weeks (+/ -14 day s) for su rvival until the subject dies 
or withdraws consent or is lost to follow up, or up to a time period as defined in Section 
16.3.  Survival follow up may  be performed via clinic visit, a telephone contact, an
email or by  [CONTACT_2319].  The initiation of any  new anti -cancer treatment(s) and date of last 
contact [CONTACT_681827].
d.Subjects will have a head and neck exam performe d every  [ADDRESS_923117] and/or MRI  scans of the chest and abdomen every  6 months to 
monitor for secondary  or recurrent malignancy .
Footnote List.  Corrected previous mis -numbering error that caused inaccurate 
references for footnotes 39  through 58.
Section 7.4.8. Table 6. Added Footnote 6 to clarify that although HbA1c testing is 
included in “Clinical Chemistry ” section it is performed at an interval of every  12 
weeks (+/ -3 day s).
Section [IP_ADDRESS]. L aboratory  and Disease Assessments: HCL .  Updated post -baseline 
assessments statement to align with change indicated in footnote 31 of Time and Event 
Table.
Section 9.1.2. Added a new section to include the contraception requirements for male 
subjects.
1.“Male subjects (including those that have had a vasectom y) must use a condom 
during intercourse while taking dabrafenib and/or trametinib treatment.  Once 
dabrafenib and trametinib are both pe rmanentl y discontinued, the patient must use a 
condom for [ADDRESS_923118] dose of the study  treatments.  The patient should 
not father a child during the study  treatment period or during the specified time 
frames after discontinuation of study  treatment.”
Section 10.3. Medications to be used with Caution.  Removed statement regarding 
Dabrafenib solubility  at higher pH. Consequently , proton pump inhibitors removed 
from Table 28 of Medications to be used with Caution.
Section 11.7. Reinstated a sentence outlining the time period for detecting adverse 
events and serious adverse events inadvertentl y removed at amendment 7 .
Section 12.1. Pharmacokinetic Endpoints.  Change of [COMPANY_001] department name 
[CONTACT_681947] “I
nstitutes for BioMedical Research (NIBR) PK Sciences 
(PKS)”
Section 12.2.2. Pharmacokinetic Sample Anal ysis.  Change of [COMPANY_001] department 
name [CONTACT_681948] “PKS Bioanal ytics”
Section 13.2.1. Peripheral Blood Sample Collection and Anal ysis.  Corrected the 
number of samples and amount of peripheral blood to be collected.
[COMPANY_001] Confidential Page 15
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 21.13. Appendix 13: RANO Response Criteria: Response Ass essment Criteria 
for WHO Grade 1 or 2 Glioma.  Clarified the second bullet point under “Disease 
Progression (PD)”,
(Bolded text below added to statement as previously written)
“A 25% increase in the sum of the products of perpendicular diameters of the T2 or 
FLAIR enhancing or non -enhancing lesion on stable or increasing doses of 
corticosteroids compared with baseline scan or best response after initiation of therap y, 
not attributable to radiation effect or to comorbid events.”
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Boards 
(IRB)/Independent Ethics Committees (IECs), Research Ethics Boards (REBs) and Health 
Authorities.
The changes described in this amended protocol require IRB/IEC/REB approval prior to its 
implementation.
The 
changes herein affect the Informed Consent.  Sites required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
amended protocol.
AMENDMENT 07 
Amendment R ationale
Subse quent to the acquisition of GlaxoSmithKline ([COMPANY_004]) compounds [COMPANY_004]1120212 and 
[COMPANY_004]2118436, the purpose of this protocol Amendment 07 is to:
-Delete or replace references to GlaxoSmithKline or its staff with that of [COMPANY_001] 
and its authorized agents to align wi th the change of sponsorship;
-Make administrative changes to align with [COMPANY_001] processes and procedures;
As of 07-Feb-2017:
-[ADDRESS_923119] received study  treatment in 11 countries (Austria, Belgium, 
Canada, Denmark, [LOCATION_009], German y, Italy, Korea, Netherlands, Norway and US); 
-[ADDRESS_923120] completed or discontinued study  treatment.
The changes described in this amended 
protocol require IRB/IEC approval prior to 
implementation. 
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities (HAs).
The changes herein affect the Informed Consent and all sites are required to update and 
submit for approval, a revised Informed Consent that takes into account the change of study 
sponsorship described in the protocol amendment.
Upon approval of this amendment, patients who have alread y been enrolled in the study  will 
sign a new informed consent form indicating [COMPANY_001] is the new study  sponsor and continue 
the appropriate visit schedule .
[COMPANY_001] Confidential Page 16
Amended Protocol Version 11            Protocol No. CDRB436X2201
REVISION CHRONOLOGY
GlaxoSmithKline
Document NumberDate Version
2012N145247_00 2013 -JUL-09 Original
2012N145247_01 2013 -JUL-25 Amendment No. 1
List of Authors was updated to add ,  and  and to 
remove  due to changes in study assignments within [COMPANY_004].
Previous primary Medical Monitor ( ) was replaced by  (formerly
secondary Medical Monitor) and named secondary Medical Monitor.
EudraCT Number was added.
List of Abbreviations updated to insert any abbreviations omitted in original protocol
Section 7.3.8, Clinical Laboratory Assessments, Table 4, removed cardiac enzyme:
troponin from list of assessments to be completed.
Section 7.4.1, Physical Examination, revised to indicate that other medical personnel (i.e.,
physician assistant or nurse practi tioner) may be able to perform the physical examinations
Section 8: Time and Event tables were revised to correct for inconsistencies with 
individual cohort text pertaining to samples to be obtained for BRAF mutation status, 
disease assessment, PD and biomarker assessments.
Section 8: Time and Events tables were revised the frequency of select assessment for the 
first 52 weeks of treatment to 48 weeks of treatment to align with the timing of other 
assessments
Section 8.1.2, Section 8.2.2, Section 8.3.2, Section 8.4.2, Section 8.5.2, Section 8.6.2, 
Section 8.7.2, In clusion Criteria: clarified mandatory tumor sample required at Screening
Section 8.8.2 and Section 8.9.2, Inclusion Criteria: clarified mandatory BM aspi[INVESTIGATOR_681695]
Section 8.6.2, Section 8.7.2, Section 8.8.2, and Section 8.9.2, Exclusion Criteria: added
text to confirm that no histology -specific exclusion criteria were included
Section 8.4.3 andSection 8.5.3, Disease Assessments: corrected reference toCTscan; 
changed to MRI as CT is not permitted in these cohorts
Section 8.6.4, Laboratory Assessments: corrected reference in cohort number
Section [IP_ADDRESS], Restarting Stud yTreatment was revised to remove reference to restart of 
study treatment.
Section 14.1.2: removed statement that PD sample collection was mandatory for ATC,
HCL and MM cohorts as it was inconsistent with Time and Events tables.
2012N145247 02 2013 -DEC -18 Amendment No. 2
Section 3, Objectives and End points, revised Table [ADDRESS_923121] use of 
Modified RANO and RANO is assessing tumor response in gliomas.

[COMPANY_001] Confidential Page 17
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 4, Study Design: revised sentence regarding eligibility of subjects to be 
consistent with new general inclusion criteria #5; revised to correctl y identify timing of
screening assessments and exceptions for consistency  with Time and Events Tables.
Section 5.2.1, General Inclusion Criteria #5: revised to delete the reference to a CLIA 
approved laboratory as this certification is not applicable to countries other than the US.
Section 5.2.1, General Inclusion Criteria #7 (renumbere d to #8): revised to describe
contraception consistently  with other sections of protocol; added “highl y”toeffective
contraception.
Section 5.2.1, General Inclusion Criteria (new) #5: new criteria added to clarify
inclusion of subjects with specified histology and no available treatment options per 
local or regional standard of care.
Section 7.3, Safet y: inserted new text to provide estimation of blood volume collected
during the stud y and to reference Appendix 17.
Section 7.3.1, Physical Examination: replaced term ‘neurological’ to ‘CNS’ to better
describe assessment to be made.
Section 7.3.6, Electrocardiogram, second paragraph, revised to remove reference to 
QTcF as stoppi[INVESTIGATOR_681696].
Section 7.3.7, Echocardiogram, revised to remove the use of MUGA scans to assess 
cardiac ejection fraction.
Section 7.3.9, Monitoring of Non-Cutaneous Secondary /Recurrent Malignancy , added 
as a new section to reflect monitoring required per the speci al warnings and precautions
required for use of dabrafenib.
Section 8.3.2, Eligibility Criteria: GIST,added new inclusion criteria (#4) requiring
progression with imatinib and sunitinib treatment; subsequent criteria were renumbered.
Section 8.4.2, Eligibility Criteria: WHO Grade 1 or 2 Glioma: added new criteria for 
subjects with WHO Grade 2 glioma: only subjects for whom chemotherap y are not an
option may be eligible for study participation
Section 8.8.2, Eligibility Criteria: HCL ,Inclusion Criteria #2, revised inclusion criteria
#2 to provide examples of a purine analog and to clarify definition of refractory disease.
Section 8.9.2, Eligibility Criteria: MM, Inclusion Criteria #2, revised to clarify prior
treatment received by[CONTACT_681828].
Section 9.2.1, Cardiovascular Events, revised to indicate that cardiovascular events may
occur with not only trametinib but also dabrafenib or both in combination.
Section [IP_ADDRESS], QTc Prolongation, revised to be in line with the special warnings and
precautions r equired for use of dabrafenib.
Section [IP_ADDRESS], LeftVentricular Ejection Fraction Stoppi[INVESTIGATOR_2121], revised to remove
use of MUGA scan and to request procedure to be performed by [CONTACT_681829] ;removed requirement ofreporting symptomatic events as SAE, 
and to provide that in case of asymptomatic absolute decrease of >10% in LVEF 
[COMPANY_001] Confidential Page [ADDRESS_923122], study treatment 
(trametinib and dabrafenib) must be temporary  or definitely  discontinued.
Section [IP_ADDRESS].2, Management of Hypertension, clarified dose added new text directing
subjects with persistent increase in systolic and/or diastolic BP that may be treatment -
related to be managed by[CONTACT_681830] 21 and revised to indicate that
continuing treatment by[CONTACT_681831]. Inthis situation, study treatment (trametinib and 
dabrafenib) must be temporary or definitely discontinued.
Section [IP_ADDRESS], Cutaneous SCC, revised to remove reference to keratoacanthomas and 
added requirement of dermatological examinations monthly for 6 months after 
treatment discontinuation.
Section 9.3.5, Renal Insufficiency ,revised to include guidelines for management and
dose reduct ion for renal insufficiency when considered treatment related (Table 26 
added). (Tables from this point forwarded were renumbered accordingly .)
Section 10.1.1, Female Subjects, revised in order to describe contraception consistently 
with other sections of protocol; added “highly ” to effective contraception
Section 11.3, Medications tobeUsed with Caution, revised toaddupdated reference
for drugs known toinduce QTc prolongation.
Section 14.1, Tumor Tissue for BRAF V600E Mutation Pre-Screening, revised todelete
the reference to a CLIA approved laboratory as this certification is not applicable to 
countries other than the US.
Section 20.1, Data Monitoring Committee, new section added to address the formation 
ofa data monitoring committee forreview ofdataduring interim analy sisand to indicate
that independent hematologist and oncologist will serve on data monitoring committee.
Appendix 9, Country Specific Requirements, deleted text pertaining to French -specific
QTc stoppi[INVESTIGATOR_681697] w as incorporated into Section [IP_ADDRESS].
Appendix 17, Volumes of Collected Blood Samples, added new table to provide the 
volume of blood collected at various time points during stu dy.
2012N145247 03 2014 -JUL-21 Amendment No. 3
Amendment No.: [ADDRESS_923123] 
IBs.
Revised information pertaining to BRAF mutation test and companion diagnostic.
Reformatted the inclusion/exclusion criteria to eliminate repeated language found when 
previously presented in separate cohort sections.
Revised inclusion/exclusion cohort where appropriate based onadditional input from
investigators orsubject experts orto clarify criteria; revised textpertaining totreatment of
overdose forboth dabrafenib andtrametinib toalign with newstandard protocol language.
Condensed 9separate Time and Events table into one table to eliminate duplication of 
information for ease ofuser; added language pertaining to retrospective confirmation of 
histology type for ATC cohort.
[COMPANY_001] Confidential Page 19
Amended Protocol Version 11            Protocol No. CDRB436X2201
Revised vision changes and ophthalmic exam language inappropriate sections with 
revised standard asset language.
Reformatted document to eliminate individual cohort sections andreduce duplication of
textdescribing study assessments such as laboratory and disease assessment, etc.
Revised disease assessment sections to clarify  typeof assessment, timing and evaluation 
criteria.
Stoppi[INVESTIGATOR_681698].
Liver chemistry  stoppi[INVESTIGATOR_681699].
Concomitant medication and non-drug therapi[INVESTIGATOR_681700], palliative radiation anduseof dabrafenib during radiotherapy.
Addressed change in information collected for screen failures.
New reference citat
ions added, references no longer cited in text were removed.
List of abbreviations updated to reflect revisions in overall text.
Other general administrative changes were made to correct typographical errors, etc.
2012N145247 [ADDRESS_923124] -24 Amendment No. 4
The changes made with Amendment No. 4 are to revise the protocol in response to the
recent decision for the substantial amendment of a Voluntary Harmonization Procedure
(VHP -SA) submission of Amendment 03 of the protocol.  Specific changes made with
Amendment No. 04include thefollowing:
Section 1.3: revised to update regulatory approval status of trametinib monotherapy  and 
trametinib in combination with dabrafenib
Section 4.0: revised to correct inconsistency between text in protocol section and text 
change noted in summary of amendment changes in Appendix 20 for Amendment 03.
Section [IP_ADDRESS].4 and Section [IP_ADDRESS].5: revised Inclusion Criteria #5 and #4,respectively ,
to clarify that the criterion applies to subjects who are alread yreceiving corticosteroid 
therapy .
Section 5.2.2: revised to Criterion #1 to clarify that the status of delay edtoxicity applies 
to all typesof therap yand not solely chemotherapy .
Section [IP_ADDRESS], Table 12: reverted text in Table 20 to the Amendment 02 version as it was 
previously approved by[CONTACT_681832].
Section [IP_ADDRESS], Section [IP_ADDRESS].1, Section [IP_ADDRESS].2, Section [IP_ADDRESS].3: the liver chemistry
stoppi[INVESTIGATOR_681701] a portion of the criteria and 
to reformat the text originally found in Appendix 18 in Amendment 03 to assure that 
all 
guidelines were located together in Section 8.1.3.
Section 8.2: revised to delete table that was incorrectly placed under this section heading; 
should have been included in previous section of protocol

[COMPANY_001] Confidential Page 20
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 8.2.3: revised based onrecent revision oftheasset standard language for 
pneumonitis
Section 8.2.6, Table 21: revised text in Table [ADDRESS_923125] 
Characteristics (SmPC) language as requested b ythe VHP
Section 13.1: revised to correct inconsistency between text in protocol section and text 
change noted in summary of amendment changes in Appendix 20 for Amendment 03.
Other changes were made due to reassignment of [COMPANY_004] personnel (i.e., list of authors,
secondary  medical monitor and sponsor signatory  for protocol).
2012N145247 [ADDRESS_923126]
andcompanion diagnostic
Revised inclusion/exclusion cohort where appropriate based on additional input from
investigators or subject experts or to clarify criteria.
Revised language inappropriate sections with revised standard asset language.
Clarified who can perform physical exams.
Clarified number ofblood pressure readings tobetaken and averaged value to be reported.
Revised disease assessment sections to clarify  type of assessment, timing and evaluation 
criteria.
Revised LVEF stoppi[INVESTIGATOR_681702].
Removed BRAT dietfrom diarrhea management guidelines.
Removed oral contraceptives from theprohibited medications listandprovided supporting
information regarding interaction with dabrafenib; specified oralformulation for selected
prohibited medications andmedications tobe used with caution.
Concomitant medication andnon-drug therapi[INVESTIGATOR_681703].
Clarified which samples to be submitted forconfirmation of BRAF mutation status.
Definition ofSAEs revised for protocol specific SAEs based onupdated list of AE of 
special interest.
Added new section formalignancies toinclude section oncutaneous squamous cell
carcinoma, new primary melanoma and non-cutaneous malignancies based on updated 
asset language fordabrafenib andtrametinib.
Clarified useofNSAI Dsinsubjects wit
hMM forpyrexia andaction tobetaken with
dabrafenib with pneumonitis.
Revised disease assessments forsolid tumors to clarify imaging modality  to be used for
specific cohorts.
Statistical section revised toreflect change in study  sample size and trial simulation
output.
[COMPANY_001] Confidential Page 21
Amended Protocol Version 11            Protocol No. CDRB436X2201
Revised theTime andEvent Table tocorrect footnoting, clarify  timing ofassessments in
particular PDbiomarkers (tumor sample, BM aspi[INVESTIGATOR_681704]) for all cohorts.
Revised Bay esian hierarchical model specification to correct typographical error.
Updated reference citations, listofabbreviations updated toreflect revisions in overall
text, andother general administrative changes were made to correct typographical errors.
2012N145247 06 2016 -JAN-05 Amendment No. 6
Amendment 6implements additional updates tothe protocol Sections noted below:
Section Sponsor/Medical Monitor Information Page: Updates the contact [CONTACT_681833].
List of Abbreviations: Adds “SPEP –Serum Protein Electrophoresis” and“UPEP -
Urine Proteine Electrophoreis” to the list.
Section 1.2 Dabrafenib ([COMPANY_004]2118436): Updates thelastparagraph as follows: Refer to
thedabrafenib monotherap y and dabrafenib+trametinib combination therap yand
updates thenew IB v.07 document number.
Section 1.3 Trametinib ([COMPANY_004]1120212): 
oUpdates the second paragraph as follows: “….Trametinib in combination with 
dabrafenib has been approved in the US, EU, Chile, and Australia forthe treatment 
of patients with unresectable or metastatic melanoma with BRAF V600E or V600K 
mutation.
oUpdates the third paragraph as follows: Refer to the dabrafenib monotherapy and 
dabrafenib IBfor a complete summary ….. and updates the new IB document 
number.
Section 1.4 Risk Assessment for Dabrafenib + Trametinib Combination Therap y:
oAdds a new paragraph about the safety  profile for dabrafenib + trametinib 
combination therap y.
oUpdates theguidance and timepoints for dermatolgical exams for cuSCC as follows: 
A brief dermatological exam should be performed every 4 weeks (±7days)for the 
first 6 months after discontinuation of study treatments to monitor for new cutaneous 
malignancies.
oUpdates information for Pyrexia as follows: … About one-third of the subjects who 
experienced p yrexia had 3 or more events.
oAdds thefollowing guidance: trametinib should be continued at the same dose.
oAdds information for decrease left ventricular ejection fraction as follows: Left 
ventricular dysfunction has been reported with trametinib as well aswith other MEKi 
in clinical development. In the 2 Phase III studies decreased ejection fraction 
occurred in 7% of subjects receiving combination therapy and the majority of 
the LVEF decreases that met interrupt ioncriteria were asymptomatic and
resolved. Most subjects who were re
-challenged were able to continue on 
treatment without further dose modification. Subjects enrolled in studies with 
dabrafenib in combination with trametinib undergo regular cardiac asse ssments with
[COMPANY_001] Confidential Page 22
Amended Protocol Version 11            Protocol No. CDRB436X2201
echocardiograms (ECHOs). Guidelines forclinical management of treatment -related 
LVEF decreases have been provided in Section [IP_ADDRESS].
oAdds new information for hemorrhage as follows: Hemorrhage :Hemorrhagic
events, including major hemorrhagic events defined as symptomatic bleeding in 
a critical area or organ, and fatal intracranial hemorrhages , have occurred in 
patients taking dabrafenib in combination with trametinib. The majority of 
bleeding events were mild. Three of 209 subjects (1%) recei ving trametinib in 
combination with dabrafenib in a phase III trial had fatal intracranial
hemorrhagic events. The management of hemorrhagic events may require 
treatment interruption, dose reduction, or treatment discontinuation .
oUpdates new information for Hyperglycemia as follows: Hyperglycemia :
Hyperglycemia requiring an increase in the dose of, or initiation of, insulin or oral 
therapy  can occur with dabrafenib or dabrafenib in combination with trametinib .
oUpdates information for Pancreatitis as follows: Pancreatitis: Subjects receiving 
dabrafenib or dabrafenib in combination with trametinib have reported AEs of 
acute pancreatitis or pancreatitis. Insome cases, serious adverse events (SAEs) of
Grade 4 pancreatitis were reported as treatment -related by[CONTACT_093]. The time  
to onset of pancreatitis ranged from study Day 21 to 292 (median 138 days) with 
dabrafenib monotherapy, and from Study Day 24 to 312 (median 50 days) with 
combination therapy.  Discontinuation of study treatment due to pancreatitis was 
not deemed necessary in anyof the cases by[CONTACT_232033].
oUpdates information for Fertility as follows: Trametinib may impair fertility in 
humans .
oUpdates information for Pregnancy as follows: Women of childbearing potential 
should use effective methods of contraception during therapy and for 4 months 
following discontinuation of trametinib when taken incombination with dabrafenib, 
or for 4 weeks following discontinuation of dabrafenib.
Section 1.5.6 Cohort 6: Non-Seminomatous/Non-G erminomatous Germ Cell Tumors 
(NSGCT/NGGCT): Updates the second paragraph as follows: Chest pain and difficulty  
breathing are early signs of NSGCT. Other symptoms include: cough, fever, headache, 
andchange in bowel habits, fatigue, difficult ywalking and visual problems (difficulty
seeing or moving ey es).
Section 2.1 Rational: Updates information about overall survival data for combination 
therap y in advanced melanoma.
Section 2.3 Dose Rationale:
oUpdates the trametinib PK [GlaxoSmithKline Document Number to
CM2010/[ZIP_CODE]/[ADDRESS_923127] sentence“The combination was relativel y 
well tolerated in study  BRF113220, study  MEK115306 and study MEK116513 , 
with toxicities manageable with appropriate intervention.
oModifies the second paragraph as follows: As determined in Phase IIIstudies, the 
safet y profile of the combination of dabrafenib and trametinib generall y reflects the 
well established safet y profiles of the individual approved agents, with toxicities that 
are manageable with appropriate interven tion.
[COMPANY_001] Confidential Page 23
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 4 Study Design:
oUpdates thefirst paragraph asfollows: “…For each cohort, up to 25evaluable 
subjects will be enrolled in the primary analysis cohort as defined in Section 5.1. 
Ifagiven cohort isstopped early forefficacy, ahistology specific expansion 
cohort may be opened to allow for additional patient enrollment (see Section 
5.2)”
oUpdates the fourth paragraph regarding disease assessments as follows: “Subjects 
will undergo disease assessment of response after receiving atleast 8 weeks of 
treatment”
Section 5.1 Primary analy sis cohort: Adds new section as follows: The “primary
analysis cohort” will be comprised of those patients enrolled within a histology -specific 
group prior to cappi[INVESTIGATOR_25577] 25 patients per cohort or prior toearly stoppi[INVESTIGATOR_681705] . The primary  analy sis cohort will form the basis of the Bay esian modelling.
Section 5.2 Expansion cohort: Adds a new section as follows: If a cohort closes early 
at an interim analy sis because it meets the rules for early stoppi[INVESTIGATOR_34303] , an 
expansion cohort may be opened to allow additional patient enrollment for that 
particular histology . The patients in the expansion cohort will provide supportive 
efficacy  data and will NOT contribute to the Bayesian modeli ng. The expansion 
cohort (s)will enroll subjects forthe duration of trial enrollment.   The same
general and histology specific eligibility criteria and T&E tables and 
biomarker/histology confirmation analyses will apply to patients in the expansion 
cohort.
Section 5.1 became 5.3 Number of Subjects: Updates first paragraph as follows: For 
the primary analysis cohort, enrollment will not exceed [ADDRESS_923128] been enrolled, the histology cohort will be closed to further enrollment.
See Section 18.2 for sample size assumptions.
5.4 Eligibility : Updates reference to updated for the IB of dabrafenib + trametinib
combination
Section 5.4.1 Inclusion Criteria Table 3 Adequate Baseline Organ Function: Updates 
legend 2 as follows: PTT and PT/INR >1.[ADDRESS_923129] will beacceptable in case of 
subjects receiving therapeutic anticoagulants such as warfarin as long as INR is 
monitored during the study accordi ng to clinical practice.
5.4.2 Exclusion Criteria: Modifies the time window for radiotherap yfor theGlioma 
Grade 1-4 cohort only: Subjects may be ≥2 weeks from radiotherap yif anew lesion 
relative to the pre -radiation MRI develops outside the primary radiation field.
[IP_ADDRESS].3 WHO Grade 1, 2, 
3 or 4 Glioma: Adds additional clarification to the Note 
concerning the WHO Grade 1,2,3 or 4 Gliom aas follows: NOTE: Extended period of 
time (>3 months) needed to prevent subjects with pseudo- progression from radiotherapy  
being enrolled in the study .Subjects may be ≥[ADDRESS_923130] resolved prior to enrollment.
[COMPANY_001] Confidential Page 24
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 7.1 T&E Table: Clarifies the assessment timelines and corrects discrepancies 
between the T&E Table and footnotes as follows:
oUpdates footnote and legend numbering as deemed necessary .
oUpdates footnote 4: Subjects may be enrolled based on local determination of BRA F 
V600E mutation status.  A subject may be tested for the BRAF V600E mutation 
greater than 28 days prior to enrollment NOTE: For subjects with HCL or MM:  A 
fresh BM aspi[INVESTIGATOR_12671] a peripheral blood sample are required for 
confirmation testing bya sponsor designated central reference laboratory .If a BM 
aspi[INVESTIGATOR_681706] a dry tap, please contact [CONTACT_1689]. In 
theevent of a dry tap, fresh or archived tumor tissues such as lymph node or 
plasmacytoma biopsies may be acceptable pending medical monitor approval.
oUpdates footnote 6: All screening assessments must be completed within [ADDRESS_923131] dose except i nformed consent. Disease Assessment (if MRI is used) can 
occur within [ADDRESS_923132] dose. Note: Procedures conducted as part of 
the subject’s routine clinical management(e.g., blood counts, imaging study ) and 
obtained prior to signing of infor med consent may be utilized for screening or 
baseline purposes provided these procedures meet the protocol requirements.
oDeletes footnote 7: Screening ECGs, ECHO, laboratory assessments and tumor 
marker tests must be performed within [ADDRESS_923133] dose of study
treatments.
oFoot Note 12, 14 and 17: Clarifies the time window for screening assessment for the 
dermatological exam, ophthalmic exam and ECHO by [CONTACT_1583] “(orwithin [ADDRESS_923134] dose) ”.
oImplements “Tissue Sample for Histology Confirmation” for independent pathology
confirmation of ATC and WHO Grade 1-4 Glioma cohort onl yand corresponding 
footnote 28 (A tissue specimen for possible retrospective histology confirmation 
should be obtained and submitted to a [COMPANY_004] designated centra l reference laboratory . 
Please refer to the SPM forthe requirements of the tissue specimen that is required 
for the histology  confirmation.
oUpdates foot note 29: AFP, B-HCG and LDH are the disease assessment markers 
for the NSGCT/NGGCT cohort. LDH result obtained from clinical chemistry panel 
can be used as a tumor marker result. Regardless of baseline values of AFP, β- HCG 
and LDH, a blood sample will be drawn every [ADDRESS_923135] 48 weeks of study
treatment, then every 8 to 12 weeks thereafter, and at the time of disease progression.
Synchronize the collection of the blood sample with the imaging schedule.
oUpdates foot note 31 for HCL cohort only as follows: All required disease 
assessments necessary  for a post-baseline response determination should be 
performed every  4 weeks +/ -3 day s. A response is to be determined every  4 weeks 
based on the response criteria (please consult Appendix 12) using data collected from 
thescheduled disease assessments.
oClarifies foot note 32 forthe HCL cohort only as follows: BM biopsy and aspi[INVESTIGATOR_495268] H/E stain and IHC will be performed when blood counts are consistent 
with CR or PR for [ADDRESS_923136] baseline (BM biopsy and aspi[INVESTIGATOR_419500] H/E stain 
and IHC and BM aspi[INVESTIGATOR_681707] ) for HCL cohort only within 
corresponding section in T&E table as follows: When counts are consistent with CR 
or PR for 4 weeks; if evidence of response, then after every 6 months twice, then 
after a yearlytwice andthen every 2years
oClarifies foot note 33 forthe HCL cohort only as follows: Recommend that flow 
cytometry panel consists of CD19, CD20, CD22, SmIg, CD11c, CD25, CD103 and 
CD123. Flow cytometry of the bone marrow aspi[INVESTIGATOR_681708] 4 weeks (please consult
Appendix 12). If a patient has a PR, and then blood counts become consistent 
with a CR for [ADDRESS_923137] be performed every 6 months for two time intervals, then 
after a year for two time intervals, then every two years.
oAdds foot note 34 for HCL cohort as follows: BM biopsy (with H/E stain and IHC), 
BM aspi[INVESTIGATOR_337] (with flow cytometry) and peripheral blood sample (with flow 
cytometry) will be assessed within 28 days prior to enrollment.
oClarifies foot note 35 regarding the timelines for tumor assessment (chest CT scan, 
abdominal CT scan with contrast and MRI (if needed) at baseline for the HCL cohort 
only as follows: A chest CT scan and an abdominal CT scan with contrast will be 
performed within [ADDRESS_923138] baseline (Chest CT scan and A bdominal CT scan 
w/o contrast) for HCL cohort only within corresponding section in T&E table as 
follows: When counts are consistent with CR or PR for 4 weeks; then 6 months later
oClarifies foot note 36 regarding timelines of skeletal survey at screening for MM 
cohort only as follows: A skeletal survey should be performed within [ADDRESS_923139] oflateral radiographs of the skull, AP and lateral views ofthe spi[INVESTIGATOR_050], 
and AP views of the humeri, ribs, pelvis, and femurs.
oModifies foot note 37 for MM cohort only as follows: Each patient should be 
clinically examined for soft tissue plasmacytomas /extramedullary disease at 
baseline and at each visit for respo nse assessment. If extramedullary disease is 
present at baseline, then Chest/Abdominal/Pelvis CT scan with contrast should be 
performed toconfirm and to determine size and location of the soft tissue 
plasmacytoma .If no dis ease is identified at baseline, then subsequent scans are only
required if clinically indicated.  Alternative imaging modality (i.e., MRI) may be used 
[COMPANY_001] Confidential Page 27
Amended Protocol Version 11            Protocol No. CDRB436X2201
Section 7.4.8 Clinical Laboratory Assessments Table 6: Adds lab tests information as 
follows: Amy lase and lipase [monitor via local laboratory  whenclinically  indicated to 
evaluate certain AEs (i.e., abdominal pain, pancreatitis, etc.)
Section [IP_ADDRESS] Modifies the header to read as follows: Additional Histology Specific 
Assessments and Histology Confirmation :
oAdds a new paragraph for histology confirmation for the ATC cohort and Glioma 
G1-G4 cohort only as follows: A tissue specimen from thebiopsy of a primary
or metastatic site that served as the basis for the
oOriginal diagnosis must be submitted to a [COMPANY_004] designated central reference 
laboratory as soon as possible after enrollment for possible retrospective 
confirmation of histologic type. Refer to the SPM for details regarding sample 
submission.
Section 7.49 Monitoring for Non-Cutaneous Secondary /Recurrent Malignancy :
Modifies the second paragraph as follows: Abnormal findings should be managed
according to standard clinical practice.
Section 7.5.1 Disease Assessments Methods for Glioma Grade 1-4 cohorts: Updates
both Ta bles to indicate that MRI with contrast is the only method of tumor assessment 
allowed at baseline and post -baseline for this particular cohort.
Section [IP_ADDRESS] L aboratory and Disease Assessments HCL :
oClarifies timelines as follows: “The following baseline disease assessments will be 
performed at the time points indicated in the Time and Event Table (Section 7.1)”
oClarifies that a BM aspi[INVESTIGATOR_346659].
oClarifies the timelines for 
post-baseline assessments as follows: A response is to be 
determined every 4 weeks based on the HCL response criteria (please consult 
Appendix 12) using data collected from the scheduled disease assessments.
oClarifies that a BM aspi[INVESTIGATOR_681709]- baseline.
oModifies the the 4thbullet point (post -baseline) to read as follows “Flow cytometry
on BM aspi[INVESTIGATOR_681710] 
(Section 7.1)”
oClarifies assessments of ly mph nodes and spleen as follows: Iflymph nodes and /or 
spleen were enlarged at baseline, they must be followed by[CONTACT_447]-baseline assessments 
using a consistent imaging modalit yasindicated in the Time and Event Table 
(Section 7.1)
Section [IP_ADDRESS] Laboratory and Disease Assessment: MM:
oClarifies timelines of baseline assessments as follows: The following baseline disease
assessments will be performed at the time points indicated in the Time and Event 
Table (Section 7.1):
oSimplifies list of baseline assessments as follows: Extramedullary disease.
oSimplifies list of baseline assessment s as follows: UPEP
[COMPANY_001] Confidential Page [ADDRESS_923140]-baseline assessment for MM cohort only as follows: Laboratory tests 
(SPEP, UPEP, CRP, β- 2 microglobulin, serum FLC assay , levels ofIgG, IgA, and 
IgM will be performed as indicated in the Time and Event Table (Section 7.1).
oModifies post-baseline assessment for MM cohort only as follows: Extramedullary
disease assessment:   Ifno disease is identified at baseline, then subsequent 
assessments are onl y required if clinicall y indicated.
Section 8.1 Dose Modification:
oRevises the dose modification guidelines for trametinib as follows: Ifadose 
reduction of trametinib is required, but the toxicity resolves and no additional 
toxicities are seen after one treatment cycle(4 weeks) , the dose of trametinib may
be re -escalated but sho uld not exceed 2 mg once daily .
oClarifies: If a dose reduction of dabrafenib is required, but the toxicity resolves 
and noadditional toxicities areseen after onetreatment cycle (4weeks), thedose
ofdabrafenib may bere-escalated but should not exceed 150 mg BID daily.
Section [IP_ADDRESS].2 Management of Hypertension Table 14: Clarifies foot note 3 as
follows: Escalation to previous dose level can be considered if BP remains well-
controlled for 4 weeks after restarting. Approval from the Medical Mo nitor is required.
Section 8.1.2 Pancreatitis: Clarifies the first paragraph as follows: “Subjects should be 
closely monitored when re -starting study treatment after an epi[INVESTIGATOR_28547].”
Section [IP_ADDRESS] Palmar- plantar Erythrod ysesthesia: Adds a new Section asfollows:
Palmar- plantar erythrodysesthesia (PPE) syndrome: Measures for PPE syndrome 
should include lifesty le modification (avoidance of hot water, traumatic activity , 
constrictive footwear, or excessive friction on the skin and the use o f thick cotton socks 
and gloves, and shoes with padded insoles) and symptomatic treatments. Apply  
moisturizing creams frequently , topi[INVESTIGATOR_681711] (e.g., urea 20 to 40% cream, 
salicy lic acid 6%, tazarotene 0.1% cream, fluorouracil 5% cream), clobetasol propi[INVESTIGATOR_16847] 
0.05% ointment for erythematous areas, topi[INVESTIGATOR_24242] 2%, and/or systemic pain 
medication such as nonsteroidal anti-inflammatory  drugs, codeine, and pregabalin for
pain. Dose modification may  also be required.
Section [IP_ADDRESS] Cutaneous squamous cell carcinoma (cuSCC):
oUpdates the document reference number for the new  Investigator’s Brochure (v07) .
oDeletes the following text: Approximately 70 % of events occurred within the first 
12 weeks of treatment with a median time to onset of 8 weeks. These should be 
surgically  removed according to institutional practices. Dose modification or 
interruption of study  treatment is not required forcuSCC or KA, however cuSCC 
should be reported as an SAE. Tumor tissue should also be submitted for further 
analyses as described in the SPM.
oAdds the following paragraph : “In a Phase III study , 10% of patients receiving 
dabrafenib monotherap y developed cuSCC, with a median time to onset of the first 
occurrence of approximately  8  w eeks. Inpatients who received dabrafenib in 
combination with trametinib, 3% of patients developed cuSCC with median time to 
onset of the first occurrence of 32 weeks”
[COMPANY_001] Confidential Page 30
Amended Protocol Version 11            Protocol No.CDRB436X2201
Immunosuppressants may result in decreased concentrations and loss of 
effectiveness.
∀11.2 Definition of Serious Adverse Event:
oUpdates h) Protocol-specific SAEs first bullet point as follows: cuSCC (Section 
[IP_ADDRESS]), new primarymelanomas (Section [IP_ADDRESS]) and non-cutaneous malignancies (Section [IP_ADDRESS]) with the exception of basal cell carcinoma (BCC). BCC should be reported as an AE or SAE based on the discretion of the investigator.
∀Section 18.1 Hypotheses and Treatment Comparisons:
oRevises the third paragraph to read as follows: “The studyis powered to detect a high 
clinicallymeaningful response rate and is based on the hierarchical model assessment of whether there is sufficiently high probability that  jexceeds C j. The posterior 
probability that the ORR for a given histology is greater than C jwill be computed 
according to the following comparison:”
∀18.2.1 Sample Size Assumptions:
oUpdates the first paragraph as follows: Each cohort of BRAF V600E mutation-
positive tumor type of a given histol ogywill enroll a maximum of 25 subjects in the
primary analysis cohort as defined in Section 5.1 . If all histologies enroll the 
maximum of 25 subjects, this will result in no more than 225 subjects in the primary 
analysis cohort.
oUpdates the second paragraph to include expansion cohort as follows: Enrollment 
into specific histology cohorts may be halted early based on results from interim analyses incorporating emerging response data. Response data from a minimum of 5 subjects will be required in a histologic cohort before it maydiscontinue enrollment for futilityand response data from a minimum of 10 subjects will be required beforediscontinuing a histologic cohort for efficacy. If a cohort closes early for efficacy 
at an interim analysis, a histology specific expansion cohort (see Section 5.2) may 
be opened to allow additional enrolment. At the final analysis and after the study
has been closed, a minimum of 2 subjects will be required in a histologic cohort in order to meet statistical success at the final analysis.  See Section 18.3.2 for more details.
∀Section 18.3.1 Analysis Population: Updates this particular section as follows: 
As the design for the study calls for repeated interim analyses to evaluate the 
accumulating efficacy data, it is necessary to shift the focus of the analysis population for efficacy depending upon the time at which the data are being analyzed.  Table [ADDRESS_923141] based on the timing of the analysis for both efficacy and safety; accompanying definitions are provided beneath the table.
Table 30 Definition of Population for specific analysis
Analysis Period
Analysis Intent Interim Analyses Final Analysis
Efficacy Primary ITT/Evaluable BRAF V600E
[COMPANY_001] Confidential Page 31
Amended Protocol Version 11            Protocol No. CDRB436X2201
Supportive BRAF
V600/EvaluableITTHistology -
specific cohortsa
Safety Primary ATS ATS
aSubset of the BRAF V600E population that include histologically similar 
subjects for cohorts that were stopped for promising efficacy; includes those from 
the primary analysis cohort and those from the expansion cohort, asdefined in 
Section 5.1 and Section 5.2.
The BRAF V600E Population is defined as all enrolled subjects regardless of whether 
or not treatment was administered, who obtain positive verification of the BRAF 
V600E mutation from a certified central reference laboratory .
The Intent -to-Treat (ITT) population is defined as all enrolled subjects regardless of 
whether ornot treatment was administered.
The All -Treated Subjects (ATS) popula tion is defined as all subjects who receive at 
least one dose of dabrafenib ([COMPANY_004]2118436) or trametinib ([COMPANY_004]1120212).
The Intent -to-Treat (ITT)/Evaluable 
population is defined as allITT subjects in 
the primary analysis cohort who are also evaluable accord ing to the evaluability
defined intheinterim analysis RAP.
The BRAF V600E/Evaluable Population is defined as all BRAF V600E subjects 
in the primary analysis cohort who are also evaluable according to the evaluability 
defined in the interim analysis RAP.
18.3.3 Final Anal ysis: Updates first paragraph as follows: The final primary analysis 
for ORR will occur once all subjects in the primary analysis cohorts have either 
discontinue treatment or have received treatment for at least 6months, whichever comes 
first.
Section [IP_ADDRESS] Safet yAnaly sis: Updates as follows: Safet ydata will bepresented in 
tabular and/or graphical format and summarized descriptively  according to [COMPANY_004]’s
IDSLstandards. The ATS population will be used for the analysis of safety  data. In 
general, safet ydata will be summarized by [CONTACT_681834].
Complete details of the safet y analyses will be provided in the RAP.
Section [IP_ADDRESS].3 Other Safety Measures:
oDeletes the word “MUGA” as planned on amendment 5.Itreads asfollows: The 
results of scheduled assessments of vital signs, 12-lead ECG, ECHO and ECOG 
performance status will be summarized.
Section [IP_ADDRESS] Efficacy Analy ses:
oDeletes the following paragraph: The BRAF V600E Population will beused for all 
final efficacy  analyses and used as the supportive population for interim analy ses for 
[COMPANY_001] Confidential Page 32
Amended Protocol Version 11            Protocol No. CDRB436X2201
ORR. The ITT Population will be used for interim analy ses for ORR and used as the 
supportive population for efficacy analyses.
oUpdates the second paragraph as follows: “ORR will be analyzed using anintegrated 
analysis with the hierarchical model as well as analy zed independently for each 
histology”
oUpdates the Response Subcategories in Table [ADDRESS_923142]/NGGCT cohort
oAdds a reference to the RAP in regards to further details on response confirmation 
criteria for each histological cohort.
oModifies the following sentence: “Bay esian inference based on summary statistics 
from the posterior distributions of each ORR will be reported”
oClarifies the definition for Duration of Response as: Duration of response for the 
subset of subjects who have a confirmed response (See Table 31) is defined as the 
time from first docum
ented evidence of response until the first documented sign of 
disease progression or death.
18.4.1 Simulation Description: Updates section to clarify that the expansion cohort will 
not be taken into consideration in the simulation description.
Section 20 References: Updates the reference to the new version of Dabrafenib
([COMPANY_004]2118436) Monotherapy  a nd Dabrafenib+Trametinib ([COMPANY_004]1120212)
Combination Therapy  Investigator’s Brochure (v7).
Section 21.19 Appendix 19 Protocol Amendment Changes: Updates inconsistency with 
T&E Table: Laboratory tests (24-hr urine collection; SPEP, UPEP [perform if protein 
is present in 24-hr urine], CRP, β -2microglobulin, serum free FLC assay , 
immunoglobulin levels [IgG,IgA, andIgM]) will be performed asindicated in the Time 
and Event Table.
2012N145247 [ADDRESS_923143] references to [COMPANY_004] or its staff with that of [COMPANY_001]/[COMPANY_001] and its 
authorized agents.
2.Make administrative changes to align with [COMPANY_001] processes and procedures.
[COMPANY_001] Confidential Page [ADDRESS_923144] to ensure that site staff 
receives the appropriate information throughout the stud y.
Investigator Name:
[CONTACT_10670] A ddress:
Investigator Phone Number:
Investigator Signature [CONTACT_681949] [ADDRESS_923145] OF A BBREVIATIONS
AA Anaplastic astrocytoma
ABMT Autologus bone marrow transplant
ACS American Cancer Society
ADL Activities of daily living
AFP Alpha fetoprotein
AE(s) Adverse Event(s)
alloSCT Allogenic stem cell transplantation
ALT Alanine aminotransferase
ANC Absolute neutrophil count
AO Anaplastic oligodendroglioma
APXA Anaplastic pleomorphic xanthroastrocytoma
ASI Adenocarcinoma of small intestine
AST Aspartate aminotransferase
ATC Anaplastic thyroid cancer
ATP Adenosine triphosphate
ATS All-Treated Subjects
autoSCT Autologous stem cell transplantation
BAL Bronchioalveolar lavage
BBB Blood brain barrier
BEP Bleomycin, etoposide and cisplatin
-HCG Beta-Human Chorionic Gonadotropin
BID Twice daily or two times a day
BLQ Below the lower limit of quantification
BM Bone marrow
BP Blood pressure
BRAFi BRAF inhibitor
BTC Biliary tract cancer
BUN Blood urea nitrogen
C Degrees centigrade
CBC Complete blood count
cfDNA Circulating free DNA
CI Confidence interval
cm Centimeter
Cmax Maximum observed concentration
CNS Central nervous system
CONSORT Consolidated Standards of Reporting Trials
CR Complete response
CRO Clinical Research Organization
CRP C-reactive protein
CT Computed tomography
CTCAE Common Toxicity Criteria for Adverse Events
cuSCC Cutaneous squamous cell carcinoma
CYP Cytochrome
DBP Diastolic blood pressure
DILI Drug -induced liver injury

[COMPANY_001] Confidential Page [ADDRESS_923146]
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
ECHO Echocardiogram
EDTA Ethylenediamine tetraacetic acid
eCRF Electronic case report form
EGFR Epi[INVESTIGATOR_681712]
F Degrees Fahrenheit
FDA Food and Drug Administration
FDG -PET [18F]fluorodeoxyglucose -positron emission tomography
FET Fluoroethyltryrosine
FFPE Formalin -fixed paraffin -embedded
FISH Fluorescence in situ hybridization
FLAIR Fluid attenuation inversion recovery
FLC Free light chain
FSH Follicle Stimulating Hormone
g Gram
GBM Glioblastoma
GCP Good Clinical Practice
GCPH Global Clinical Program Head
GCT Germ cell tumor
GGT Gamma glutamyl transferase
GI Gastrointestinal
GIST Gastrointestinal stromal tumor
[COMPANY_004] GlaxoSmithKline
HA Health Authority
HbA1C Hemoglobin A1C
HBsAg Hepatitis B surface antigen
HCC Hepatocellular carcinoma
HCL Hairy cell leukemia
HDCT High dose chemotherapy
H/E Hematoxylin and eosin stain
HMG-CoA 3-hydroxy -3-methylglutaryl -coenzyme A
HPMC Hydroxypropyl methylcellulose
hr/hrs Hour(s)
HR Hazard ratio
HRT Hormone replacement therapy
IB Investigator brochure
IBW Ideal body weight

[COMPANY_001] Confidential Page [ADDRESS_923147] visit
m2 Meter squared
MAO Mixed anaplastic oligoastrocytoma
MAPK Mitogen -activated protein kinase
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MedDRA Medical Dictionary forRegulatory Activities
MEK Mitogen -activated extracellular signal -regulated kinase kinase
MEKi MEK inhibitor
MET Methionine
mg Milligram
MGMT 06-methylguanine -DNA -methyl transferase
mL Milliliter
MM Multiple myeloma
mm Millimeter
mm3Cubic millimeter
mmHg Millimeters of mercury
MR Minimal/minor response
MRD Minimal residual disease
MRI Magnetic resonance imaging
MSDS Material Safety Data Sheet
msec Milliseconds
MUGA Multigated acquisition scan
NA Not applicable
[COMPANY_001] Confidential Page [ADDRESS_923148] Non-geminomatous germ cell tumor
NHL Non-Hodgkin’s lymphoma
NSAID(s) Non-steroidal anti -inflammatory drug(s)
NSCLC Non-small cell lung cancer
NSGCT Non-seminomatous germ cell tumor
NYHA [LOCATION_001] Heart Association
ORR Overall response rate
OS Overall survival
PBSCT Peripheral blood stem cell transplant
PCR Polymerase chain reaction
PCV Procarbazine, lomustine and vincristine
PD Pharmacodynamic or progressive disease
PDGFRA Platelet -derived grow factor receptor alpha
pERK Phosphorylated extracellular signal related kinase
PET Positron emission tomography
PFS Progression -free survival
PK Pharmacokinetics
PPE Palmar -plantar erythrodysesthesia
PR Partial response or partial remission
PS Performance status
PT Prothrombin time
PTC Papi[INVESTIGATOR_681713] -corrected QT interval
RANO Response Assessment for Neuro-Oncology
RAP Reporting and Analysis Plan
RBC Red blood cell
RECIST Response Evaluation Criteria in Solid Tumors
RNA Ribonucleic acid
RPED Retinal pi[INVESTIGATOR_681714](s)
SBP Systolic blood pressure
sCR Stringent complete response
SCAR Severe Cutaneous Adverse Reaction
SD Stable disease or standard deviation
SEER Surveillance, Epi[INVESTIGATOR_681715] [ADDRESS_923149] uptake value
T/B Tumor background ratio
TKI Tyrosine kinase inhibitor
TMZ Temozolomide
TSH Thyroid stimulating hormone
ULN Upper limit of normal
UGT Uridine 5’ -diphospho glucuronosyltransferase
UPEP Urine Protein Electrophoresis
US [LOCATION_002]
VEGF Vascular endothelial growth factor
VGPR Very good partial response
VHP Voluntary harmonization procedure
VHP-SA Substantial amendment of a Voluntary Harmonization Procedure
vs Versus
WBC White blood cells
WHO World Health Organization
[COMPANY_001] Confidential Page 40
Amended Protocol Version 11            Protocol No. CDRB436X2201
1 INTRODUCTION
1.1 Background
The RAS/RAF/MEK/ERK pathway , also known as the mitogen -activated protein kinase
(MAPK) pathway , is a critical signal transduction cascade implicated in normal growth and 
the uncontrolled proliferation of many  human cancers. Under normal physiological
conditions, signal transduction through the MAPK pathway is tightl y regulated through
multiple negative feedback mechanisms [Niault , 2010]. However, this pathway can be
constitutively activated by[CONTACT_681835], including BRAF, which 
phosphory lates mitogen- activated extracellular signal -
regulated kinase kinase (MEK) on
two regulatory serine residues. BRAF mutations have been identified at a high frequency in 
specific cancers [ Davies , 2002].  Approximately  90% of all identified BRAF mutations that 
occur in human cancers are T1799A transversions (exon 15), which result in a V600E amino 
acid substitution [Wellbrock , 2004]. Inmelanoma, the BRAF V600E mutation has been 
identified in about 50% of subjects as a keydriver mutation of tumorigenesis, and BRAF 
inhibitors (BRAFi), such as vemurafenib and dabrafenib, have demonstrated substantial 
efficacy in this setting [ Chapma n, 2011a].
While the introduction of BRAFi represent a significant advance in the treatment of BRAF 
V600 mutation -positive metastatic melanoma [Chapman , 2011a], limitations ofthis novel 
therap y have alread y been identified. As has been the pattern with other highl yselective 
small molecule kinase inhibitors (e.g., imatinib, erlotinib and gefitinib) the rapid onset of 
drug resistance restricts the efficacy .  Understanding the specific mechanisms ofresistance 
to BRAFi is critical for the development of more effective strategies to inhibit the MAPK -
pathway in order to delay or prevent the onset of resistance in BRAF -mutant melanoma.
Experimental data generated with a BRAFi and MEK inhibitor (MEKi) combination therapy 
in BRAF -mutant melanoma cell lines in vitro and xenografts in vivo support this concept by
[CONTACT_681836].  
More importantl y, superior anti-tumor activity of the BRAFi and MEKi combination as 
compared to each agent as monotherap y was also observed in BRAF -sensitive models. These 
data clearl y indicate that a concomitant and more potent inhibition of the MAPK -pathway at 
the critical level of the BRAF -and MEK
-kinases leads to a more pronounced tumor 
inhibition, thus significantly  delay ing the onset of resistance. In addition, pre -clinical safety 
data obtained with this combination therap yinarat-model indicate that the potential for 
proliferative skin lesions and secondary cutaneous malignancies is reduced in comparison to 
treatment with a BRAFi alone [ Su, 2012].
1.2 Dabrafenib (DRB436/ [COMPANY_004]2118436)
Dabrafenib ([COMPANY_004]2118436) is an orally bioavailable, potent and selective RAF kinase
inhibitor of human wild -type B-RAF and C-RAF enzymesas well as the mutant forms of the 
BRAF enzyme, BRAF V600E, BRAF V600K and BRAF V600D. The mode ofaction of 
dabrafenib is consistent with adenosine triphosphate (ATP) -competitive inhibition.  
Dabrafenib has demonstrated suppression of a down stream pharmacody namic (PD) 
biomarker phosphory lated extracellular signal -related kinase (pERK) in tumor cell lines, 
demonstrated anti- proliferative activity against multiple BRAF -mutant tumor cell lines, and 
achieved biomarker suppression and tumor regres sion in BRAF mutant xenograft 
models.BRAF mutations have been identified at a high frequency in specific cancers, 
including approximately 40 to 60% of melanomas.  The frequency of this activating mutation 
[COMPANY_001] Confidential Page [ADDRESS_923150] addiction to which it leads makes mutated BRAF an extremely attractive 
target. Dabrafenib has been approved in the [LOCATION_002] (US), European Union (EU), and 
multiple other countries for the treatment of BRAF -mutant unresectable or metastatic
melanoma. In addition, dabrafenib is also bei ng studied in a Phase II trial in BRAF -mutant 
non-small cell lung cancer (NSCL C).
Refer to the dabrafenib monotherap yand dabrafenib+trametinib combination therapy
Investigator’s Brochure (IB) for a complete summary of currentl yavailable preclinical, safety , 
pharmacokinetic (PK), and clinical data.
1.3 Trametinib (
TMT212/ [COMPANY_004]1120212)
Trametinib ([COMPANY_004]1120212) is a reversible, highl y selective, allosteric inhibitor of MEK1 and 
MEK2 and kinase activity  [Gilmartin , 2011].  Trameti nib has been approved for the treatment 
of BRAF -mutant unresectable or metastatic melanoma in several countries, including the US, 
EU, Kazakhstan and Australia. Trametinib has been studied in Phase II trials in pancreatic 
cancer and RAS -mutant NSCL C as wel l as RAS- mutant acute m yeloid leukemia.
Trametinib is non-competitive towards ATP and inhibits both MEK activation and kinase 
activity . Because BRAF and MEK are in the same pathway, and because MEK is a substrate 
of activated BRAF, inhibiting both proteins simultaneously  rather than individually  could 
provide more effective pathway  inhibition. In addition emerging data indicate that acquired 
resistance to BRAFi is often associated with reactivation of the MAPK pathway , which might 
render BRAFi -resistant melanoma cells susceptible to the combination of BRAF and MEK 
inhibition [Alcala , 2012]. Data generated in cell line, mouse xenograft, and rat safety models 
with the combination of BRAFi and MEKi suggest enhanced effects on eff icacy  and less 
potential for proliferative skin lesions as compared to treatment with a BRAFi alone. 
Trametinib in combination with dabrafenib has been approved in the US, EU, Chile, and 
Australia for the treatment of patients with unresectable or metastat ic melanoma with BRAF 
V600E or V600K mutation.
Refer to the dabrafenib monotherap y and dabrafenib+trametinib IB for a complete summary 
of the currently  available chemistry , nonclinical, and clinical data to support the use of the 
combination in subjects wi th BRAF V600 mutation -positive solid tumors [GlaxoSmithKline 
Document Number CM2010/[ZIP_CODE]/05 ]. A separate IB is also available summarizing the 
preclinical, safety , PK, and clinical data for trametinib monotherapy  [GlaxoSmith Kline 
Document Number HM2009/[ZIP_CODE]/05].
1.4 Risk Assessment forDabrafenib +Trametinib Combination
Therapy
The assessment of the risk of dabrafenib + trametinib combination therapy ,andsuggestions 
for management of risk, is based on non -clinical data and clinical data from the ongoing and 
completed dabrafenib and trametinib monotherapy and combination studies in adults.  Inthe 
event that anyadverse events (AEs) are reported or observed, supportive treatment will be 
provided according to standard medical practice. Subjects will be withdrawn from the study
if a clinicall y significant toxicity is reported or observed.
The safet y profile for dabrafenib + trametinib combination therapy  has been established and 
is well-characteriz ed in subjects with unresectable/metastatic melanoma, 
with consistent 
results across two randomized Phase III studies. The safet y profile of the combination of 
[COMPANY_001] Confidential Page [ADDRESS_923151] AEs of the individual agents; some notable 
exception s are described below.
Cutaneous squamous cell carcinoma (cuSCC): In vitro experiments have demonstrated a 
paradoxical activation of MAPK signalling in kerationcy tes and potentially other cells
harboring a wild-type BRAF kinase but a mutated RAS kinase upon exposure to a BRAFi.  
This paradoxical MAPK pathway activation is potentially associated with a higher risk for 
the development of cuSCC induction. Cases of cuSCC (which include those classified as 
keratoacanthoma or mixed keratoacanthoma subtypes) have been reported in subjects treated 
with dabrafenib + trametinib.
Skin examination should be performed prior to initiation of dabrafenib or dabrafenib +
trametinib treatment and while receiving therapy. Dermatologic examinations should be
performed follow ing discontinuation of dabrafenib monotherapy  or in combination with
trametinib, or until initiation of another anti-neoplastic therap y (see Section 7.1, Time and 
Events Table for schedule of assessments). Cases of cuSCC should be managed by
[CONTACT_681837]; dabrafenib and trametinib treatment should be continued without 
anydose adjustment. A brief dermatological exam should be performed every 4 weeks (±
7
days)for the first 6 months after discontinuation of study treatments tomonitor for new 
cutaneous malignancies.
Subjects should be instructed to immediately inform their physician if new skin lesions
develop.
New primary melanoma: New primary melanomas have b een reported in subjects with pre -
existing unresected or metastatic melanoma treated with dabrafenib monotherapy orin 
combination with trametinib.  These were identified within the first 5 months of treatment 
with dabrafenib and did not require treatment modification other than excision. Monitoring 
for skin lesions should occur as described for cuSCC.
Non-cutaneous secondary/recurrent malignancy: In vitro experiments have demonstrated 
paradoxical activation of MAP -kinase signaling in BRAF wild-type cells with RAS 
mutations which are exposed to BRAFi, which may lead to increased risk of non- cutaneous 
malignancies in 
subjects treated with dabrafenib.  Cases of RAS -driven malignancies have 
been seen with BRAFi including dabrafenib monotherapy  or incombination with trametinib. 
Subjects should be monitored as clinically appropriate. Following discontinuation of 
dabrafenib monotherap yor in combination with trametinib, monitoring for non-cutaneous 
secondary /recurrent malignancies should continue for up to6 month s or until initiation of 
another anti -neoplastic therapy .
Rash: Skin-related toxicities, primarily rash (maculo -papular t
ype rash with dabrafenib and 
acneiform -type rash with trametinib) have been reported with trametinib and dabrafenib 
monotherapi[INVESTIGATOR_014].  Theincidence of trametinib -related rash across all previous trametinib 
monotherap ystudies was 57%, with 7% of subjects experiencing Grade [ADDRESS_923152]
often seen with either trametinib or dabrafenib monotherapy , appear to be reduced when both 
compounds are combined.  Rash management guidelines are incorporated into all dabrafenib 
+ trametinib combination studies (see Section 8.2.1 .1).
Severe Cutaneous Adverse Reactions: Cases of severe cutaneous adverse reactions (SCARs), 
including Stevens -Johnson syndrome, and drug reaction with eosinophilia and systemic 
symptoms (DRESS), which can be life-threatening or fatal, have been reported during 
[COMPANY_001] Confidential Page 43
Amended Protocol Version 11            Protocol No. CDRB436X2201
treatment with dabrafenib in combination with trametinib.  Guidelines for clinical 
management of treatment -related SCARs are provided in Section [IP_ADDRESS].
Ocular effects: Both dabrafenib and trametinib as monotherapi[INVESTIGATOR_681716].  An ophthalmologist should be consulted if changes in 
vision develop. However, if the visual changes are clearl y unrelated to study treatment (e.g., 
allergic conjunctivitis), then monitor closel y as it may be reasonable todefer ophthalmic 
examination.
Treatment with dabrafenib has been associated with the development of uveitis, including 
iritis. Monitor subjects for visual signs and symptoms (such as, change in vision,
photop hobia and eyepain) during treatment.  Special attention should be given to retinal
findings (e.g., retinal pi[INVESTIGATOR_6678] (RPED)) or retinovascular abnormalities 
(i.e., branch or central retinal vein occlusions (RVO)). For events of visual changes 
(regardless of severit y) for which an ophthalmic examination is conducted, ablood sample 
for PK analysis must be drawn as close as possible to the time of the event. Subjects with a 
history of RVO should not receive trametinib.
Guideline s for clin ical management of treatment- related ocular events including stoppi[INVESTIGATOR_681717] 8.2.7. An ophthalmic evaluation is
required for subjects at Screening, Week 4 and as clinically
indicated with additional exams 
required for subjects developi[INVESTIGATOR_681718] .
Pyrexia: Pyrexia has been reported in clinical trials with dabrafenib monotherap yandin
combination with trametinib. Indabrafenib monotherapy  studies, pyrexia was one of themost 
frequentl yoccurring AEs in up to 27% of subjects across all dabrafenib studies. Most of the 
pyrexia events (64%) were considered treatment -related.  The incidence and severit y of
pyrexia are increased when dabrafenib is used in combination with trametinib. In subjects 
who received the combination dose of dabrafenib 150 mg twice dail y(BID) and trametinib [ADDRESS_923153] ofthe subjects who 
experienced pyrexia had 3 or more events. Pyrexia may be accompanied by[CONTACT_681838]/rigors, dehydration and hypotension which in some cases can lead to acute renal 
insuf ficiency .
Subjects should be instructed on the importance of immediately reporting febrile epi[INVESTIGATOR_1841].
Therap y with dabrafenib should be interrupted if the patient’s temperature is ≥38.5ºC or 
101.3ºF but trametinib should be continued at the same dose. In the event of a fever, the 
subject should be instructed to take anti-pyretics (i.e., ibuprofen oracetaminophen/
paracetamol) as appropriate to control fever. The use of oral corticosteroids should be 
considered in those instances in which anti-pyretics are insufficient. Monitor serum 
creatinine and other evidence of renal function during andfollowing severe events of pyrexia.
(See Section 8.2.3 for additional details.)
Decreased left ventricular ejection fraction (LVEF):   Left ventricular d ysfunction has been 
reported with trametinib as well as with other MEKi in clinical development. In the 2 Phase 
III studies decreased ejection fraction occurred in 7% of subjects receiving combination 
therap y and the majority  of the LVEF decreases that met interruption criteria were 
asymptomatic and resolved.  Most subjects who were re -challenged were able to continue on 
treatment without further dose modification. Subjects enrolled in studies with dabrafenib in 
combination with trametinib undergo regular cardiac assessments with echocardiograms 
[COMPANY_001] Confidential Page 44
Amended Protocol Version 11            Protocol No. CDRB436X2201
(ECHOs). Guidelines for clinical management of treatment -related LVEF decreases have 
been provided in Section [IP_ADDRESS].
Hemorrhage :Hemorrhagic events, including major hemorrhagic events defined as 
symptomatic bleeding in a critical area or organ, and 
fatal intracranial hemorrhages, have 
occurred in patients taking dabrafenib in combination with trametinib. The majority  of 
bleeding events were mild. Three of 209 subjects (1%) receiving trametinib in combination 
with dabrafenib in a phase III trial had fatal intracranial hemorrhagic events. The management 
of hemorrhagic events may require treatment interruption, dose reduction, or treatment 
discontinuation.
Acute renal failure: Acute renal failure/renal failure has been reported in subjects receiving 
dabrafenib (monotherapy or in combination with trametinib), and a case ofgranulomatous 
interstitial nephritis has also been reported in a clinical study .In some cases, complicated 
pyrexia may be associated with renal insufficiency /renal failure, possibly secondary to
dehy dration or hypotension. Renal function should be monitored carefully , especiall yin 
subjects with pyrexia.  ( see Section 8.2.3 for additional details on pyrexia.) Prior to the start 
of study treatment, concomitant medications should bereviewed for the potential risk of 
inducing nephrotoxicity .  Concomitant medications should be modified if clinically possible. 
Management guidelines for renal failure, including management of pyrexia to minimize the 
risk of renal failure is included in
Section 8.2.6.
Hyperglycemia :  
Hypergly cemia requiring an increase in the dose of, or initiation of, insulin 
or oral therapy  can occur with dabrafenib or dabrafenib in combination with trametinib.   
Monitor serum glucose levels as clinicall yappropriate during treatment with dabrafenib in 
subjects with pre-existing diabetes or hypergly cemia.  Advise subjects to report symptoms of 
severe h ypergl ycemia such as excessive thirst or any increase in the volume or frequency of 
urination.
Pancreatitis: Subjects receiving dabrafenib or dabrafeni b in combination with trametinib 
have reported AEs of acute pancreatitis or pancreatitis.  In some cases, serious adverse events 
(SAEs) of Grade 4 pancreatitis were reported as treatment -related by[CONTACT_36705]. The 
time to onset of pancreatitis ranged from study Day 21 to 292 (median 138 days) with 
dabrafenib monotherap y, and from Study Day 24 to 312 (median 50 days)with combination 
therap y.  Discontinuation of study treatment due to pancreatitis was not deemed necessary in 
anyof the cases by[CONTACT_473]. For AEs of abdominal pain orsuspected pancreatitis, 
amylase and lipase laboratory samples should be monitored locally .  Subjects should be 
closely  monitored when re -starting dabrafenib after an epi[INVESTIGATOR_28547].
Hypersensitivity :Hypersensitivity with dabrafenib has been reported by1 subject who
experienced blister formation (bullous rash) within hours (hrs) of exposure to dabrafenib and 
upon re-challenge, requiring discontinuation of dabrafenib.  The subject recovered after 
interruption/discontinuation of dabrafenib. Hypersensitivity to trametinib has been reported 
by1 subject 7 days after starting trametinib who experienced fever, asthenia, visual 
disturbance, and symptoms suggestive of a hypersensitivity reaction de scribed by[CONTACT_54117] “vascularity .” This subject also developed liver function test (LFT) elevations, 
lower limb nodules that by[CONTACT_373204] y showed “dermo -hypodermatitis with plasmocy te and 
lymphocy te infiltrate.”  The subject recovered after discontinuation of trametinib.
Renal impairment: No dosage adjustment of dabrafenib or trametinib is required insubjects 
with mild or moderate renal impairment. Mild or moderate renal impairment had no 
significant effect on the population PK of dabrafenib or trametinib. There are no clinical data 
[COMPANY_001] Confidential Page 45
Amended Protocol Version 11            Protocol No. CDRB436X2201
with dabrafenib or trametinib in subjects with severe renal impairment andthe potential need 
for starting dose adjustment cannot be determined.  Dabrafenib and trametinib should be used 
with caution in subjects with severe renal impairment.
Hepatic impairment: No dose adjustment is required for subjects with mild hepatic
impairment. Based on the population PK analysis, mild hepatic impairment had no
significant effect on dabrafenib or trametinib oral clearance and thus exposure was not
significantl ydifferent in subjects with mild hepatic impairment compared to subjects with 
normal hepatic function.  There are no clinical data in subjects with moderate or severe 
hepatic impairment; therefore, the potential need for starting dose adjustment cannot be 
determined.  Dabrafenib and trametinib should be used with caution in subjects with 
moderate or severe hepatic impairment.
Use during Pregnancy and Lactation
Fertility: There is no information on the effect of dabrafenib or trametinib on human fertility .  
Animal studies with dabrafenib monotherap yor in combination with trametinib have shown 
reproductive toxicity which may impair fertility in humans. In dogs, rats and mice given 
dabrafenib and in dogs given dabrafenib in combination with trametinib, male reproductive 
effects, including testicular degeneration/depletion with secondary epi[INVESTIGATOR_681719], 
have occurred without clear evidence of reversibility .Male subjects should be informed of 
the potential risk for impaired spermatogenesis, which may be irreversible. Trametinib may
impair fertility in humans.
Pregnancy: No adequate and well -controlled studies of dabrafenib or trametinib inpregnant 
women have been conducted. Animal studies with trametinib and dabrafenib have shown 
embry ofetal developmental toxicities, including teratogenic effects. Dabrafenib or trametinib 
should not be administered to pregnant women or nursing mothers.  Women of childbearing 
potential should use effective methods of contraception during therapy  and for 16 weeks
following discontinuation of trametinib when taken in combination with dabrafenib, or for 2
weeks following discontinuation of dabrafenib monotherap y. Dabrafenib may decrease the 
efficacy of oral hormonal contraceptives; therefore, an alternative method of contraception 
must be used. (see Section 9.1.1 . for acceptable methods of contraception.)  If dabrafenib or 
trametinib is used during pregnancy , or if the subject becomes pregnant while taking
dabrafenib or trametinib, the subject should be informed of the potential hazard to the fetus.
Lactation: It is not known whether dabrafenib or trametinib is excreted in human milk.
Because manymedicinal produc ts are excreted in human milk, a risk to the nursing infant
cannot be excluded. A decision should be made whether to discontinue nursing or to 
discontinue dabrafenib and/or trametinib, taking into account the importance of study
treatment to the mother.
1.4.1 Benefit A ssessment
This is not the initial clinical experience with dabrafenib in combination with trametinib, 
therefore, the riskbenefit ratio has been established and should be favorable if the anticipated
level of efficacy is demonstrated.
Other consid
erations for subjects who participate in this study may include:
Contribution to the ongoing process of developi[INVESTIGATOR_007] a new treatment
Medical evaluations/assessments associated with study procedures (e.g., phy sical
examinations, electrocardiograms [ECGs], cli nical laboratory tests, etc.)
[COMPANY_001] Confidential Page 46
Amended Protocol Version 11            Protocol No. CDRB436X2201
1.4.2 Overall Benefit: Risk Conclusion
Taking into account the measures to be taken to minimize the risk to subjects participating in 
this study , the potential risks identified in association with dabrafenib + trametinib 
combination therap y are justified by[CONTACT_681839].
1.5 Histology- Specific Background
1.5.1 Cohort 1: Anaplastic Thyroid Cancer (ATC)
The American Cancer Society (ACS) estimates approximately 56,460 new cases ofthyroid 
cancer in the US alone for 2012 [ ACS , 2012].  Only 0.5% to 1.7% of all thyroid cancers are 
diagnosed as ATC [ Papay , 2009; Pi[INVESTIGATOR_32887], 2010]. While differentiated thyroid cancers are 
typi[INVESTIGATOR_1306] y curable, ATC is one of the most aggressive and fatal forms of thyroid cancer 
[Caronia , 2011]. Patients with ATC have the worst survival; a 1-year survival rate of 
approximately 10% [Goutsouliak , 2005].  Anaplastic thyroid carcinoma (ATC) is more 
commonly seen in females than males and is ty pi[INVESTIGATOR_681720]  (median age: 
70years) [Papay , 2009; Pi[INVESTIGATOR_32887], 2010].
Patients with ATC typi[INVESTIGATOR_31889] a rapi[INVESTIGATOR_681721], hoarseness, coughing, dysphagia, dyspnea, and neck pain. Airway
and esophageal compromise is a major concern; therefore, obtaining local control of the 
disease in the neck is critical and essential to the quality of life of the patient in order to 
prevent asphy xiation and maintain oral nutrition with the hope of improving overall survival 
[Haigh , 2001; Papay , 2009; Pi[INVESTIGATOR_32887], 2010].  Methods utilized to improve local control in ATC 
include surgery and/or radiation therap y(e.g., radioactive iodine). The median survival from 
these methods is <6 months.
Surgery is limited as ATC tumors are rarely resectable at time of diagnosis due to ill-defined 
borders and/or attachment to surrounding vital structures in the neck [Haigh , 2001].  If the 
disease is confined to a local area, a total thyroidectomy iswarranted to reduce symptoms 
due to the tumor mass; a tracheostom y is frequently required [GlaxoSmithKline Document 
Number HM2009/[ZIP_CODE]/05; Goldman
, 1980]. There is some evidence suggesting that 
surgery followed by[CONTACT_447]-operative radiation therapy  and chemotherapy  results in improved 
outcome than radiotherapy alone [Haigh , 2001].
Patients who are not candidates for surgery or whose tumor cannot be surgically excised may
receive external beam radiation therap y.  However, treating ATC with high dose radiation is 
limited by [CONTACT_681840][INVESTIGATOR_681722].  Combining radiation therap ywith chemotherap y has been shown to prolong survival 
in patients who have also completed surgical resection [Posner , 2000].
Single -agent doxorubicin is typi[INVESTIGATOR_681723] 
“standard” chemotherap y agent for
treating ATC in advanced disease with a reported response rate of approximately 22%
[Nagaiah , 2011]. Itappears that the combination of doxorubicin plus cisplatin is more active 
than doxorubicin alone and has been reported to result in a greater number of responses (3
complete responses [CRs] and 3 partial responses [PRs]) being reported [Shimaoka , 1985].
Ain et al reported a 53% response rate ( using a non -conventional definition of response rate) 
with one CR and nine PRs reported in 19 evaluable subjects treated with a 96 -hr continuous 
infusion of paclitaxel [Ain, 2000]. However, the response rate did not translate to 
prolongation of median survival which was only 25weeks.  Chemotherapy combined with 
radiation therap yin patients following complete resection has been evaluated and may
[COMPANY_001] Confidential Page 47
Amended Protocol Version 11            Protocol No. CDRB436X2201
provide prolonged survival [Haigh , 2001; DeCrevoisier , 2004].  None of the approaches to 
date provide sustainable duration of response.
Molecular signaling mechanisms such as activation of the RTK -RAS -RAF -MAPK pathway , 
p53 mutation, epi[INVESTIGATOR_19074] r (EGFR) expression andvascular epi[INVESTIGATOR_66535] (VEGF) secretion, are thought to be significant factors in the progression of 
ATC [ Kojic , 2011]. Mutations of the RAS oncogene and p53, a well- known tumor -
suppressor gene, are frequently seen in molecular studies of ATC [Papay , 2009; Pi[INVESTIGATOR_32887], 2010].  
Recently alternations in the BRAF oncogene have been seen andmay be involved in the 
progression of BRAF -mutated papi[INVESTIGATOR_6686] (PTC) to ATC.  Specifically , BRAF 
V600E mutation has been found in both PTC and papi[INVESTIGATOR_1396] -derived ATC in which it initiates 
follicular cell transformation [ Caronia , 2011; Kojic , 2011].  The average frequency of BRAF 
mutations in ATC is 24% and tends to have more aggressive phenoty pes that often become 
resistant to traditional therapi[INVESTIGATOR_014]. BRAF mutations may lead to changes in the sodium -iodide 
symporter limi
ting adjunct radioactive iodine treatment by [CONTACT_681841] [ Kojic , 
2011].
Pre-clinical studies in human ATC cell lines have shown the importance of therapeutic agents 
that selectively  target BRAF kinase, significantly inhibiting tumor growth [Caronia , 2011; 
Kojic , 2011].  Vemurafenib, a BRAFi, has shown decreased cell proliferation and 
aggressiveness and markedly  inhibit tumor growth in animal models using human ATC cell 
lines [Nucera , 2011].  Rosove et al reported a significant response to vemurafenib in a patient 
with BRAF -mutated ATC with radiological assessment confirming nearl ycomplete clearing 
of metastatic disease after 38 days [Rosove 2013]. Trametinib in combination with 
dabrafenib is more active than dabrafenib and trametinib alone in BRAF V600E thyroid 
cancer lines.  The combination was syne
rgistic and/or enhanced cell growth inhibition in 
three out of four, and induced apoptosis in [ADDRESS_923154] that thecombination of dabrafenib (BRAFi) with trametinib (MEKi) 
could be more effective than either MEKi or BRAFi alone forthyroid cancer therapy .
1.5.2 Cohort 2: Biliary Tract Cancer (BTC)
Biliary tract cancers (BTC) include a spectrum of invasive adenocarcinomas encompassing 
both cholangiocarcinoma, which refers to cancers arising in the intrahepatic, peri-hilar, or 
distal biliary tree, and gall bladder carcinoma.  Gallbladder carcinoma is an uncommon 
cancer in developed Western countries, afflicts approximately 12,000 people in the US 
annually , with a recentl yappreciated increasing incidence of intrahepatic 
cholangiocarcinoma [Hezel, 2010]. Cholangiocarcinoma is anadenocarcinoma of the bile 
duct with a poor prognosi s given the invasiveness of the disease and its resistance to 
conventional chemotherapy . About 
5 to 10% of all primary liver cancers are 
cholangiocarcinoma. Only  10% of patients present with early -stage disease and are 
considered candidates for surgical resection, which offers the only chance for cure. The 
prognosis is poor for the majority  of patients with locally  advanced or metastatic BTC, with 
a median survival of <1year.No standard post -operative treatment has been established.
Gemcitabine with or without cisplatin is being studied for treatment in the adjuvant setting 
for gallbladder carcinoma, intra-hepatic and extra -hepatic bile duct.  Results of a study by
[CONTACT_681842] a significant survival advantage 
over gemcitabine alone. The median overall survival (OS) is 11.7 months with gemcitabine 
plus cisplatin vs. 8.1 months with gemcitabine monotherap y [Valle , 2010].
[COMPANY_001] Confidential Page [ADDRESS_923155] study of mutationa l status of BRAF in liver tumors where 
the frequency of mutations of BRAF and KRAS oncogenes in hepatocellular carcinoma 
(HCC) and cholangiocarcinoma was evaluated [Tannapfel , 2003]. No BRAF mutations were 
detected in HCC; however, specific BRAF mutations were noted in approximately 21% of 
the cholangiocarcinoma cases. Saetta et 
al reported in the second year that the BRAF 
mutations were observed in 7 of 21 (33%) gallbladder carcinomas examined [ Saetta , 2004].  
Inthe Tannapfel et al study , mutations of KRAS (45% ofcases) together with BRAF 
mutations (22%), the RAS/RAF/MEK/ERK/MAPK pathway had a high frequency of 
alteration in cholangiocarcinoma.  The results of such studies support the significance of the 
role disruption of the MAPK cascade may have in the development of gallbladder cancer.  
The alterations in the RAS/RAF/MEK/ERK/MAPK pathway may also play a significant role 
in new treatment strategies for BTC and su pport the use of BRAFi and/or MEKi.
1.5.3 Cohort 3: Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal stromal tumors (GISTs) are the most common mesenchy mal tumors inthe 
gastrointestinal (GI) tract, mainly  within the stomach and small intestine. Most GISTcells 
are positive for c
-kit.  Malignant GISTcells are expected to harbor a mutation of c-kit that 
results in the activation of c -kit leading to cell division and tumor growth. Tyrosine receptor 
inhibitors (TKI s) such as imatinib selectively inhibit c-kit andtherefore, are indicated for the 
treatment of GIST.  Tyrosine kinase inhibitors (TKI s),imatinib and sunitinib, are currently 
the standard of care in treating metastatic orunresectable GIST. Imatinib is approved for 
first-line therap y of metastatic GISTwith disease control achieved in approximately 85% of 
treated patients; median progression -free survival (PFS) is 20 to 24 months [ Italiano ,2011].  
Sunitinib is the only approved drug for imatinib -resistant GIST.  Clinical benefit was reported 
in approximately 50% of the patients treated, with a PFS of 7 to 10 months [ Demetri , 2006].  
Mutational status ofKIT and platelet -derived growth factor receptor alpha (PDGFRA) and 
albumin levels have been significantl y associated with PFS [Italiano, 2011]. Low levels of 
albumin may be indicative of the nutritional 
status but also the presence of a systemic 
inflammatory response.
Following treatment with imatini b and/or sunitinib, patients with advanced GISToften
develop drug-resistant tumors which drive the need for alternative treatment. Imatinib -
resistance is observed in 10 to 15% of patients following initial treatment with secondary 
resistance observed in almost all patients who initially have a clinical response from imatinib 
[Italiano ,2011].  Data has suggested that the resistance to imatinib in GISTs may be due to 
the activation of the MAPK pathway andmay explain why some patients with GISTwho are 
treated with imatinib fail to respond to treatment despi[INVESTIGATOR_681724]
-sensitive mutations 
[Miranda , 2012].   While most of the GISTscarry mutations in KIT (80%) or the PDGFRA 
gene (8%), 3 to13% of adult GIST cases have a wild-type genot ype [Hostein , 2010; Agaram , 
2008; Caram , 2011].  The MAPK pathway (RAS/RAF/MEK/ERK) is one that is activated 
by[CONTACT_681843]. The BRAF protein when activated transmits signaling through the
MAPK pathway as well but only further downstream without the stimulation of KIT or 
PDGFRA.  BRAF mutations have been detected in a limited number of patients with 
imatinib -naïve or –resistant GISTs, occurring preferentially  in small intestinal and gastric
high risk GI STs that lack the KIT and PDGFRA mutations [ Agaram , 2008; Hostein
,2010].  
Drugs that inhibit KIT and PDGFRA would be ineffective in treating GISTs with BRAF 
mutations.  Patients with wild-type GIST have poor responses to TKIs and poor overall 
survival [ Heinrich, 2008].  Therefore, these patients c ould benefit from having select BRAF 
inhibitors as an alternative treatment to imatinib and other ty rosine kinase inhibitors.
[COMPANY_001] Confidential Page 49
Amended Protocol Version 11            Protocol No. CDRB436X2201
1.5.4 Cohort 4: WHO Grade 1 and 2 Glioma
According to the ACS, there were an estimated 22,910 new cases of malignant brain and 
other cen tral nervous s ystem (CNS) tumors in 2012, leading to over 13,700 deaths in the US 
alone [ACS , 2012].  Worldwide the number of new cases of brain and other CNS tumors 
diagnosed in 2008 was approximately 238,000 with an estima ted 175,000 deaths [Ferlay , 
2011].  Gliomas account for 32% of all the primary brain tumors and arehistorically
classified b y the World Health Organization (WHO) as either Grade [ADDRESS_923156] common pediatric brain tumor, pi[INVESTIGATOR_681725], occurs in 20% of brain
tumors in patients under 20 years of age and is classified as a WHO Grade 1 glioma [Sadighi , 
2013]. While the 10-year OS rate is high at 96%, recurrent and progressive disease occurs 
in 20% of patients [ Sadighi , 2013].  Inthese patients, total resection remains the treatment of 
choice. For inoperable tumors, radiotherap y or chemotherap yisthe first line treatment 
[Sadighi , 2013]. Recent findings have indicated that certain types of low grade and pediatric 
brain tumors, such as pi[INVESTIGATOR_681726], may have a higher rate of BRAF alterations 
[Schindler , 2011]. BRAF V600E mutations are also found in WHO Grade 1 gliomas 
including 18% of WHO Grade 1 gangliogliomas and 9% of pi[INVESTIGATOR_681726] (especiall y
extra -cerebellar pi[INVESTIGATOR_681726]) [Dias-Santagata ,2011; Schindler , 2011].  Such 
aberrations are known to activate the MAPK pathway which provides the platform by [CONTACT_681844]. Agents such as MEKi can serve as novel 
treatment options for patients with progressive pi[INVESTIGATOR_681727].
Currently there are Phase II studies with MEKi such as selumetinib underway .Preliminary
results have indicated a favorable pharmacologic profile.  However, drug-resistance when 
administered as a single agent has been seen in some tumor models [Sadighi , 2013].  One 
explanation for this resistance may be due to the activation of an alternative pathway such as 
MEK
-1 mutations.  Therefore, it may be more effective to offer a combination therapy than 
single agent to decrease the potential for resistance.
WHO Grade 2 tumors such as diffuse astrocy toma, oligodendroglioma andoligoastrocy toma 
are usuall y non- enhancing (>90%) and typi[INVESTIGATOR_1306] y affect patients in their third and fourth 
decade of life. Although WHO Grade [ADDRESS_923157] 
been identified in 
approximately 60% of WHO Grade 2pleomorphic xanthoastrocy toma (PXA), (a similar 
mutation rate as seen in melanoma).
For adult WHO Grade [ADDRESS_923158] treatment option.  For patients with unfavorable progno stic
factors such as older age, incomplete or no resection and existing neurological symptoms,
adjuvant radiotherap y is indicated. Chemotherapy  is an option for patients with recurrence 
after surgery and radiation therapy and is also an option as initial t reatment for patients with 
large residual tumors after surgery or unresectable tumors, especiall ywhen 1p/19q loss is 
present.  Treatment with procarbazine, lomustine and vincristine (PCV) or temozolomide 
(TMZ) yield similar response rate and duration of response with a toxicity profile favoring 
TMZ.  The prognosis of patients who have recurrent or progressive disease following 
radiotherap y and chemotherap yis usually poor.
The Response Assessment for Neuro -Oncology (RANO) Working Group proposed a
response criteria for non-enhancing low grade tumors to be adapted in clinical trials when
response rate or PFS is used as the primar yendpoint. Inaddition to CR and PRcategories in 
[COMPANY_001] Confidential Page 50
Amended Protocol Version 11            Protocol No. CDRB436X2201
WHO Grade 3 or 4 glioma Modified RANO response criteria, minor response (MR) is 
proposed as an additional response category of the WHO Grade [ADDRESS_923159] achievable response category
[van den Bent , 2011].
Several preclinical studies have been performed to evaluate the brain penetration of 
dabrafenib.  A single dose brain study in mice and a positron emission tomograph y(PET)
study in pi[INVESTIGATOR_681728].  There is additional data after 
repeat dosing in mice that may suggest that the metabolite, M8, could possibly  penetrate an 
intact blood -brain barrier (BBB).  In the clinic, activity has been reported insubjects with 
brain metastases but the penetration is thought to be related to non-intact BBB or limited 
contribution with M8.
With trametinib, following a single oral dose of [14C] [COMPANY_004]1120212 (trametinib) at 8mg/m2, 
tissue distribution of radioactivity was wides pread and consistent with the high permeability
and moderate to high distribution of trametinib, detectable levels of drug- related material 
were observed in brain tissue [ADDRESS_923160] -dose but declined rapi[INVESTIGATOR_681729] (BLQ) by24 hrs post -dose.
In vivo anti-tumor activity of trametinib has been assessed in mice with doses as low as1 
mg/kg reaching blood concentrations that caused sustained reductions of pERK, an 
accumulation of p27, and a decrease of Ki67 in tumor xenografts; brain exposure levels were 
~10% of those in blood, and no significant pERK inhibition was measured in brain tissue.
1.5.5 Cohort 5: WHO Grade 3 and 4 Glioma
Gliomas classified by[CONTACT_681845] 3 or 4 are often referred to as high-grade.
Theincidence of adult high grade gliomas is 2 to 4 per 100,000 patients [ Perry , 2004]. WHO 
Grade 3 or 4 gliomas are locally invasive and associated with a poor prognosis and include 
Grade 3 anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed 
anaplastic oligoastrocy toma (MAO), anaplastic pleomorphic xanthroastrocy tomas (APXA) 
and Grade 4 glioblastoma (GBM) and accounts forapproximately 60 to 75% of all gliomas 
[Hadzia hmetovic , 2011].  Metastasis outside of the CNS has been reported but is extremely
infrequent until multiple local relapses have occurred. Biologic markers, such as O6-
methy lguanine -deox yribonucleic acid (DNA) -methy ltransferase (MGMT) and mutation 
status, may be useful predictors of outcome inpatients with WHO Grade [ADDRESS_923161] BRAF V600E mutations [ Dias
-Santagata , 2011; Schindler , 2011].  pERK was detected 
in all tumors independent of the BRAF mutation status [ Dias-Santagata , 2011].
Historically , thegold standar d for treating WHO Grade 3 or 4 gliomas has been surgery
followed by[CONTACT_681846] 5 -year OS of 2 to 3 % [Hadziahmetovic , 
2011].  Demonstrating efficacy with the addition of chemotherapy tothe treatment standard 
has been more difficult. The treatment of WHO Grade 3 or 4 gliomas with carmustine or a 
combination regimen of PCV has recentl yshifted to the addition of concurrent or adjuvant 
TMZ with radiation.  Until recentl ythe treatment of all WH O Grade 3 or 4 gliomas has been 
much the same; however, ongoing clinical trials are segmenting the Grade 4 gliomas so the 
treatment modalities can focus on AA, AO and anaplastic MOA tumors [Hadziahmetovic , 
2011].  The Europe an Organization forResearch and Treatment of Cancer (EORTC) 
conducted a randomized trial in AA, AO and anaplastic MOA tumors in adjuvant 
[COMPANY_001] Confidential Page 51
Amended Protocol Version 11            Protocol No. CDRB436X2201
radiotherap y with or without PCV chemotherapy.  The addition of PCV improved the PFS 
(1.9 vs. 1.1 years) but not OS(3.4 vs. 2.6 years) [Hadziahmetovic , 2011].  Seeking a more 
favorable regimen, studies with TMZ have reported objective response rates of 58% with 32%
 
CRs, rate of progression of only 10% with TMZ administered prior to radiati on.
Considerable interest in determining the frequency  and distribution of BRAF V600E 
mutations in central and peripheral nervous system tumors has been generated recently to
help identify the tumor entities that may potentially benefit from BRAF V600E targeted 
therap y.In study BRF113929, which was to evaluate the safety  and efficacy  ofdabrafenib 
in subjects with BRAF V600E/K mutation -positive melanoma metastatic tothe brain, 
response rates of 31% and 39% were observed in [ADDRESS_923162] activity in 
brain tumors.
1.5.6 Cohort 6: Non-Seminomatous/Non -Germinomatous Germ Cell
Tumors (NSGCT/NGGCT)
The worldwide incidence of germ cell tumors (GCT) has more than doubled in the past 40
years.  Germ cell tumors (GCTs) are relativel y uncommon and account for only 2% ofall 
human malignancies.  Non-seminomatous germ cell tumors (NSGCT) are malignant
extragonadal germ cell tumors that generall y form in the pi[INVESTIGATOR_681730], the
mediastinum or the abdomen from cells meant to form sperm in the testicles or eggs in the 
ovaries and account for 48% of all 
GCTs.  These tumors are managed in the same way as 
testicular GCTs. In the US, approximately  8,590 new cases of testicular cancer will be 
diagnosed in 2012 [ Siegel , 2012].  Testicular cancer is the most common solid tumor in males 
between the ages of 15 and 35years with 95% of the testicular cancers being testicular GCTs 
(evenl y
reported as seminoma and non- seminoma) [ Le Gal , 2005; Mannuel , 2011].
Non-seminomatous 
GCTs (NSGCTs) tend to be more clinicall y aggressive and grow quicker 
than the seminoma -type of GCT.  If untreated, NSGCTs can spread to the lungs, liver, lymph 
nodes, or bones. Common risk factors include being male, under the age of 20 and having 
Klinefelter s yndrome [ Nichols, 1987].  Chest pain and difficulty breathing are early  signs of 
NSGCT. Other symptoms include: cough, fever, headache, and change in bowel habits, 
fatigue, difficulty walking and visual problems (difficulty seeing ormoving eyes).  Testicular 
GCTs present with a painless, solid testicular mass and often discomfort or swelling; 
persistent conditions warrant further evaluation.
Serum tumor markers alpha -fetoprotein (AFP), lactate dehydrogenase (LDH) and beta-
human chorionic gonadotropin (β
-HCG) are used in determining the diagnosis andprognosis 
as well asassessing treatment in GCTs. These tumor markers are especiall yuseful in 
monitoring NSGCT at all stages. Tumor markers AFP and β-HCG are more specific than 
LDH; AFP may be seen atanystage of disease.  An elevation in AFP generally  indicates the 
presence of an undetected focus of non-seminoma [Nazeer , 1998; Weissbach , 1997]. An 
elevated β-HCG should be interpreted with caution if the use ofmarijuana is suspected or 
the development of hypogonadism as benign elevation in   β-HCG may result.
In 1997, the International Germ Cell Cancer Consensus Group (IGCCCG) developed a
classification system based upon prognostic factors such as extent of disease and serum tumor 
markers. Post-orchiectomy markers are used to determine theIGCCCG risk classification 
[IGCCCG , 1997].  This classification categorizes patients into risk groups designated as good, 
intermediate or poor.
[COMPANY_001] Confidential Page [ADDRESS_923163] patients with persistent elevation of serum tumor markers are
typi[INVESTIGATOR_1306] y treated with a cisplatin -based chemotherap y regimen consisting of 4 cycles of 
bleomy cin, etoposide and cisplatin (BEP) considered the standard first-line therap y
[Williams, 1987; Hinton , 2003]. Although the tumor volume tends to be very large, initial 
debulking surgery is rarely considered useful.  Long-term disease -free survival may be 
achieved following post-chemotherap y surgery to resect residual disease following initial 
chemotherap y treatment [Schneider , 2004]. Patients with NSGCT who relapse following 
first-line chemotherap ygenerall yhave poor responses to salvage chemotherap y or bone 
marrow (BM) transplantation and are therefore candidates for new therapi[INVESTIGATOR_014] [ Saxman, 1994; 
Beyer, 1996]. Gemcitabine containing palliative chemotherap yprovides 30 to 40% ORR 
with median survival only betw een 5 to 9 months [ Bokemey er, 2008; 
Einhorn , 2007].
The median OS is [ADDRESS_923164] supportive care
[Kollmannsberger , 2004; Einhorn, 2007].  The cure rate for intermediate risk (Stage IIIB)
NSGCT is approximately 70% following 4 cycles of BEP [ DeWit , 1998; Frohlich, 1998]. In 
the poor risk (Stage IIIC) patients, between 20 and 30% of all patients with metastatic
NSGCT remain not cured following cisplatin -based chemotherap y.Less than 50% of
patients experience a durable CR to BEP, leaving them with limited treatment options other 
than i nvestigational therapy [Jones, 2003].
Of the patients with NSGCT who develop refractory disease, the BRAF 
V600E mutation is 
detected in 2 to 3% [Mayer , 2010; Honecker , 2009].  The BRAF V600E mutation isnot 
detected in seminomatous GCT. The tumors with the positive mutation tend to be
extragonadal, especiall ywith an origin in the mediastinum.  Furthermore, the BRAF V600E 
mutation has only  been reported in adult NSGCT patients, excluding pediatric or adolescent 
patients 
[Masque -Soler , 2012].  As seen in melanoma, those patients with NSGCT and the 
BRAF positive -mutation show a trend to longer PFS.
1.5.7 Cohort 7: Adenocarcinoma of the Sm all Intestine (ASI)including
Periampullary and Ampullary
Adenocarcinoma of the small intestine (ASI) is a rare cancer; less than 2.3% of GIcancers 
arise in the small intestine. According to the ACS, 6230 new cases and 1110 deaths due to 
small intestine cancers were estimated in 2009 in the US. Adenocarcinoma of the small 
intestine (ASI) has historically been the most commonly diagnosed histologic subtype of 
small bowel tumors, but has recently been surpassed by[CONTACT_681847] (NCDB). There areapproximately 2000 to 3000 new patients 
peryear in the US [Bilimoria , 2009; Jemal ,2009]. Adenocarcinoma of the small intestine 
(ASI) typi[INVESTIGATOR_1306] y includes those arising from the ampulla of Vater and the periampullary region; 
however, these were not included inthe NCDB in the categor y of small bowel tumors.
Tumors of amulla of Vater include tumors arising in the ampulla (intra -ampullary type), 
tumors arising in the periampullary region of the duodenum (periampullary type), or tumors 
involving both the intra-ampullary and periampullary region of the duodenum (mixed 
periampullary  and intra-ampullary type).  The rare nature of ASI has led to a poor 
understanding of disease pathogenesis, delay in diagnosis, and a paucity of information 
regarding treatment. Thirty -two percent of patients with ASIpresent with advanced disease 
[Overman , 2012]. The treatment of choice for ASIis curative surgical resection. However, 
no standard protocol has been defined for use when the disease is unresectable or relapsed.
The majority of chemotherap y
experience has been with 5-fluororuacil, alone or in
combination with some of the newer chemother
apeutic agents such as irinotecan, platinum 
[COMPANY_001] Confidential Page [ADDRESS_923165] ranged from 
6% and 41%.  The median OS was between 9 to 18.6 months [Speranzaa ,2010]. Mutations 
of BRAF V600E were detected in 4 out of 37 subjects with ASIby[CONTACT_681848] [Warth , 2011] 
and in one periampullary adenocarcinoma by[CONTACT_681849] [ Schonleben
, 2009].
1.5.8 Cohort 8: Hairy Cell Leukemia (HCL)
Hairy cell leukemia (HCL) is a rare B-celllymphoproliferative disease accounting for2 to 
3% of all leukemias in adults in Western world [Riccioni , 2007]. The incidence inthe US 
was 0.33 per 100,000 in 2011 [ Morton , 2006]. Virtually all patients with HCL carry  the 
BRAF V600E mutation, the HCL variant, which t ypi[INVESTIGATOR_681731], and absence of CD25, TRAP or Annexin A1,isuniformly wild-type for BRAF 
[Xi, 2012; Tiacci , 2011; Matutes , 2003]. Sequencing the gene in 47 HCL patients disclosed 
BRAF V600E mutations in nearly all patients.  pERKwas also found in BM biopsies from 
these patients indicating that the BRAF mutation was activating. Incubation of primary hairy
cells with a BRAFi led to reversal of ERK and MEK phosphory lation [Tiacci , 2011].  
Recently , Dietrich et al reported that a refractory HCL  patient had been successfull y treated 
with a BRAFi validating that BRAF mutation is an appropriate therapeutic target in HCL
[Dietrich, 2012].
Patients are categorized as having untreated HCL or progressive HCL for the purpose of 
determining treatment. Treatment is based on symptomatic cytopenias, massive
splenomegaly or the presence of other complications.  Ten percent of 
all patients will not
require anytreatment [Saven , 2001].  Untreated HCL is characterized by[CONTACT_5342] y,
leukopenia and/or pancytopenia, and BM infiltration by[CONTACT_317022][INVESTIGATOR_681732] (i.e., hairy cells). Bone marrow (BM) biopsy  is required for
diagnosis and to determine the degree of hairy cell infiltration. Asymptomatic disease is
often not treated if blood counts remain in an acceptable range [ Grever , 2011]. Replacement 
of the BM b yhairy cells with pancy topenia refractory to treatment characterizes progressive 
HCL.  The treatment of choice for patients with advanced HCL is cladribine (2-
chlorodeox yadenosine, 2
-Cda) or pentostatin (2-deoxy coform ycin); both with comparable 
response rates [Gidron, 2006; Grever , 2011]. The survival rate with systemic therap yis 
estimated to be >85% at 5 yearsfollowing the initiation of systemic therapy [Estey , 1992;
Frassoldati , 1994].
Consolidation or maintenance therap y with additional purine analog in preventing relapse or 
disease progression following purine analog treatment has not been formally  evaluated, but 
the clinical impression is that repeated courses of purine analog have increasing cumulative 
toxicity with decreasing benefit, and should not be added unless patients require retreatment 
due to cytopenias. Moreover, cytopenias due to disease requiring retreatment must be 
differe ntiated from cytopenias due to toxicity , and it is very rare for retreatment within [ADDRESS_923166] relapsed disease
by16years [Else, 2009].  There is no plateau on the disease -free survival curves to suggest 
that purine analogs can cure HCL [Goodman, 2003; Else, 2009].  At a median of 16 years 
after treatment, the Scripps population of 358 subjects contained 19 who were still being 
followed in continuous complete remission, nine of whom were still without evidence of 
minimal residual disease (MRD) [Sigal ,2010].  Thus, it is not clear if purine analogs have 
curat ivepotential, but clearl ythey fail in most patients who live long enough. Multiple 
immune defects present in HCL appear to have a role in the development of second cancers.
Skin cancers were found to be the most numerous before the availability of nucleoside 
[COMPANY_001] Confidential Page 54
Amended Protocol Version 11            Protocol No. CDRB436X2201
analogs for the treatment of HCL [ Dasanu , 2010].  Treatment with either nucleoside analogs 
canresult in profound CD4 suppression that may last up to 4 years [Seymour , 1994; Seymour , 
1997], and this may increase the risk of secondary malignancies [Goodman, 2003; Hisada
2007]. A study of HCL survivors from the Surveillance Epi[INVESTIGATOR_70299] 
(SEER) database confirmed the increased risk of second cancers, especially
for Hodgkin 
lymphoma and non-Hodgkin’s lymphoma (NHL), among those treated with cladribine but 
not with pentostatin [Morton , 2006; Hisada , 2007; Dasanu ,2010]. Forthose patients who 
experience severe thrombocy topenia, splenectomy may be considered, particularl y if all 
other options have failed. However, while splenectom yderiv es a
palliative, usuall y
temporary benefit in blood counts, few patients have sustained remissions [Golomb , 1983], 
and disease may continue to worsen in the blood, lymph nodes, BM and visceral sites.
Virtually all patients progress and the median OS in large retrospective studies were less than 
6years [Jansen , 1981; Chrobak , 1993; Haberman ,2006; Haberman ,2011]. Interferon
-alpha 
is largel ya drug of historical significance [Haberman , 2006; Haberman , 2011]. Infact, the 
response rate was 0% in subjects notresponding to pentostatin who crossed over to interferon 
[Grever , 1995].
Patients who relapse after the first course of cladribine or pentostatin treatment often respond, 
but with less chance of CR, to repeated treatment with purine analog, with no 
benefit if a 
different purine analog is used [Saven , 1998; Else, 2009]. Rituximab, although not approved 
for HCL by[CONTACT_681850] (FDA), remains a common treatment but 
most patients, particularly those with prior purine analog treatment and significant disease 
burden, do not respond and need alternative treatment. In a
 study of 24 subjects with prior 
therap y with purine analogs and need for retreatment due to cytopenias, the overall response 
rate (ORR) of rituximab was only 26% with only 13% CRs [Nieva , 2003].  Rituximab with 
cladribine or pentostatin may bean alternative, but the increased efficacy of this combination 
must be weighed again st its toxicity , and it is not considered standard at this time [Else, 2007; 
Else, 2009; Ravandi ,2006]. Inclinical practice, pentostatin is usually not consi dered for 
patients alread yresistant to cladribine, and vice versa. Thus, there is an unmet medical need 
for a non-chemotherap y option in HCL resistant to purine analogs.
1.5.9 Cohort 9: Multiple Myeloma (MM)
Multiple myeloma (MM) is a systemic malignancy of plasma cells in the BM that secretes 
all or part of a monoclonal antibody . Itis the second most common hematologic malignancy , 
accounting for 10% of all hematologic cancers and 2% of annual cancer - related deaths 
[Anderson , 2011].  The incidence of multiple myeloma in the US in 2008 was 5.579 per 
100,000 
[Ferlay , 2011]  According to the ACS, it was expected that almost 21,700 new cases 
of MM and 10,700 MM related deaths would occur during 2012 [ ACS , 2012].
Chapman et al and Walker et al genot yped MM patients and detected the BRAF V600E
mutation in 2.4% and 4%, respectivel y [Chapman, 2011b; Walker , 2012]. The finding of
BRAF mutations in patients with MM has important clinical implications because such 
patients may benefit from treatment with a BRAFi. These results also support the observation 
that inhibitors acting downstream of BRAF (i.e., MEK) mayhave activity inMM [Kim, 
2010].
Multiple myeloma (MM) is further classified on the basis of the patient’s characteristics.
Patients who areyounger than 65 years of age and without other severe co-morbidities are 
considered eligible for allogenic stem cell transplantation ( alloSCT). Patients older than [ADDRESS_923167] candidates and a gentler 
[COMPANY_001] Confidential Page 55
Amended Protocol Version 11            Protocol No. CDRB436X2201
approach is needed.  Although MM is not curable, it is treatable.  Th emedian survival with 
chemotherap y is 24 to 30 months with a 10 -year survival rate of 3%.  With newer therapi[INVESTIGATOR_681733] (IMiD: thalidomide, lenalidomide), proteosome inhibitor 
(bortezomib) and stem cell transplantation, themedian OS hasbeen prolonged 7 to8years 
[Kumar , 2008; Anderson ,2011].
In the bortezomib registration study of over [ADDRESS_923168] one systemic therap ynot 
containing bortezomib was 38% [Richardson, 2005]. The PFS for the bortezomib arm in this 
study was 6.2 months (median follow -up of 8.3 months). A subset analy sisshowed that the 
ORR and survival was higher for the less heavil ypre-
treated subjects. Amongst the IMids, 
both thalidomide and lenalidomide have been extensively  investigated in the 
induction/consolidation/maintenance settings and both agents have been approved by[CONTACT_681851].
Despi[INVESTIGATOR_681734], MM 
continues to remain incurable.  In particular, patients resistant to novel agents represent a 
challenging group. Kumar et al. conducted an analysis in subjec ts who relapsed or were 
refractory to one of the IMiDs as well as bortezomib that determined the median event -free 
survival to be 5 months and the median OS was 8 months [Kumar , 2010]. Therefore, these 
patients require novel strategies.
[ADDRESS_923169] demonstrated that the combination of dabrafenib and trametinib is
synergistic and/or enhances cell growth inhibition 
in majority of the BRAF V600E mutant 
melanoma, colon, thyroid, and lung cancer cells.  The combination delayed dabrafenib 
resistance and reduced hyperproliferation skin adverse effect in pre-clinical models.  The 
scientific rationale suggesting MEK- mediated re-activation of the MAPK pathway as a 
prominent mechanism of resistance to BRAFi single -agent therap y supports the combination 
study of trametinib with BRAFi in cancer [Alcala , 2012; Greger , 2012]. Because BRAF 
V600E mutated tumors have been shown to develop resistance to BRAF inhibitors, the 
combination of a BRAFi and MEKi provides a rational approach for dual vertical inhibition 
within the MAPK pathway to address such drug resistance [Johannessen
, 2010].  Both have 
demonstrated substantial clinical activity with ORR between 28 to 53% and PFS ranging 
between 4.8 to 5.1 months. Further, the combination of both dabrafenib and trametinib 
indicated increased efficacy over both monotherapi[INVESTIGATOR_681735] 63% and an increase of 
PFS to approximately 10 to11 months for the 150 mg BID dabrafenib and 2mg once daily 
trametinib dose cohort [Flahert y, 2012; Hauschild
, 2012; Weber , 2012]. Furthermore, the 
combination of dabrafenib and rametinib has demonstrated overall survival of a median of
more than 25months in advanced melanoma. This robust survival data for the combination 
is further supported by[CONTACT_681852] >11 
months , overall response rates  of about 64-69% (13-16% of patients achieving a complete
response) with duration of response of 12.9-13.8 months and a disease control rate of94% 
across two rando mized Phase -III studies. (Long GV ,2015; 
Robert C, 2015).
Substantial safety andefficacy data across these clinical development programs in metastatic 
melanoma demonstrated the scientific validity of dual inhibition targeting the MAPK 
[COMPANY_001] Confidential Page [ADDRESS_923170] through dabrafenib and trametinib in human cancer.  The combination therap y of 
dabrafenib + trametinib may offer greater benefit to BRAF V600E mutated cancers than 
either agent alone.
2.[ADDRESS_923171]/NGGCT, BTC, MM, ASI (including periampullary and 
ampullary ), WHO Grade 1 and 2 gliomas and WHO Grade 3 and 4(high -grade) gliomas.  
These rare cancers have an incidence rate in the US ranging between 0.[ADDRESS_923172] a frequency of BRAF V600E mutations ranging between 3% in WHO Grade 3 and 
4 glioma to 90% in HCL (refer to Table 1) [Caronia , 2011; Tiacci , 2011; Hostein , 2010; 
Mayer, 2010; Honecker , 2009; Borger , 2012; Chapman, 2011a; Chapman, 2011b; 
Schonleben
, 2009; Warth , 2011; Schindler , 2011]. These BRAF -mutated rare cancers have 
no effective treatment available either in the first-line setting for ATC, ASI and BRAF 
V600E -mutated GISTorin the refractory disease setting for NSGCT/NGGCT, BTC, WHO 
Grade 1 or 2 glioma, WHO Grade 3 or 4 glioma, HCL and MM.  Therefore, there is a high 
unmet medical need for these rare cancer indications.
Table 1Overall Incidence Rate and BRA FV600E Mutation Rate of Rare Cancer s
Tumor Ty peOverall Incidence Rate per
100,000 inUS (2011)BRAF V600E Mutation
Rate (% )
Anaplastic Thyroid Cancer (ATC) 0.10 24%
Biliary Tract Cancer (BTC) 0.6 7 to 30%
Gastrointestinal Stromal Tumor (GIST) 0.7 to 1.1 2 to 5%
Germ Cell Tumor (GCT)
(approximately 50% non-seminomatous)6.31 ( White males)
1.38 (Black males)3%
World Health Organization (WHO) Grade 1 or 2 
glioma6.5 Approximately 7%
WHO Grade 3 or 4 glioma 2 to 4 Approximately 3%
(glioblastoma [GBM])
Hairy Cell Leukemia (HCL) 0.33 90to 100%
Multiple Myeloma (MM) 5.579 4%
Adenocarcinoma of the Small Intestine (ASI) 0.073 Approximately 10%
References: Caronia ,2011; Tiacci ,2011; Hostein ,2010; Mayer,2010; Honecker ,2009; Borger ,
2012; Chapman ,2011b; Schonleben ,2009; Warth,2011; Schindler ,2011
It is expected that in some of these BRAF -mutated rare cancers substantial clinical activity
of BRAF and MEK inhibition will be observed similar to that in metastati cmelanoma 
(breakthrough efficacy ).  For most rare cancers, conventional drug development programs 
are not feasible due to the low incidence of disease and the limited commercial opportunities.
These challenges may reduce the incentive to explore the potential benefit of new targeted 
therapi[INVESTIGATOR_681736]. An alternative and likely more feasible approach may be based on 
the detection of BRAF V600E mutations in these rare cancers as a common denominator for 
investigation of a BRAF + MEK inhibitor in such well-defined subject populations.  Enriched 
Bayesian statistical designs and a high target effect size may enable meaningful clinical 
investigation of targeted therapi[INVESTIGATOR_681737].
A somewhat similar approach was taken with imati nib, where several label indications were 
granted by[CONTACT_681853] -label, Phase II clinical trial of imatinib insubjects with 
multiple rare tumor types associated with imatinib sensitive tyrosine kinases along with 
[COMPANY_001] Confidential Page 57
Amended Protocol Version 11            Protocol No. CDRB436X2201
published reports. The results of this one Phase II study  in 186 subjects provided the basis 
for approvals in myelody splastic/ myeloproliferative diseases, aggressive systemic 
mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, and 
dermatofibrosarcoma protuberans.  There were three responders out of seven subjects with 
myelodysplastic/ myeloproliferative diseases, one in five subjects with aggressive systemic 
mastocy tosis, four out of 14 in the hypereosinophilic syndrome/chronic eosinophilic 
leukemia cohort and 10 out of 12 in the dermatofibrosarcoma protuberans cohort of that 
particular study [Heinrich ,2008]. Itrepeatedl yappeared in the US FDA review of the 
submission for the extension of indication for Gleevec (2006) that “the (US) FDA medical 
reviewers recommended approval based on ‘long duration of responses’ and the rarity  of 
disease and the occurrence of associated gene arrangement makes randomized trials 
impractical”.
While it is anticipated that several rare cancers with V600E mutations will have clinically
substantial response rates of 50% or more to BRAF plus MEK inhibition, in some settings 
resistance mechanisms may prevent such high response rates.  For example, the BRAFi 
vemurafenib and dabrafenib have shown response rates of greater than 50% inBRAF -mutant 
metastatic melanoma, but show substantially lower response rates inBRAF -mutant 
metastatic colorectal cancer based on resistance mechanisms through receptor tyrosine 
kinases (RTKs) [Prahallad
, 2012].  This reaffirms that pathway s ofresistance may vary
between histologic disease entities and underscores –in the absence of a full understanding 
of such mechanisms of resistance for all histologies –thatindividual assessment of histolog ic 
types remains a relevant component of the investigation together with adequate PD markers 
to understand them.
Therefore, a Phase II study is proposed to investigate BRAF -mutant rare cancers inindividual 
cohorts defined by[CONTACT_681854] + trametinib. To address theinevitable small 
sample sizes per histologic cohort, the study will utilize a Bayesian hierarchical statistical 
design, which increases the power of the overall investigation by[CONTACT_681855].  
Pharmacod ynamic markers will be evaluated to ensure we gain insights
into the biology of 
each cancer t ype and also understand potential mechanisms of resistance .
2.3 Dose Rationale
Administration of dabrafenib + trametinib in the ongoing study BRF113220 indicates that 
dabrafenib does not have a clinically  relevant effect on trametinib PK [GlaxoSmithKline
Document Number CM2010/[ZIP_CODE]/05 ].  Cross -study comparisons indicate that exposure to 
dabrafenib may be greater after repeat -dose administration of dabrafenib incombination with 
trametinib relative to administration of dabrafenib alone at 150 mgBID. The combination 
was relativel y well tolerated in study BRF113220, study MEK115306 and study 
MEK116513 , with toxicities manageable with appropriate intervention.
In this study , dabrafenib will be administered at the dose of 150 mg BID continuous
lythat 
demonstrated significant benefit in PFS in a Phase III trial [Hauschild, 2012]. Trametinib 
administered at adose of 2 mg once dailyhas demonstrated significant benefit in PFS (hazard 
ratio [HR] = 0.45), a confirmed response rate (22% vs. 8%), and OS (HR = 0.54) relative to 
chemotherap y [Flahert y,2012]. As determined in Phase IIIstudies, the safety profile of 
the combination of dabrafenib and trametinib generally reflects the well established 
[COMPANY_001] Confidential Page [ADDRESS_923173] activation with theBRAF V600E mutation, multiple histologies 
may demonstrate substant ial response to BRAF plus MEK inhibition. However, pathways of 
resistance may vary between histologic diseases resulting indifferent responses to the 
targeted combination therap y.
This single -arm, multi- histology study incorporates analyses based on a hierarchical model 
that allows for the possibility that the response profile for the population of histologies may
be homogenous or heterogeneous.  There may be ‘clusters’, or subsets of histologies, some 
in which the combination therap y is effective, and others not.  The design borrows 
information in a limited sense from histologies that demonstrate similar response rates based 
on the accumulated trial data. If response rates are sufficiently different across particular 
histologies, the design recognizes this and borrowing is minimal.  The analy sis is entirel y
data driven.  The number of clusters used tocharacterize the distribution of histologies is 
solely  based on the observed responses. At each interim analysis as well as the final analy sis, 
the entire model including clustering specification is fit based on the available data.
Prospectively , the entire design including model specification and decision criteria is
developed by[CONTACT_681856].  Hence, the false -positive rate 
can be controlled and power assessed.  The advantages of a hierarchical model, both due to 
borrowing, are 1) increased precision of estimates of ORR, and 2) more accurate estimates 
of ORR.
Borrowing via a hierarchical model analysis is a typeof shrinkage estimation; it provides a 
formal mechanism by[CONTACT_681857]. Shrinkage 
estimators have 
long been supported by[CONTACT_387788]. In particular, Berry etal.[Berry , 2013] 
highlighted thatin the 1950s, Charles Stein [Stein , 1956; James, 1961], under normality , 
demonstrated that when there are three or more groups, estimating thegroups separately 
(without borrowing) is inadmis
sible in the sense that the mean squared error is improved 
uniformly by[CONTACT_681858].
For all these reasons, borrowing information generall yincreases the power to detect a
clinically meaningful ORR compared to a traditional analysis while controlling the type I
error rate.  Independent analyses do not consider the possibility that some of thehistologic 
cohorts may respond similarly to the targeted combination therapy . And due to the rarity  of 
the biomarker subtypes of the diseases being considered, a traditional approach will likely
have difficult yaccruing a sufficient number of subjects 
to have adequate power to detect even 
a very large treatment effect in several of the histologic cohorts.
3 OBJECTIVES AND ENDPOINTS
The study objectives and corresponding endpoints are presented in Table 2 .
Table 2 Study Objectives and Endpoints
OBJECTIVES ENDPOINTS
Primary
● To determine the ORR of dabrafenib and trametinib 
anti-cancer combination therapy in subjects with ● Tumor response as defined by: [CONTACT_393], v1.1 for 
solid tumor histologies, Modified RANO and RANO 
[COMPANY_001] Confidential Page 60
Amended Protocol Version 11            Protocol No. CDRB436X2201
histologically  or cytologically  confirmed advanced disease with no available treatment 
options as determined b y locall y or regionally available standards of care and b y the treating 
physician’s discretion will be eligible for enrollment. Subjects may be enrolled based on local 
BRAF V600E mutation results and mutation status will be confirmed by  a central reference 
laboratory .
Subjects will undergo screening assessments prior to the start of treatment to determine their 
eligibility  for study  enrollment.  Baseline disease assessment must be completed prior to the 
first dose of study  treatment.  For female subjects, a pregnancy  test must be performed within 
[ADDRESS_923174] 
dose of study  treatment according to the assessment schedule (see Time and Events Table, 
Section 7.1). Assessments may be performed more frequentl y if medically  necessary .  A 
treatment cycle is [ADDRESS_923175] 8 weeks of treatment. Dose adjustments will be made as needed based on 
toxicity .  Subjects will continue treatment until an unacceptable toxicity , disease progression, 
or death occurs.  Subjects who continue on treatment will undergo disease assessment 
according to the applicable response assessment criteria for the specific histology  (i.e., for 
solid tumors, radiologic assessment every  8 w eeks following initial response assessment).  
Subjects who experience disease progression will discontinue study  treatments and be 
withdrawn from the study , unless the investigator, with approval of the Medical Lead, 
indicates that the subject may  receive clinical benefit from continued study  treatment.  Once 
a subject discontinues treatment and/or is withdrawn from the study , a post-treatment follow -
up visit will be conducted within 28 days (+7 days) after the last dose of study  treatment(s) 
with extended follow -up visits conducted every  4 weeks ( ±7 day s) for the first 6 months and 
then every  3 months ( ±14 day s) thereafter.
A hierarchical model that borrows information across cohorts will be utilized to strengthen 
the overall evidence within each cohort.  Using the hierarchical model, continuous monitoring 
for both futility  and efficacy  will be undertaken throughout the study . Reviews will take place 
in approximately  12-week intervals depending on the enrollment rate.  Enrollment for each 
cohort may be stopped early  for futility  or efficacy  should various criteria occur based on 
accrued data.  Response data from a minimum of five subjects will be required in a histologic
cohort before it may  discontinue enrollment for futility , and response data from a minimum 
of 10 subjects are required before discontinuing a histologic cohort for efficacy.  In addition, 
at the final anal ysis and after the study  has been closed, response data from a minimum of 2 
subjects will be required in a histologic cohort in order to meet statistical success at the final 
analysis.
[COMPANY_001] Confidential Page 61
Amended Protocol Version 11            Protocol No. CDRB436X2201
Decisions are based on whether the posterior probability  that the ORR exceeds its 
corresponding historical control is sufficiently  low or high compared to fixed statistical 
thresholds. Historical controls vary across histologic cohorts, but are all very low due to a 
lack of effective treatment options (Section [IP_ADDRESS] ).  If this posterior probability  is 
sufficiently  low within a given histology  (≤0.30), then enrollment may be halted early for 
futility .  Conversel y, if this posterior probability  is sufficiently  high within a given histology 
(≥0.95), then enrollment may be halted early for success. At the 
final analy sis and after the 
study  has been closed, if the posterior probability  is sufficientl y high (≥0.92), then the 
combination will be declared efficacious for that histology .  Separate from model estimates, 
the observed ORR will also be reported for each histology .Further details regarding the 
statistical study  design and analysis along with simulated example trials to illustrate the study 
may run is provided in Section 18.4.
Protocol waivers or exemptions are not allowed with the exception of immediate safet y 
concerns. Therefore, adherence to the study  design requirements, including those specified 
in the Time and Events Table (
Section 7.1) is essential and required for study  conduct. 
Supplementary  study conduct information not mandated to be present in this protocol is 
provided in the accompany ing study  procedures manual (SPM).  The SPM will provide site 
personnel with administrative and detailed technical information that does not impact subject 
safet y.
4.1 Discussion ofDesign
The design of this Phase II study  allows for the simultaneous evaluation of clinical activity 
and earl y signals of efficacy  in each of the his tologies under study . In addition, the safet y of 
dabrafenib in combination with trametinib will be evaluated to support the use of the 
combination treatment in subjects with selected rare tumor types. Study  treatment will begin 
on Study  Day 1 and will cont
inue until protocol -defined treatment withdrawal criteria are met 
(Section 16).  While on study  treatment, subjects will be closel y monitored for safet y.  
Procedures to minimize or monitor potential risks, dose modification guidance, and 
supportive care recommendations are provided in Section 8.1.
In the event one of the combination agents is discontinued, subjects may still receive the 
remaining agent (either dabrafenib or trametinib) as monotherap y provided the investigator 
concludes that continued therap y will be in the best interest of the subject and will result in 
potential clinical benefit. Once subjects are permanently  withdrawn from all study  treatments, 
a post-treatment follow -
up assessment should be completed within approximately  [ADDRESS_923176] and Companion Diagnostic
Subjects will be enrolled in the study  based on local BRAF V600 mutation tes t results.
For subjects with solid tumors to be eligible for the study , archived tumor tissue
sample(s) and/or fresh tumor tissue sample(s) must be available to allow for central 
confirmation of BRAF V600E mutation status.
For subjects with HCL or MM, a fr esh BM aspi[INVESTIGATOR_12671] a peripheral blood
sample must be available to allow for central confirmation of BRAF V600E mutation 
status.  See Section 7.3.[ADDRESS_923177] is not feasible, an alternative approach of 
BRAF V600E mutation testing by [CONTACT_9064]  (IHC) or Sanger sequencing may 
be employ ed.
[ADDRESS_923178] SELECTION
5.1 Primary analy siscohort
The “primary  analysis cohort” will be comprised of those patients enrolled within a histology -
specific group prior to cappi[INVESTIGATOR_25577] 25 patients per cohort or prior to early stoppi[INVESTIGATOR_681705] . The primary  analy sis cohort will form the basis of the Bay esian modelling.
5.2 Expansion cohorts
If a cohort closes earl y at an interim analysis because it meets the rules for earl y stopp ing for 
efficacy , an expansion cohort may be opened to allow additional patient enrollment for that 
particular histology . The patients in the expansion cohort will provide supportive efficacy 
data and will NOT contribute to the Bay esian modeling. The expan sion cohort(s) will enroll 
subjects for the duration of trial enrollment. The same general and histology  specific 
eligibility  criteria and T&E tables and biomarker/histology  confirmation analy ses will appl y 
to patients in the expansion cohort.
5.[ADDRESS_923179] been enrolled, 
the histology cohort will be closed to further enrollment for patients contributing to the 
Bayesian modeling. Histology specific expansion cohorts may beopened to allow additional 
patient enrollment.  See Section 18.2 for sample size assumptions.
The study is expected to enroll subjects over an approximate 3 to 4 yeartime period. This 
flexibility is intended to accommodate recruitment rates in these rare histologic cohorts.
Projected 3-year recruitment rates are described in Section [IP_ADDRESS] , and are used for 
simulated trials to assess design operating characteristics.
5.4 Eligibility
Specific information regarding warnings, precautions, contraindic ations, AEs, and other 
pertinent information on the study treatment(s) thatmay impact subject eligibility is provided 
in the IB for dabrafenib + trametinib combination [GlaxoSmithKline Document Number 
CM2010/[ZIP_CODE]/05 ].
Devi ations from inclusion/exclusion criteria are not allowed because they can potentially
jeopardize the scientific integrit y of the study , regulatory  acceptability  or subject safet y.
Therefore, adherence to the eligibility criteria as specified in the protocol is essential.
[COMPANY_001] Confidential Page [ADDRESS_923180] meet all of the following inclusion criteria in order to be considered eligible 
for this study :
1.Signed, written informed consent
2. Sex: male or female
3.Age: 18years of age at the time of providing informed consent
4.Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1 or 2 ( Appendix 
1).
5.Must have advanced disease and no standard treatment options as determined by  
[CONTACT_54045] /regionally available standards of care and t reating ph ysician’s discretion.
6.Must have a BRAF V600E mutation -positive tumor as confirmed by[CONTACT_681859] a sponsor designated central reference laboratory .
7.NOTE: All subjects must provide an archived or fresh tumor sample (for solid tumors) 
or a fresh BM aspi[INVESTIGATOR_681738] (for HCL  and MM) for 
confirmation testing of the BRAF V600E mutation by a sponsor designated central 
reference laboratory using a sponsor designated assay
. See Section 7.3.[ADDRESS_923181]/NGGCT, and ASI ONLY: Must have at least one
measurable lesion per RECI ST 1.1 outside of a prior radiation field or within the field 
with evidence of progression.
9.Able to swallow and retain orally administered medication.
10.Female Subjects of Childbearing Potential:  Subjects must have a negative serum
pregnancy test within [ADDRESS_923182]/NGGCT, ASI1.2109/L
MM1109/L
Hemoglobin3 ATC, BTC, GIST, WHO
Grade [ADDRESS_923183]/NGGCT, ASI9 g/dL
Platelets3 ATC, BTC, GIST, NSGCT/NGGCT, ASI75109/L
MM50109/L
WHO Grade 1 -4 Glioma100109/L
PT,PTT, INR2 ATC, BTC, GIST, WHO
Grade [ADDRESS_923184]/NGGCT, ASI, 
HCL, MM1.[ADDRESS_923185]/NGGCT, ASI, 
HCL, MM2.5 g/dL
ATC 1.[ADDRESS_923186] Histology LABORATORY VALUES1
Total Bilirubin4 BTC [ADDRESS_923187]/NGGCT, MM[ADDRESS_923188]
HCL <[ADDRESS_923189]
ASI [ADDRESS_923190] OR  [ADDRESS_923191]/NGGCT [ADDRESS_923192] without liver
metastases  2.[ADDRESS_923193] if 
documented liver metastases
BTC, ASI, MM [ADDRESS_923194] without liver
metastases  [ADDRESS_923195] if
documented liver metastases
HCL <[ADDRESS_923196]
WHO Grade 1, 2, 3 or 4 Glioma [ADDRESS_923197]/NGGCT, ASI, 
HCL, MM1.5 mg/dL
OR
Calculated Creatinine
Clearance6or [ADDRESS_923198]/NGGCT, ASI, 
HCL, MM50 mL/min
Cardiac LVEF ATC, BTC, GIST, WHO
Grade [ADDRESS_923199]/NGGCT, ASI, 
HCL, MMLLN7by [CONTACT_681860]: ALT, alanine aminotransferase; ANC, absolute neutrophil count; ASI, adenocarcinoma ofsmall intestine AST, aspartate
aminotransferase; CBC, complete blood count; ECHO, echocardiogram; HCL, hairy cellleukemia; hr,hour; INR, international
normalization nratio; LLN, lower limitofnormal; LVEF, leftventricular ejection fraction; PT,prothrombin time; PTT, partial thromboplastin
time; ULN, upper limitofnormal
1. Laboratory values areobtained within 14days prior tofirstdose ofstudy treatment.
2. PTT andPT/INR >1.[ADDRESS_923200] willbeacceptable incase ofsubjects receiving therapeutic anticoagulants such aswarfarin aslong
asINRismonitored during thestudy according toclinical practice.
3. HCL: Nominimum CBC criteria ifthecytopenias areduetodisease under study.
4. HCL: Subjects willbeallowed toenroll withindirect hyperbilirubinemia; however, thiscondition must beconfirmed duetohemolysis,
hypersplenism ordirect bilirubin ratio <35%, andrequires approval from theMedical Lead.
5. HCL: Subjects willbeallowed toenrol lwith elevated ALT/AST values upto5times ULN; however thiscondition must beconfirmed
duetohemolysis and/or hypersplenism and not associated withhepatic dysfunction andrequired approval from theMedical Lead.
6. Calculated by[CONTACT_36575] -Gault formula (see Appendix 3).
7. IfLLNisnotdefined foragiven institution, then ejection fraction must be≥ 50%.
NOTE: Subjects withAST, ALT ortotal bilirubin values outside therange(s) inTable 3duetoGilbert's syndrome
orasymptomatic gallstones arenotexcluded. Laboratory results obtained during Screening should beused todetermine eligibility
criteria. Insituations where laboratory results areoutside thepermitted range, theinvestigator may opttoretest thesubject andthe
subsequent within- range screening result may beused toconfirm eligibility
12.French subjects: In [LOCATION_009], a subject will be eligible for inclusion in this study  only if 
either affiliated to or a beneficiary of a social security category .
[COMPANY_001] Confidential Page 65
Amended Protocol Version 11            Protocol No. CDRB436X2201
[IP_ADDRESS] Histology Specific Inclusion Criteria
[IP_ADDRESS].1 ATC
1.Histologicall yorcytologically confirmed, unresectable, metastatic ATC including ATC 
originating from within well-differentiated thyroidcancers or an ATC as part of a
thyroid carcinoma of another histologic t ype.
NOTE: Squamoid differentiated subty pe is not permitted. Diagnosis noted to be
“consistent with ATC” with presence of thy roid mass is acceptable.
2.Has undergone evaluation via indirect or direct laryngoscop y to ensure patency of
trachea/airway prior to enrollment if bulky thyroid/neck masses are present and/or
airway obstruction is suspected.
3.Has undergone prior external beam radiotherap yand/or surgery to the primary tumor.
NOTE: Subjects with small primary tumor that has been totally removed by [CONTACT_681861] y no radiotherap ywas indicated (only  metastatic lesions are 
manifested) or subjects with metastatic disease who do not require radiation or surgery
to the neck mass will be eligible for participation in the study .
[IP_ADDRESS].[ADDRESS_923201] progressed on or demonstrated intolerance (despi[INVESTIGATOR_681739]) to treatment with a gemcitabine -based
chemotherap yregimen.
[IP_ADDRESS].[ADDRESS_923202] progressed on or demonstrated intol erance (despi[INVESTIGATOR_681739]) to treatment with a TKI (i.e., imatinib, sunitinib).
[IP_ADDRESS].4 WHO Grade 1 or 2 Glioma
1.Histologicall y confirmed recurrent or progressive WHO Grade 1 or 2 glioma
2.For WHO Grade 1 glioma ONLY: To be considered eligible for study treatment,
subject must:
a.Present with adequate level offavorable risk/benefit ratio including, but not limited 
to, the exhibited initial sy mptoms, AND
b.Be evaluated by [CONTACT_681862] -oncologists and the Medical Lead prior to 
enrollment.
3.For WHO Grade 2 glioma ONLY:   To be considered eligible for study treatment, 
subject must not be eligible for treatment with chemotherap y.
4.Must have measurable non
-enhancing disease based on two -dimensional magnetic
resonance imaging (MRI) with contrast assessments as per RANO response criteria 
(Appendix 13).
NOTE: Enhancing disease is acceptable for pi[INVESTIGATOR_681740].
5.For WHO Grade 1 or 2 glioma subjects receiving corticosteroid trea tment: Must be 
receiving a stable or decreasing dose of corticosteroid treatment for [ADDRESS_923203] 
[COMPANY_001] Confidential Page 66
Amended Protocol Version 11            Protocol No. CDRB436X2201
dose of study treatment.
NOTE: Steroids dose is limited to up to 8 mg/day of dexamethasone or equivalent dose 
of steroid.
NOTE: Subjects are not requ ired to be on corticosteroids to be eligible.
[IP_ADDRESS].[ADDRESS_923204] -line chemotherap y or concurrent
chemoradiation therapy .
NOTE: Subjects who have a WHO Grade 3 or 4 glioma for which chemotherap y
and/or radiotherap y is not considered standard of care may remain eligible for the study .
Consult the Medical Lead to discuss and determine if subject is eligible for enrollment.
3.Must have measurable disease at least 1 cm x 1 cm as per RANO response criteria
(Appendix 14).
4.For WHO Grade 3 or 4 glioma subjects receiving corticosteroid treatment :
Must be receiving a stable or decreasing dose of corticosteroid treatment for [ADDRESS_923205] dose of study treatments.
NOTE: Steroids dose is limited to up to 8 mg/day of dexamethasone or equivalent dose 
of steroid.
NOTE: Subjects are not required to be on corticosteroids to be eligible.
[IP_ADDRESS].[ADDRESS_923206] /NGGCT
1.Histologicall y confirmed NSGCT/NGGCT.
2.Must have either:
Refractory disease defined as disease progression during or relapsed after salvage 
high-dose chemotherapy (HDCT), or disease progression during cisplatin -based 
salvage chemotherapy .
OR
Relapsed disease and ineligible for cisplatin -based salvage chemotherap y or
HDCT.
[IP_ADDRESS].[ADDRESS_923207] progressed on or demonstrated intolerance (despi[INVESTIGATOR_681739]) to one line of chemotherap y.
[IP_ADDRESS].8 HCL
1.Histologicall y confirmed diagnosis of HCL according to morphological and
immunophenoty pic criteria of WHO classification [ WHO , 2008] of ly mphoid
neoplasms.
2.Must have either:
Refractory disease defined as no response or disease progression in 1year
following first -line treatment with a purine analog (i.e., pentostatin, cladribine or 
fludarabine)
OR
[COMPANY_001] Confidential Page 67
Amended Protocol Version 11            Protocol No. CDRB436X2201
Relapsed disease defined as having relapsed following treatment with at least two 
prior treatments
3.Must have the presence of leukemic cells in the peripheral blood or BM aspi[INVESTIGATOR_681741]:
Bulk y/symptomatic splenomegaly
Hemoglobin <10 g/dL
Platelets <100 109/L
Absolute neutrophil count (ANC) <1 109/L
4. For subjects with an opportunistic infection: the infection must be adequately  managed 
and the subject must be clinically stable. The investigator may discuss this issue with 
the Medical Lead.
[IP_ADDRESS].[ADDRESS_923208] 2 prior lines of therap y, such as prior treatment with a proteasome 
inhibitor and IMiD,and is now refractory or has demonstrated intolerance (despi[INVESTIGATOR_681742]) to the most recent therap y
received
3.Must have measurable disease of MM as defined by [CONTACT_375814]:
Serum M -protein 
1 g/dL ( 10 g/L)
Urine M -protein  200 mg/24 hr
Serum free light chain (FLC) assay: involved FLC level 5 mg/dL ( 50mg/L) and 
an abnormal serum FLC ratio (<0.26 or >1.65), or
Biopsy proven plasmacy toma (measured within 28 daysof Screening)
4.For subjects with an opportunistic infection: the infection mu st be adequately  
managed and the subject must be clinically stable. The investigator may discuss this 
issue with the Medical Lead.
5.4.[ADDRESS_923209] who meets anyof the following criteria is excluded from enrollment in this
study :
1. Prior treatment with:
BRAF and/or MEK inhibitor(s)
Chemotherap y, immunotherap y, biologic therap y
or chemoradiation with delay ed
toxicity within 21 day s(or within 42 day sif prior therap ycontains nitrosourea or 
mitomy cin C) prior to enrollment
Chemotherap y or b iologic therap y without evidence of delay edtoxicity within 14 
daysprior to enrollment
Investigational product(s) (IP) within 30 daysor 5 half -lives, whichever is longer, 
prior to enrollment
Subjects enrolled in [LOCATION_009]: Subject has participated in anystudy using an 
IP(s) within 30 daysprior to enrollment in this study .
2.History of malignancy with confirmed activating RAS mutation at any time.
NOTE:   Prospective RAS testing is not required. However, if the results of previous 
RAS testing are known, then those results must be used in assessing eligibility .
[COMPANY_001] Confidential Page [ADDRESS_923210] resolved prior to enrollment.
For WHO Grades 1, 2, 3, or 4 Glioma ONLY :  Radiotherap y is not permitted within 
3 months prior to enrollment (extended period of time of > 3 months needed to prevent 
subjects with pseudo -progression from radiotherapy  from being enrolled in the study ).  
Subjects may  be ≥ [ADDRESS_923211] resolved prior to enrollment.
For ATC Only: Radiotherap y is not permitted within 7 daysprior to enrollment.
Treatment -related A E(s) must have resolved prior to enrollment.
4.Prior major surgery less than 14 daysprior to enrollment.  Any surgery -related AE(s) 
must have resolved prior to enrollment.
5. Prior solid organ transplantation or allogenic stem cell transplantation (alloSCT)
NOTE: Previous autologous BM transplant (autoSCT) or autologous peripheral blood 
stem cell transplant (PBSCT) is permitted.
6.History of another malignancy
NOTE : Subjects with another malignancy are eligible if: 
a.disease -free for [ADDRESS_923212] a history ofcompletely  resected non-melanoma skin cancer, and/or 
c.have an indolent second malignancy (ies).
Consult a Medical Lead if unsure whether second malignancies meet requirements 
specified above.
7.Presence of:
Brain metastases ( except for subjects in the WHO Gr ade 1 or 2 Glioma or WHO 
Grade 3 or 4 Glioma histology cohorts) that are s ymptomatic or untreated or not 
stable for  3 months (must be documented by[CONTACT_9661]) or requiring 
corticosteroids. Subjects on a stable dose of corticosteroids > [ADDRESS_923213] not
required treatment with enzy me-inducing anticonvulsants for >30 daysprior to 
enrollment can be enrolled with approval of the Medical Lead.
Symptomatic or untreated leptomeningeal or spi[INVESTIGATOR_681743]:  Subjects who have been previously treated for these conditions and have 
stable CNS disease (documented by[CONTACT_681863]) for >[ADDRESS_923214] 30 daysprior to enr ollment, are permitted.
Interstitial lung disease or pneumonitis
Any unresolved  Grade 2 (per Common Terminology Criteria for Adverse Events 
[CTCAE] version 4.0) toxicity from previous anti -cancer therap yat the time of 
enrollment, except alopecia or Grade 2 anemia
NOTE:  Subjects with MM who have ≤Grade 2 peripheral neuropathy (per 
CTCAE v4.0) are permitted.
Any serious and/or unstable pre -existing medical disorder, ps ychiatric disorder, or 
other conditions that could interfere with subject’s safet y,obtaining informed 
consent or compliance to the study procedures
8.History of RVO
[COMPANY_001] Confidential Page [ADDRESS_923215] no more than 50% of the large intestine removed and no sign of malabsorption 
(i.e., diarrhea).
NOTE : Ifclarification is needed as to whether a condition will significantly affect the 
absorption of study treatments, contact [CONTACT_681864].
10.History or evidence of cardiovascular risk including anyof the following:
Acute coronary syndromes (including m yocardial infarction and unstable angina), 
coronary angioplasty , or stenting within 6 months prior to enrollment
Clinically significant uncontrolled arr hythmias
NOTE:  Subjects with controlled atrial fibrillation for >30 daysprior to enrollment 
are eligible.
Class II or higher congestive heart failure as defined by [CONTACT_247555] (NYHA) criteria ( Appendix 2 )
Left ventricular ejection fraction (LVEF) below the institutional LLN
NOTE: Ifa LLN does not exist at an institution, then use LVEF <50%.
Abnormal cardiac valve morphology (≥Grade 2) documented by [CONTACT_681865]:  Subjects with Grade 1 abnormalities (i.e., mild regurgitation/stenosis) may
be entered on study . Subjects with moderate valvular thickening should NOT be 
enrolled.
Corrected QT (QTc) interval for heart rate using Bazett- corrected QT interval 
(QTcB) 480 msec
Intracardiac defibrillator
Treatment -refractory hypertension defined as a blood pressure (BP) >140/90 
mmHg which may not be controlled by [CONTACT_14181]-hypertensive medication(s) and/or 
lifesty le modifications
Subjects enrolled in [LOCATION_013]: Subjects with a left bundle branch block (LBBB)
areNOT eligible forinclusion inthis study .
11.Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody  test 
result within [ADDRESS_923216] dose of study treatment.
NOTE : Subjects with positive Hepatitis C antibody due to prior exposure can be
enrolled, only ifa confirmatory negative Hepatitis C RNA poly merase chain reaction 
(PCR) test is obtained.
12.
Current use of prohibited medication(s) or requirement for prohibited medications 
during stud y (see Section 10.2).
NOTE: Use of anticoagulants such as warfarin is permitted; however, international 
normalization ratio (INR) must be monitored according to local institutional practice.
13.Clinically significant known immediate or delay edhypersensitivity reaction or
idiosy ncrasyto drugs chemically related to study treatment, or excipi[INVESTIGATOR_840], or to
dimethy l sulfoxide (structural component of dabrafenib).
14.Female subjects: Pregnant, lactating or activel y breastfeeding
[COMPANY_001] Confidential Page 70
Amended Protocol Version 11            Protocol No. CDRB436X2201
[IP_ADDRESS] Histology Specific Exclusion Criteria
[IP_ADDRESS].[ADDRESS_923217] of care.
[IP_ADDRESS].[ADDRESS_923218] obstruction, unless a treatable, clinically relevant obstruction has been 
relieved by [CONTACT_169831]/stenting, palliative by -pass surgery or 
percutaneous drainage prior to enrollment.
[IP_ADDRESS].3 WHO Grade 1, 2, 3 or 4 Glioma
1. Prior treatment with enzyme- inducing anticonvulsants within 14 day sprior to
enrollment.
2.Radiotherap y treatment within 3 months prior to enrollment.
NOTE: Extended period of time (>3 months) needed to prevent subjects with pseudo -
progression from radiotherap y being enrolled in the study .Subjects may be 2weeks 
from radiotherapy if anew lesion relative to the pre -radiation MRI develops 
outside the primary radiation field. Treatment -related AEs must have resolved 
prior to enrollment.
6 STUDY TREA TMENTS
The term ‘study  treatment’ is used throughout the protocol to 
describe anycombination ofIP
received by[CONTACT_278813]. Study treatment may therefore refer to the 
individual study treatments or the combination of those study treatments.
6.[ADDRESS_923219] number that will remain consistent for the 
duration of the study .  Subjects will be categorized by [CONTACT_681866] a non- randomized manner.
Upon completion of 
all the required screening assessments, including signed informed
consent; eligible subjects will be registered into the designated interactive voice response 
system (IVRS) by [CONTACT_109529].
6.2 Blinding
This is an open -labeled study .
6.3 Investigational Products
6.3.1 Dabrafenib (DRB436/ [COMPANY_004]2118436) Capsule
Dabrafenib capsules will be provided to sites by[CONTACT_456]. The contents of the label will 
be in accordance with all applicable regulatory  requirements.
Product name :[CONTACT_681950] ( DRB436/ [COMPANY_004]2118436) 50 mg Dabrafenib ( DRB436 /[COMPANY_004]2118436) 75 mg
[COMPANY_001] Confidential Page 71
Amended Protocol Version 11            Protocol No. CDRB436X2201
Formulation
description:Each capsule contains DRB436/ [COMPANY_004]2118436B (mesylate salt) equivalent to 50 mg 
or75 mg of DRB436/ [COMPANY_004]2118436A and inactive ingredients including: 
microcrysta lline cellulose, magnesium stearate, and colloidal silicon dioxide.
50 mg capsule shell composition: hypromellose or HPMC (E464), red iron oxide
(E172), and titanium dioxide (E171)
75 mg capsule shell composition: hypromellose or HPMC (E464), red iron oxide
(E172) and titanium dioxide (E171)
Black bars printed on capsules: black ink containing black iron oxide (E172),
shellac, propylene glycol, and ammonium hydroxide.
Dosage form : Capsule
Unit dose strength(s): 50 mg 75 mg
Physical Description: 50 mg: Swedish orange, size 2
capsules with identifying markings of 4 
black bars75 mg: Pi[INVESTIGATOR_8745], size 1capsules with
identifying markings of 4black bars
Route/Schedule/
Duration:Oral/ BID/Continuous
Abbreviations: BID, twice daily; HPMC, hydroxypropyl methyl cellulose
[IP_ADDRESS] Administration and Storage of Dabrafenib Capsules
Administration: Dabrafenib capsules must be dispensed only to subjects enrolled in the
study and in accordance with the protocol. Dabrafenib should be administered under fasted 
conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL ofwater.  
Subjects should be encouraged to take their doses at 12 hr intervals and at similar times every
day.
Missed Dose : If a subject misses a dose of dabrafenib, the subject may take the dose
immediately if the next dose is scheduled for at least [ADDRESS_923220] should skip the dose and resume dosing at thenext 
scheduled dose.
Storage: Dabrafenib must be stored in a secure area under the appropriate physical
conditions for the product. Access to and administration of the dabrafenib will be limited to 
the investigator and authorized site staff.
Dabrafenib is to be stored and dispensed in an opaque bottle. The recommended storage 
conditions for dabrafenib are stated on the product label.  Maintenance of a temperature log 
(manual or automated) at the site is required.
6.3.2 Trametinib ( TMT212/ [COMPANY_004]1120212) Tablet
Trametinib tablets will be provided to sites by [CONTACT_456].  The contents of the label will be 
in accordance with all applicable regulatory requirements.
Product name :[CONTACT_681951] ( TMT212/ [COMPANY_004]1120212) 0.5 mg Trametinib ( TMT/ [COMPANY_004]1120212) 2 mg
Formulation description: Each immediate -release oral tablet contains TMT212/ [COMPANY_004]1120212B 
equivalent to 0.5 mg or 2 mg of TMT212/ [COMPANY_004]1120212 (non -solvated parent) 
blended with inert ingredients (mannitol, sodium lauryl sulfate, colloidal silicon 
dioxide, microcrystalline cellulose, hypromellose, croscarmellose sodium, and
magnesium stearate [non -animal]) and compressed into tablets.
The 0.5 mg tablets are aqueous film- coated with Opadry W hite (OY -S-[ZIP_CODE];
hypromellose, titanium dioxide and polyethylene gycol) or Opadry yellow
(03B120 006; containing hypromellose, titanium dioxide, polyethylene glycol,
and iron oxide yellow).
The 2 mg tablets are aqueous film -coated with Opadry Pi[INVESTIGATOR_8745] (YS -1-[ZIP_CODE] -A;
containing hypromellose, titanium dioxide, polyethylene glycol, polysorbate
80, and iron o xide red).
[COMPANY_001] Confidential Page 72
Amended Protocol Version 11            Protocol No. CDRB436X2201
Dosage form : Tablet
Unit dose strength(s): 0.5 mg 2 mg
Physical Description: White or yellow, modified oval,
biconvex, film -coated tabletsPi[INVESTIGATOR_8745], round, biconvex film-coated
tablets
Route/Schedule/Duration: Oral/once -daily/Continuous
[IP_ADDRESS] Administration and Storage of Trametinib Tablets
Administration: Trametinib must be dispensed only to subjects enrolled in the stud yandin 
accordance with the protocol.  Trametinib should be administered under fasted conditions, 
either 1 hr before or 2 hrs after a meal with approximately 200mLof water. Subjects should 
be instructed to take their dose of trametinib concurrently with the morning dose of 
dabrafenib.
Vomiting: Ifa subject vomits after taking study  treatment, the subject should beinstruct ed 
not to retake the dose but should be instructed to take the next scheduled dose.
Missed Dose: If a subject misses a dose of trametinib, the subject may take the dose
immediately if the next dose is scheduled for at least [ADDRESS_923221] should skip the dose and resume dosing at thenext 
scheduled dose.
Storage: Trametinib must be stored in a secure area under the appropriate physical
conditions for the product.  Trametinib is to be stored at the temperature specified on the label.  
Maintenance of a temperature log (manual or automated) is required. Access toand 
administration of trametinib will be limited to the investigator and authorized site staff.  Refer 
to the SPM for further detaile d instructions on IPstorage.
6.4 Handling/A ccountability ofInvestigational Products
Handling: Adequate precautions must be taken to avoid direct contact [CONTACT_443476].The
occupational hazards and recommended handling procedures are provided in the Material 
Safety Data Sheet (MSDS).  A d escription of the occupational hazards and recommended
handling precautions for each IP (MSDS) will be provided to the site staff and/or subjects if 
required by[CONTACT_681867].  In the 
case of unintentional occupational exposure, notify thestudy monitor, the Medical Lead, 
and/or study manager.
Accountability: Inaccordance with local regulatory requirements, the investigator,
designated site staff, or head of the medical institution (where applicable) must document the 
amount of each IP dispensed and/or administered to study subjects, the amount returned by
[CONTACT_562555], and the amount received from and returned to the sponsor, when applicable.  
Accountability records for each IPmust be maintained throughout thecourse of the study .
Refer to the SPM for further detailed instructions onIPaccountability .
6.[ADDRESS_923222] should return the dosing diary ; an evaluation of subject 
compliance with study treatments taken will be performed.  The investigator will make every
effort to bring non -compliant subjects into compliance. A record of the number of trametinib 
tablets and dabrafenib capsules dispensed to and taken by[CONTACT_681868].  Compliance with dosing will 
[COMPANY_001] Confidential Page [ADDRESS_923223] during site visits and documented in the source 
documents and electronic case report form (eCRF) including treatment start and stop dates, 
dates for treatment delays and/or dose reductions.
6.6 Treatment ofOverdose
6.6.1 Dabrafenib
In the event of a dabrafe nib overdose (defined as administration of >[ADDRESS_923224] dose administered to date), the investigator should contact [CONTACT_681869]/SAEs and laboratory
abnormalit ies.  The sponsor does not recommend specific treatment.  The investigator will 
use clinical judgment to treat any overdose. Hemodialy sis is notexpected to enhance the 
elimination of dabrafenib as it is highly bound to plasma proteins.
A plasma sample forPK anal ysismay be requested by [CONTACT_681870] a case -by-case 
basis. This plasma sample should be collected as soon aspossible; record date andtime of 
the PK sample and last dose of study treatment.
Information regarding the quantity of the excess dose as well as the duration of the
overdosing should be documented in the eCRF.
6.6.2 Trametinib
In the event of a trametinib overdose, defined as administration of more than 3.0 mg once
daily (the maximum tolerated dose defined in the study MEK111054), the investigator should 
contact [CONTACT_681871]/SAEs and 
laboratory  abnormalities.  The sponsor does not recommend specific treatment. The 
investigator will use clinical judgment to treat an y overdose. Hemodia lysis is not expected to 
enhance the elimination of trametinib as it is highly bound to plasma proteins.
Decisions regarding dose interruptions or modifications will be made by[CONTACT_681872].
A plasma sample for PK anal ysismay be requested by [CONTACT_681870] a case -by-case 
basis.  This plasma sample should be collected as soon as possible, but within [ADDRESS_923225] is still clinically benefitting from 
study treatment(s) and the subject is willing to continue study treatment(s); c onsultation with 
the Medical Lead is required. If further progressive disease is noted at the next response 
assessment, the subject must discontinue study treatment(s).
If the study  treatment(s) is continued beyond the initial disease progression, study procedures, 
including response assessments, will be continued according to the Time and Events Table 
(
Section 7.1)
[COMPANY_001] Confidential Page 74
Amended Protocol Version 11            Protocol No. CDRB436X2201
7 STUDY A SSESSMENTS AND PROCEDURES
Study assessments and procedures, including the timing of the assessments, are summarized 
in the Time and Events Table (Section 7.1).
A signed, written informed consent form (ICF) must be obtained from the subject or a legal 
representative prior to any study -specific procedures or assessments.
Procedures conducted as part of the subject’s routine clinical management (e.g., blood count, 
imaging study ) and obtained prior to signing of informed 
consent may be utilized for 
screening or baseline purposes provided the procedure meets the protocol -defined criteria 
and has been performed in the timeframe of the study .
Investigators may be requested to perform additional safet y tests during the course of the
study based on newl y available data to ensure appropriate safety  monitoring. Appropriate 
local regulatory and ethical approvals should be obtained before any additional testing is 
performed .
[COMPANY_001] Confidential Page 75
Amended Protocol Version 11                                                                                                 Protocol No. CDRB436X2201
7.1 Time andEventTable
Table 4 Time and Event Table for AllCohorts
ScreeningTreatment5 Follow -upVisit55 Extended
Follow -
up58
Day 17 Day 15
(1day)Every
4weeks
(3days)Every
8weeks
(3days)Every
12
weeks
(3
days)Every
16weeks
(3days)Treatment orStudy
WithdrawalEvery
3months
(14
days)
except
when
noted
Clinical Assessments: ALL Cohorts
Informed Consent1 X
Demographics X
Medical History2 X X8
Disease Characteristics3 X
BRAF V600E Mutation Testing
(Mandatory)4X
ECOG Performance Status X6 X8 X X
Safety Assessments: ALL Cohorts
Physical Exam (including
weight)X
(Complete)6,9X
(Brief)10X
(Brief)10X
(Complete)9
Height X6,11
Dermatologic Exam X(Full)12 X(Brief)13 X(Brief)13 X(Brief)13
Ophthalmic Exam14 XWeek 4
Only
Vital Signs15X6 X8 X X
12-lead ECG16X6 X8 X X56
ECHO17 XWeek 4
OnlyX X57

[COMPANY_001] Confidential Page 76
Amended Protocol Version 11                                                                                                 Protocol No. CDRB436X2201
ScreeningTreatment5 Follow -upVisit55 Extended
Follow -
up58
Day 17 Day 15
(1day)Every
4weeks
(3days)Every
8weeks
(3days)Every
12
weeks
(3
days)Every
16weeks
(3days)Treatment orStudy
WithdrawalEvery
3months
(14
days)
except
when
noted
Adverse Events Continuous
Safety Assessments: ALL Cohorts continued
Concomitant Medications X6 X8 X X X
Laboratory Assessments: ALL Cohorts
Chemistry andHematology X6 X8 X X56
Pregnancy test19X20
(serum)X21
(serum or
urine)X21
(serum or
urine)X21,56
(serum orurine)
HbA1c X6 X
Coagulation:
PT,PTT, INRX6
Urinalysis X6 X8 X X56
Monitoring for Non -Cutaneous Secondary/Recurrent Malignancy22: ALL Cohorts 
Head andneck exam23X6 X X24
Chest andAbdominal CTscan
orMRIX6 Asclinically indicated X24
Disease Assessment: ATC, ASI, BTC, GIST, NSGCT/NGGCT, and WHO Grade 1-4Glioma Cohorts ONLY
Disease Assessment:
Imaging25X26 X27 X27 X27 X27
TSH, Free T4 (ATC Only) X6 X X
Histology Confirmation: ATC and WHO Grade 1-4 Glioma Cohorts ONLY
Tissue Sample forHistology
Confirmation28X
Disease Assessment: NSGCT/NGGCT Cohort ONLY
AFP,-HCG X6 X29 Every 8to12weeks29 AtDisease Progression29
[COMPANY_001] Confidential Page 77
Amended Protocol Version 11                                                                                                 Protocol No. CDRB436X2201
ScreeningTreatment5 Follow -upVisit55 Extended
Follow -
up58
Day 17 Day 15
(1day)Every
4weeks
(3days)Every
8weeks
(3days)Every 12
weeks
(3
days)Every
16weeks
(3days)Treatment orStudy
WithdrawalEvery
3months
(14
days)
except
when
noted
Disease Assessment: BTC and ASI Cohorts ONLY
CEA, CA19 -9 X6 X30 Every 8to12weeks30 AtDisease Progression30
Disease Assessment: HCL Cohort ONLY31
Blood sample forCBC X6X31 X31
Peripheral Blood Sample
Staining forHairy CellcountXX31 X31
BMbiopsy andaspi[INVESTIGATOR_419500]
H/Estain andIHCX34When counts areconsistent withCRorPRfor4weeks; ifevidence of
response, then after every 6months twice, then after ayear twice and
then every 2years32Attime ofrelapse
Flow cytometry:
BMaspi[INVESTIGATOR_681744]34When counts areconsistent withCRorPRfor4weeks; ifevidence of
response, then after every 6months twice, then after ayear twice, and
then every 2years33Attime ofrelapse
Flow cytometry: peripheral
blood sample33X34 X31X31
Chest CTscan andAbdominal
CTscan w/contrastX35When counts areconsistent withCRorPRfor4weeks; then 6months
laterAttime ofrelapse
Disease Assessments: MM Cohort ONLY
Skeletal surveys36 X X X
Extramedullary Disease
Assessment37X X X
BMaspi[INVESTIGATOR_337] X38AtWeek 8andattime ofachieving CRor
best response39AtDisease Progression
BMbiopsy X38AtWeek 8andattime ofachieving CRor
best response39AtDisease Progression
SPEP40 X X X X
UPEP41,42 X X X X
[COMPANY_001] Confidential Page 78
Amended Protocol Version 11                                                                                                 Protocol No. CDRB436X2201
ScreeningTreatment5 Follow -upVisit55 Extended
Follow -
up58
Day 1 7 Day 15
(1day)Every
4weeks
(3days)Every
8weeks
(3days)Every
12 
weeks
(3
days)Every
16 weeks
(3days)Treatment or Study
WithdrawalEvery
3 months
(14
days) 
except 
when
noted
CRP,2microglobulin; IgG,
IgAandIgM43X X X X
Serum FLC assay43 X X X X
Pharmacokinetic Assessments forSubjects Receiving Dabrafenib Capsules and/or Trametinib Tablets: ALL Cohorts
PK: blood sample(s)Week 4
Only44Week 8
Only45Week 12
Only45X45

[COMPANY_001] Confidential Page 79
Amended Protocol Version 11                                                                                                 Protocol No. CDRB436X2201
ScreeningTreatment5 Follow -upVisit55 Extended
Follow -
up58
Day 1 7 Day 15
(1day)Every
4weeks
(3days)Every
8weeks
(3days)Every
12 
weeks
(3
days)Every
16 weeks
(3days)Treatment or Study
WithdrawalEvery
3 months
(14
days) 
except 
when
noted
Study Treatments: ALL Cohorts
Dispensation of study
treatmentsX54 X
Dabrafenib Dosing Continuous Twice Daily Dosing
Trametinib Dosing Continuous Once Daily Dosing
Compliance Assessment X X
Abbreviations: AFP, alpha -fetoprotein; ANC, absolute neutrophil count; AP,anteroposterior; ASI, adenocarcinoma ofsmall intestine; -HCG, beta-human chorionic gonadotropin; BM, bone 
marrow ;CBC, complete blood count; CR, complete response; CRP, C-reactive protein; CT, computed tomography; ECG, electrocardiogram; ECHO, echocardi ogram; ECOG, Eastern 
Cooperative Oncology Group; ; FFPE, formalin -fixed, paraffin -embedded; FISH, 
fluorescence in situ hybridization; FLC, free lightchain; H/E, Hematoxylin andeosin; hr(s), hour(s); ICF, informed consent form; IHC, immunohistochemistry; INR, international normalization 
ratio; PD, pharmacodynamic; ;PK, pharmacokinetics; PT, prothrombin time; PTT, partial thrombopl astin time; SPEP, serum protein electrophoresis; TSH, thyroid 
stimulating hormone; UPEP, urine protein electrophoresis
1.ICF: Informed consent should beobtained prior to performing any study -related procedure(s).
2.MEDICAL HISTORY: Medical History will include past and current medical conditions, including cardiovascular medical history and risk factors
3.DISEASE CHARACTERISTICS: Disease characteristics will include date of initial diagnosis, primary tumor type, histology, stage, etc.  NOTE: For WHO g rade 1-4cohorts only: IDH 
1/2 mutation status and MGMT m ethylatio n status will be collected , where available .
4.MUTATION TESTING:   Subjects may be enrolled based on local determination of BRAF V600E mutation status. Asubject may be tested for the BRAF V600E mutation greater than 28 
days prior to enrollment. (Any past results of local BRAF V600E mutation testing may be used to determine eligibility regardless of when the results were obtained.) Toenroll asubject,
the result of mutation testing from asponsor designated central reference laboratory is not required; however, if the subject does not have alocal result available, the sponsor 
designated central reference laboratory mutation test result will be required to determine eligibility for enrollment. NOTE:   Forsubjects with a solid tumor: Anarchived or fresh tumor 
tissue sample must be available to send toasponsor designated central reference laboratory for confirmation testing. NOTE: For subjects with HCL orMM:  Afresh BM aspi[INVESTIGATOR_681745] a peripheral blood sample are required for confirmation testing by [CONTACT_681873]. If aBMaspi[INVESTIGATOR_681746], 
please contact [CONTACT_681864]. In the event of adry tap, fresh or archived tumor tissues such as lymph node or plasmacytoma biopsies may be acceptable pending
medical lead approval. An archived tissue sample (such as FFPE tissue sample from aBM biopsy)  BM core samples and BM clot samples cannot be used. The same BM aspi[INVESTIGATOR_681747], thebaseline assessment

[COMPANY_001] Confidential Page 81
Amended Protocol Version 11                                                                                                 Protocol No. CDRB436X2201
26.DISEASE ASSESSMENTS (Solid Tumor Cohorts only): Baseline disease assessments must beperformed within 28days prior toenrollment (orwithin 35days ifMRI isused for
disease assessment).
27.DISEASE ASSESSMENTS (Solid Tumor Cohorts only): Disease assessments areevery 8weeks during thefirst48weeks ofstudy treatment, then every 12 weeks thereafter unless
otherwise noted, and at theFollow- upVisit. Confirmatory scan(s) aretobeperformed ≥28days after documented CRorPR. Ifsubject discontinues treatment forreasons other than
disease progression, disease assessments should continue every [ADDRESS_923226] withdrawal ofconsent, ordeath.
28.HISTOLOGY CONFIRMATION: (ATC andWHO grade 1-4cohorts only) Atissue specimen forpossible retrospective histology confirmation should beobtained andsubmitted toa
[COMPANY_001] designated central reference laboratory. Please refer totheSPM for the requirements ofthetissue specimen thatisrequired forthehistology confirmation.
29.NSGCT/NGGCT ONLY: AFP, B-HCG andLDH arethedisease assessment markers for the NSGCT/NGGCT cohort .LDH result obtained from clinical chemistry panel canbeused
asatumor marker result. Regardless ofbaseline values ofAFP,-HCG andLDH, ablood sample willbedrawn every 4weeks forfirst48weeks ofstudy treatment, then every 8to12
weeks thereafter, and at thetime ofdisease progression. Synchronize thecollection oftheblood sample withtheimaging schedule.
30.BTC/ASI ONLY : Ablood sample willbedrawn toassess CEA andCA19-9 every 4weeks forfirst48weeks ofstudy treatment, then every 8to12weeks thereafter, and at thetime of
disease progression. Synchronize thecollection oftheblood sample withtheimaging schedule.
31.HCL ONLY: Allrequired disease assessments necessary forapost- baseline response determination should beperformed every 4weeks (+/- 3days) for the first [ADDRESS_923227] every 12weeks (+/- 3 days) (Changed fro m “at least every 8 weeks (+/ -3 days) ”indicated in Protocol Amendment s 8 through 11) .  Patients that are not 
tolerating study drug in the judgement of the treating investigator must continue (or return to) response assessment evaluati on every 4 weeks (+/ -3 days).  Assessments 
must be collected in agreement with those required in the resp onse criteria (please consult Appendix 12) .
32.HCL ONLY: BMbiopsy andaspi[INVESTIGATOR_85878] H/Estain andIHCwillbeperformed when blood counts areconsistent with CRorPRfor4weeks (please consult Append ix 12 ).If
apatient hasaPR,andthen blood counts become consistent with aCRfor4weeks, arepeat BMaspi[INVESTIGATOR_681748]. Following
best response, abone marrow biopsy andaspi[INVESTIGATOR_681749] 6 months fortwotime intervals, then after ayear fortwotime intervals, then every twoyears.
33.HCL ONLY: Recommend thatflowcytometry panel consists ofCD19, CD20, CD22, SmIg, CD11c, CD25, CD103 andCD123. Flow cytometry ofthebone marrow aspi[INVESTIGATOR_681750]4weeks (please consult Appendix 12 ).Ifapatient hasaPR,andthen blood counts become consistent
with aCRfor4weeks, arepeat flow cytometry oftheBMaspi[INVESTIGATOR_681751].Following best response, aflow cytometry ofthebone marrow
aspi[INVESTIGATOR_681749] 6 months fortwotime intervals, then after ayear fortwotime intervals, then every twoyears.
34.HCL ONLY: BMbiopsy andaspi[INVESTIGATOR_337] (with H/Estain andIHC), BMaspi[INVESTIGATOR_337] (with flow cytometry) andperipheral blood sample (with flow cytometry) willbeassessed within 28
days prior toenrollment.
35.HCL ONLY: Achest CTscan and an abdominal CTscan withcontrast willbeperformed within 28days prior toenrollment .Ifanabdominal CTscan withcontrast cannot be
performed, then aMRI may beperformed within 35days prior toenrollment .If lymph nodes or spleen areenlarged atbaseline, then theabnormal organ needs tobefollowed on
post- baseline assessments using thesame modality ofimaging.
36.MMONLY: Askeletal survey should beperformed within 28days prior toenrollment. Ifmyeloma associated bony lesions arepresent at baseline, skeletal surveys should beperformed
every [ADDRESS_923228] oflateral radiographs oftheskull, AP
andlateral views ofthespi[INVESTIGATOR_050], andAPviews ofthehumeri, ribs, pelvis, andfemurs.
37.MMONLY: Each patient should beclinically examined forsofttissue plasmacytomas/extramedullary disease atbaseline and at each visitforresponse assessment. Ifextramedullary
disease ispresent at baseline, then Chest/Abdominal/Pelvis CTscan withcontrast should beperformed toconfirm andtodetermine sizeandlocation ofthesofttissue plasmacytoma.   If
nodisease isidentified atbaseline, then subsequent scans areonly required ifclinically indicated. Alternative imaging modality (i.e., MRI) may beused if it is better toassess thelesion
and approved by [CONTACT_681874]. Thesame imaging modality should beused forallsubsequent assessments.
38.MMONLY: BMaspi[INVESTIGATOR_681752], flowcytometry, FISH andcytogenetics within 90days prior enrollment .
[COMPANY_001] Confidential Page 84
Amended Protocol Version 11       Protocol No. CDRB436X2201
7.2 Demographic/Medical History Assessments
The following demographic parameters will be captured: date of birth, gender, race and 
ethnicity .  Medical/medication history will also be assessed as related to the eligibility criteria.
7.[ADDRESS_923229] may continue in the study .
ForSolid Tumor Histologies:
For solid tumor histologies, archived tumor tissue sample or fresh tumor tissue sample 
obtained by [CONTACT_373204] y must be submitted to the sponsor designated central reference laboratory
for central confirmatory testing of the BRAF V600E mutation.
If sufficient archived tumor tissue is not available for central confirmation of BRAF mutation 
status and the subject cannot undergo a repeat biopsy  to obtain an additional tumor tissue 
sample(s), the subject is NOT eligible for the study.
Table [ADDRESS_923230]
Performed? Result?Archived
Tumor
Tissue 
Sample?Tumor Sample 
tobe Obtained Eligible for Enrollment?BRAF V600E
Mutation Test
tobe
Performed?
[ADDRESS_923231] is not eligible for participation.
For Hematologic Histologies:
For the HCL and MM cohorts, a fresh BM aspi[INVESTIGATOR_12671] a corresponding peripheral 
blood sample are requ ired.
NOTE: For subjects in the HCL and MM cohorts, an archived tissue sample (such as 
formalin -fixed paraffin-embedded [FFPE] tissue sample from a BM biopsy ), BM core 
[COMPANY_001] Confidential Page [ADDRESS_923232] be performed within 28 daysof enrollment except
where indicated differently in the T&E table (Section 7.1). Guidance on baseline
documentation of target and non -target lesions will be provided in the SPM.
7.4 Safet y
Safety assessments and procedures, including the timing of the assessments, are summarized 
in the Time and Events Table (
Section 7.1). Additional time points for safety tests (such as 
vital signs, physical examinations, and laboratory safet y tests) may be added during the 
course of the stud ybased on newly available data to ensure appropriate safety  monitoring.
7.4.1 Physical Examinations
Complete Physica l Examination: A complete physical examination will be performed by
a qualified physician, physician assistant or nurse practitioner under the supervision ofa 
qualified physician, or another designee as permitted by[CONTACT_681875]. Atminimum, 
the examination should include assessments of the head and neck, eyes,ears, nose, throat, 
skin, thy roid, CNS, lungs, cardiovascular s ystem, abdomen (liver and spleen), ly mph nodes, 
extremities and genitalia.  Height (measured onl
yat Screening) a nd weight will be measured 
and recorded. Complete physical examinations will beperformed at Screening and at the 
post-treatment follow -up visit.
Complete physical examinations will also include thorough rectal and genitourinary (pelvic) 
examinations to assess secondary malignancies.
Rectal Examinations: Including digital rectal examination and visual inspection of
the anus and perianal area.
Pelvic Examinations (for female subjects only): Including visualization of cervix. At 
Screening, pelvic examination s may be completed up to [ADDRESS_923233] 
dose; thus, a subject’s most recent gynecological examination may be used to satisfy the 
screening requirements.  (Pap smear and/or colposcopy are not required unless 
clinically indicated.)
Brief Physical Examination: A brief ph ysical examination will include assessments of
thelymph nodes, skin, lungs, cardiovascular s ystem and abdomen (including liver and 
spleen assessment). Weight will be measured and recorded. Brief ph ysical 
examination will be performed on Day  [ADDRESS_923234], atthediscretion ofthe investigator. A complete or full body
dermatological examination will be performed at the time points indicated in the Time and 
Event Table ( Section 7.1) to identify  a ny abnormal skin lesions. All abnormal findings (i.e.,
[COMPANY_001] Confidential Page 87
Amended Protocol Version 11       Protocol No. CDRB436X2201
7.4.6 Electrocardiogram
Electrocardiogram s(12-Lead ECGs) will be obtained using an ECG machine that 
automatically  calculates heart rate and measures PR, QRS, QT, and QTc intervals. At each 
assessment, a 12-lead ECG will be performed by [CONTACT_681876] 5 minutes in a semi -recumbent or supi[INVESTIGATOR_2547].
Those QTc values >[ADDRESS_923235] be confirmed manually  
using Bazett’s formula given below:
QTcB = QT x (1/ √RR)
If there are any clinicall y significant abnormalities including, but not limited to,a QTcB >[ADDRESS_923236] 5 minutes apart.
As of Protocol Amendment 11, transmission of ECGs to a central storage facilit y is 
discontinued.  For all new ECGs obtained, two copi[INVESTIGATOR_681753]; the first copy  will be kept in the subject’s medical chart and the 
second copy will be kept in the study  file for retrospective collection by [CONTACT_681877] .
Refer to Section [IP_ADDRESS] for QTc withdrawal criteria and additional QTc readings that may
be necessary .
7.4.7 Echocardiogram
Echocardiograms (ECHOs) will be performed to assess cardiac ejection fraction and cardiac 
valve abnormalities. ECHOs will be performed at the time points indicated in the Time and 
Event Table (Section 7.1). The evaluation by[CONTACT_681878]- sided valvular lesion s.
The procedure (ECHO) to document the 
subject’s baseline LVEF status must be used 
consistently  throughout the study .  If possible, it is also preferred that interpretation of LVEF 
status be performed consistently  by [CONTACT_681879] . Copi[INVESTIGATOR_681754] b y the sponsor for review.  Instructions 
for submission of ECHOs are provided in the SPM.
7.4.[ADDRESS_923237] results available for review 
by [CONTACT_301216].
Urine tests for protein/creatinine may  be done up to 3 day s prior to the scheduled visit date. 
If a 24-hr urine collection for protein has been completed within 5 days prior to scheduled 
visit date, a urine sample for protein/creatinine is not necessary .
If additional non-protocol specified laboratory  assessments are performed at the institution’s 
local laboratory  and result in a change in subject management or are considered clinical 
significant by [CONTACT_093] (i.e., AE, SAE or dose modification) the results must be 
recorded in the subject’s eCRF.
All laboratory  tests with values that are significantly  abnormal during study  participation or 
within [ADDRESS_923238] dose of study  treatment(s) should be repeated until the values 
[COMPANY_001] Confidential Page [ADDRESS_923239] number, protocol number, site/center number, and visit date. Refer to the lab 
manual for appropriate processing and handling of samples to avoid duplicate and/or 
additional blood draws.
Refer to Appendix 17 for an estimation of the volume of blood samples collected during the 
study .
Table 6 Clinical Laboratory Assessments
Hematology
RBC CountRBC Indices (atScreening andifhemoglobin
decreases 2g/dL compared tobaseline):Automated
WBC
Differential:
Platelets MCV
MCH
MCHC
Reticulocyte CountLymphocytes
Monocytes
Eosinophils
BasophilsWBCCount
(absolute)
Hemoglobin
Hematocrit
Absolute neutrophil
count (ANC)
Clinical Chemistry
BUN Potassium Total Protein Total anddirect bilirubin1
Creatinine3Chloride2Phosphorus AST
Glucose UricAcid2 Magnesium ALT
Sodium Calcium LDH Alkaline Phosphatase
Albumin HbA1c6GGT
Coagulation
PT
PTT
INR
Urinalysis4
Color Specific gravity Ketones Urobilinogen
Appearance Glucose Blood
pH Protein5Leukocyte esterase
Other Tests
Amylaseandlipase [monitor vialocal laboratory when clinically indicated toevaluate certain AEs
(i.e., abdominal pain, pancreatitis, etc.)
Serum orurine -hCG6
Forsubjects withahistory ofchronic HBV and/or HCV, thefollowing tests willbeperformed at
Screening:
● Viral hepatitis serology;
● Hepatitis Bsurface antigen andHepatitis Bcore antibody (IgM); and/or
● Hepatitis CRNA
[COMPANY_001] Confidential Page 89
Amended Protocol Version 11       Protocol No. CDRB436X2201
Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate
aminotransferase; -hCG, Beta- human chorionic gonadotropin; BUN, blood urea nitrogen; GGT,
gamma glutam yltransferase; INR, international normalization ratio; HbA1C, hemoglobin A1C; HBV,
hepatitis Bvirus; HCV, hepatitis Cvirus; LDH, lactate dehy drogenase; MCV, meancorpuscular
volume; MCH, meancorpuscular hemoglobin; MCHC, meancorpuscular hemoglobulin
concentration; PT,prothrombin time;PTT, partial thromboplastin time;RBC, redblood cells; TSH,
thyroid stimulating hormone; ULN, upper limitofnormal; WBC,white blood cells
1. Direct bilirubin isrequired only ifthetotal bilirubin iselevated (2timestheULN)
2. Chemistry evaluation ofchloride oruricacid isnotrequired where there arelogistical constraints.
3. Ifserum creatinine is>2.0 mg/dL,calculate creatinine clearance using standard Cockcroft -Gault
method (Appendix 3).
4. Ifurine protein result isnotavailable, urine albumin result may beused.
5. For female subjects ofchildbearing potential only,unless subject has had ahysterectom y,
undergone atubal ligation within 1yearprior toScreening orhasbeen post-menopausal foratleast
1year prior toScreening.
HbA1c testing to be performed every 12 weeks (+/ -3 days) 
[IP_ADDRESS] Additional Histology Specific Assessments and Histology  
Confirmation
For ATC Cohort ONLY: Thyroid stimulating hormone (TSH) and Free T4: Serum TSH 
suppression (lowering TSH below the LLN) through the use of thyroid hormone replacement 
(e.g., levothy roxine) should be considered prior to the first dose of study  treatment and 
throughout the study .  However, the decision to suppress TSH is optional and dependent 
upon the investigator weighing the risk and benefits for each individual subject.  If the 
investigat or is unsure about suppressing the TSH, it is recommended that an endocrinologist 
be consulted. Free T4 will also be evaluated.
For NSGCT/NGGCT Cohort ONLY: -HCG and AFP: These laboratory  assessments
will be completed as indicated in the Time and Event Table ( Section 7.1).
For BTC and ASI Cohorts ONLY: CEA and CA19 -
9:These laboratory assessments will 
be completed as indicated in the Time and Event Table (Section 7.1).
Histology Confirmation for ATC and WHO Grade 
1-4 Glioma Cohorts ONLY:
A tissue specimen from the biopsy of a primary or metastatic site must be submitted to 
a [COMPANY_001] designated central reference laboratory as soon as possible after enroll ment 
for possible retrospective confirmation of histologic type. Refer to th eSPM and the Lab 
Manual for details regarding sample submission.
7.4.9 Monitoring for Non -Cutaneous Secondary /Recurrent Malignancy
Prior to initiation of treatment subjects should under go a head and neck examination with 
minimally  visual inspection of oral mucosa and lymph node palpi[INVESTIGATOR_332], as well as 
chest/abdomen CT scan. Subjects should be monitored as clinically indicated during 
treatment and for up to 6 months after treatment discon tinuation or until a new anti-cancer 
therap y is initiated. Anal examinations and pelvic examinations (for women) are required 
before and at the end of treatment or 
when considered clinicall y indicated. Complete blood 
cell counts should be performed as clinicall y indicated. Abnormal findings should be 
managed according to standard clinical practice.
Any new non -cutaneous secondary /recurrent malignancy  should be reported as an SAE and 
treated according to standard clinical practice.
[COMPANY_001] Confidential Page 90
Amended Protocol Version 11       Protocol No. CDRB436X2201
7.4.10 Pregnancy Testing and Reporting
[IP_ADDRESS] Pregnancy Testing
The need for a screening pregnancy test depends on whether a female subject is of 
childbearing or non -childbearing potential.
A female of non-childbearing potential (i.e., physiologically  incapable of becoming
pregnant) is defin ed as anyfemale who has had a hysterectomy , bilateral oophorectomy
(ovariectomy ) or bilateral tubal ligation, or is post-menopausal defined as 1 yearwithout
menses with an appropriate clinical profile, e.g., age appropriate, >45 years in the absence 
of hormone replacement therap y (HRT). Inquestionable cases, the subject must have a 
follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value <40 pg/mL 
(<140 pmol/L ).
Afemale ofchild -bearing potential is defined as anyfemale who does not meet the criteria 
of non -childbearing potential as described in the previous paragraph.
If a female subject is of 
childbearing potential, she must have a serum -HCG pregnancy test 
performed within [ADDRESS_923240] agree to use a highl y effective contraception method (see Section 9.1)during 
the study and for 16 weeks following discontinuation of trametinib when taken in combination 
with dabrafenib, or for 2 weeks following discontinuation of dabrafenib monotherap y.
[IP_ADDRESS] Pregnancy Reporting
Any pregnancy  that occurs during study  participati on must be reported using a clinical trial 
pregnancy  form. To ensure subject safet y, each pregnancy  must be reported 
to the sponsor 
within 24hours of learning of its occurrence.  The pregnancy  must be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported as 
an AE or SAE. Spontaneous abortions must be reported as an SAE.  Any SAE occurring in 
association with a pregnancy  brought to the investigator’s attention after the subject has 
completed the study  and considered by [CONTACT_107440] y related to the study  
treatment, must be promptly  reported to the sponsor.
[IP_ADDRESS] Time period for collecting pregnancy information
All pregnancies in female subjects and/or female partners of male subject will be collected 
after the start of dosing until the follow -up visit.
[IP_ADDRESS] Action to be taken if pregnancy occurs in a female partner of a male
study subject
The investigator will attempt to collect pregnancy information on any female partner of a 
male study subject who becomes pregnant while participating in this study.  The investigator 
will record pregnancy  information on the appropriate form and submit it to the sponsor within 
24hours of learning of the partner’s pregnancy .  The partner will also be followed to 
determine the outcome of the pregnancy .  Information on the status of the mother and child 
will be forwarded to the sponsor.  Generally, follow -up w ill be no longer than [ADDRESS_923241] is contraindicated (except for chest CT scan), a MRI  may be used 
as an alternative method of baseline disease assessment. If a chest CT scan with contrast is 
contraindicated, a chest CT scan without contrast should be performed.
The method used to document baseline status should be used consistently throughout study 
to facilitate comparison of scan results. Assessments must be performed on a calendar 
schedule and should not be affected by [CONTACT_681880] s. Refer to the Time and 
Events Table ( Section 7.1) for the schedule of disease assessments.
7.5.1 Disease Assessment for Solid Tumor Histologies
Disease assessment for solid tumor types (ATC, BTC, GIST, NSGCT/NGGCT, WHO Grade 
1 and 2 gliomas, WHO Grade 3 and 
4 gliomas and ASI) will be conducted as noted below.  
For subjects whose disease may be followed by [CONTACT_10070]-characterized tumor markers, disease 
assessment should also include results of tumor marker measurements.
Disease assessments will be completed as indicated in the Time and Events Table (Section 
7.1).
Please refer to the IAG for additional details on imaging assessments for this study .
Baseline Assessments: The following baseline disease assessments are required for all 
subjects within 28 days prior to enrollment (or withi n 
35 days if MRI is used for disease 
assessment:
HistologyArea(s) of
AssessmentImaging tobe
PerformedAlternative Imaging Methods if
Contraindications are Present
ATC1Brain MRI with
contrast1stalternative: MRI without contrast
2ndalternative: CTscan with contrast
Neck CT scan with
contrast1stalternative: aMRI with contrast 2nd
alternative: CT scan without contrast (if
1stalternative is contraindicated)
Chest/Abdomen
(including liver and
adrenal glands)CTscan2  N/A
BTC/ASI Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the
Chest and MRI with contrast of
Abdomen/Pelvis
NSGCT/NGGCT Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the
Chest and MRI with contrast of
Abdomen/Pelvis
GIST Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the
Chest and MRI with contrast of
Abdomen/Pelvis
ATC1BTC GIST
NSGCT/NGGCT ASI
WHO Grade 1-[ADDRESS_923242] scan, MRI,
orbone scan
asappropriate  N/A
WHO Grade 1- 4
GliomaBrain MRI with
contrast3N/A
NSGCT/NGGCT4 Brain (for pi[INVESTIGATOR_681755])MRI with
contrast1stalternative: MRI without contrast
2ndalternative: CTscan with contrast
Abbreviations: ASI, adenocarcinoma ofsmall intestine; ATC, anaplastic thyroid carcinoma; BTC, biliary tract carcinoma;
CNS, central nervous system; CR, complete response; CT,computed tomography; GCT, germ celltumor; GIST,
[COMPANY_001] Confidential Page 92
Amended Protocol Version 11       Protocol No. CDRB436X2201
gastrointestinal stromal tumor; MRI, magnetic resonance imaging; NGGCT, non-geminomatous germ celltumor;
NSGCT, non-seminomatous germ celltumor; PET, positron emission tomography; SPM, Study Procedures Manual;
WHO, World Health Organization
1. ForATC subjects without CNS andneck disease atbaseline, subsequent brain andneck imaging
should only beperformed asclinically indicated.
2. Optional: Whole body PET/CT scan
3. MRI ofthebrain withcontrast ismandated inthiscohort; CTscan isnotpermitted. Please refer to
imaging details intheSPM.
4. ForNSGCT/NGGCT subjects without CNS disease atbaseline, subsequent MRI ofthebrain with
contrast should only beperformed asclinically indicated (e.g., symptoms suggestive ofCNS
progression). Forsubjects withCNS disease atbaseline, aMRI ofthebrain withcontrast isrequired
every 4to8weeks or as clinically indicated. In addition, inorder toconfirm aCR in asubject withbrain
disease atbaseline, aMRI ofthebrain withcontrast must beperformed 1week prior tothefirstsetof
images showing CRto4weeks after thenext protocol specified assessment.
Post-Baseline Assessments: All post-baseline assessments require imaging of disease sites 
identified b y baseline scans.  The same imaging modality used at baseline should be utilized 
for all post-baseline assessments. If subject discontinues treatment prior to Week 48 for 
reasons other than disease progression, disease assessments (imaging) should continue every 
12 weeks until a new treatment is initiated.
HistologyArea(s) of
AssessmentImaging tobe
PerformedAlternative Imaging Methods if
Contraindications are Present
ATC Chest/Abdomen
(including liverand
adrenal glands)CTscan1  N/A
BTC, ASI Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the Chest and 
MRI with contrast of Abdomen/Pelvis
WHO Grade 1 -4
GliomaBrain MRI with
contrast2N/A
NSGCT/NGGCT,
GISTChest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the Chest and 
MRI with contrast of Abdomen/Pelvis
Abbreviations: ASI, adenocarcinoma ofsmall intestine; ATC, anaplastic thyroid carcinoma; BTC, biliary tract carcinoma;
CT,computed tomography; GIST, gastrointestinal stromal tumor; MRI, magnetic resonance imaging; NGGCT, non-
geminomatous germ celltumor; NSGCT, non-seminomatous germ celltumor; SPM, Study Procedu resManual; WHO,
World Health Organization
1. Optional: Whole body PET/CT scan
2. MRI withcontrast ismandated inthiscohort; CTscan isnotpermitted. Please refer toimaging details in
SPM.
[IP_ADDRESS] Response Criteria for Solid Tumor Histologies
For solid tumor ty pes (ATC, BTC, GI ST,NSGCT/NGGCT, WHO Grade 1 and 2 gliomas, 
WHO Grade 3 and 4 gliomas and ASI), response evaluations will be determined according 
to the response assessment criteria listed in Table 7 .
Table 7 Response Criteria for Solid Tumor Histologies
Histology Response CriteriaResponse Subcategories defined
as ‘Response4
ATC, BTC, GIST, ASI,
NSGCT/NGGCTRECIST v 1.11 CR, PR
WHO Grade 1 and 2
Gliom aRANO Response Criteria: Response
Assessment Criteria for
WHOGrade 1 and 2 Glioma2CR, PR and MR
[COMPANY_001] Confidential Page 93
Amended Protocol Version 11       Protocol No. CDRB436X2201
WHO Grade 3 and 4
Gliom aRANO Response Criteria: Updated
Response Assessment Criteria for 
WHOGrade 3 and 4 Glioma3CR,PR
Abbreviations: ATC, anaplastic thyroidcarcinoma; BTC, biliary tract cancer; CR,comple teresponse;
GIST, gastrointestinal stromal tumor; MR,minorresponse; NGGCT, non-geminomatous germ cell
tumor; NSGCT, non- seminomatous germ celltumor; PR,partial response; RANO, Response
Assessment inNeuro -Oncology; RECIST, Response Evaluation Criteria inSolid Tumors; SPM,
StudyProcedures Manual; WHO,WorldHealth Organization
1. Refer toAppendix 10 fordetails response criteria.
2. Refer toAppendix 13 fordetails response criteria
3. Refer toAppendix 14 fordetails response criteria
4. Serum tumor markers normalization willnot be considered aspartofresponse criteria.
7.5.2 Disease Assessment for Histologies of Hematologic Malignancies
For hematologic malignancies (HCL and MM), disease assessment will be conducted as 
noted below. For subjects whose disease may be followed by [CONTACT_10070]-characterized tumor 
markers, disease assessment should also include results of tumor marker measurements. 
Disease assessments will be completed as indicated in the Time and Events Table (Section 
7.1).
[IP_ADDRESS] Laboratory and Disease Assessments: HCL
Baseline Assessments: The following baseline disease assessments will beperformed at the 
time points indicated in the Time and Event Table (
Section 7.1):
Complete blood count
Routine stain of peripheral blood sample
BMaspi[INVESTIGATOR_681756] H/E stain and IHC
Flow cy tometry on BM aspi[INVESTIGATOR_681757]
Chest CT scan and abdominal CT scan with contrast
NOTE: MRI of the abdomen may be performed if abdominal CT cannot be performed. The 
method used to document baseline status is used consistently throughout the study to 
facilitate comparison of results.
If lymph nodes and spleen were enlarged at baseline, they must be followed by [CONTACT_447]-baseline 
assessments using a consistent imaging modality .
Post- Baselin eAssessments: A response is to be determined every  4 weeks (+/-3 days) for 
the first [ADDRESS_923243] every  12weeks (+/ -3 day s)(Changed from “at least every  8 weeks (+/ - 3 
days)” indicated in Protocol Amendments 8 through 11).  Patients that are not tolerating study 
drug in the judgement of the treating investigator must continue (or return to) response 
assessment evaluation every  4
 weeks (+/-3 days).  Assessments must be collected in 
agreement with those required in the respon se criteria (please consult Appendix 12).
Complete blood count
Routine stain of peripheral blood sample
BM aspi[INVESTIGATOR_681758] H/E stain and IHC
Flow cytometry on BM aspi[INVESTIGATOR_681759] ( Section 7.1).
[COMPANY_001] Confidential Page 94
Amended Protocol Version 11       Protocol No. CDRB436X2201
Flow cytometry on peripheral blood sample will be performed as indicated in the Time 
and Event Table ( Section 7.1)
If lymph nodes and/or 
spleen were enlarged at baseline, they must be followed by [CONTACT_447]-
baseline assessments using a consistent imaging modality as indicated in the Time and 
Event Table ( Section 7.1).
[IP_ADDRESS] Laboratory and Disease Asses
sment: MM
Baseline Assessments: The following baseline disease assessments will be performed atthe 
time points indicated in the Time and Event Table (Section 7.1):
Skeletal survey s
Extramedullary disease assessment BM aspi[INVESTIGATOR_681760]:  Samples
will be 
assessed by[CONTACT_4658], flow cytometry, fluorescence in situ hybridization (FISH) and 
cytogenetics.
UPEP
SPEP
CRP, -2 microglobulin, serum FLC assay, levels of immunoglobulin (Ig)G, IgA, and 
IgM
Post-baseline Assessments: All post -baseline assessments require imaging of disease sites 
identified by [CONTACT_301196].  The same imaging modality used at baseline should be utilized 
for all post -baseline assessments.
BM aspi[INVESTIGATOR_681761] ( Section 7.1)
Laboratory tests (SPEP, UPEP , CRP, -
2microglobulin, serum FLCassay ,levels of 
IgG, IgA, and IgM will be performed as indic ated in the Time and Event Table (Section 
7.1).
Skeletal survey s:  Post -baseline assessments onl y
need to be performed if disease is 
noted on the baseline assessment. If no disease is identified at baselin e, then subsequent 
skeletal survey s are onl y required if clinically  indicated.
Extramedullary disease assessment:  Post -baseline assessments only need to be
performed if disease is noted on the baseline assessment.  Ifno disease is identified at 
baseline, then subsequent assessments are onl y required if clinicall yindicated.
[IP_ADDRESS] Response Criteria for Hematologic Histologies
For hematologic malignancies (HCL and MM), response evaluations will be determined
according to the response assessment criteria listed in Table 8.
Table 8 Response Criteria for Hematologic Histologies
Histology Response Criteria Response Subcategories
defined as ‘Response'
HCLAdapted from NCCN guidelines, Consensus
Resolution Criteria and previous studies definition1CR±MRD, PR
[COMPANY_001] Confidential Page 95
Amended Protocol Version 11       Protocol No. CDRB436X2201
MM IMWG Uniform Response Criteria for MM2 sCR, CR, PR, VGPR
Abbreviations: CR,complete response; HCL, hairycellleukemia; IMWG,International Myeloma
WorkingGroup; MM, multiple myelom a;MRD, minimalresidual disease; NCCN, National
Comprehensive Cancer Network; PR,partial response; sCR, stringent complete response; SPM,
StudyProcedures Manual; VGPR, very good partial response
1. Refer toAppendix [ADDRESS_923244] dose level reduction is require d, study treatment should be permanentl y 
discontinued.
If a dose reduction of trametinib is required, but the toxicity resolves and no additional
toxicities are seen after one treatment cycle (4weeks
), the dose of trametinib may be re-
escalated but shoul d not exceed 2 mg once daily .
If a dose reduction of dabrafenib is required, but the toxicity  resolves and no additional 
toxicities are seen after one treatment cycle (4 weeks), the dose of dabrafenib may be re-
escalated but should not exceed [ADDRESS_923245] s err on the side of caution in these 
settings if treatment -related toxicity is a possibility .
Dose delay: Treatment with dabrafenib and trametinib ma y be delay ed for up to 21 daysto 
allow resolution of toxicity , or based on investigator discretion (e.g., scheduling issues).  If 
the investigator and the Medical Lead conclude that continued treatment will benefit a subject 
who has experienced a treatmen t delay >[ADDRESS_923246] may continue treatment 
with the approval of the Medical Lead .If a dose delay continues for 60 or more day s, then 
both study treatments (dabrafenib and trametinib) will be permanently  discontinued.
Subjects should complet e the Follow -Up Visit and then proceed to the extended follow -up 
phase as indicated in the Time and Events Table (Section 7.1).
Dose reduction: A dose reduction below 75 mg BID for dabrafenib or below 1 mgonce
daily for trametinib is not allowed.  If a dose reduction below 75 mg BID for dabrafenib is 
required, dabrafenib will be permanentl y discontinued, but the subjects will be allowed to 
continue treatment with trametinib.  I f a dose reduction below 1 mg once daily for trametinib 
is required, then trametinib will be permanently discontinued, but these subjects will be 
allowed to continue treatment with dabrafenib.
[COMPANY_001] Confidential Page 96
Amended Protocol Version 11       Protocol No. CDRB436X2201
If both study treatments are reduced below the minimum dose levels (75 mg BID for 
dabrafenib and 1 mg once daily for trametinib), then both study treatments will be 
permanentl y discontinued. Subjects should complete the Follow -Up Visit and then proceed 
to the extended follow -up phase as indicated in the Time and Events Table (Section 7.1).
For Grade 2 or 3 laboratory abnormalities that are considered unrelated to the study  treatment 
or those that are reversible in <48 hrs (except for liver enzymes) such aselectrol yte 
abnormalities may continue wi thout dose reductions.
Dose Escalation: Following a dose reduction, subjects may bere-escalated to a higher dose 
level with the approval of the Medical Lead .  If the AE has resolved to Grade 1or baseline 
at the reduced dose level, and no additional toxicities are seen after 4weeks of study
treatment at the reduced dose, the dose may be increased to the previous dose level.
Table 9 describes 
the dose /schedule to be used for any necessary dose modifications (based 
on the initial dose level of 150 mg BID) for dabrafenib.
Table 9 Dabrafenib Dose Levels
Dose Level Dose/Schedule
0 150 mg BID
-1 (first dose reduction) 100 mg BID
-2 (second dose reduction) 75 mg BID
Table 10 describes the dose /schedule to be used for anynecessary dose modifications (based 
on the initial dose level of 2 mg once dail y) for trametinib.
Table 10 Trametinib Dose Levels
Dose Level Dose/Schedule
0 2mg once daily
-1 (first dose reduction) 1.5 mg once daily
-2 (second dose reduction) 1mg once daily
Table 11 Dose Modification Guidelines –General
CTCAE Grade Action andDose Modification1,2
Grade 1or Grade 2(Tolerable)
Any occurrence  Continue treatment with dabrafenib and trametinib at same dose 
level (no dose modification)
  Grade 2(Intolerable) or Grade [ADDRESS_923247], 2ndor 3rdoccurrence  Interrupt dabrafenib and trametinib until toxicity resolves to ≤
Grade 1 then restart at next lower dose level
4thor greater occurrence  Discontinue treatment with dabrafenib and trametinib
  Grade 4
[COMPANY_001] Confidential Page 97
Amended Protocol Version 11       Protocol No. CDRB436X2201
1stoccurrence  Interrupt dabrafenib and trametinib until toxicity resolves to ≤
Grade 1 or baseline then restart at next lower dose level or 
discontinue at the discretion of the investigator
2ndoccurrence  Interrupt dabrafenib and trametinib until toxicity resolves to ≤
Grade 1 or baseline then restart at 2 dose levels lower than the 
starting dose or discontinue at the discretion of the investigator 
and after discussion with the Medical Lead.
3rdoccurrence  Discontinue treatment with dabrafenib and trametinib
1. Treatment should bediscontinued ifmore than 2dose reductions arerequired
2. Approval from theMedical Lead isrequired torestart study treatment after ≥21days
8.1.[ADDRESS_923248] been seen in subjects receiving trametinib, dabrafenib or both in
combination.  Guidelines for prolonged QTc interval, LVEF decreases, and hypertension are 
provided in Section [IP_ADDRESS], Section [IP_ADDRESS] and Section [IP_ADDRESS] ,respectively.
[IP_ADDRESS] QTc Prolongation
Guidelines for dose modification and stoppi[INVESTIGATOR_681762] 12.
Table 12 Withholding and Stoppi[INVESTIGATOR_681763]1 Action and Dose Modification
QTcB ≥501 msec Interrupt treatment with trametinib and dabrafenib until QTc 
prolongation resolves to Grade 1or baseline
Test serum potassium, calcium, phosphorus and magnesium. If 
abnormal, correct per routine clinical practice to within normal 
limits.
Review concomitant medication usage for agents that prolong 
QTc.
If event resolves, restart trametinib and dabrafenib at current dose 
level2
If event does not resolve, permanently discontinue study 
treatme nts. Consider evaluation with cardiologist.
If event recurs, permanently discontinue trametinib and dabrafenib. 
Consider evaluation with cardiologist.
Abbreviations: ECG, electrocardiogram; msec, milliseconds; QTc, corrected QTinterval; QTcB, QTinterval onECG
corrected using theBazett’s formula
1. Based onaverage QTc value oftriplicate ECGs. Forexample, ifanECG demonstrates aprolonged QTinterval,
obtain 2ormore ECGs over abrief period, andthen usetheaveraged QTc values ofthe3ECGs todetermine
iftrametinib anddabrafenib should be interrupted or discontinued.
2. IftheQTc prolongation resolves toGrade 1orbaseline, thesubject may resume treatment withtrametinib and
dabrafenib iftheinvestigator andMedical Lead agree thatthesubject willbenefit from further treatment.
[IP_ADDRESS] Left Ventricular Ejection Fraction (LVEF) Stoppi[INVESTIGATOR_681764].  Therefore, ECHOs must be performed to assess cardiac 
ejection fraction at regular intervals as outlined in the Time and Events Table ( Section 7.1).
[COMPANY_001] Confidential Page 98
Amended Protocol Version 11       Protocol No. CDRB436X2201
Echo assessment should be performed by[CONTACT_681881] .  Copi[INVESTIGATOR_681765].  I nstructions for 
submission of ECHOs are provided in the SPM. Dose modification guidance andstoppi[INVESTIGATOR_681766] 13.
Table 13 Dose 
Modification Guidelines and Stoppi[INVESTIGATOR_681767] (%)
orCTCAE Grade Action andDose Modification
Asymptomatic Absolute decrease of
>10% inLVEF
compared tobaseline
andejection fraction
below theinstitutional
LLN● Interrupt study treatment andrepeat ECHO within 2 weeks1
● Report asanAEIftheLVEF recovers within 4 weeks (defined as
LVEF ≥LLNandabsolute decrease ≤10% compared tobaseline)
● Consult withtheMedical Lead andrequest approval forrestart
● Restart treatment withtrametinib reduced dose by [CONTACT_681882]
● Restart dabrafenib atprevious dose level
● Repeat ECHO 2 , 4 , 8 and12weeks after re-start; continue in
intervals of 12 weeks thereafter
● IfLVEF does notrecover within 4weeks
● Consult withcardiologist
● Permanently discontinue study treatment
● Repeat ECHO after 2, 4, 8, 12, and 16weeks oruntil
resolution
● Consult withtheMedical Lead
Symptomatic2Grade 3: ● Permanently discontinue study treatment
resting LVEF 39to
20%
or>20% absolute● Report asaSAE
reduction from
baseline● Consult withcardiologist
Grade 4:
resting LVEF <20%● Repeat ECHO after 2,4, 8, 12,and 16 weeks oruntil resolution 2,
Abbreviations: AE,adverse event; CTCAE, Common Toxicity Criteria forAdverse Events; ECHO,
echocardiogram; LLN, lower limitofnormal; LVEF, leftventricular ejection fraction; SAE, serious
adverse event
1. IfECHO does notshow LVEF recover yafter 2weeks, repeat ECHO 2weeks later.
2. Sy mptoms may include: dyspnea, orthopnea ,andother signs andsymptoms ofpulm onary
congestion andedema.
[IP_ADDRESS] Hypertension
Increases in BP have been observed in subjects receiving trametinib. Recommendations for 
blood pressure monitoring and management are provided in Section [IP_ADDRESS].1 andSection
[IP_ADDRESS].2, respectivel y.
[IP_ADDRESS].1 Monitoring of Hypertension
All BP assessments should be performed under optimal conditions:
the subject i s seated in a semi
-supi[INVESTIGATOR_681768], ensuring that legs are 
uncrossed and flat on the floor
the subject sits relaxed comfortably for at least 5 minutes
restrictive clothing is removed from the cuff area and the right cuff size is selected
the subject’s arm is supported so that the middle of the cuff is at the heart level
the subject remains quiet during the measurement
[COMPANY_001] Confidential Page [ADDRESS_923249] readings averaged to give the measurement to be recorded in the eCRF.
Persistent hypertension is defined as an increase of systolic blood pressure (SBP) >140 
mmHg and/or diastolic blood pressure (DBP) >90 mmHg in 3 consecutive visits with BP 
assessments from the readings collected as described above. Visits to monitor increased BP 
should be scheduled independentl y from the per-protocol visits outlined inthe Time and 
Events Table (Section 7.1).Ideall y, subsequent BP assessments should beperformed within 
7 day s.
Asymptomatic hypertension is defined as an increase of SBP >140 mmHg and/or DBP >90 
mmHg in the absence of headache, lightheadedness, vertigo, tinnitus, epi[INVESTIGATOR_681769].
[IP_ADDRESS].2 Management of Hy pertension
For subjects experiencing an increase in systolic and/or diastolic BP that is persistent and
may be associated with the study treatment, recommendations for the clinical management 
of hy pertension are described in Table 14.
Table 14 Management and Dose Modification Guidelines for Hy pertension
Hypertension Action and Dose Modification
(A). Asymptomatic and persistent1
SBP of ≥140 mmHg and <160
mmHg, or DBP
≥90mmHg and <100 mmHg, or a 
clinically significant increase in
DBP of 20 mmHg (but still
<100 mmHg).● Continue study treatments at the current dose
● Adjust current or initiate new antihypertensive medication(s)
● Titrate antihypertensive medication(s) during the next 2 weeks as
indicated to achieve well -controll ed2BP
● If BP is not well controlled within [ADDRESS_923250] and go to scenario (B).
(B). Asymptomatic SBP
≥160mmHg, or
DBP ≥100 mmHg, or failure to
achieve well -controlled BP within
2 weeks in scenario (A).● Interrupt study treatments if clinically indicated
● Adjust current or initiate new antihypertensive medication(s)
● Titrate antihypertensive medication(s) during the next 2 weeks as
indicated to achieve well -controlled BP
● Once BP is well controlled2,restart study treatments reduced by [CONTACT_163828]3
(C).Symptomatic4hypertension
or persistent SBP ≥160 mmHg, or 
DBP ≥100mmHg, despi[INVESTIGATOR_681770](s)
and dose reduction of study
treatment● Interrupt study treatments
● Adjust current or initiate new antihypertensive medication(s)
● Titrate antihypertensive medication(s) during the next 2 weeks as
indicated to achieve well -controlled BP
● Referral to a specialist for further evaluation and follow -up is
recommended
● Once BP is well cont rolled2, restart study treatments reduced by [CONTACT_163828]3
Hypertension Action and Dose Modification
(D). Refractory hypertension
unresponsive to above
interventions or hypertensive crisis● Permanently discontinue study treatments
● Continue follow -upper protocol.
Abbreviations: BP,blood pressure; DBP, diastolic blood pressure; mmHg, millimeters ofmercury; SBP, systolic blood
pressure
1. Hypertension detected in2separate readings during upto3consecutive visits
2. Well- controlled BPdefined asSBP140mmHg andDBP90mmHg in2separate readings during upto3
consecutive visits
3. Escalation toprevious dose level canbeconsidered ifBPremains well-controlled for4weeks after
restarting. Approval from theMedical Lead isrequired.
[COMPANY_001] Confidential Page 100
Amended Protocol Version 11       Protocol No. CDRB436X2201
4. Symptomatic hypertension defined ashypertension aggravated by[CONTACT_23805] (e.g. headache,
lightheadedness, vertigo, tinnitus, epi[INVESTIGATOR_681771]) thatresolve after the BPi[INVESTIGATOR_681772].
8.1.2 Pancreatitis
In the event of abdominal pain or suspected pancreatitis, amylase and lipase laboratory
samples should be collected for confirmation of the diagnosis.  Subjects should be closely
monitored when re -starting study treatment after an epi[INVESTIGATOR_28547].
8.1.3 Hepatobiliary Events
[IP_ADDRESS] Liver Chemistry Stoppin g Criteria
Liver chemistry stoppi[INVESTIGATOR_681773] y and evaluate liver event etiology  in alignment with the FDA premarketing
clinical liver safety guidance
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid 
ances/UCM174090.pdf
[IP_ADDRESS].1 Liver Chemistry Stoppi[INVESTIGATOR_681774] ≤2.5xULN

[COMPANY_001] Confidential Page 101
Amended Protocol Version 11       Protocol No. CDRB436X2201
Table 15 Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_681775]≤2.5xULN
ALT-absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4weeks
Bilirubin1,2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be related
to liver injury or hypersensitivity
Abbreviations: ALT, alanine aminotransferase; INR, international normalization ratio; ULN, upper limitofnormal
1. Serum bilirubin fractionation should beperformed iftesting isavailable. Ifserum bilirubin fractionation isnot
immediately available, discontinue study treatment forthat subject if ALT 3xULN and bilirubin 2xULN.
Additionally, ifserum bilirubin fractionation testing isunavailable, record presence ofdetectable urinary bilirubin
ondipstick, indicating direct bilirubin elevations andsuggesting liver injury.
2. Allevents ofALT3xULN and bilirubin 2xULN (>35% direct bilirubin) orALT3xULN and INR>1.5, ifINR
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must bereported as an SAE (excluding
studies ofhepatic impairment orcirrhosis) ;INRmeasurement isnotrequired andthethreshold value stated
willnotapply tosubjects receiving anticoagulants
3. New orworsening symptoms believed toberelated toliver injury (such asfatigue, nausea, vomiting, right upper
quadrant pain ortenderness, orjaundice) orbelieved toberelated tohypersensitivity (such asfever, rash or
eosinophilia)
[IP_ADDRESS].2 Liver Chemistry Stoppi[INVESTIGATOR_301074] A lgorithm
including Subjects WITH Documented Liver Metastases/Tumor
Infiltration at Baseline AND entry criteria A LT>2.5xULN but ≤5xULN

[COMPANY_001] Confidential Page 102
Amended Protocol Version 11       Protocol No. CDRB436X2201
Table 16 Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_53056]: 
Subjects with Documented Liver Metastases/Tumor Infiltration at Baseline AND Entry Criteria ALT >2.5xULN but ≤5xULN
ALT-absolute Both ALT ≥5xULN and≥2x baseline value
ALT Increase Both ALT ≥3xULN and≥1.5x baseline value that persistsfor 4 weeks
Bilirubin1,2 ALT ≥3xULN andbilirubin2xULN (>35% direct bilirubin)
INR2 ALT ≥3xULN andINR>1.5, if INR measured
Cannot Monitor Both ALT ≥3xULN and≥1.5x baseline value that cannot be monitored for 4weeks
Symptomatic3 Both ALT ≥3xULN and≥1.5x baseline value associated with symptoms (new or
worsening) believed to be related to liver injury or hypersensitivity
Abbreviations: ALT, alanine aminotransferase; INR, international normalization ratio; ULN, upper limit of normal
1.Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not immediately
available, discontinue study treatment for that subject if ALT %3xULN andbilirubin %2xULN. Additionally, if serum bilirubin
fractionation testing is unavailable, record presence of detectable urinary bilirubin on dipstick , indicating direct bilirubin
elevations and suggesting liver injury.
2.All events of ALT %3xULN and bilirubin %2xULN (>35% direct bilirubin) or ALT %3xULN and INR>1.5, if INR measured
which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding studies of hepatic
impairment or cirrhosis) ; INR measurement is not required and the threshold value stated will not apply to subjects
receiving anticoagulants
3.New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper quadrant
pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or eosinophilia)
[IP_ADDRESS].3 Liver Safety Required Actions and Follow-Up
Table 17 Required Actions and Follow-Up Assessments Following ANY
Liver Stoppi[INVESTIGATOR_159833]-Up Assessments
∀Immediately discontinue study treatments
∀Report the event to the sponsor within 
24 hrs
∀Complete the liver event eCRF andcomplete an SAE data collection tool if the event also meets the criteria for an SAE
2
∀Perform liver event follow-up assessments
∀Monitor the subject until liver 
chemistries resolve, stabilize, or return 
to within baseline (see MONITORING
below)
∀Do not restart/rechallenge subject 
with study treatment unless allowed perprotocol and the sponsor Medical
Governance approval is granted (refer
toAppendix 18 )∀Viral hepatitis serology1
∀Only in those with underlying chronic hepatitis 
B at study entry (identified by [CONTACT_23977] B surface antigen) quantitative hepatitis B DNA and hepatitis delta antibody
3.
∀Blood sample for PK analysis, obtained 24-[ADDRESS_923251] dose
4
∀Serum creatine phosphokinase and lactate dehydrogenase.
∀Fractionate bilirubin, if total bilirubin %2xULN
∀Obtain complete blood count with 
differential to assess eosinophilia
∀Record the appearance or worsening of clinical symptoms of liver injury, or hypersensitivity, on the AE eCRF
∀Record use of concomitant medications on the concomitant medications report 
[COMPANY_001] Confidential Page 103
Amended Protocol Version 11       Protocol No. CDRB436X2201
Ifrestart/rechallenge not allowed per
protocol or not granted , permanently
discontinue study treatments and may
continue subject in the study for any
protocol specified follow -up 
assessments
MONITORING:
Forbilirubin orINR criteria:
Repeat liver chemistries (include ALT,
AST, alkaline phosphatase, bilirubin) 
andperform liver event follow -up 
assessments within 24 hrs
Monitor subjects twice weekly until 
liver chemistries resolve, stabilize or 
return to within baseline
Aspecialist or hepatology consultation 
isrecommended
For Allother criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow -up assessments within 24-
72hrs
Monitor subjects weekly until liver
chemistries resolve, stabilize or return to
within baselineform including acetaminophen, herbal 
remedies, other OTC medications
Record alcohol use on the liver event alcohol 
intake eCRF
For bilirubin or INR criteria:
Anti-nuclear antibody, anti-smooth muscle 
antibody, Type 1anti-liver kidney microsomal 
antibodies, and quantitative total 
immunoglobulin G(IgG or gamma globulins).
Serum acetaminophen adduct HPLC assay
(quantifies potential acetaminophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week
[James ,2009]).
Liver imaging (ultrasound, MRI or CT) and /or 
liver biopsy to evaluate liver disease;
complete Liver Imaging and/or Liver Biopsy 
eCRF.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, computed
tomography; DNA, deoxyribonucleic acid; eCRF, electronic case report form; HPLC, high performance liquid
chromatography; hrs, hours; IgG, Immunoglobulin G;IgM, Immunoglobulin M;INR, international normalization ratio; MRI,
magnetic resonance imaging; OTC, over-the-counter; PCR, polymerase chain reaction; PK, pharmacokinetic; RNA,
ribonucleic acid; SAE, serious adverse event; SRM, study reference manual; ULN, upper limitofnormal
1. Includes: Hepatitis AIgMantibody; Hepatitis Bsurface antigen andHepatitis BCore Antibody (IgM); Hepatitis CRNA;
Cytomegalovirus IgMantibody; Epstein -Barr viral capsid antigen IgMantibody (orifunavailable, obtain heterophile
antibody or monospot testing); Hepatitis EIgMantibody.
2. Allevents ofALT3xULN and bilirubin 2xULN (>35% direct bilirubin) orALT3xULN and INR>1.5, ifINR
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must bereported as an SAE (excluding
studies ofhepatic impairment orcirrhosis) ;INRmeasurement isnotrequired andthethreshold value stated will
notapply tosubjects receiving anticoagulants
3. Ifhepatitis delta antibody assay cannot beperformed, itcanbereplaced withaPCR ofhepatitis DRNA virus (where
needed) [LeGal,2005].
4. PKsample may not be required forsubjects known tobereceiving placebo or non- sponsor comparator treatments.)
Record thedate/time ofthePKblood sample draw andthedate/time ofthelastdose ofstudy treatment prior toblood
sample draw ontheeCRF. Ifthedate ortime ofthelastdose isunclear, provide thesubject’s best approximation. If
thedate/time ofthelastdose cannot beapproximated ORaPKsample cannot becollected inthetime period
indicated above, do not obtain aPKsample. Instructions forsample handling andshippi[INVESTIGATOR_681776].
[COMPANY_001] Confidential Page [ADDRESS_923252] with entry criteria ALT≤2.5xULN
ALT 3xULN but <5xULN and bilirubin
<2xULN, without symptoms believed to be 
related to liver injury or hypersensitivity and
who can be monitored weekly for
[ADDRESS_923253] with documented liver
metastases/tumor infiltration at baseline 
AND entry criteria ALT>2.5xULN but 
≤5xULN
ALT ≥3xULN and 1.5x baseline value but
ALT <5xULN and 2x baseline value and
bilirubin <2xULN ,without symptoms
believed to be related to liver injury, or
hypersensitivity andwho can be monitored 
weekly for 4weeksNotify the Medical Lead within [ADDRESS_923254] safety.
Subject can continue study treatments
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
For subjects with entry criteria ALT ≤2.5xULN
If, after 4weeks of monitoring, ALT <3xULN and 
bilirubin
<2xULN, monitor subjects twice monthly until live r
chemistries normalize or return to within baseline.
For subjects with documented liver metastases/tumor
infiltration at baseline AND entry criteria ALT>2.5xULN but
≤5xULN
If, after 4weeks of monitoring, ALT <3xULN and <1.5x
baseline value, and bilirubin <2xULN, monitor subjects twice 
monthly until liver chemistries normalize or return to within 
baseline
Refer to Appendix [ADDRESS_923255]
The severit y of AEs will be graded utilizing the CTCAE v4.0 [ NCI, 2009]. Brief guidelines 
for dose modifications and interruptions for management of common toxicities associated 
with the study  treatments are provided in this section.
8.2.1 Dermatological Events
[IP_ADDRESS] Rash
Rash is frequently observed in subjects receiving trametinib, dabrafenib, or the combination 
of both therapi[INVESTIGATOR_014].  Guidelines for management are based on experience with other MEK 
inhibitors and epi[INVESTIGATOR_147778] [Balagula , 2011; LaCouture , 2011].
The institutional standards for the management of skin-related AEs can differ from these
guideli nes. In this case, best clinical judgment should be applied and a consultation with the 
Medical Monitor may be required.
Table 19 Guidelines for Supportive Care of Rash
[COMPANY_001] Confidential Page 105
Amended Protocol Version 11       Protocol No. CDRB436X2201
Type of Care Action
Prevention/Prophylaxis1 Avoid unnecessary exposure to sunlight
 Apply broad -spectrum sunscreen (containing titanium dioxide orzinc 
oxide) with askin protection factor (SPF) ≥[ADDRESS_923256] BID.
 Use thick, alcohol -free emollient cream (e.g., glycerine and 
cetomacrogol cream) on dry areas of the body at least BID.
 Topi[INVESTIGATOR_681777] 1of study treatment, to body areas such as face, 
chest, and upper back.
 Use mild -strength topi[INVESTIGATOR_27560] (hydrocortisone 1% 
cream)
or
 topi[INVESTIGATOR_11978] (e.g., clindamycin) or oral antibiotics 
(e.g., doxycycline 100 mg BID, minocycline 100 mg 
BID)
Symptomatic Care2 Pruritic lesions: cool compresses and oral antihistamine therapi[INVESTIGATOR_014]
 Fissuring lesions: Monsel’s solution, silver nitrate, or zinc oxide cream
 Desquamation: thick emollients and mild soap
 Paronychia: antiseptic bath, local potent corticosteroids in addition 
to oral antibiotics; if no improvement, consult dermatologist or 
surgeon
 Infected lesions: appropriate bacterial/fungal culture- driven 
systemic or topi[INVESTIGATOR_681778]: BID, twice daily; SPF, sunprotection factor
1. Rash prophylaxis isrecommended for the first6weeks ofstudy treatment
2. Subjects who develop rash/skin toxicities should beseen by[CONTACT_681883]/supportive care management
Guidelines for management and dose reduction for rash considered to be related to study
treatment are provided in Table 20.
Table 20 Management and Dose Modification Guidelines for Rash
CTCAE Grade Adverse Event Management Action and Dose Modification
Grade 1

Initiate prophylactic and
symptomatic treatment measures1
Use moderate strength topi[INVESTIGATOR_681779]2
Reassess after 2weeks Continue study treatment
 If rash does not recover to
baseline within 2weeks 
despi[INVESTIGATOR_681780], reduce trametinib by 
[CONTACT_30560]3
Grade 2

Initiate prophylactic and
symptomatic treatment measures
Use moderate strength topi[INVESTIGATOR_681779]2
Reassess after 2weeks Reduce study treatment by 
[CONTACT_100699]
Ifrash recovers to
≤Grade 1within 2weeks, 
increase dose to previous 
dose level
[COMPANY_001] Confidential Page 106
Amended Protocol Version 11       Protocol No. CDRB436X2201
CTCAE Grade Adverse Event Management Action and Dose Modification
If no recovery to≤Grade 
1within 2weeks, 
interrupt study treatment 
until recovery to
≤Grade 1
 Restart study 
treatment at reduced
dose level3
Grade ≥3
Use moderate strength topi[INVESTIGATOR_225215]2PLUS oral methyl -
prednisolone dose pack
Consult dermatologist Interrupt study treatment until 
rash recovers to Grade ≤1
 Restart3with study 
treatment reduced by 
[CONTACT_30560]4
 If no recovery to Grade ≤2
within 4 weeks, permanently 
discontinue study treatment.
Abbreviations: CTCAE, Common Terminology Criteria forAdverse Events
1. Rash prophylaxis isrecommended for the first6weeks ofstudy treatment
2. Moderate- strength topi[INVESTIGATOR_8826]: hydrocortisone 2.5% cream or fluticasone propi[INVESTIGATOR_16847] 0.5%cream
3. Approval oftheMedical Lead isrequired torestart study treatment after >4weeks ofinterruption.
4. Escalation ofstudy treatment toprevious dose level may beconsidered ifno rash isevident 4weeks after restarting
study treatment
[IP_ADDRESS] Palmar -plantar Erythrody sesthesia
Palmar- plantar erythrody sesthesia (PPE) syndrome: Measures for PPE syndrome should 
include lifest yle modification (avoidance of hot water, traumatic activity , constrictive 
footwear, or excessive friction on the skin and the use of thick cotton socks and gloves, and 
shoes with padded insoles) and symptomatic treatments. Appl y moisturizing creams 
frequentl y, topi[INVESTIGATOR_477365] (e.g., urea 20 to 40% cream, salicy lic acid 6%, tazarotene 0.1% 
cream, fluorouraci l 5% cream), clobetasol propi[INVESTIGATOR_16847] 0.05% ointment for erythematous areas, 
topi[INVESTIGATOR_24242] 2%, and/or systemic pain medication such as nonsteroidal anti-
inflammatory  drugs, codeine, and pregabalin for pain.  Dose modification may also be 
required.
[IP_ADDRESS] SCA Rs (Sev ere Cutaneous A dverse Reactions)
Cases of severe cutaneous adverse reactions (SCARs), including Stevens -Johnson syndrome, 
and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-
threatening or fatal, have been reported during treatment with dabrafenib in combination with 
trametinib.  Before initiating treatment, patients should be advised of the signs and symptoms 
and monitored closely  for skin reactions.  If signs and symptoms suggestive of SCARs appear, 
dabrafenib and tram etinib should be permanentl y discontinued.
[COMPANY_001] Confidential Page 108
Amended Protocol Version 11       Protocol No. CDRB436X2201
8.2.3 Pyrexia
Pyrexia, defined as a body temperature 38.5○C (101.3○F), has been observed in subjects
receiving dabrafenib monotherap y,and is increased in incidence and severity in subjects
receiving dabrafenib in combination with trametinib.  Ina minority  of cases, pyrexia was
accompanied by[CONTACT_483020]/rigors, deh ydration, hypotension, dizziness 
or weakness and required hospi[INVESTIGATOR_059].
Subjects should be instructed on the importance of immediately reporting febrile epi[INVESTIGATOR_1841].  
In the event of a fever, the subject should be instructed to take anti-pyretics (i.e., ibuprofen 
or acetaminophen/paracetamol) as appropriate to control fever. The use of oral 
corticosteroids should be considered in those instances in which anti-pyretics areinsufficient. 
In subjects experiencing and after pyrexia associated with rigors, severe chills, dehy dration, 
hypotension, serum creatinine and other evidence of renal function should be monitore d 
carefully .
Guidelines regarding management and dose reduction for pyrexia considered to be related to 
dabrafenib are provided in Table 21.
Table [ADDRESS_923257] Event2: 1.Administer anti -pyretic treatment if clinically indicated and initiate prophylactic
treatment if associated with rigors, renal failure, dehydration or hypotension5
2.Interrupt treatment with dabrafenib; continue treatment with trametinib.
3.Once pyrexia resolves to baseline, restart treatment with dabrafenib at the 
same dose level; continue treatment with trametinib at current dose level.
4.If fever is associated with dehydration, hypotension, or renal insufficiency,
reduce dabrafenib by [CONTACT_30560]; continue treatment with trametinib at 
current dose level7.
Second Event 1.Follows same guidelines as for First Event (see above), and
2.Within 3days of onset
Optimize anti-pyretic therapy
Consider oral corticosteroids (i.e., prednisone 10 mg) for at least 5days 
or as clinically indicated6
Subsequent
Events :1.Interrupt treatment with dabrafenib; continue treatment with trametinib.
2.Once pyrexia resolves to baseline, restart treatment with dabrafenib at dose
reduced by [CONTACT_30560]; continue treatment with trametinib at current dose
level.6
3.Within 3days of onset:
Optimize oral corticosteroid dose as clinically indicated for recalcitrant
pyrexia.7
If corticosteroids have been tapered and pyrexia recurs, restart steroids.
If corticosteroids cannot be tapered, consult Medical Lead.
Abbreviations: BUN, blood urea nitrogen; CRP, C-reactive protein
1. Pyrexia isdefined asabody temperature equal toorabove 38.5○C(101.3○F)
2. Forsubjects experiencing pyrexia complicated by[CONTACT_483021], severe chills, etc., aclinical evaluation andlaboratory work -
upi[INVESTIGATOR_681781]; non-steroidal anti-pyretic treatments should bestarted immediately atthe first
occurrence and prophylactic non-steroidal anti-pyretic treatment isrecommended when restarting after an
interruption.
[COMPANY_001] Confidential Page 109
Amended Protocol Version 11       Protocol No. CDRB436X2201
3. Thorough clinical examination forsigns andsymptoms ofinfection orhypersensitivity isrequired; laboratory work -up
should include full-blood -count, electrolytes, creatinine, BUN, CRP, liver function tests, blood culture, and urine
culture.
4. Oral hydration should beencouraged insubjects without evidence ofdehydration. Intravenous (IV)hydration is
recommended insubjects experiencing pyrexia complicated by [CONTACT_114475]/hypotension.
5. Non-steroidal anti-pyretic treatment may include acetaminophen (paracetamol), ibuprofen, orother suitable anti-
pyretic medication according toinstitutional standards. Prophylactic non-steroidal anti-pyretic treatment may be
discontinued after 3days intheabsence ofpyrexia
NOTE: Forsubjects withMM, alternative anti-pyretic treatment (i.e., acetaminophen [paracetamol] orother suitable
anti-pyretic medication should betaken asNSAIDs areprohibited (see Section 10.2)
6. Dabrafenib should be reduced by [CONTACT_681884], including increasing doses oforal steroids. Re-
escalation ofdabrafenib isallowed ifnoepi[INVESTIGATOR_681782]4weeks subsequent todose reduction.
7. Insubjects experiencing pyrexia complicated by[CONTACT_483021], severe chills, etc., which cannot becontrolled with non-
steroidal anti-pyretic medication, oralcorticosteroids should bestarted atthesecond event anddoses should be
gradually increased forsubsequent events.
8.2.4 Pneumonitis
Pneumonitis has been observed in subjects receiving trametinib monotherapy  and trametinib 
in combination with dabrafenib.  To reduce the risk of pneumonitis, subjects will be 
monitored closely  for symptoms and evaluated with imaging and functional tests. Dose 
modification and supportive care guidelines for pneumonitis are described in Table 22.
Table 22 Guidelines for Management and Dose Modification for 
Pneumonitis
CTCAE Grade Adverse Event Management Action and Dose Modification
Grade 1 CT scan (high -resolution with 
lung windows) recommended
Clinical evaluation and 
laboratory work -up for 
infection
Monitoring of oxygenation via 
pulse -oximetry recommended
Consultation of 
pulmonologist
recommendedContinue trametinib at current dose
Grade 2 CT scan (high -resolution with 
lung windows)
Clinical evaluation and 
laboratory work -up for 
infectionInterrupt trametinib until 
recovery to Grade ≤1
Restart with trametinib reduced 
by [CONTACT_681885] 3 


Consult pulmonologist
Pulmonary function tests –
if < normal, repeat every 8weeks
until ≥normal
Bronchoscopy with biopsy and/or BAL
recommended
Symptomatic therapy including
corticosteroids if clinically indicatedConsider use of corticosteroids 
prior to and during restart
Escalation to previous dose level 
ispossible after 4weeks and 
consultation with the Medical Lead
If no recovery to Grade ≤1
within 4 weeks, permanently 
discontinue trametinib
[COMPANY_001] Confidential Page 110
Amended Protocol Version 11       Protocol No. CDRB436X2201
CTCAE Grade Adverse Event Management Action and Dose Modification
Grade 3 cont... 




CT scan (high -resolution with lung
windows)
Clinical evaluation and laboratory work-
up for infection
Consult pulmonologist
Pulmonary function tests -if <normal,
repeat every 8weeks until ≥normal
Bronchoscopy with biopsy and/or BAL
if possible
Symptomatic therapy including
corticosteroids as clinically indicatedInterrupt trametinib until 
recovery to Grade ≤1
After consultati on with the 
Medical Lead ,trametinib may 
be restarted reduced by [CONTACT_23615]
Consider use of corticosteroids 
prior to and during restart
If no recovery to Grade ≤1
within 4 weeks, permanently 
discontinue trametinib
Grade 4 Same as Grade 3 Permanently discontinue trametinib
Abbreviations: BAL, bronchioalveolar lavage; CT,computed tomography
8.2.[ADDRESS_923258] occurred in subjects receiving dabrafenib in combination with 
trametinib and /or trametinib monotherap y. Other frequent causes for diarrhea, including 
concomitant medications (e.g., stool softeners, laxatives, antacids, etc.), infections by C. 
difficile or other pathogens, partial bowel obstruction, should be clinically  excluded. 
Guidelines regarding management and dose reduction for diarrhea considered to be related 
to dabrafenib and/or trametinib by  [CONTACT_301178] 23.
Table 23 Management and Dose Modification Guidelines for Diarrhea
Grade ManagementAction and Dose
Modification
Uncomplicated
Diarrhea1
Grade 1 or2Diet: stop all lactose -containing products, eat small
meal portions; recommend bland diet to avoid fatty 
andgreasy foods, raw fruits and vegetables, 
alcohol, dairy products, and citrus fruits
Hydration: 8to10 large glasses of clear liquids per 
day(e.g., Gatorade or broth)
Loperamide3:initially 4mg, followed by 2mg 
every 4 hrs or after eve ry unformed stool; 
maximum
16 mg/day. Continue until diarrhea free for 12 hrs
Diarrhea > 24h: loperamide 2mg every 2hrs;
maximum 16 mg/day. Consider adding oral 
antibiotics
Diarrhea >48h: loperamide 2mg every 2hrs;
maximum 16 mg/day. Add budesonide or other
second -line therapi[INVESTIGATOR_014] (otreotide, or tincture of 
opi[INVESTIGATOR_1890]) and oral antibioticsContinue 
treatment with
trametinib and
dabrafenib
If diarrhea is Grade 
2for >48 hrs, 
interrupt treatment 
with trametinib and
dabrafenib until
diarrhea resolves to
≤Grade 1
Restart treatment 
with trametinib and 
dabrafenib at the
same dose levels
Uncomplicated
Diarrhea1
Grade 3 or4Clinical evaluation mandatory
Loperamide3:initially 4mg, followed by 2mg 
every 4 hrs or after every unformed stool; 
maximumInterrupt treatment
withtrametinib
and dabrafenib 
[COMPANY_001] Confidential Page 111
Amended Protocol Version 11       Protocol No. CDRB436X2201
Grade ManagementAction and Dose
Modification
Any
Complicated
Diarrhea216 mg/day. Continue until diarrhea -free for 12 hrs
Oral antibiotics and second -linetherapi[INVESTIGATOR_681783]
Hydration: IV fluids if clinically indicated
Antibiotics (oral or IV) if clinically indicated
Intervention should be continued until the 
subject is diarrhea -free for ≥24 hrs
Intervention may require hospi[INVESTIGATOR_681784]-threatening complicationsuntil diarrhea 
resolves to
≤Grade 1
Restart treatment 
with trametinib and
dabrafenib each
reduced by [CONTACT_23615]4
If 3dose 
reductions of 
trametinib and
dabrafenib are
clinically
indicated,
permanently
discontinue treatment
withtrametinib and
dabrafenib.
Abbreviation: hrs, hours; IV,intravenous; PS,performance status
1. Uncomplicated diarrhea defined by[CONTACT_681886]: crampi[INVESTIGATOR_007], nausea/vomiting ≥Grade 2,decreased
PS,pyrexia, sepsis, neutropenia ≥Grade 3,frank bleeding, and/or dehydration requiring IVfluid substitution.
2. Complicated diarrhea defined by[CONTACT_681887]: crampi[INVESTIGATOR_007], nausea/vomiting ≥Grade 2,decreased
PS,pyrexia, sepsis, neutropenia ≥Grade 3,frank bleeding, and/or dehydration requiring IVfluid substitution.
3. Loperamide should bemade available prior tostart ofstudy treatment soloperamide administration canbegin
atthefirstsigns ofdiarrhea.
4. Escalation oftrametinib anddabrafenib toprevious dose level isallowed after consultation withtheMedical
Lead and intheabsence ofanother epi[INVESTIGATOR_681785]4weeks subsequent to
dose reduction.
8.2.[ADDRESS_923259] occurred in subjects receiving dabrafenib and the 
combination of dabrafenib and trametinib.  Prior to start of study  treatment, concomitant 
medications should be reviewed for the potential risk of inducing nephrotoxicity  and 
concomitant medications should be modified if clinically possible.
Guidelines regarding management and dose reduction for renal insufficiency  considered to 
be related to study treatment by [CONTACT_301178] 24.
Table 24 Management and Dose Modification Guidelines for Renal
Insufficiency
Serum Creatinine Level Adverse Event Management Action and Dose
Modification
Serum creatinine increase
>0.2 mg/dL (18 umol/L) but 
0.5 mg/dLRecheck serum creatinine within 1 week
Serum creatinine increase >1 week:
contact [CONTACT_681864] .  If elevationContinue study
treatment at the 
same dose level
[COMPANY_001] Confidential Page 112
Amended Protocol Version 11       Protocol No. CDRB436X2201
(44umol/L) above baseline persists beyond 4weeks, recommend
evaluation (consider renal biopsy) for
etiology; consider nephrology
consultation.
If pyrexia is present, treat pyrexia as 
perguidelines1
Serum creatinine increase
>0.5 mg/dL (44 umol/L)
above baseline or serum
creatinine >2 mg/dL
(>177 umol/L)Monitor serum creatinine ≥2 times 
perweek
Hospi[INVESTIGATOR_681786]
If pyrexia is present, treat pyrexia per
guidelines1
Consult nephrologist if clinically indicated
Perform renal biopsy if clinically 
indicated, forexample:
Renal insufficiency persists despi[INVESTIGATOR_681787]
Subject has new rash or signs of
hypersensitivity (such as
elevated eosinophil count)Interrupt study
treatment until 
serum
creatinine 
recovers to
baseline
Restart with 
study
treatment2
Abbreviations: NSAIDS, non-steroidal anti-inflammatory drugs
1. NSAIDs can induce renal insufficiency, especially insubjects withdehydration; encourage oralfluids or
consider intravenous fluids asclinically indicated. Seeguidelines forpyrexia inSection 8.2.[ADDRESS_923260] should be consulted if changes in vision 
develop. However, if the visual changes are clearly unrelated to study  treatment (e.g., allergic 
conjunctivitis), then monitor closely  as it may bereasonable to defer ophthalmic examination.  
Treatment with dabrafenib has been associated with the development of uveitis, including 
iritis. Monitor subjects for visual signs and symptoms (such as, change in vision, photophobia 
and ey e pain) during thera py.
Special attention should be given to retinal findings (e.g., RPED) or retinovascular 
abnormalities (i.e., branch or central RVO). For events of visual changes (regardless of 
severit y) for which an ophthalmic examination is conducted, a blood sample for PK anal ysis 
must be drawn as close as possible to the time of the event.
Guidelines regarding management and dose reduction for visual changes considered to be 
related to trametinib treatment are provided in Table 25. 
For events ofuveitis andrelated toxicities (e.g. iritis, iridocyclitis), no dose modifications 
are required as long aseffective local therapi[INVESTIGATOR_681788]. If
uveitis does not respond to local ocular therapy, withhold dabrafenib until resolution
[COMPANY_001] Confidential Page 113
Amended Protocol Version 11       Protocol No. CDRB436X2201
ofocular inflammation and then restart dabrafenib reduced by [CONTACT_30560]. No dose 
modification of trametinib is required when taken in combination with dabrafenib.
Table 25 Management and Dose Modification Guidelines for Visual
Changes and/or Ophthalmic Examination Findings
CTCAE Grade1Adverse Event Management Action andDose Modification
Grade 12 Consult ophthalmologist within
7days ofonset Ifdilated fundus examination cannot beperformed
within 7days ofonset, interrupt treatment with
trametinib until RPED andRVO canbeexcluded
by[CONTACT_681888]/ophthalmologist. Dabrafenib
may becontinued.
 IfRPED andRVO excluded, continue (orrestart)
treatment withtrametinib atsame dose level
 IfRPED suspected ordiagnosed: seetable below;
report asSAE ifdiagnosed.
 IfRVO diagnosed: Permanently discontinue
trametinib andreport asSAE.
Grade 2and
Grade 3 Consult ophthalmologist
immediately
 Interrupt treatment withtrametinib. If
subject isreceiving
trametinib/dabrafenib combination
therapy dabrafenib may be
continued IfRPED andRVO excluded, restart trametinib at
same dose level
 IfRPED diagnosed ,seeRPED dose modification
table (Table 26);report asSAE.
 IfRVO diagnosed, permanently discontinue
trametinib andreport asSAE
Grade 4  Consult ophthalmologist
immediately
 Interrupt treatment withtrametinib. If
subject isreceiving trametinib/
dabrafenib combination therapy
dabrafenib may becontinued IfRPED andRVO excluded, may consider
restarting trametinib atsame or reduced dose
after discussion withMedical Lead
 IfRVO orRPED diagnosed, permanently
discontinue trametinib andreport asSAE.
Abbreviations: CTCAE, Common Terminology Criteria forAdverse Events; RPED, retinal pi[INVESTIGATOR_681789]; RVO, retinal vein occlusion; SAE, serious adverse event
1. Refers toCTCAE Version 4.0‘Eye disorders –Other, specify’
2. Ifvisual changes areclearly unrelated tostudy treatment (e.g., allergic conjunctivitis), monitor closely
butophthalmic examination isnotrequired.
Table 26 Recommended Dose Modifications for Trametinib for RPED
CTCAE Grade1 Action and Dose Modification
Grade 1 RPED
(Asymptomatic; clinical or diagnostic observations
only)Continue treatment with dabrafenib +
trametinib with retinal evaluation monthly 
until resolution. IfRPED worsens follow 
instructions below and withhold trametinib 
for up to 3weeks
Grade 2 or 3RPED
(Symptomatic with mild to moderate decrease in
visual acuity; limiting instrumental ADL)Interrupt trametinib forup to 3weeks ; 
continue treatment with dabrafenib
Retinal evaluation monthly
If improved to ≤Grade 1within 3weeks , 
restart trametinib at lower dose (reduced by 
0.5mg) or discontinue in subjects taking 
trametinib 1mgonce daily
[COMPANY_001] Confidential Page 114
Amended Protocol Version 11       Protocol No. CDRB436X2201
CTCAE Grade1 Action and Dose Modification
Grade 2-[ADDRESS_923261] Grade 1within 3weeks, 
permanently discontinue trametinib.
Abbreviations: ADL, activities ofdaily living; CTCAE, Common Terminology Criteria forAdverse Events; RPED, retinal
pi[INVESTIGATOR_6678]
1.Refers toretinopathy inCTCAE v4.0
9 LIFESTYLE AND/ ORDIETA RYRESTRICTIONS
9.[ADDRESS_923262] oppi[INVESTIGATOR_056] .
Highl y effective contraception methods include:
a.Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject).  Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and wi thdrawal are not acceptable methods of contraception.
b.Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y, or tubal ligation at least six weeks before taking 
study  treatment.  In case of oophorec tomy alone, only  when the reproductive status of 
the woman has been confirmed by  [CONTACT_104].
c.Sterilization (at least 6 months prior to screening) for male partners.  The vasectomized 
male partner should be the sole partner for that subject.
d. Placement of a hormonal or non- hormonal intrauterine device (IUD) or intrauterine 
system (IUS) with a documented failure rate of less than 1% per y ear.
Notes:
a.Double- barrier contraception: condom and occlusive cap (diaphragm or cervical/vault 
caps) with a vaginal spermicidal agent (foam/gel/cream/suppository ) are not considered 
highl y effective methods of contraception.
b.Hormonal based methods (e.g. oral contraceptives) are not considered as highly  
effective methods of contraception due to potential drug-drug interactions with 
dabrafenib and/or trametinib (see Section 10.2).
c.Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(i.e. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral
oophorectom y (with or without hy sterectomy ), total hy sterectom y, or tubal ligation at 
least six weeks ago.  In the case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment is she 
considered not of child bearing potential.
All menstruating female subjects (as required per local requirements and/or regulations) must 
have a negative serum pregnancy test within [ADDRESS_923263] dose of study
treatment(s), preferably  as close tothe first dose as possible. Subjects must have used highly 
[COMPANY_001] Confidential Page [ADDRESS_923264] becomes pregnant during the treatment period of the study , the study  treatments 
should be stopped immediately .
9.1.2 Male Subjects
Male subjects (including those that have had a vasectom y) must use a condom during 
intercourse while taking dabrafenib and/or trametinib treatment.  Once dabrafenib and 
trametinib are both permanently  discontinued, the patient must use a condom for [ADDRESS_923265] dose of study  treatments.
9.3 Caffeine andAlcohol
On PK sampling days, subjects will abstain from ingesting caffeine -or xanthine -containing 
products (e.g., coffee, tea, cola drinks, energy drinks) and alcohol for [ADDRESS_923266] sample.
9.4 Activit
y
Subjects will abstain from strenuous exercise (e.g., competitive sports) for [ADDRESS_923267] dose of study  treatment.  Any concomitant 
medication(s), including dietary  supplements, taken during the study  will be recorded in the 
eCRF. The minimum requirement is that drug name, dose, and the dates of administration 
are to be recorded. Additionally , a complete list of all prior surgical procedures will be 
recorded in the eCRF.
If emerging data results in a change to the list of permitted/prohibited medications, formal 
documentation will be provided to the investigative site by [CONTACT_456].  Any such changes 
[COMPANY_001] Confidential Page [ADDRESS_923268] of permitted/prohibited medications.
Questions regarding concomitant medications should be directed to the Medical Lead for 
clarification.
10.1 Permitted Medications andNon-Drug Therapi[INVESTIGATOR_681790] , including transfusions of blood 
and blood products, and treatment with antibiotics, anti-emetics, anti -diarrheals, and 
analgesics, and other care as deemed appropriate, and in accordance with their institutional 
guidelines. Use of anticoagulants such as warfarin is permitted however, caution should be 
exercised and additional INR monitoring is recommended when dabrafenib is used 
concomitantly  with warfarin.
Radiation: While subjects are on study  treatment, palliative radiation therapy  is permitted
for non-target lesions that are either new or present at baseline. Radiation skin injury has been 
reported with concurrent use of dabrafenib and radiation. I tis recommended that dabrafenib 
be held for 7 daysbefore and 2 daysafter radiotherapy in subjects receiving dabrafenib 
monotherap y or in combination with trametinib. These recommendations can be modified 
based on the ph ysician’s assessment of the risk of radiation skin injury .
10.2 Prohibited Medications andNon-Drug Therapi[INVESTIGATOR_681791] 28 daysor 5half-lives,
whichever is shorter, prior to start of treatment will not be allowed:
Antiretroviral drugs
Herbal remedies (e.g., St. John’s wort)
Oral hormonal contraceptives
Drugs that are strong inhibitors or inducers of CYP2C8 or CYP3A4 (Table 27)
The following medications or non-drug therapi[INVESTIGATOR_014] (excluding topi[INVESTIGATOR_29899]) are also 
prohibited while on treatment in this study :
Other anti -
cancer therapi[INVESTIGATOR_014]
Other investigational drugs
Antiretroviral drugs
Herbal remedies (e.g., St. John’s wort)
For MM c ohort only: non -steroidal anti -inflammatory drugs (NSAIDS)
NOTE: Use of NSAIDS by[CONTACT_681889] .
Drugs that are strong inhibitors or inducers of CYP2C8 or CYP3A4 (Table 27)
NOTE:  Dabrafenib is metabolized primarily by[CONTACT_097]2C8 and CYP3A4.  Co-administration 
of dabrafenib with ketoconazole, a CYP3A4 inhibitor, or gemfibrozil, a CYP2C8 inhibitor, 
increased the area under the concentration -time curve (AUC) ofdabrafenib by71% and 47%, 
respectivel y.Drugs that are strong inhibitors or inducers of
CYP2C8 or CYP3A4 are likel y
to increase or decrease, respectively , dabrafenib concentrations.  Strong inhibitors or 
inducers should only be used under special circumstances (e.g., as a single use for a 
procedure) while study treatment is interrupted as they may alter dabrafenib concentrations; 
[COMPANY_001] Confidential Page 117
Amended Protocol Version 11       Protocol No. CDRB436X2201
consider therapeutic substitutions for these medications.  Approval from the Medical Lead 
is required in these situations.
Table 27 Prohibited Medications
PROHIBITED1–strong inducers of CYP3A4 or CYP2C8, since concentrations of dabrafenib may be
decreased
Class/Therapeutic Area Drugs/Agents
Antibiotics Rifamycin class agents (e.g., rifampin, rifabutin, rifapentine),
Anticonvulsant Carbamazepi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_283567], phenytoin, s-mephenytoin
Miscellaneous Bosentan, St -John’s wort
PROHIBITED1–Strong inhibitors of CYP3A4, or CYP2C8 since concentrations of dabrafenib may be
increased
Class/Therapeutic Area Drugs/Agents
Antibiotics Clarithromycin, telithromycin, troleandomycin
Antidepressant Nefazodone
Antifungals Itraconazole, ketoconazole, posaconazole, voriconazole
Hyperlipi[INVESTIGATOR_681792], saquinavir, atazanavir
Miscellaneous Conivaptan
1. Topi[INVESTIGATOR_681793](s) arepermitted.
10.3 Medications tobeused with Caution
The following medications should be used with caution as their concentrations may bealtered 
by[CONTACT_681890]:
Drugs that are moderate inhibitors or inducers of CYP3A and CYP2C8 as they may 
alter concentrations of dabrafenib.
Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam 
(CYP3A4 substrate) and S -warfarin (CYP2C9 substrate). Dabrafenib is an in vitro 
inducer of CYP2B6 and may affect other enzy mes such as CYP2C8, CYP2C19, UDP -
glucuron yl transferases, and transporters.  Co -administration of dabrafenib and 
medicinal products which are affected b ythe induction of these enz ymes such as 
warfarin, dexamethasone, an tiretroviral agents, or immunosuppressants may result in 
decreased concentrations and loss of effectiveness. Where possible consider 
substitutions of these medicinal products if therapeutic effects cannot be monitored.
Onset of induction is likely to occur after [ADDRESS_923269] few day s of
treatment.  Upon discontinuation of dabrafenib, concentrations of these sensitive 
substrates may increase and subjects shoul d be monitored for toxicity and dosage of
these agents may need to be adjusted.
Where possible consider substitutions of these medicinal products if therapeutic effects 
cannot be monitored. If co-administration of these medications is necessary ,
investigat ors should monitor subjects for loss of efficacy or consider substitutions of 
these medications.  A partial list of these medications is provided in Table 28 and in the 
SPM.
Therapeutic level dosing of warfarin can be used with approval by [CONTACT_681891]/I NR by [CONTACT_779]. Exposure decreased b y 37% due to
[COMPANY_001] Confidential Page 118
Amended Protocol Version 11       Protocol No. CDRB436X2201
enzy me induction when on treatment, thus warfarin dosing may need to be adjusted 
based upon PT/INR.  Consequently , when discontinuing dabrafenib, warfarin exposure 
may be increas ed and thus close monitoring via PT/I NR and warfarin dose adjustments 
must be made as clinically appropriate. Prophy lactic low dose warfarin may be given 
to maintain central catheter patency .
Drugs known to induce QT prolongation interval should be used with caution.  Refer to 
the following link for a list of drugs known to have a risk of QT prolongation:
crediblemeds.org/every one/composite -list-all-qtdrugs/
Table 28 Medications to be used with Caution
USE WITH CAUTION: Moderate inhibitors of CYP3A4, or C YP2C8 since concentrations of
dabrafenib may be increased
Class/Therapeutic Area Moderate CYP3A4 and CYP2C8 Inhibitors
Antiarrhythmics Diltiazem, verapamil
Antibiotic Erythromycin
Antifungal Fluconazole
Miscellaneous Aprepi[INVESTIGATOR_681794]: Co-administration of these drugs with study treatment may result in loss of
efficacy. Monitor subjects for loss of efficacy or substitute with another medication.
Class/Therapeutic AreaCYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or Transporter
Substrates that May be Affected by [CONTACT_681892], buprenorphine, celecoxib, codeine, fentanyl, methadone,
oxycodone
Antiarrhythmics Disopyramide, dronedarone, mexiletine, propafenone, quinidine
Antibiotics Chloramphenicol, doxycycline, erythromycin, moxifloxacin
Anticoagulants/ Antiplatelets Cilostazole, warfarin
Anticonvulsants Divalproex, lamotrigine, valproate, zonisamide
Antidepressants and
AntipsychoticsAripi[INVESTIGATOR_4253], bupropi[INVESTIGATOR_2394], buspi[INVESTIGATOR_5331], desipramine, haloperidol, mirtazapi[INVESTIGATOR_050],
pi[INVESTIGATOR_3924], quetiapi[INVESTIGATOR_050], trazodone, amitriptyline, clomipramine, imipramine
AntidiabeticsGlyburide, saxagliptin, tolbutamide, nateglinide, pi[INVESTIGATOR_051], repaglinide,
rosiglitazone
Antifungals Caspofungin, fluconazole, terbinafine
Antihistamines Astemizole, chlorpheniramine, ebastine
USE WITH CAUTION: Moderate inhibitors of CYP3A4, or CYP2C8 since concentrations of
dabrafenib may be increased
AntihypertensivesAmlodipi[INVESTIGATOR_050], diltiazem, felodipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nilvadipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050],
verapamil
Antimigraine Agents Diergotamine, eletriptan, ergotamine
Corticosteroids Dexamethasone, methylprednisolone, oral budesonide
Erectile Dysfunction Agents Sildenafil, tadalafil, vardenafil
HMG -CoA Reductase
InhibitorsAtorvastatin, lovastatin, simvastatin, rosuvastatin, pravastatin
Hypnotics and SedativesAlprazolam, brotizolam, diazepam, estazolam, midazolam, triazolam,
zolpi[INVESTIGATOR_6730], zopi[INVESTIGATOR_681795], sirolimus, tacrolimus
[COMPANY_001] Confidential Page 119
Amended Protocol Version 11       Protocol No. CDRB436X2201
Miscellaneous Aprepi[INVESTIGATOR_053], cisapride, darifenacin, disopyramide, leflunomide, methohexital,
quinine, ranitidine, solifenacin, sulfasalazine, tramadol, tolvaptan, 
chloroquine, zopi[INVESTIGATOR_681796]: CYP =cytochrome P450; HMG- CoA = 3-hydroxy -3-methylglutaryl -coenzyme A.
[ADDRESS_923270].
Note: An AE can therefore be anyunfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated ) temporall y
associated with 
the use of a medicinal product.  For marketed medicinal products, this also includes failure 
to produce expected benefits, abuse, or misuse. Examples of events meeting the definition of 
an AE include:
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or grade of the condition
New conditions detected or diagnosed after study treatment administration even though 
it may have been present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self-
harming intent.  This should be reported regardless of sequelae).
“Lack of efficacy ” or “failure of expected pharmacological action” per se is not to be 
reported as an AE or SAE. However, anysigns and sy mptoms and/or clinical sequelae 
resulting from “lack of efficacy” will be reported as an AE or SAE, if they fulfill the 
definition of an AE or SAE.
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., e ndoscopy , appendectom y); the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-dayfluctuations of pre -existing disease(s) o r condition(s) present or 
detected at the start of the study that do not worsen.
The disease/disorder under study , or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
[COMPANY_001] Confidential Page [ADDRESS_923271] medical occurrence that, at any dose:
a.Results in death
NOTE: Death due to disease under stud yis to be recorded in the Death eCRF and
does not need to be reported as an SAE.
b.Is life -threatening
NOTE: The term 'life -threatening' in the definition of 'serious' refers to an event in
which the subject was at risk of death at the time of the event.  It does not refer to 
an event, which h ypothetically might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]: Ingeneral, hospi[INVESTIGATOR_5184] (usuall y
involving at least an overnight stay)at the hospi[INVESTIGATOR_681797]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting.  Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_681798], the event is serious. When in doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred or was necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen
from baseline is not considered an AE.
d.Results in disabilit y/incapacity ,or
NOTE: The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions.  This definition is not intended to include 
experiences of relativel y minor medical significance such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g. 
sprained ankle) which may  interfere or prevent every daylife functions but do not 
constitute a substantial disruption.
e.Is a congenital anomal y/birth defect.
f.Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be
immediately life-threatening or result in death or hospi[INVESTIGATOR_681799].  These should also be considered serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dy scrasias or
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
g.All events of possible treatment- induced liver injury with hyperbilirubinemia defined
as:
ALT[ADDRESS_923272] and bilirubin [ADDRESS_923273] (>35% direct) or ALT [ADDRESS_923274] and INR >1.5, if INR is measured, with no existing liver disease
OR
ALT ≥[ADDRESS_923275] andbilirubin ≥[ADDRESS_923276] (>35% direct) or INR >1.5, if
INR is measured, with pre- existing liver disease
NOTE: INR measurement is not required and the threshold value stated will not apply
to subjects receiving anticoagulants.
[COMPANY_001] Confidential Page 121
Amended Protocol Version 11       Protocol No. CDRB436X2201
NOTE: Bilirubin fractionation is performed if testing is available. If testing is
unavailable, record presence of detectable urinary bilirubin on dipstick indicating 
direct bilirubin elevations and suggesting liver injury.  If testing is unavailable and 
asubject meets the criterion of total bilirubin  [ADDRESS_923277], if no existing liver
disease or [ADDRESS_923278] if pre -existing liver disea se; the event is still reported as 
anSAE.  If INR is obtained, include values on the SAE form.  Elevations in 
INR >1.[ADDRESS_923279] severe liver injury .
h.Protocol -specific SAEs:
cuSCC (Section [IP_ADDRESS]), new p rimary melanomas (Section [IP_ADDRESS]) and non -
cutaneous malignancies (Section [IP_ADDRESS]) with the exception of basal cell
carcinoma (BCC). BCC should be reported as an AE or SAE based on the
discretion of the investigator.
LVEF that meets the dose interruption criteria (Section [IP_ADDRESS]): absolute LVEF
decreases of >10% from baseline (not relative decreas e) and below the LLN
Liver chemistry events of AL T 3xULN andbilirubin 2xUL N (>35% direct
bilirubin) or ALT3xULN and INR>1.5, ifINR measured which may  indicate
severe liver injury (possible ‘Hy ’s Law’) (Section [IP_ADDRESS])
RPED also referred to as central serous retinopathy (CSR) or RVO (Section 8.2.7)
Pyrexia accompanied by[CONTACT_681893]/chills in the absence of an obvious infectious cause 
(Section 8.2.3).
11.[ADDRESS_923280] results (hematology, clinical chemistry, or urinalysis), or other 
safet yassessments (e.g., ECGs, radiological scans, vital signs measurements) including those 
that worsen from baseline, and events felt to be clinically significant inthe medical and 
scien tific judgment of the investigator are to be recorded as an AE 
or SAE, in accordance 
with the definitions provided.
In addition, an associated AE or SAE is to be recorded for anylaboratory test result or other 
safet yassessment that led to an intervention , including permanent discontinuation of study
treatment(s), dose reduction, and/or dose interruption/delay .
However, any clinically significant safet y assessments that are associated with the
underly ing disease, unless judged by[CONTACT_681894]'s condition, are not to be reported as AEs or SAEs.
11.4 Cardiovascular Events
Investigators will be required to fill out event specific data collection tools for the following 
AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary hypertension
[COMPANY_001] Confidential Page 122
Amended Protocol Version 11       Protocol No. CDRB436X2201
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thrombosis
Deep Venous Thrombosis
Revascularization
This information should be recorded within 1 week of when the AE/SAE(s) is first reported.
11.5 Death Events
In addition, all deaths, whether or not they are considered SAEs, will require a specific death 
data collection tool to be completed.  The death data collection tool includes questions 
regarding c ardiovascular (including sudden cardiac death) and non- cardiovascular death.
This information should be recorded within [ADDRESS_923281] reported.
11.6 Disease -Related Events and/or Disease -Related Outcomes Not
Qualif yingasSAEs
An event which is part of the natural course of the disease under study (i.e., disease
progression or hospi[INVESTIGATOR_44814]) does not need to be reported as an 
SAE. Death due to disease under study is to be recorded on the Death eCRF form.  However, 
if the underl ying disease (i.e., progression) is greater than that which would normally be 
expected for the subject, or if the investigator considers that there was a causal relationship 
between treatment with study treatment(s) or protocol design /procedures and the disease 
progression, then this must be reported as an SAE.
11.7 Time Period andFrequency ofDetecting AEsandSAEs
The investigator or site staff is responsible for detecting, documenting and reporting events 
that meet the definition of an AE or SAE.
Adverse events (AEs) will be collected from the time the first dose of study  treatment(s) is 
administered until 30 days following discontinuation of study  treatment(s) regardless of 
initiation of a new cancer therap y or transfer to hospi[INVESTIGATOR_6125].
Serious adverse events (SAEs) will be collected over the same time period as stated above 
for AEs.  In addition, anySAE assessed as related to study participation (e.g., protocol -
mandated procedures, invasive tests, or change in existing therap y),study treatment or 
concomitant medication(s) must be recorded from the time a subject consents to participate 
in the study up to and including any follow -up contact.
After discontinuation of study treatment(s), the investigator will monitor all AEs/SAEs that 
areongoing until resolution or stabilization of the event or until the subject is lost to follow -
up. At an ytime after 30 day s the investigator may  report any AE that they believe possibly
related to stud ytreatment(s).
11.8 Method ofDetecting AEs andSAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about AE 
occurrence.  Appropriate questions include:
“How are
you feeling?” or “How does yourchild seem to feel?”
[COMPANY_001] Confidential Page 123
Amended Protocol Version 11       Protocol No. CDRB436X2201
“Have you had any(other) medical problems since your last visit/contact?” or “Has
your child had any (other) medical problems or seem to act differently in any way since 
his/her last visit/contact?”
“Have you taken anynew medicines, other than those provided in this study , since your 
last visit/contact?” or “Has yourchild needed to take an y medicines, other than those 
provided in this study , since his/her last visit/contact?”
11.9 Recording ofAEsandSAEs
When an AE/SAE occurs, it is the responsibility of the investigator to review all
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) relative to 
the event. The investigator will then record all relevant information regarding an AE/SAE 
in the appropriate data collection tool.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical records 
to the sponsor in lieu of completion of the AE/SAE data collection tool.
However, there may be instances when copi[INVESTIGATOR_681800].  Inthis instance, all subject 
identifiers, with the exception ofthe 
subject number, will be blinded on the copi[INVESTIGATOR_681801].
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Insuch cases, the diagnosis will bedocumented as the 
AE/SAE and not the individual signs/sy mptoms.
Subject -completed health outcomes questionnaires and the collection of AE data are
independent components of the study .  Responses to each question in the health outcomes
questionnaire will be treated in accordance with standard scoring and statistical procedures 
detailed by[CONTACT_227417]’s developer. The use of a single question from amultidimensional 
health survey to designate a cause -effect relationship to an AE is inappropriate.
11.10 Evaluating AEsandSAEs
11.10.1 Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study  and will assign it to one of the following categories:
Mild: An event that is easily tolerated b ythe subject, causing minimal discomfort and 
not interfering with ever ydayactivities.
Moderate:  An event that is sufficiently discomforting to interfere with normal every day
activities.
Severe:  An event that prevents normal every dayactivities.
An AE that is assessed as severe will not be confused with an SAE.  Severity is acategory
utilized for rating the intensity  of an event ; and both AEs and SAEs can beassessed as severe.  
An event is defined as ‘serious’ when it meets at least one of the pre-defined outcomes as 
described in the definition of an SAE.
[COMPANY_001] Confidential Page 124
Amended Protocol Version 11       Protocol No. CDRB436X2201
11.10.2 Assessment of Causality
The investigator is obligated to assess the relationship between study treatment and the
occurrence of each AE/SAE.  A "reasonable possibility " is meant to convey that there is
facts/evidence or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out. The investigator will use clinical judgment to determine therelationship.
Alternative causes, such as natural history of the underly ing diseases, concomitant therap y, 
other risk factors, and the temporal relationship of the event to the study treatment will be 
considered and investigated.  The investigator will also consult the IB and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she has
reviewed the AE/SAE and has provided an assessment of causalit y.
11.11 Follow -UpofAEsandSAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each subject 
at subsequent visits/contacts.  All AEs and SAEs will be followed until resolution, until the 
condition stabilizes, until the event is otherwise explained, or until the subject is lost to 
follow -up.
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or asrequested by[CONTACT_681895]/or causality of the AE or SAE. The investigator 
is obligated to assist.  This may include additional laboratory tests or investigations, 
histopathological examinations or consultat ion with other health care professionals.  If a 
subject dies during participation in the study or during a recognized follow -up period, the 
investigator will provide the sponsor with a copy of anypost-mortem findings, including 
histopathology .
New or updated information will be recorded in the originall ycompleted data collection tool.  
The investigator will submit anyupdated SAE data to the sponsor within the designated 
reporting time frames.
11.[ADDRESS_923282] all information regarding an SAE, he/she will not wait to
receive additional information before notify ing the sponsor of the event and completing the 
appropriate data collection tool. The investigator will alway s provide an assessment of 
causality at the time of the initial report as described in Section 11.10.2, Assessment of
Causality .
The primary mechanism for reporting SAEs to the sponsor will be the electronic data 
collection tool. If the electronic system is unavailable for greater than 24 hrs, 
the site will 
use the paper SAE data collection tool and fax it to the Medical Lead .  Then the site will enter 
the SAE data into the electronic system as soon as it becomes available. After the study is 
completed at a given site, the electronic data collection tool (e.g., InForm system) will be 
taken off -line to prevent the entry of new data or changes to existing data.  If a site receives 
a report of a new SAE from a study participant or receives updated data on a previousl y
[COMPANY_001] Confidential Page [ADDRESS_923283] by[CONTACT_756].
The sponsor contacts for SAE receipt can befound at thebeginning of this protocol on the 
Sponsor/Medical Lead Contact [CONTACT_23774].
11.13 Regulatory Reporting Requirements forSAEs
Prompt notification of SAEs by[CONTACT_681896] y of subjects are met.
The sponsor (currentl y [COMPANY_001]) has a legal responsibility tonotify both the local regulatory
authority and other regulatory agencies about the safet y of a product under clinical
investigation. The sponsor will complywith country specific regulatory requirements
relating to safet y reporting to the regulatory authority , IRB/IEC and investigators.
Investigator safety reports are prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and [COMPANY_001] policy and are forwarded to 
investigators as necessary .An investigator who receives an investigator safet y report
describing a SAE(s) or other specific safety information (e.g., summary or listing of SAEs) 
from the sponsor will file it with the IBand will notify the IRB/IEC, if appropriate according 
to local requirements.
12 PHA RMACOKINETICS
12.1 Pharmacokinetic Endpoints
Pharmacokinetic (PK) analy sis will be the responsibility of the [COMPANY_001] Institutes for 
BioMedical Research (NIBR) PK Sciences (PKS) department. Mixed -effects PK models
developed previously for dabrafenib and trametinib may be fit to the dabrafenib and 
trametinib concentration -time data using NONMEM.  Post-hoc estimates of population PK 
parameters (CL/F, V/F, Ka, and predicted exposure) may be determined for trametinib and 
dabrafenib.
12.2 Pharmacokinetic Assessments
12.2.1 Blood Sample Collection
NOTE: Sample collection for this purpose is no longer requested as of Protocol 
Amendment 11
Blood samples for PK analy sis of dabrafenib and its metabolites (hydroxy -anddesmeth yl-
dabrafenib) and trametinib will be collected at the time points indicated in the Time and 
Events Table (
Section 7.1).  The actual date and time of each blood sample collection and 
the date and time of each dose administration of study treatments prior tothe PK sample will 
be recorded.
Details of PK blood sample collection (including volume to be collected, timing of sample 
and recording of PK sample information), processing, storage and shippi[INVESTIGATOR_681802].
[COMPANY_001] Confidential Page 126
Amended Protocol Version 11       Protocol No. CDRB436X2201
12.2.2 Pharmacokinetic Sample Analysis
Plasma analysis will be performed under the management of PKS Bioanalyticals, [COMPANY_001].
Concentrations of dabrafenib and its metabolites (hydroxy -and carbox y-dabrafenib) and 
trametinib will be determined in plasma samples using the currently approved analytical 
methodology .  Raw data will be stored in the GLP Archives, [COMPANY_001].
[ADDRESS_923284] for
BRAF V600E mutation status.
Confirmatory Testing: All local test results for BRAF V600E mutation will be subject to
central confirmation using a sponsor designated central reference lab.
1.For the solid tumor histology cohorts ,an archived or fresh tumor tissue sample must 
be submitted to the central reference laboratory .
2.For the HCL and MM cohorts , a fresh BM aspi[INVESTIGATOR_681803] d a corresponding peripheral 
blood sample are required to be submitted to the central reference laboratory.
NOTE: An archived tissue sample (such as a FFPE tissue sample from a BM biopsy ), 
BM core samples, and BM clot samples are NOT acceptable for BRAF V600E 
testing. If a BM aspi[INVESTIGATOR_681706] a dry tap, please contact [CONTACT_681897] .
Details on sample collection, processing, storage and shippi[INVESTIGATOR_681804].

[COMPANY_001] Confidential Page 130
Amended Protocol Version 11       Protocol No. CDRB436X2201
Subject is lost to follow -up
Study is closed or terminated by [CONTACT_681898](s) were permanently discontinued must be documented 
in the subject’s medical record and the eCRF.  If the subject voluntaril y discontinues from 
treatment due to toxicity , ‘AE/SAE’ will be recorded as the primary reason for permanentl y
discontinuation in the eCRF.
16.3 Follow -UpAssessments after Discontinuation ofStud y
Treatment orStudyWithdrawal
If study treatment is permanently discontinued without disease progression:
the subject will complete the Post -Treatment Follow- Up Visit (see Time and Events 
Table) within 28 days(+7days) after last dose of study treatment and prior to starting a 
new anti -cancer treatment or treatment with an investigational agent.
the subject will continue to have disease assessments performed every [ADDRESS_923285].
If study treatment is permanently discontinued with disease progression and/or subject is 
withdrawn from the study:
The subject must make every effort to complete the Post-Treatment Follow -UpVisit 
(see Time and Events Table [ Section 7.1]) within 28 days(+7days) after last dose of 
study treatment and prior to starting an yother anti-cancer treatment or treatment with 
an investigational agent.
All subjects permanently discontinuing study treatment will have a dermatologic exam
performed monthly (7days) for the first 6 months following discontinuation of study
treatment. Subjects will be followed concurrently for survival and subsequent anti-cancer
treatment every 3 months ( 14days) until they die, withdraw consent, are lost to follow, or 
up to a time period that is dependent on the criteria defined in Section 16.4. When subjects 
are no longer required to be followed for survival, they will be notified accordingl y.
If subjects are unable to attend clinic visits during survival follow -up, contact [CONTACT_681899] (e.g., phone, mail, etc.).
16.[ADDRESS_923286] completed the study ifthey die while receiving study  
treatment(s) or during the extended follow -up pe riod.  The cause of death should be
documented in the eCRF.
Data collection will continue until a subject has completed or discontinued the study .
16.5 Stud yCompletion
The study will be considered complete at a date that would represent a minimum follow up 
ofapproximately  3years for all subjects enrolled .
[COMPANY_001] Confidential Page 131
Amended Protocol Version 11       Protocol No. CDRB436X2201
Subjects who continue to benefit from study treatment at the time of study completion or 
closure may transition to an alternative supply  of MEK and/or BRAF inhibitor through 
commercial supply  or post trial access mechanism such as a rollover study ,if available ,at the 
time of study  completion. Inthe event subjects aretransitioned to a rollover study , only
safet y will be followed in that study .
16.[ADDRESS_923287] should be followed
until:
AE or SAE stabilizes or resolves
AE or SAE is otherwise explained
Subject is lost 
to follow -up
If subject is withdrawn from  study treatment with an ongoing Grade 3 or 4 laboratory  
abnormality :
Subject should be followed until laboratory abnormality improves to Grade [ADDRESS_923288] wishes to and/or should continue in the study based on 
previous non-compliance. In cases where the subject does not return forthe rescheduled 
visit or cannot be reached to r eschedule the missed visit, the site should make ever yeffort to 
regain contact [CONTACT_1155] (three telephone calls and if necessary a certified letter to the 
subject’s last known mailing address) so that they can appropriatel y be withdrawn from the 
study.These contact [CONTACT_681900]’s medical record.  Should 
the subject continue to be unreachable, then and only then will he/she be considered to have 
withdrawn from the study with a primary reason of “Lost to Follow -up”.  For all other 
subjects withdrawing from the study , an alternative reason for discontinuation should be 
recorded in the eCRF.
[ADDRESS_923289] data will be entered into the sponsor -defined eCRFs, transmitted
electronically to the spons or or designee and combined with data provided from other sources 
in a validated data s ystem.
Management of clinical data will be performed in accordance with applicable [COMPANY_001] 
standards and data cleaning procedures to ensure the integrit y of the data, e.g., removing
errors and inconsistencies in the data.  Adverse events (AEs) and concomitant medications 
terms will be coded using Medical Dictionary for Regulatory Activities (MedDRA) and a 
custom drug dictionary . An appropriate medical dictionary that co vers all approved drugs in 
studies where Japan is participating will be referenced. Electronic CRFs (eCRFs), including 
queries and audit trails, will be retained by[CONTACT_681901][INVESTIGATOR_301101] y.
[COMPANY_001] Confidential Page 133
Amended Protocol Version 11       Protocol No. CDRB436X2201
WHO Grade 1or 2Glioma 10% 50%
WHO Grade 3or 4Glioma (high -grade) 10% 50%
MM 15% 60%
NSGCT/NGGCT 25% 75%
Small Intestine Adenocarcinoma 10% 50%
Abbreviations: ATC, anaplastic thyroidcancer; BTC, biliary tract cancer; C,control; GIST,
gastrointestinal stromal tumor; HCL, hairy cellleukemia; MM, multiple myeloma; NGGCT, non-
geminom atous germ celltumor; NSGCT, non- seminomatous germ celltumor; WHO,WorldHealth
Organization
Full details regarding the hierarchical modeling framework are in Appendix 6 .
18.2 Sample Size Considerations
18.2.1 Sample Size Assumptions
Each cohort of BRAF V600E mutation -positive tumor typeof a given histology will enroll a 
maximum of 25 subjects in the primary analysis cohort as defined inSectio n 5.1.Ifall 
histologies enroll the maximum of 25 subjects, this will result in no more than 225 subjects 
in the primary analysis cohort.
Enrollment into specific histology cohorts may be halted early  based on results from interim 
analy sesincorporating emerging response data.  Response data from aminimum of 5subjects 
will be required in ahistologic cohort before it may discontinue enrollment for futility and 
response data from a minimum of 10 subjects will be required before discontinui ng a 
histologic cohort for efficacy .If a cohort closes early for efficacy at an interim analysis, 
a histology specific expansion cohort (seeSection 5.2)may beopened to allow additional 
enrollment. Atthefinal analy sisand after the study has been closed, a minimum of 2 subjects 
will be required in a histologic cohort in order to meet statistical success at the final analy sis.
See Section 18.3.2 for more detai ls.
Simulation studies were conducted to evaluate the performance of the design under various 
assumptions for the distribution of true ORRs across the histologic cohorts andaccounting 
for the anticipated small sample sizes (refer to Section [IP_ADDRESS]). Operating characteristics 
including power, type I error, estimation of the ORR, and the probability of halting 
enrollment at interim analy ses were assessed.
When the treatment effects are similar across all histologies, the design maintains power 84% 
to 98% and type I error rate ≤0.04.  Estimation efficiencies due to borrowing result in very
good operating characteristics in these situations, even in histologies with very low sample 
sizes.
In mixed scenarios where some histologies show large treatment effects and others do not, 
the typeI error can range from 0.03 to 0.14 while the power ranges from 55%
-96%. This 
variation is hugel y dependent upon the expected sample sizes of the individual histologi es 
as well as the overall distribution of treatment effects across the histologies.
Full presentation and discussion of the simulation parameters and corresponding simulation 
results are in Section 18.4.
18.2.[ADDRESS_923290] Library
(IDSL) reporting standard where applicable. Complete details will be provided in the 
Reporting and Anal ysis Plan (RAP).
18.3.[ADDRESS_923291] based on the timing of theanalysis for both efficacy  and safet y; accompan ying 
definitions are provided beneath the table.
Table 30 Definition of Population for Specific Analysis
Analysis Period
Analysis Intent Interim Analyses Final Analysis
Efficacy Primary ITT/Evaluable ITT
Supportive BRAF V600/Evaluable BRAF V600E
Safety Primary ATS ATS
The BRAF V600E Population is defined as all enrolled subjects regardless of whether or not 
treatment was administered, who obtain positive verification of the BRAF V600E mutation 
from a certified central reference laboratory .
TheIntent -to-Treat (ITT) population is defined as all enrolled subjects regardless ofwhether 
or not treatment was administered.
The All-Treated Subjects (ATS) population is defined as all subjects who receive at leastone 
dose of dabrafenib (DRB436/[COMPANY_004]2118436) or trametinib (TMT212/ [COMPANY_004]1120212).
The Intent -to-Treat (ITT)/Evaluable population is defined as allITT subjects in the
primary analysis cohort who are also evaluable according to the evaluability defined in 
the interim analysis RAP.
The BRAF V600E /Evaluable Population is defined as all BRAF V600E subjects in the 
primary analysis cohort who are also evaluable according to the evaluability defined in
theinterim analysis RAP.
18.3.2 Interim Analysis
Interim data will be evaluated to monitor efficacy  and safet y.Enrollment may be stopped
early for futility or efficacy , should various criteria occur based on accrued data.  The
decision criteria for futility and efficacy are described below.
[COMPANY_001] Confidential Page 135
Amended Protocol Version 11       Protocol No. CDRB436X2201
[IP_ADDRESS] Early Stoppi[INVESTIGATOR_154805] /Harm
For each histology , the therapeutic effect of the combination therapy will be declared
insufficient and enrollment terminated if a minimum of [ADDRESS_923292] response data
available and the posterior probability that the ORR is greater than its corresponding 
historical control (C j) is sufficientl y low (<30%) based on the hierarchical model. That is,
P (j> C j|current data) < 30%, for the j -th histology .
[IP_ADDRESS] Early Stoppi[INVESTIGATOR_681805] , the combination therap ywill be declared efficacious and enrollment
terminated if a minimum of [ADDRESS_923293] response data available and the posterior 
probability that the ORR exceeds its corresponding historical control (Cj) is sufficientl yhigh 
(>95%) based on the hierarchical model.  That i s,
P (j> C j|current data) > 95%, for the j -th histology .
18.3.[ADDRESS_923294]. Secondary efficacy endpoints will likely not be mature atthis time, 
but will still be reported. Subsequent analyses for secondary endpoints will occur at a date 
that would represent a minimum follow up of approximately  3years for all subjects enrolled.
These latter analyses will provide mature estimates/incidence for duration of response, PFS, 
OS, and safet y.
[IP_ADDRESS] Safety Analyses
Safety data will be presented in tabular and/or graphical format and summarized descriptivel y 
according to [COMPANY_004] ’ IDSL standards.
The ATS population will be used for the analy sis of safety  data. In general, safet ydata will 
be summarized by [CONTACT_681902] y analyses will be provided in the RAP.
[IP_ADDRESS].1 Adverse Events
Adverse events (AEs) will be coded using the standard MedDRA and grouped by[CONTACT_29974].  Adverse events (AEs) will be graded by[CONTACT_681903], version 4.0.
Events will be summarized based on frequency and proportion of total subjects, by [CONTACT_53428]. Separate summaries will be given for all AEs, treatment -
related AEs, AEs by[CONTACT_154429], SAEs and AEs leading to discontinuation of study
treatment and dose modification.
Adverse events (AEs) of special interest will be identified and additional summaries provided.
The incidence of deaths and the primary cause of death will be summarized.
[COMPANY_001] Confidential Page 136
Amended Protocol Version 11       Protocol No. CDRB436X2201
[IP_ADDRESS].2 Clinical Laboratory  Evaluations
Hematology and clinical chemistry data will be summarized by[CONTACT_681904], version 4.0, grade .The proportion of values lying outside the 
reference range will also be presented for laboratory tests that are not graded because there 
are no associated CTCAE grading criteria. Summaries will include data from scheduled 
assessments onl y, and all data will be reported according to the nominal visit date for which 
it was recorded (i.e., no visit windows will be applied). Unscheduled data will be included 
in “overall” and “any post-screening” summaries which willcapture a worst case across all 
scheduled and unscheduled visits post first dose of study  treatment.
[IP_ADDRESS].3 Other Safety Measures
The results of scheduled assessments of vital signs, 12-lead ECG, ECHO and ECOG
performance status will be summarized.  Summaries will include data from scheduled 
assessments only.All data will be reported according to the nominal visit date for which it 
was recorded; no visit windows will be applied.  All data will be listed.
[IP_ADDRESS] Efficacy Analyses
ORR will be analyzed using an integrated analysis with the hierarchical model as well as
analyzed independentl yfor each histology
.
At the final analy sis a histology will be declared active if the posterior probability that the
ORR exceeds its corresponding historical control (10%) is sufficient lyhigh (>92%)
based on the hierarchical model.  That is,
P (j> C j% |current data) > 92%, for the j -thhistology .
The observed ORR and the estimated ORR based on the hierarchical model will be reported 
for each histology .Confirmed ORR will be calculated as the proportion of subjects that have 
a confirmed response relative to the total number of subjects enrolled.  Standard response 
assessments vary by[CONTACT_27183] ;the following subcategories for each histology will be 
considered a ‘response’ to t herap y when computing confirmed ORR.
Table 31 Response Subcategories Defined as ‘Response’ by [CONTACT_681905]‘Response ’
ATC, BTC, GIST, Small
Intestine AdenocarcinomaRECIST 1.[ADDRESS_923295]/NGGCT RECIST 1.1.
Tumor Markers: -HCG andAFPMarker -Negative CR,Marker -
Positive CR, Marker -Negative PR,
Marker -Positive PR
MM IMWGUniform Response Criteria forMM sCR, CR,PR,VGPR
HCL Adapted from NCCN guidelines, Consensus
Resolution Criteria andprevious studies definitionCR±MRD, PR
WHOGrade 1and2
GliomasResponse Assessment Criteria forWHOGrade 1
or2Gliomas: RANO Working GroupCR,PR,MR
WHOGrade 3and4
GliomasUpdated Response Assessment Criteria forWHO
Grade 3or4Gliomas: RANO Working GroupCR,PR
Abbreviations: AFP, alpha -fetoprotein; ATC, anaplastic thyroid cancer; -hCG, beta-human chorionic
gonadotropin; BTC, biliary tract cancer; CR,complete response; GIST, gastrointestinal stromal tumor; HCL,
hairy cellleukemia; IMWG,International Myeloma Working Group; MM, multiple myeloma; MR,minor response;
[COMPANY_001] Confidential Page [ADDRESS_923296] entry  until the response 
assessment was performed is assumed to be 8 weeks. The maximum length of time for each 
study  is 156 weeks 6 weeks (roughl y 3 years).
Although actual enrollment may vary, predicted enrollment during a 3-year time period is
incorporated into the simulations.  Because enrollment varies by [CONTACT_27183] , a numbering
scheme (1 through 9) is used in simulations and corresponding results to index the nine
histologies. Histology  indexing, projected enrollments and the historical control and
clinically  meaningful response rates used in simulations are shown in Table 32.
Table 32 Projected Enrollment andIndexing by[CONTACT_681906]3-year
time periodHistorical Control/
Clinically
Meaningful RRs Case 1Case 2Case 3Case 4
ATC 3 10 20 25 25 15% /60%
BTC 2 10 16 16 10 10% /50%
GIST 7 5 5 5 2 10% /50%
HCL 1 15 17 20 20 10% /50%
WHO Grade 1or2Glioma6 5 8 8 5 10% /50%
WHO Grade 3or4Glioma
(high -grade) 5 5 16 16 8 10% /50%
MM 8 5 17 20 20 15% /60%
NSGCT/NGGCT 9 5 5 5 2 25% /75%
ASI 4 8 5 5 2 10% /50%
Abbreviations: ASI, adenocarcinoma of small intestine; ATC, anaplastic thyroid cancer; BTC, biliary tract cancer; GIST,
gastrointestinal stromal tumor; HCL, hairy cell leukemia; MM, multiple myeloma; NGGCT, non-geminomatous germ cell
tumor; NSGCT, non-seminomatous germ cell tumor; RR, response rate; WHO, World Health Organiza tion
[IP_ADDRESS] Overall Response Rate Scenarios
Due to the ‘borrowing’ nature of the model, the design is evaluated across a variety of
scenarios for the distribution of true ORRs across the histologic cohorts. These areshown 
in Table 33.
The “Alternative ”scenario assumes all histologies are responsive at the defined clinically
meaningful RR levels.  The “Null” case assumes all histologies are non-responsive at the 
historical control RRs.  The “All Moderate” scenario assumes all histologies show moderate 
RR levels inbetween the historical control and clinically meaningful RR levels. The “Mixed 
(0.1-0.5)” assumes a range of response rates across the nine histologies. The other three 
scenarios consider various situations where histologies are either responsi ve (at the clinicall y
meaningful RR level) or not (at the historical control RR level).
[COMPANY_001] Confidential Page 140
Amended Protocol Version 11       Protocol No. CDRB436X2201
Table 33 Simulation Scenarios: Various Assumptions for the True ORR for
each Histology
ScenarioHistology
1 2 3 4 5 6 7 8 9
Alternative 50% 50% 60% 50% 50% 50% 50% 60% 75%
Null 10% 10% 15% 10% 10% 10% 10% 15% 25%
All Moderate 30% 30% 40% 30% 30% 30% 30% 40% 50%
Mixed 50% 10% 30% 40% 10% 20% 30% 45% 75%
5Greats: Mixed 50% 10% 60% 10% 50% 10% 10% 60% 75%
5Greats: Low 10% 10% 15% 10% 50% 50% 50% 60% 75%
2 Greats 10% 50% 15% 10% 50% 10% 10% 15% 25%
Abbreviations: ORR =overall response rate
NOTE: Color indicates responsiveness ofthetrueORR foreach histology. Red indicates non-responsive andisequal to
the assumed historical control rate, green indicates responsive andisequal totheclinically meaningful ORR, and blue
indicates moderate responsiveness andis in-between thehistorical control rateandclinically meaningful ORR.
[IP_ADDRESS] Output from Simulated Trials
For each scenario specified in Table 33, overall descriptive measures are reported foreach 
histology and sample sizes specified in Case 1 and include:
Proportion of studies that declare the histology efficacious at the final anal ysis
Proportion of studies that halt enrollment to each histology early for futility
Proportion of studies that halt enrollment to each histology early for efficacy
For each possible combination of sample size and observed number of responses, the 
proportion and number of times the model declares such data efficacious at the fina l 
analysis (by[CONTACT_89665], combining across histologic cohorts)
In-depth information is also provided for a small number of simulated example trials. These 
illustrate the flow and outcome of possible trials based on the pre-specified statistical 
decision ru les.
18.4.2 Operating Characteristics
[IP_ADDRESS] Power and TypeI Error Rate
Power and type I error rate are examined across scenarios for the distribution of assumed
true ORRs for each histology . The power is the probability of declaring efficacy within a
histology when the true underly ing ORR is greater than its corresponding historical control.  
Type 1 error rate is the probability of declaring efficacy within a histology when the true 
underly ing response rate is equal to the historical control. Figure 1 illustrates the proportion 
of trials that declare each histology efficacious at the final analysis across simulation 
scenarios. Supporting tables for the simulation results are provided in Appendix 7 .
The power and type I error rate are dependent 
upon the sample sizes and response rates across 
the distribution of histologies. When the treatment effects are the same across all histologies 
(either all responsive or all non-responsive), estimation efficiencies, due toborrowing, result 
in very good operating characteristics, even in histologies
with very low sample sizes.  Under 
sample size Case 1, the typeI error rate is controlled to 0.04 across all histologies (All Null 
scenario). The design maintains power 93% to 98% for the higher enrolling cohorts, and 84% 
[COMPANY_001] Confidential Page 141
Amended Protocol Version 11       Protocol No. CDRB436X2201
to 90% for the smallest enrolling 5 cohorts (All Great scenario).  Also, the design exhibits 
reasonable power to detect a moderate level of activity (All moderate scenarios).
When the treatment effects vary across histologies, the amount of appropriate borrowing also 
varies, impacting the operating characteristics. The ‘2 Greats: Mixed’ investigates design 
performance where most histologies are not responsive.  In this situation , the typeI error rate 
is controlled to 0.06 and the power is 82% for the higher enrolling cohort and 55% for the 
low enrolling cohort. The ‘5 Greats: Mixed’, ‘5 Greats: Low’ and ‘Mixed’ scenarios 
investigate the design performance in situations where roughly half thehistologies are 
responsive. The t ype I error rate ranges from 0.09 to 0.14 while the power ranges from 93% 
to 96% for the higher enrolling cohorts and ranges from 67% to 84% for the lower enrolling 
cohorts. Generall y, improvement in the overall distribution oftreatment effects tends to 
coincide with slight increases in type I error rate and moderate increases in power.
Figure 1 Proportion of Studies that Declare each Histology Efficacious at 
theFinal Analysisunder Sample Size Case 1
[IP_ADDRESS] Probability that the Model Declares Success Across Different 
Sample Sizes and Numbers of Observed Responses
No pre-determined number of responses or response rate will necessarily  dictate model
success or model failure.  Inaddition to a particular histolo gyresponse data, their
corresponding historical control response rate and the overall distribution of treatment
effects across the histologies impacts the model decision in that particular histology .To
further understand the likelihood of model success, for each possible combination of sample 
size (≤15) and number of observed responses, the proportion of times the model declares 
such data efficacious at the final analy sis is assessed by[CONTACT_681907]. Hence, the likelihood of 
declaring success is explored for histologies with historical control response rates of 0.10 
(histologies 1, 2, 4, 5, 6, and 7), 0.15 (histologies 3 and 8), and 0.25 (histology 9).Actual 
histologies, their simulation indexing number, and the appropriate historical control response 
rates are in Table 29 in Section [IP_ADDRESS].

[COMPANY_001] Confidential Page [ADDRESS_923297]’s response status. When the observed ORR is 10%, success is 
never declared for anyhistology across all seven scenarios.  Hence, if zero responses are 
observed, a histology  will never meet the success criteria. And, at least two responses are 
needed if response data is available for more than 10 subjects within a particular histology .
When one response is observed within a histology , there is positive probability of meeting 
success onl y in mixed situations when the sample size is small (roughly 5). When 2, [ADDRESS_923298] s sufficient to 
meet statistical success regardless of the sample size, scenario, and historical control response 
rate.  Further details for all situations can be visually explored in Figure 3 .
[IP_ADDRESS] Probability that the Model Declares Success Across Different 
Sample Sizes
To evaluate the model performance for vario us sample sizes, simulations are also performed 
under the following four scenarios for sample sizes specified in Case 2, 3, and 4 with the 
maximum sample size for a given histology can be as high as 25.
Table 34 Simulation Scenarios for Enrollment Sensitivity :Various
Assumptions for the True ORR for Each Histology
ScenarioHistology
1 2 3 4 5 6 7 8 9
Mixed1 20% 30% 60% 30% 40% 40% 10% 15% 75%
5Greats: Mixed1 10% 50% 60% 50% 10% 50% 10% 15% 75%
4Greats: Low 10% 10% 15% 50% 10% 50% 50% 15% 75%
2Greats: Mixed1 10% 10% 60% 10% 10% 10% 50% 15% 25%
When the sample size for some histology increases from [ADDRESS_923299] typeI error
increases from 0.14 to 0.18. Under sample size Case 2, the type I error rate is ranges from
0.04-0.17; the design maintains power 94% to 98% for the higher enrolling cohorts (>10 
subjects enrolled per cohort), and 61% to 87% for the smallest enrolling three cohorts (5 
subjects enrolled per cohort).  Under sample size Case 3, the typeI error rate is ranged from
0.04 to 0.18; the power is ranged from 92% to 98% for high enrolling cohorts (>10 subjects 
enrolled per cohort) and ranged from 62% to 86% for low enrolling cohorts (5-8 subjects 
[COMPANY_001] Confidential Page 143
Amended Protocol Version 11       Protocol No. CDRB436X2201
enrolled per cohort).  Under sample size case 4, the type I error ranges fro m 0.02 to 0.16; the 
power ranges from 93% to 96% for high enrolling cohorts (>10 subjects enrolled per cohort), 
59% to 71% for low enrolling cohorts (5 -8 subjects enrolled per cohort) and 26% to 44% for 
ultra low enrolling cohorts (2 subjects enrolled per cohort). Figure 4illustrates the proportion 
of trials that declare success across all possible combinations of sample sizes and number of 
observed responses and for each historical control response rate. Supporting tables for the 
simulation results are provided in Appendix [ADDRESS_923300] super low enrollment (n=2 or less) can be lower than 50%.  Overall the design 
performance is robust to overenrolling up to 25 subjects for a given histology .
[COMPANY_001] Confidential Page 144
Amended Protocol Version 11                                                                                              Protocol No. CDRB436X2201
Figure 2 For Each Combination of Sample Size and Observed Number of Responses, the Probability  of Model 
Success at the Final Anal ysis (by[CONTACT_89665], combined across histologies with the same historical 
control RR)

[COMPANY_001] Confidential Page 145
Amended Protocol Version 11                                                                                        Protocol No. CDRB436X2201
Figure 3 ForAllSample Sizes and When the Number of Observed Responses is 1, 2, 3, or 4, the Probability of 
ModelSuccess attheFinal Analysis(by[CONTACT_89665], combinated across histologies with the same 
historical control RR)

[COMPANY_001] Confidential Page [ADDRESS_923301] five subjects in a particular histology prior to stoppi[INVESTIGATOR_681806] 10 subjects in a histology prior to stoppi[INVESTIGATOR_681807] , theability for 
histologies to stop earlyislargel y dependent upon the projected maximum sample size per 
histology .  The overall distribution of treatment effects across histologies also impacts the 
likelihood of halting enrollment earl y.
When the expected 3 -year enrollment is greater than 5, non -responsive histologies stop early 
for futility
between 32% and 66% of the time.  When the expected 3 -yearenrollment is five 
subjects, non -responsive histologies stop early  for futility  between 8% and 35% of the time.
When the expected 3-year enrollment is at least 10, responsive histologies stop early  for 
futility between 41% and 90% of the time.  When the expected 3-year enrollment is less than 
10, the probability of stoppi[INVESTIGATOR_681808]. Across simulation scenarios, 
non-responsive histologies generall y do not stop earlyfor efficacy while responsive 
histologies generally  do not stop early  for futility .
Figure [ADDRESS_923302] CONSIDERA TIONS
19.1 Posting ofInformation onPublicly Available Clinical Trial
Registers
Study information from this protocol will be posted on publicly available clinical trial 
registers before enrollment of subjects begins.
19.2 Regulatory andEthical Considerations, Including theInformed
Consent Process
Prior to initiation of a study site, the sponsor will obtain favorable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory agency to conduct the study in accordance with I nternational Council

[COMPANY_001] Confidential Page 149
Amended Protocol Version 11         Protocol No. CDRB436X2201
on Harmonization (ICH) Good Clinical Practice (GCP) and applicable country -specific 
regulatory requirements.
The study will be conducted in accordance with all applicable regulatory requirements.
The study will be conducted in accordance with ICH GCP, all applicable subject privacy 
requirements, and the ethical principles that are outlined in the Declaration of Helsinki 2008, 
including, but not limited to:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of study protocol and any subsequent 
amendments
Subject informed consent
Investigator reporting requirements
The sponsor will provide full details of the above procedures, either verbally , in writing, or 
both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
In approving the clinical protocol the IEC/I RB and, where required, the applicable regulatory
agency are also approving the optional assessments  
, unless otherwise indicated.  Where permitted by[CONTACT_12721], 
approval of the optional assessments can occur after approval is obtained for the rest of the 
study .If so, then the written approval will clearl y indicate approval of the optional 
assessments is being deferred and the study , except for the optional assessments, canbe 
initiated. When the optional assessments are not approved, then the approval for the rest of 
the study will clearl y indicate this and therefore, the optional assessments will
not be 
conducted.
19.3 Data Monitoring Committee
A Data Monitoring Committee (DMC) will be utilized in this study and will be comprised of 
individuals who are not members of the clinical study team. At least one independent 
hematologist and one independent oncologist (external to the sponsor) will serve on the 
committee.  The objective of the DMC will be to ensure objective medical and/or statistical 
review of safety and/or efficacy issues in order to protect the ethical and safet y interests of 
subjects and to protect the scientific validit y of thestudy .The schedule of anyplanned 
interim analy ses and the anal ysis plan for DMC review will be described in the committee’s 
charter.
19.4 Qualit yControl (Study Monitoring)
In accordance with applicable regulations, GCP, and [COMPANY_001] procedures, [COMPANY_001] personnel 
(or designated Clinical Research Organization [CRO]) will contact [CONTACT_681908], study  requirements, and their 
responsibilities to satisfy regulatory , ethical, and the sponsor’s requirements.  When 
reviewing data collection procedures, the discussion will include identification, agreement 
and documentation of data items for which the eCRF will serve as the source document.
The investigator and the head of the medical institution (where applicable) agrees toallow 
the monitor direct access to all relevant documents and to allocate their time and the time to 
their staff to monitor to discuss findings and an yissues.

[COMPANY_001] Confidential Page 150
Amended Protocol Version 11         Protocol No. CDRB436X2201
Monitoring visits will be conducted in a manner to ensure that the:
Data are authentic, accurate, and complete.
Safety and rights of subjects are being protected.
Study is conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
19.[ADDRESS_923303] a quality assurance assessment and/or audit of the site records, and theregulatory
agencies may conduct a regulatory inspection at anytime durin g or after completion of the 
study . In the event of an assessment, audit or inspection, theinvestigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant 
documents and to allocate their time an d the time of their staff to discuss the conduct of the 
study , anyfindings/relevant issues and toimplement anycorrective and/or preventative 
actions to address an yfindings/issues identified
19.[ADDRESS_923304] visit.
Upon completion or termination of the study , [COMPANY_001] personnel (or designated CRO) will 
conduct site closure activities with the investigator or site staff (as appropriate), in accordance 
with applicable regulations, ICH GCP, and [COMPANY_001] Standard Operating Procedures.
The sponsor reserves the right to temporarily suspend or terminate the study at an ytime for 
reasons including (but not limited to) safety issues, ethical issues, or severe noncompliance.  
If the sponsor determines that such action is required, the sponsor will discuss the reasons for 
taking such action with the investigator or head of the medical institution (where applicable).
When feasible, the sponsor will provide advance notice to the investigator orhead of the 
medical institution of the impending action.
If a study  is suspended or terminated for safet y reasons, the sponsor will promptly inform all 
investigators, heads of the medical institutions (where applicable),and/or institutions 
conducting the study .  The sponsor will also promptly inform the relevant regulator y
authorities of the suspension/termination along with the reasons for such action.  Where 
required by[CONTACT_5279], the investigator or head of the medical institution must 
inform the I RB/IEC promptly and provide the reason(s) for the suspension/termination.
Study sites and/or the study may be closed by[CONTACT_681909]/study fails to recruit
within a pre -defined timeframe, as defined within the SPM.
19.7 Records Retention
Following closure of the study , the investigator or head of the medical institution (where
applicable) must maintain all site study records (except for those required by[CONTACT_681910]) in a safe and secure location. The recor ds must be easily 
accessible when needed (e.g., for a sponsor audit or regulatory  inspection) and must be 
available for review in conjunction with assessment of the facility , supporting systems, and 
relevant site staff.
[COMPANY_001] Confidential Page 151
Amended Protocol Version 11         Protocol No. CDRB436X2201
Where permitted by[CONTACT_1207]/regulations or institutional policy , some or all of the records 
may be maintained in a format other than hard copy (e.g., microfiche, scanned, electronic); 
however, caution must be exercised before such action is taken. The investigator must ensure 
that all reproductions are legible and are a true and accurate copyof the original.  In addition, 
they must meet accessibility and retrieval standards, including regeneration of a hard cop y, if 
required. The investigator must also ensure thatan acceptable back -up of the reproductions 
exists and that there is an acceptable quality control procedure in place for creating the 
reproductions.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from thecompletion of the Clinical Trial unless the Sponsor provides 
written permission to dispose of them or, requires their retention for an additional period of 
time because of applicable laws, regulations and/or guidelines.
The investigator must notify the sponsor of any changes in the archival arrangements, 
including, but not limited to archival of records at an off -site facilit yor transfer of ownership 
of the records in the event that the investigator is no longer associated with the site.
19.[ADDRESS_923305] a results summary  to the [COMPANY_001] Clinical Trial Results website 
(www.novartisclinicaltrials.com ) and other publicly  available registers no later than twelve 
(12) months after the last subject’s last visit (LSLV). I n addition, upon study completion and 
finalization of study  report, [COMPANY_001] aims to submit result s of the study  for publication.
When publication is not feasible, please refer to the [COMPANY_001] Clinical Trial Results website 
(novartisclinicaltrials.com) for a summary  of the trial results.
[COMPANY_001] Confidential Page 154
Amended Protocol Version 11         Protocol No. CDRB436X2201
Flahert yKT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF -
Mutated Melanoma.  N Engl J Med. 2012;367(2):107 -114.
Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based 
on 725 cases of the Italian Cooperative Group (ICGHCL). Leuk Lymphoma .1994;13(3-
4):307-316.
Frohlich MW, Small EJ. Stage II non -seminomatous testis cancer: the roles of primary and 
adjuvant chemotherap y. Urol Clin North Am. 1998;24:451 -459.
Gidron A. Tallman MS. 2 -Cda in the treatment of hairy cell leukemia: a revi ew of long -
term follow -up. Leuk Lymphoma . 2006;47(11):2301 -2307.
Gilmartin AG, Bleam MR. Groy R, et al. [COMPANY_004]1120212 (JTP -[ZIP_CODE]) is an inhibitor of MEK 
activity and activation with favorable pharmacokinetic properties for sustained in vivo 
pathway inhibitio n. Clin Cancer Res, 2011;17:989-1000.
GlaxoSmithKline Document Number CM2010/[ZIP_CODE]/05. Dabrafenib ([COMPANY_004]2118436) 
Monotherap y and Dabrafenib+Trametinib ([COMPANY_004]1120212) Combination Therap y
Investigator's Brochure. Version 07. Report dated [ADDRESS_923306]-2015.
GlaxoSmithK line Document Number HM2009/[ZIP_CODE]/05. [COMPANY_004]1120212 (trametinib) 
Investigator’s Brochure. Version 06. Report dated 28- Jan-2015.
Goldman JM, Goren EN, Cohen BL, Webber M, Brennan F, Robbins J. Anaplastic thy roid 
carcinoma: long term survival after radical surg ery. J of Surg Onc .1980;14(4):389-394.
Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell
leukemia: an evaluation of spleen weight and bone marrow involvement. Blood.
1983;61(2):349 -352.
Goodman GR, Burian C, Koziol Ja, et al. Extended follow -up of patients with hairy cell
leukemia after treatment with cladribine. J Clin Oncol . 2003;21(5):891 -896.
Goutsouliak V, Hay JH. Anaplastic thy roid cancer in British Columbia 1985 –1999: a
population -based study .Clin Oncol (R Coll Radiol) . 2005;17:75-78.
Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI 3K/mTOR
inhibitors overcome acquired resistance to the BRAF inhibitor [COMPANY_004]2118436 dabrafenib,
mediated by[CONTACT_681911]. Mol Cancer Ther 2012;11(4):909 -920.
Grever M, Kepeck y K, Foucar MK, et al. Randomizzed comparison of pentostatin versus
interferon alfa -2a in previously  untreated patients with hairy  cell leukemia: an intergroup
study . J Clin Oncol . 1995;13(4):974 -982.
Grever MR, Lazanski G. Modern strategies for hairy cell leukemia. J Clin Oncol .
2011;29(5):483 -590.
Haberman TM, Rai K. Historical treatments of hairy cell leukemia, splenectomy and
interferon: past and current uses. Leukemia &Lymphoma . 2011(6);52(S2):[ADDRESS_923307] in hairy cell
leukemia. Hematol Oncol Clin North Am . 2006;20(5):1075 -1086.
Hadziahmetovic M, Shirai K Chakravarti A. Recent advancements in multimodality  
treatment of gliomas. Future Oncol. 2011;7(10):1169 -1183.
Haigh PI, Ituarte PHG, Wu HS, et al. Completely resected anaplastic th yroid carcinoma
combined with adjuvant chemotherap yand irradiation is associated with prolonged
survival. Cancer. 2001;91:2335-2342.
[COMPANY_001] Confidential Page 155
Amended Protocol Version 11         Protocol No. CDRB436X2201
Hauschild, A, Jacques JG, Demidov LV, et al.  Phase III, randomized, open -label,
multicenter trial (BREAK -3) comparing the BRAF kinase inhibitor dabrafenib
([COMPANY_004]2118436) with dacarbazine (DTI C) in patients with BRAF V600E- mutated
melanoma. J Clin Oncol. 2012;30:(suppl;abstr8500).
Heinrich MC, Corless CL, De metri GD, et al. Kinase mutations and imatinib response in 
patients with metastatic gastrointestinal stromal tumors. J Clin Oncol . 2003;21(23):4342-
4349.
Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open -label stud y evaluating the
activity of imat inib in treating life -threatening malignancies known to be associated with 
imatinib -sensitive ty rosine kinases. Clin Cancer Res. 2008;14(9):[ADDRESS_923308] Cancers and Emerging 
Targeted Therapi[INVESTIGATOR_014]. J Clin Oncol. 2010;28(10):3531
-3540.
Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomy cin or
ifosfamide in the treatment of disseminated germ cell tumors: final anal ysis of an
intergroup trial. Cancer 2003;97(8):1869 -1875.
Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause -specific
mortality among 3104 patients with hairy cell leukemia: a population -based study . J Natl
Cancer Inst . 2007;99(3):215
-222.
Honecker F, Wermann H, May er F, et al. Microsatellite Instability , Mismatch Repair
Deficiency and BRAF Mutation in Treatment- Resistant Germ Cell Tumors. J Clin Oncol.
2009;27:2129-2136.
Hostein I,Faur N, Primois C, et al. BRAF Mutation Status in Gastrointestinal Stromal
Tumors. Am J Clin Pathol. 2010;133:14 1-148.
Hunt CM.  Mitochondrial and immunoallergic injury increase risk of positive drug
rechallenge after drug -induced liver injury : A s ystematic review.
Hepatol. 2010;52:2216 -
2222.
International Germ Cell Cancer Collaborative Group (IGCCCG): International Germ Cell 
Consensus Classification: A Prognostic Factor -Based Staging S ystem for Metastatic Germ 
Cell Cancers. J Clin Oncol. 1997;15(2):594 -603.
Italiano A, Cioffi A, Coco P, et al. Patterns of care, prognosis, and survival in patients with 
metastatic gastrointestinal stromal tumors (GI ST) refractory  to first -line imatinib and 
second -line sunitinib. Ann Surg Oncol. 2011;19(5):[ADDRESS_923309] in
Adults with Acetaminophe n Overdose and Acute Liver Failure. Drug Metab Dispos. 2009; 
37:1779-1784.
James W, Stein C.  Estimation with Quadratic Loss. Proc Fourth Berkeley Symp on Math 
Statist and Prob . 1961;1:361 –379.
Jansen J, Hermans J. Splenectom y in hairy cell leukemia: a retrospective multicenter
analysis. Cancer
. 1981;47:2066-2076.
Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2009. CA Cancer J Clin. 2009;59:[ADDRESS_923310] reactivation. Nature.
2010;468:968-972.
[COMPANY_001] Confidential Page 156
Amended Protocol Version 11         Protocol No. CDRB436X2201
Jones RH, Vasey PA. Part II: testicular cancer –management of advanced disease.
Lancet Oncol. 2003;4:738 -747.
Kim, K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by 
[CONTACT_113879]703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti -myeloma activit y
in vitro and in vivo. Br. J. Haematol . 2010;149:537–549.
Kojic SL ,Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review 
of novel therap y.Expert Rev. Anticancer Ther. 2011;11(3):387-402.
Kollmannsberger C, Beyer J, L iersch R, et al. Combination chemotherap ywith gemcitabine 
plus oxaliplatin in pati ents with intensively pretreated or refr actory germ cell cancer: A 
Study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22:108 -114.
Kreitman RJ, Fitzgerald DJ, Pastan I.Approach to the patient after relapse of hairy cell
leukemia. Leuk Lymphoma. 2009a;50(suppl 1):32-37.
Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti -CD22 recombinant
immunotoxin moxetumomab pasudotox (CAT- 8015 or HA22) in patients with hairy cell
leukemia. J Clin Oncol . 2012;30:1822 -1828.
Kreitman, RJ , Stetler -Stevenson, M, Margulies, I, et al. Phase II trial of recombinant
immunotoxin RFB4(dsFv) -PE38 (BL22) in patients with hairy cell leukaemia. J Clin
Oncol. 2009b;27:2983–2990.
Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S. Outcome of
patients with my eloma relapsing after IMiD and bortezomib therapy : a multicentre study
from the IMFWG. Haematologica. 2010;95(suppl.2):151, abstract 0376.
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and 
the impa ct of novel therapi[INVESTIGATOR_014]. Blood. 2008;111(5):2516- 2520. Prepublished on 2007/11/03 
as DOI 10.1182/blood -2007 -10-116129.
LaCouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical Practice guidelines for the
prevention and treatment of EGFR inhibitor
-associated dermatologic toxicities. Support
Care Cancer. 2011;19:1079-1095.
Le Gal F, Gordien E, Affolabi D, et al. Quantification of Hepatitis Delta Virus RNA in 
Serum by [CONTACT_31861] -Time PCR I ndicates Differe nt Patterns of Virological Response 
to Interferon Therapy in Chronically Infected Patients.  J Clin Microbiol .2005;43(5):2363 –
2369.
Long GV et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 
BRAF -
mutant melanoma: a multicentre, doub le-blind, phase 3 randomised controlled trial. 
Lancet. 2015; 386(9992): 444-51
Louis DN et al. The 2016 World Health Organization Classification of Tumors of the 
Central Nervous S ystem: a summary .Acta Neuropathologica. 2016 Jun;131(6):803- 20. doi: 
10.1007/s00401 -016-1545- 1. Epub 2016 May  9.
Mannuel H, Mitikiri N, Hussain A. Update on testicular germ cell tumors. Current Opin in 
Oncology. 2011;23:265 -270.
Masque -
Soler N, Szczepanowski M, Leuschner I, et al. Brief Report: Absence of BRAF
Mutation in P ediatric and Adolescent Germ Cell Tumors I ndicate Biological Difference to 
Adult Tumors. Pediatr Blood Cancer . 2012;59:732-735.
Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy cell leukemia. Best
Pract Res Clin Hematol . 2003;16(1):41 -56.
[COMPANY_001] Confidential Page 157
Amended Protocol Version 11         Protocol No. CDRB436X2201
Mayer F, Wermann H, Albers P, et al. Histopathological and molecular features of late
relapses in non- seminomas. BJUI. 2010;107:936-943.
Miranda C, Nucifora M, Molinari F, et al.  KRAS and BRAF mutations predict primary  
resistance to imatinib in gastrointest inal stromal tumors.  Clin Cancer Res.
2012;18(6):1769 -1776.
Morton LM,Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Ly mphoma
incidence patterns by[CONTACT_681912], 1992 -2001. Blood. 2006;107:265 -
276.
Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic Thyroid Cancer: 
A review of epi[INVESTIGATOR_623] , pathogenesis and treatment. J of Oncology. 2011; Article ID 
542358. Doi:10.1155/2011/542358.
Nazeer T, Ro JY, Amato RJ, et al. Histologicall y pure seminoma with elevated alpha -
fetoprotein: a clinicopathologic stud y of 10 cases. Oncol Rep. 1998;5:1425-1429.
NCI Common Terminology Criteria for Adverse Events, Version 4, DCTD, NCI, NIH,
DHHS, 28 May 2009.
Neal RM. Markov Chain Sampling Methods for Dirichlet Process Mixtur e Models. J of
Computational and Graphical Statistics. 2000;9(2):249 -265.
Niault TS, Baccarini M. Targets of RAF in tumorigenesis. Carcinogenesis.
2010;31(7):1165 -1174.
Nichols CR, Heerema NA, Palmer C, et al.: Klinefelter's s yndrome associated with
mediastinal germ cell neoplasms. J Clin Oncol 1987;5(8):1290 -1294.
Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine -
failed patients with hairy cell leukemia. Blood 2003;102:[ADDRESS_923311] . 2011;16:296 -309.
Overman MJ, Hu CYH, Kopetz S, et al. A Population- Based Comparison of
Adenocarc inoma of the Large and Small I ntestine: Insights Into a Rare Disease. Ann Surg
Oncol . 2012;19(5):1439 -
1445.
Papay JI,Clines D, Rafi R, et al.  Drug -induced liver injury following positive drug
rechallenge. Regul Tox Pharm . 2009;54:84-90.
Perry A, Aldape KD, Goerge DH, Burger PC. Small Cell Astrocytoma: An Aggressive
Variant that is Clinicopathologicall y and Genetically Distinct from Anaplastic
Oligodendroglioma. Cancer. 
2004;101(10):2318 -2326.
Pi[INVESTIGATOR_262608], Moley JF. Medullary , Anaplastic and Metastatic Cancer s of the Thy roid. Semin
Oncol. 2010;37:567 -579.
Posner MD, Quivey JM, Akazawa PF, et al. Dose Optimization for the Treatment of 
Anaplastic Th yroid Carcinoma: A Comparison of Treatment Planning Techniques. Int J
Radiation Oncology Biol. Phys. 2000;48(2):475- 483.
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103.
[COMPANY_001] Confidential Page 158
Amended Protocol Version 11         Protocol No. CDRB436X2201
Rajkumar SV, Harousseau JL,Durie B, et al. Consensus recommendations for the uniform 
reporting of clinical trials: Report of the International My eloma Workshop Consensus 
Panel 1. Blood. 2011;117:4691-4695.
Ravandi F, Jorgensen J L,O’Brien SM, et al. Eradication of minimal residual disease in
hairy cell leukemia. Blood . 2006;107(12) :4658 -4662.
Riccioni R, Galimberti S, Petrini M. Hairy Cell Leukemia. Curr Trmt Options in Onc.
2007;8:129 -134.
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or High -Dose
Dexamethasone for Relapsed Multiple My eloma. N Engl J Med. 2005;352:2487-2498.
Robert C et al. I mproved overall survival in melanoma with combined dabrafenib and
trametinib. N Engl J Med . 2015; 372(1): 30 - 9
Rosove MH, Peddi PF, Glaspy JA.  BRAF V600E Inhibition in Anaplastic Thyroid Cancer 
–Letter to the Editor. N Engl J Me d. 2013;368 (7):684-685.
Sadighi Z, Slopis J. Pi[INVESTIGATOR_681809]: A Disease with Evolving Molecular
Heterogeneity .J Child Neurol . 2013;28:625
-632.
Saetta AA, Papanastasiou P, Michalopoulos NV, Gigelou F, Korkolopoulou P, Bei T, 
Patsouris E. Mutational analy sis of BRAF in gallbladder carcinomas in association with K-
ras and p53 mutations and microsatellite instability. Virchows Arch. 2004;445:179 - 182.
Saven A, Burian C, Koziol JA, Pi[INVESTIGATOR_195449].Long -term follow -up of patients with hairy cell
leukemia after cladribine treatment. Blood. 1998;92(6):1918 -1926.
Saven A. Treatment of hairy -cell leukemia. N Engl J Med. 2001;345(20):1500-1501.
Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherap y in patients with extragonadal 
nonseminomatous germ ce ll tumors: the I ndiana University experience. J Clin Oncol. 
1994;12(7):1390 -1393.
Schindler G, Capper D, Mey er J, et al. Anal ysis of BRAF V600E mutation in 1,320 nervous 
system tumors reveals high mutation frequencies in pleomorphic xanthoastrocy toma, 
gang lioglioma and extra -cerebellar pi[INVESTIGATOR_681726]. Acta Neuropathol . 
2011;121:397-405.
Schneider BP, Kesler KA, Brooks JA, et al. Outcome of patients with residual germ cell or 
non-germ cell malignancy after resection of primary mediastinal nonseminomat ousgerm 
cell cancer. J Clin Oncol 2004;22(7):[ADDRESS_923312] Surg . 2009;13(8):1510 - 1516.
Seymour JF, Kurzrock R, Freireich EJ, et al. 2- chlorodeoxy adenosine induces durable
remissions and prolonged suppression of CD4_ lymphocy te counts in patients with hairy
cell leukemia. Blood. 1994;83:2906 -2911.
Seymour JF, Talpaz M, K urzrock R. Response duration and recovery ofCD4_ lymphocy tes 
following deox ycoform ycin in interferon -alpha -resistant hairy cell leukemia: 7 -Year 
follow -up. Leukemia. 1997;11:42 - 47.
Shimaoka K, Schoenfeld DA, Dewy s WD, et al. A randomized trial of doxorubi cin versus 
doxorubicin plus cisplatin in patients with advanced thy roid carcinoma. Cancer.
1985;56(9):2155 -2160.
[COMPANY_001] Confidential Page 159
Amended Protocol Version 11         Protocol No. CDRB436X2201
Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. Cancer Journal for Clinicians. 
2012;10-29. Doi:10.3322/caac.[ZIP_CODE])
Sigal DS, Sharpe R , Burian C, Saven A. Very long term eradication of minimal residual
disease in patients with hairy cell leukemia after a single course of cladribine. Blood.
2010;115:1893-1896.
Speranzaa G, Doroshow JH, Kummar S. Adenocarcinoma of the small bowel: changes in 
the landscape? Current Opin in Oncology . 2010;22:[ADDRESS_923313] and Prob. 1956;1:197 –206.
Su F, Viros A, Milagre C, et al. 
RAS -mutaions in cutaneous squamous -cell carcinomas in
patients treated with BRAF inhibitors. N Engl J Med; 2012;366:207-215.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pi[INVESTIGATOR_27604], Stein H, Thiele J, Vardiman JW.  
WHO Classif ication of Tumours of Haemotopoietic and Lymphoid Tissues. 4th ed.
Geneva, Switzerland: IARC; 2008.
Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in 
cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52:706 - 712.
The Criteria Committee of the [LOCATION_001] Heart Association (NYHA). Nomenclature and
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. [LOCATION_011], Mass: 
Little, Brown & Co.; 1994:253-256.
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF Mutations in Hairy Cell Leukemia. N Engl 
J Med. 2011;364:2305
-2315.
Trials and mechanisms of resistance. Clin Cancer Res. 2012;18:[ADDRESS_923314] Cancer. N Engl J Me d. 2010;362:1273-1281.
van den Bent MJ, Wefel JS, Schiff D, et al. 
Response assessment in neuro- oncology (a
report of the RANO group): assessment of outcome in trials of diffuse low grade gliomas. 
The Lancet. 2011;12:583-593.
Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity  and distinct molecular 
mechanisms characterize the development of t(4;14) and t(11:14) myeloma. Blood. 
2012;120(5):1077 -1086
Warth A, Kloor M, Schirmacher P, Blaker H. Genetics and epi[INVESTIGATOR_681810]: the interactions of CIN, MSI, and CIMP. Modern Pathology .
2011;24(4):564 –570.
Weber JS, Flaherty KT, Infante JR, et al. Updated safet y and efficacy results from a
Phase 
I/II study  of the oral BRAF inhibitor dabrafenib ([COMPANY_004]2118436) combined with the oral 
MEK 1/2 inhibitor trametinib ([COMPANY_004]1120212) in patients with BRAF- naive metastatic 
melanoma. J Clin Oncol. 2012;30:(suppl;abstr8510).
Weissbach L,Bussar -Maatz R, Mann K. The value of tumor markers in testicular
seminomas: Results of a prospective multi center study . Eur Urol. 1997;32:16 -22.
Wellbrock C, Karasaides M, Marais R. The RAF proteins take center stage. Nature Reviews 
Mol Cell Biol. 2004;5:875 -885.
Wen PY. Updated Response Assessment Criteria for High -Grade Gliomas: Response
Assessment in Neuro- Oncology Working Group. J Clin Oncol . 2010;28(11):1963-1972.
[COMPANY_001] Confidential Page 160
Amended Protocol Version 11         Protocol No. CDRB436X2201
Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ- cell tumors with 
cisplatin, bleomy cin, and either vinblastine or etoposide. N Engl J Med
.
1987;316(23):1435 -1440.
XiL,Arons E, Navarro W, et al. Both variant and IGHV4-34- expressing hairy cell
leukemia lack the BRAF V600E muta tion. Blood. 2012;119:3330 -3332
21 APPENDICES
21.1 Appendix 1:ECOG Performance Status
Assessment of Eastern Cooperative Oncology Group (ECOG) performance status to evaluate 
daily living abilities is required at Screening as well as routinel y throughout thetreatment 
and at treatment discontinuation.
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in phy sically strenuous activity but ambulatory and able to carry  out work 
of a light or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all self care but unable to carryout anywork activities; 
up and about more than 50% of waking hours
3 Capable of only  limited self care, confined to bed or chair more than 50% of wakin g 
hours
4 Completely disabled; cannot carry onanyself care; totally confined to bed or chair
Reference:
Oken MM, Creech RH, et al. Toxicity and response criteria ofthe Eastern Cooperative 
Oncology Group. American J of Clinical Oncology. 1982;5:649 -655.
21.2 Appendix 2:NYH AFunctional Classification System
The [LOCATION_001] Heart Association (NYHA) Functional Classification: Class I, II, IIIor 
IV Heart Failure provides a simple way of classify ing theextent ofheart failure. Itplaces 
subjects in one of 4 categories based on the level of limitation experienced during physical
activity .
Class Symptoms
Class I 
(Mild)No limitation of physical activity. Ordinary physical activity does not cause undue
fatigue, palpi[INVESTIGATOR_42243] (shortness of breath).
Class II 
(Mild)Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity 
results in fatigue, palpi[INVESTIGATOR_42243].
Class III 
(Mode rate)Marked limitation of physical activity. Comfortable at rest, but less than ordinary
physical activity results in fatigue, palpi[INVESTIGATOR_42243].
Class IV 
(Severe)Unable to carry out any physical activity without discomfort. Symptoms of cardiac
insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
Reference:
The Criteria Committee of the [LOCATION_001] Heart Association (NYHA).  Nomenclature and 
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. [LOCATION_011], Mass: 
Little, Brown & Co.; 1994:253-256.
[COMPANY_001] Confidential Page 161
Amended Protocol Version 11         Protocol No. CDRB436X2201
21.3 Appendix 3:Cockcroft -Gault Formula forCreatinine Clearance
Creatinine Clearance (mLmin⁄) =Qx(140−age[yr])xidealbodywt[kg] 
72xserumcreatinine [mg/dL]
Q = 0.85 for females
Q = 1.0 for males
OR
Creatinine Clearance (mLmin⁄) =Kx(140−age[yr])xidealbodywt[kg] 
serumcreatinine [μmol/L]
K = 1.0 for females
K = 1.23 for males
1. Useideal body weight (IBW) ifbody weight >30% of IBW. Otherwise, usebody weight.
2. Creatinine clearance hasamaximum value of125 mL/min. Clearance values >125 mL/min by[CONTACT_681913]125mL/min intheCalvert formula todetermine carboplatin dosing.
Calculation of IBW using the Devine Formula [ Devine , 1974]:
Males =50.0 kg +(2.3 kg xeach inch over 5ft) or 50.0 kg +(0.906 kg xeach cm over 152.4 
cm)
Females =45.5 kg +(2.3 kg xeach inch over 5ft) or 45.5 kg +(0.906 kg xeach cm over 152.4 
cm)
Example:
Male 
Actual Bod y Weight = 90.0 kg, 
Height = 68 inches 
IBW =50.0 +(2.3) (68 -60) =68.[ADDRESS_923315]’s actual body weight is >30% over IBW.Therefore, in this case, the subject’s 
IBW of 68.4 kg should be used in calculating estimated creatinine clearance.
Reference:
Devine BJ. Case Number 25 Gentamicin Therapy: Clinical Pharmacy  Case Studies. Drug 
Intelligence and Clinical Pharmacy. 1974;8:650 -655.

[COMPANY_001] Confidential Page 162
Amended Protocol Version 11         Protocol No. CDRB436X2201

[COMPANY_001] Confidential Page 163
Amended Protocol Version 11         Protocol No. CDRB436X2201

[COMPANY_001] Confidential Page 164
Amended Protocol Version 11         Protocol No. CDRB436X2201

[COMPANY_001] Confidential Page 165
Amended Protocol Version 11         Protocol No. CDRB436X2201

[COMPANY_001] Confidential Page 166
Amended Protocol Version 11         Protocol No. CDRB436X2201

[COMPANY_001] Confidential Page 167
Amended Protocol Version 11         Protocol No. CDRB436X2201
21.6 Appendix 6:Details ofBayesian Hierarchical Model
Yiis the response indicator for the ithsubject, and j=P(Yi=1 | ji= j)is the true response
rate for histology j. In the logic scale, θjis the mean log odds treatment effect of response:
  =      
1−   −      
1−   
Basic Hierarchical Model
A basic hierarchical model structure is described here and is incorporated within theclustered 
hierarchical model framework used in this study .
Borrowing occurs to the extent indicated by[CONTACT_681914] a hierarchical normal model on 
the treatment effects:
  ~ (μ,  ).
Were only this basic hierarchical model used for analy sis, the prior distributions would be:
μ~ (0,3)     ~  (0.5,0.125)
where IG(,)is the inverse gamma distribution defined by:
ƒ( | , )=  ℯ  / 
    Г( ),
This distribution is non -informative in the sense that its parameters are analogous to having
a single observation. The variance component isakeyparameter that plays arole in the 
degree of borrowing among histologies.  Small values of τ result in a greater degree of 
borrowing while large values ofcorrespond to less borrowing. The distribution of is based 
on the variability of the observations, and the observed between -histology variation is an 
important component of the model’s performance. The effects ofanyparticular prior 
distribution forcan be assessed via simulations in evaluating a design’s operating 
characteristics, typeI error rate and statistical power.

[COMPANY_001] Confidential Page 168
Amended Protocol Version 11         Protocol No. CDRB436X2201
Clustered Hierarchical Model
A clustered hierarchical model considers the possibility that “clusters” exist among the
collection o f histologies. A therapy may be effective for some histologies but not for others. 
Histologies within the same cluster have greater influence on each other than they do on 
histologies in other clusters. On the other hand, histologies in different clusters are 
conditionally independent given any particular configuration of clusters. There is borrowing 
at the cluster level and borrowing across histologies within a particular cluster.
Borrowing across clusters depends only on similarities between clusters and not ofindividual 
histologies.
The number of clusters is unknown in advance but information will be gleaned from the data 
using Dirichlet Process Mixtures (DPM). The full prior is constructed in [ADDRESS_923316] 
stage, the histologies are assigned toparticular clusters, 
with the number of clusters 
unspecified. Conditional on this particular clustering, the hierarchical model is fit within each 
cluster. A difference from the basic hierarchical model is in the parameter .Each cluster has 
its own . And the prior distribution on is now different:
  ~  (3,0.5).
Without the clustering, an informative prior on that places high probability on small values 
ofcould yield conclusions similar to simple pooling across histologies. This isnot desirable. 
Instead itis preferred to preserve the integrity  of individual histologies to theextent that they
give dissimilar results. With the clustering, a prior such as the one selected above meets this 
desideratum. When is small, as evinced by[CONTACT_26739],histologies will only be placed in the 
same cluster if the data for those histologies are sufficiently similar to other histologies in the 
cluster. When is large, the histologies will be assigned to separate clusters and response 
rates estimated separately . This clustering approach provides further protection against 
borrowing between dissimilar histologies while enhancing the borrowing between similar 
histologies.
Theprior distribution in a DPM is governed by[CONTACT_603138] .When is small, th eprior 
favors large clusters. Astends to zero, the prior tends to place all its mass on a single cluster 
containing all the histologies. Asincreases, the prior places more mass on clustering with 
a large number of clusters. Asbecomes large, the prior places all of itsmass on having a 
separate cluster for each histology (thus, no borrowing across histologies). A value of= 0 
corresponds to the usual hierarchical model with noclustering, while avery large treats 
all the histologies separately . Common values ofmight be between 0.[ADDRESS_923317] 
selected = [ADDRESS_923318] of the clustering por tion of the prior involves which histologies are clustered 
together. This is accomplished by[CONTACT_40397] a sequence of bins (in theory  there are infinitely
many  bins, but the number of bins actuall yused cannot exceed the number of histologies). 
Thus imagine a sequence of bins C1,C2,C3,… with associated probabilities pC1,pC2,pC3and 
so forth. In the prior, each histology is placed in a binaccording to the pCkprobabilities. Thus, 
if one pCkis near 1, then all histologies will be likely to randomly  fall in th e same bin. If all 
the p Ckvalues are small, it will be likely  thatall the histologies will randomly fall in separate 
bins. Histologies that fall within the same bin are defined as being in the same cluster. More 
details may be found in Escobar 1995 or Neal 2000.
[COMPANY_001] Confidential Page 169
Amended Protocol Version 11         Protocol No. CDRB436X2201
The pCkprobabilities are determined through a stick breaking process [Sethuraman, 1994]. 
Let pC1~Beta(1, α). This leaves 1-p C1probability to be allocated tothe remaining bins. Let pC2
be a Beta(1,α) proportion of that remaining mass, so p C2~Beta(1,α)*[1 -pC1]. There is now 1 -
pC1-pC2mass unallocated. Let pC3be a Beta(1,α) proportion of the remaining mass, so 
pC3~Beta(1,α)*[1-p C1-pC2] and so on for pC4, pC5,and so forth. This process generates an 
infinite sequence of p Ckvalues, but generall ythefirst few contain most of the probability. In 
terms of the posterior distribution, only thebins which contain the histologies are of interest, 
and thus only 9 of the infinite bins will actually beused.
The role of α can be seen from this construction. If α is very small, then the Beta(1,α) 
proportions will tend to be close to 1. Thus, the first pC1is quite likely to be near 1, and thus 
all the histologies will tend to lie in the first bin. If α is very large, all the Beta(1,α) values 
will tend to be small, and thus each p Ckwill tend to be small. This creates a situation where 
each histology  is likely to be in a separate bin. Our proposed value of α=[ADDRESS_923319] more similar data than histologies in separate bins. Thus, in the posterior 
distribution, hi stologies with similar data are viewed as more likely  to be from the same bin 
(and hence the same cluster). Histologies with very different data, in contrast, will have high 
posterior probability of being in separate bins/clusters, and thus will be estimated separatel y.
The posterior distribution also can be thought of in [ADDRESS_923320] being a posterior 
distribution on the clustering, and then conditional on the clustering the posterior distribution 
from the hierarchical model. Conditional on the clustering, borrowing happens within 
clusters, but not across clusters. In situations where the clustering is uncertain (alway s in 
practice), one will see a proportional amount of borrowing between histologies, proportional 
on the posterior probability the histologies are within the same cluster. The aim of the 
clustering is to identify situations where the drug generall yworks for some histologies and 
generall ydoes not work for others, so that these two disparate effects are not averaged 
together through t he borrowing.
Reference:
Sethuraman J.  A Constructive Definition of Dirichlet Priors.  Statistica Sinica .1994;4:639-
650.
21.7 Appendix 7:Supporting Simulation Results
Operating Characteristics for the Clustered Hierarchical Design for Different Sample 
Sizes: Power, Type I Error Rate
Histology
Scenario 1 2 3 4 5 6 7 8 9
Proportion of Trials that Declare each Histology Efficacious
(Measure of Power or Type I Error Rate)
Sample size Case 2 17 16 20 5 16 8 5 17 5
Mixed1 0.17 0.74 0.98 0.87 0.9 0.81 0.17 0.48 0.53
5Greats: Mixed1 0.1 0.94 0.96 0.82 0.11 0.85 0.12 0.1 0.75
4Greats: Low 0.09 0.08 0.08 0.77 0.08 0.82 0.68 0.07 0.65
2Greats: Mixed1 0.08 0.06 0.94 0.08 0.08 0.06 0.61 0.07 0.04
[COMPANY_001] Confidential Page 172
Amended Protocol Version 11         Protocol No. CDRB436X2201
Example 1: Observed ORR at each Interim Anal ysis and the Final Analysis

[COMPANY_001] Confidential Page 174
Amended Protocol Version 11         Protocol No. CDRB436X2201
Example 2: Observed ORR at each Interim Analysis and the Final Analysis
Example 3: Mixed Scenario, Most Histologies Declared Successful
In this example, the nine histologies demonstrate varyinglevels of responsiveness.  Most
histologies meet the criteria for statistical success at the final anal ysis.
Six histologies have ORRs ranging from 30% to 67%. All of these histologies declare 
success. Due to moderate ORRs in some of these histologies, it will be particularl ycritical 
that the entiret y of the data, including secondary efficacy endpoints, support clinically
relevant results to demonstrate evidence of meaningful high levels of activit y.
The ORR for the remaining three histologies is 0, 14% and 29%, none of which is
sufficient to meet the pre -specified success criteria. Two histologies halted enrollment
early for success and one for futility.

[COMPANY_001] Confidential Page 176
Amended Protocol Version 11         Protocol No. CDRB436X2201
Example 3: Observed ORR at each Interim Analysis and the Final Analysis
Example 4: Mixed Scenario, Most Histologies not Declared Successful
Inthis example, seven of the histologies demonstrate a range of ORRs from 0 to 31%. The 
remaining two histologies (histologies 7 and 9) have ORRs of 71% and 80% respectively .
Three of the histologies (histologies 1, 7, and 9) which demonstrated the highest ORRs of 
31%, 71%, and 80%, respectivel y, meet statistical success.  To demonstrate evidence of 
meaningful high levels of activity in these three histologies, it will be critical that in 
addition to statistical success, the totality of the data support clin ically relevant results.
The remaining size histologies with ORRs of 29% do not meet the pre-specified success 
criteria.  Histology 1 stopped earl yfor success while two histologies (2 and 3) stopped
early for futility .

[COMPANY_001] Confidential Page 180
Amended Protocol Version 11         Protocol No. CDRB436X2201
Example 5: Observed ORR at each Interim Analysis and the Final Analysis
Example 6: Mixed Scenario, Most of the Low -enrolling Histologies 
Declare Success while the Higher -enrolling Histologies Do Not
In this example, most of the lower enrolling cohorts (three to six subjects each) have 
relativel y high ORRs while the higher enrollment cohorts demonstrate low ORRs.
Four low -enrolling histologies (histology 6, 7, 8 and 9) have ORRs of 50%, 50%, 67%, and 
75% respectively , and statistical success is declared in each. To demonstrate evidence of 
meaningful high levels of activity in these three histologies, it will be critical that in 
addition to stati stical success, the totality of the data support clinically relevant results.
The four histologies (histologies 1, 2, 3, and 4) expected to enroll higher numbers of 
patients demonstrate much lower ORRs, ranging from 0- 12% and none declare success.
Though t he actual sample sizes aren’t very large (five to eight subjects), three of these 
histologies stopped early due to futility and larger sample sizes would likely have been
possible had they not halted enrollment earl y.  The remaining histology (histology 5) has an 
ORR of 33% (1/3) which also does not declare success.

[COMPANY_001] Confidential Page 182
Amended Protocol Version 11         Protocol No. CDRB436X2201
Example 6: Observed ORR at each Interim Anal ysis and the Final 
Anal ysis

[COMPANY_001] Confidential Page 183
Amended Protocol Version 11   Protocol No. CDRB436X2201
21.9 Appendix 9: Country -Specific Requirements
AUSTRI A:
In compliance with the Austrian Drug Law Amendment Act of 2004, the following
regulatory requirements will be applied to all study centers in Austria:
Pregnancy: §30. The clinical testing of drugs may only be carried out or continued in
women of childbearing potential, with the exception of cases as stated in §44, if non -
pregnancy is confirmed prior to and at adequate intervals during the clinical trial.
Clinical Trials in Emergency Situations:
§43a. (1) If a clinical trial, by [CONTACT_681915] , canonly be conducted in emergency
situations in which the consent of the legal representative cannot be obtained within a
reasonable length of time, then a clinical trial may be conducted on a person who is not in 
a position to give his or her consent if:
1.there is no informative basis that the subject has objected to or would object to the
clinical trial,
2.such research is implicitly  required for the validation of data that were obtained from 
clinical trials on persons able to give their informed consent or by[CONTACT_681916],
3.the drug to be tested is intended to identify , heal, mitigate or prevent diseases in an
emergency situation,
4.the application of the drug to be tested is indicated accordin g to the latest findings in 
medical science in order to identify , heal or to mitigate a disease in emergency patients 
or to protect them from further diseases and the benefit of being included in the clinical 
trial outweighs the risk for the trial particip ant,
5.the conduct of the trial and the protocol have been approved by[CONTACT_681917], specifically for the conduct 
of clinical trials in emergency situations on persons who are unable to give their 
consent personally , and
[COMPANY_001] Confidential Page 185
Amended Protocol Version 11                 Protocol No. CDRB436X2201
21.10 Appendix 10:RECIST, version 1.1
MEASURABILITY OF TUMOR LESIONS AT BASELINE
Measurable lesion:
A non-nodal lesion that can be accuratel y measured in at least one dimension (longest
dimension) of:
  10 mm with magnetic resonance imaging (MRI) or computed tomography (CT) when 
the scan slice thickness is no greater than [ADDRESS_923321] double the slice thickness 
(e.g., if the slice thickness is [ADDRESS_923322] be  20mm)
  10 mm calliper/ruler measurement by [CONTACT_681918]
  [ADDRESS_923323] x -ray
Additionally ,lymph nodes can be considered pathologicall y enlarged and measurable if:
  [ADDRESS_923324] or MRI (slice thickness recommended 
to be no more than 5 mm). At baseline and follow -up, only the short axis will be 
measured
Non-measurable lesion:
All other lesions including lesions too small to be considered measurable (longest diameter 
<10 mm or pathological lymph nodes with ≥10 mm and <15 mm short axis) as well as truly
non-measurable lesions, which include: leptomeningeal disease, ascites, pleural or 
pericardial effusions, inflammatory breast disease, ly mphangitic involvement of the skin or 
lung, abdominal masses/abdominal organomegal y identified by [CONTACT_681919] b yreproducible imaging techniques.
Measurable disease :The presence of at least one measurable lesion.  Palpable lesions that 
are not measurable b yradiologic or photographi c evaluations may not be utilized as the 
only measurable lesion.
Non-Measurable only disease :The presence of only non-measurable lesions.
Specifications by[CONTACT_681920]:
[COMPANY_001] Confidential Page 186
Amended Protocol Version 11                 Protocol No. CDRB436X2201
The same diagnostic method, including use of contrast when applicable, must be used 
throughout the stud y to evaluate a lesion.
All measurements should be taken and recorded in millimeters (mm), using a ruler or 
calipers.
Ultrasound is not a suitable modality of disease assessment. If new lesions are 
identified by [CONTACT_2207], confirmation by [CONTACT_681921].
Fluorodeox yglucose -positron emission tomography (FDG -PET) is generall y not
suitable for ongoing assessments of disease. However, FDG -PET can be useful in
confirming new sites of disease where a positive FDG-PET scans correlates with the
new site of disease present on CT/MRI or when a baseline FDG -PET was previously
negative for the site of the new lesion. FDG -PET may also be used in lieu of a standard 
bone scan providing coverage allows interrogation of all likely sites of bone disease 
and FDG -PET is performed at all assessments.
If FDG -PET/CT is performed then the CT component can only be used for standard
response assessments if performed to diagnostic quality , which includes the required
anatomical cove rage and prescribed use of contrast.  The method of assessment should 
be noted as CT on the case report form.
Clinical Examination: Clinically detected lesions will only be considered measurable 
when they are superficial (e.g., skin nodules).  Inthe case of skin lesions, documentation by
[CONTACT_90657] y, including a ruler/calipers to measure the size of the lesion, is required.
CT and MRI: 
Contrast enhanced CT with [ADDRESS_923325] by[CONTACT_91069]. Whenever possible the same
scanner should be used.
X-ray: Should not be used for target lesion measurements owing to poor lesion definition. 
Lesions on chest X -raymay be considered measurable if they are clearl ydefined and 
surrounded b y aerated lung; however, chest CT is preferred over chest X -ray.
EVALUATION OF TARGET LESIONS
Definitions for assessment of response for target lesion(s) are as follows:
Complete Response (CR): Disappearance of all target lesions.  Anypathological
lymph nodes must be <10 mm in the short axis.
[COMPANY_001] Confidential Page 187
Amended Protocol Version 11                 Protocol No. CDRB436X2201
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target 
lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change 
from baseline).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient
increase to qualify for PD.
Progressive Disease (PD): At least a 20% increase in the sum of the diameters oftarget 
lesions, taking as a reference, the smallest sum of diameters recorded since the 
treatment started (e.g. percent change from nadir, where nadir is defined as the smallest 
sum of diameters recorded since treatment start). In addition, the sum must have an 
absolute increase from nadir of 5 mm.
Not Applicable (NA): Target lesions not present at baseline.
Not Evaluable (NE): Unable to classify using one of the five preceding definitions.
NOTE:
If lymph nodes are documented as target lesions the short axis is added into the sum of 
the diameters (e.g. sum of diameters is the sum of the longest diameters for non -nodal 
lesions and the short axis for nodal lesions).  When lymph nodes decrease tonon-
pathological size (short axis <10 mm) they should still have a measurement reported in 
order not to overstate progression.
If at a given assessment 
time point all target lesions identified at baseline are not
assessed, sum of the diameters cannot be calculated for purposes of assessing CR, PR, 
or SD, or for use as the nadir for future assessments.  However, the sum of thediameters 
of the assessed lesions and the percent change from nadir should be calculated to ensure 
that progression has not been documented.  If an assessment of PD cannot be made , the 
response assessment should be NE.
All lesions (nodal and non-nodal) should have their measurements recorded even when 
very small (e.g., 2 mm).  Iflesions are present but too small to measure, 5 mm should 
be recorded and should contribute to the sum of the diameters, unless it is likely that 
the lesion has disappeared in which case 0 mm should be reported.
If a lesion disappears and reappears at a subsequent time point it should continue to be 
measured.  The response at the time when the lesion reappears will depend upon the 
status of the other lesions.  For example, if the disease had reached a CR status then PD 
would be documented at the time of reappearance.  However, if the response status was 
PR or SD, the diameter of the reappearing lesion should be added to the remaining 
[COMPANY_001] Confidential Page 188
Amended Protocol Version 11                 Protocol No. CDRB436X2201
diameters and response determined based on percent change from baseline and percent 
change from nadir.
EVALUATION OF NON- TARGET LESIONS
Definitions for assessment of response for non-target lesions are as follows:
Complete Response (CR): The disappearance of all non-target lesions. All lymph
nodes identified as a site of disease at baseline must be non -pathological (e.g., <10 mm 
short axis).
Non-CR/Non -PD:  The persistence of 1 or more non-target lesion(s) or lymph nodes
identified as a site of disease at baseline ≥10 mm short axis.
Progressive Disease (PD): Unequivocal progression of existing non-target lesions.
Not Applicable (NA): Non-target lesions not present at baseline.
Not Evaluable (NE): Unable to classify using one of the four preceding definitions.
NOTE:
In the presence of measurable disease, progression on the basis of solely non-target
disease requires substantial worsening such that even in the presence of SD or PR in 
target disease, the overall tumor burden has increased sufficiently to merit
discontinuation of therapy .
In the presence of non-measurable onl ydisease consideration should be given to
whether or not the increase in overall disease burden is comparable in magnitude to the 
increase that would be required to declare PD for measurable disease.
Sites of non-target lesions, which are not assessed at a particular time point based on
the assessment schedule, should be excluded from the response determination (e.g. non
-
target response does not have to be "NE").
Frequency of tumor re -evaluation
Target and non -target lesions will be re -evaluated every 8 weeks.
Confirmation of Response
To be assigned a status of PR or CR, a confirmatory disease assessment should be 
performed no less than 4 weeks (28 da ys) after the criteria for response are first met.
[COMPANY_001] Confidential Page 189
Amended Protocol Version 11                 Protocol No. CDRB436X2201
OVERALL RESPONSE CRITERIA
The table presents the overall response at an individual time point for all possible 
combinations of tumor responses in target and non -target lesions with or without the 
appearance of new lesions for subjects with measurable disease at baseline.
Evaluation of Overall Response for Subjects with Measurable Disease at 
Baseline
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR or NA No CR
CR Non-CR/Non -PD or NE No PR
PR Non-PD or NA or NE No PR
SD Non-PD or NA or NE No SD
NE Non-PD or NA or NE No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations: CR=complete response; NA=not applicable; NE=notevaluable; PD=progressive disease; PR=
partial response; SD=stable disease
NOTE:
Subjects with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of PD at that time should be classified as having 
"symptomatic deterioration." Objective response status is determined by[CONTACT_681922]. Every effort should be made to document the objective progression 
even after discontinuation of treatment.
In some circumstances, it may be difficult to distinguish residual disease from normal 
tissue. When theevaluation of CR depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biops y)to confirm the CR.
Reference:
Eisenhauer EA, Therasse P, Bogaerts, J, etal. New response evaluation criteria in solid 
tumors: revised RECI ST guideline (version 1.1). Eur JCancer. 2009 Jan;45(2):228 -247.
[COMPANY_001] Confidential Page 190
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.11 Appendix 11:Response Criteria forNSGCT/NGGCT with Elevated
Tumor Markers (AFPand-HCG) atBaseline
Serum tumor markers alpha -fetoprotein (AFP) and beta -human chorionic gonadotropin (-
HCG) will be measured as indicated in the Time and Events Table
Marker -Negative Complete Response (CR-) is defined as meeting the Response
Evaluation Criteria in Solid Tumors (RECI ST), v1.1 criteria for CR plus normalization 
of previousl yelevated tumor markers for a minimum of 4 weeks.
Marker -Positi ve Complete Response (CR+) is defined as meeting the RECI ST,v1.[ADDRESS_923326] 4weeks, but without complete 
normalization of previously  elevated tumor markers.
Marker -Negative Partial Remission (PR-) is define d as meeting the RECI ST,
v1.1 criteria for partial response (PR) plus normalization of previously elevated 
tumor markers for aminimum of 4weeks.
Marker -Positive Partial Remission (PR+) is defined as meeting the RECIST, v1.[ADDRESS_923327] 4weeks, but without complete 
normalization of previously  elevated tumor markers.
Progressive Disease (PD) is defined as a significant elevation (≥50%) in tumor
markers after 4 weeks of therap y; treatment will be stopped despi[INVESTIGATOR_681811].
References:
Bokemey er C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, 
oxaliplatin, and paclitaxel in patients with cisplatin- refractory or multiple relapsed germ -cell 
tumors: a study of the German Testicular Cancer Study Group. Annals of Oncology. 
2008;19:448 -453.
Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II Stud y of Paclitaxel plus
Gemcitabine Salvage Chemotherap y for Germ Cell Tumors after Progression Following
High -Dose Chemothe rapy with Tandem Transplant. J Clin Oncol. 2007;25(5):513 -516.
Kollmannsberger C, Beyer J, L iersch R, et al. Combination chemotherap ywith gemcitabine 
plus oxaliplatin in patients with intensively pretreated or refr actory germ cell cancer: A Stud y
of the German Testicular Cancer Stud yGroup. J Clin Oncol.
2004;22:108 -114.
[COMPANY_001] Confidential Page 191
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.12 Appendix 12:Response Criteria forHCL
Response status for hairy cell leukemia (HCL) will be assessed according to the following 
criteria adapted from the NCCN guideline -Consensus Resolution, and previous HCL
studies.
Complete response (CR) with or without Minimal Residual Disease (±MRD):
No evidence of leukemic cells by[CONTACT_681923] H/E stains of the peripheral blood and 
bone marrow (BM).
MRD: CR with HCL evident in blood b yflow cytometry (FACS) or in BM biopsy by
[CONTACT_9064] (IHC)
No hepatomegal y, splenomegal y, or abnormal (< 2cm minimum length)
lymphadenopathy by[CONTACT_681924].
NOTE: Enlarged liver or spleen associated with a negative nuclear medicine study
will not prevent consideration of CR for those subjects meeting all other criteria.
Normal complete blood count (CBC) as exhibited by:[CONTACT_28763] (ANC) 
≥1.5 x 109/L, platelets ≥100 × 109/L, and hemoglobin ≥11 g/dL without transfusions 
or growth factors for at least 4 weeks.
After this 4- week period, BM biopsy and computed tomograph y(CT) scan must be
performed to confirm CR. The BM biopsy  and aspi[INVESTIGATOR_681812] 4 -week interval.
Complete r esponse (CR): defined as the complete disappearance of all evidence of
disease and requires all of the following:
Normal CBC as exhibited by:[CONTACT_58846] ≥1.5×109/L, platelets ≥100×109/Landhemoglobin 
≥11 g/dL
Absence of hairy cells (by [CONTACT_681925]) in the peripheral blood and in 
the BM
Regression to normal of disease- related organomegal y
[COMPANY_001] Confidential Page 192
Amended Protocol Version 11           Protocol No. CDRB436X2201
Confirmation of CR: At the confirmatory ≥6 month visit, a BM biopsy , hematology ,
immunoglobulins and flow cy tometry will be reassessed.
Duration of CR: The duration of complete remission is calculated from the time of 
achievement of all criteria of CR to the time of relapse from CR.
Partial response (PR): requires all of the following for a period of at least 4 weeks:
Normal peripheral b lood counts (as in CR)
oANC ≥1.5×109/Lor 50% improvement over baseline without growth factors for 
at least 4 weeks, AND
oPlatelets ≥100 × 109/Lor 50% improvement over baseline, AND
oHemoglobin ≥11 g/dL or 50% improvement over baseline without transfusions or 
growth factors for at least 4 weeks.
NOTE: For subjects who are transfusion- dependent at baseline, a hemoglobin 
of ≥9 g/dL without transfusions or growth factors for at least 4 weeks.
circulating hairy cells ≤5% of ly mphocy tes
≥50% reduction of BM infiltration by [CONTACT_681926]
≥50% reduction of palpable disease- related organomegaly .
Subject must have the following (if abnormal prior to treatment):
≥50% decrease or normalization (<5000/mm3) in peripheral blood lymphocy tecount 
from the pre -treatment baseline value
≥50% reduction in lymphadenopathy , based on sum of products ofperpendicular 
diameters, or resolution to size consistent with CR
≥50% reduction in abnormal hepatosplenomegaly by[CONTACT_9661], or resolution tosize 
consistent with CR
Minor response (MR): requires all of the following:
≥50% reduction of circulating hairy cells
[COMPANY_001] Confidential Page 193
Amended Protocol Version 11           Protocol No. CDRB436X2201
Improvement of one or more of the peripheral blood counts (ANC, platelets or
hemoglobin).
Relapse: defined as the reappearance of leukemia/ly mphoma in a subject who previousl y
achieved a CR or documentation of PD in a subject who previously achieved a PR
Stable Disease (SD): defined as not meeting the criteria for CR, PR, MR or PD
Disease progression (PD): defined as the occurrence of at least one of the f ollowing
compared to pre -treatment:
≥50% increase in the sum of the products of the greatest perpendicular dimensions of 
at least two lymph nodes on two consecutive examinations at least 2 weeks apart (at 
least one node must be ≥2 cm in minimum length) orappearance of new palpable 
lymph nodes
≥50% increase in the absolute number of circulating lymphocy tes, on two consecutive 
examinations showing abnormal ly mphocy tosis at least 2 weeks apart
≥25% decrease in hemoglobin (must be <10g/dL), platelets (must be <100,000/uL ), or 
ANC (must be <1500/uL) unless these are judged to be effects of treatment.
References:
Catovsky D, Golomb HM, Golde DW. Consensus Resolution: Proposed Criteria for 
Evaluation of Response to Treatment in Hairy Cell Leukemia. Leukemia. 1987;4(1):405 -
406.
Kreitman RJ, Fitzgerald DJ, Pastan I.Approach to the patient after relapse of hairy cell
leukemia. Leuk Lymphoma. 2009a;50(suppl 1):32-37.
Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti -CD22 recombinant
immunotoxin moxetumomab pasudotox (CAT -8015 or HA22) in patients with hairy cell
leukemia. J Clin Oncol . 2012;30:1822 -1828.
Kreitman, R.J., Stetler -Stevenson, M., Margulies, I., et al. Phase II trial of recombinant
immunotoxin RFB4(dsFv) -PE38 (BL22) in patients with hairy cell leukaemia. J Clin
Oncol. 2009b;27:2983–2990.
Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine -
failed patients with hairy cell leukemia. Blood 2003;102:810 -813.
Saven A, Burian C, Koziol JA, Pi[INVESTIGATOR_195449].Long -term follow -up of patients with hairy cell
leukemia after cladribine treatment. Blood. 1998;92(6):1918 -1926.
[COMPANY_001] Confidential Page 194
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.13 Appendix 13:RANOResponse Criteria: Response Assessment
Criteria for WHO Grade 1or2Glioma
Measureable disease is defined as bidimensionally contrast non- enhancing or enhancing
lesions with clearl ydefined margins by [CONTACT_9252] (MRI) scan, with two 
perpendicular diameters of at least [ADDRESS_923328] be assessed using the same techniques as at 
baseline.
Complete response (CR): Requires allthefollowing criteria compared with thebaseline
scan:
Complete disappearance of the lesion on T2 or FLAIR(fluid attenuated inversion 
recovery ) imaging (if enhancement had been present, it must have resolved 
completely );
no new lesions, no new T2 or FLAIRabnormalities apart from those consistent with 
radiation effects, and no new or increased enhancement;
subject must be off corticosteroids or only onphysiological replacement doses, and
subject should be stable or improved clinicall y
Partial response (PR): Requires allofthefollowing criteria compared with thebaseline
scan:
greater than or equal to 50% decrease in the product of perpendicular diameters of the 
lesion on T2 or FLAIRimaging sustained for at least 4 weeks compared with baseline;
no new lesions, no new T2 or FLAIR abnormalities apart from those consistent with 
radiation effects, and no new or increased enhancement;
subject should be on a corticosteroid dose that should not be greater than the dose at 
time of baseline scan, and should be stable or improved clinical ly
[COMPANY_001] Confidential Page 195
Amended Protocol Version 11           Protocol No. CDRB436X2201
Minor response (MR): Requires the following criteria compared with the baseline scan:
a decrease of the area of enhancing or non-enhancing lesion on T2 or FLAI RMR 
imaging between 25% and 50% compared with baseline
no new lesions, no new T2 or FLAIR abnormalities apart from those 
consistent with 
radiation effect, and no new or increased enhancement; and
subject should be on a corticosteroid dose that should not be greater than the dose at 
time of baseline scan, and should be stable or improved clinic ally
Stable disease (SD): Stable disease (SD) is present if the changes do not qualify for CR, PR, 
MR or progression and requires:
stable area of enhancing or non -enhancing abnormalities on T2 or FLAIR imaging
no new lesions, no new T2 or FLAIRabnormalities apart from those consistent with 
radiation effect, and no new or increased enhancement
subject should be on a corticosteroid dose that should not be greater than the dose at 
time of baseline scan, and should be stable or improved clinicall y
Disease progression (PD): Disease progression (PD) is defined by[CONTACT_422956]:
development of new lesions or increase of enhancement (radiological evidence of 
malignant transformation)
a 25% increase in the sum of the products of perpendicular diameters of the T2 or 
FLAIRenhancing or non-enhancing lesion on stable or increasing doses of 
corticosteroids compared with baseline scan or best response after initiation of therap y, 
not attributable to radiation effect or to comorbid events
definite clinical deterioration not attributable to other causes apart from thetumour, 
or decrease in corticosteroid dose;
or failure to return for evaluation because of death or deteriorating condition, unless 
caused by[CONTACT_398156] -related disorders
Reference s:
[COMPANY_001] Confidential Page 196
Amended Protocol Version 11           Protocol No. CDRB436X2201
van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro -oncology (a 
report of the RANO group): assessment of outcome in trials of diffuse low grade gliomas. 
The Lancet. 2011;12:583-593.
[COMPANY_001] Confidential Page 197
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.14 Appendix 14:RANOResponse Criteria: Updated Response
Assessment Criteria forWHO Grade 3and4Glioma
Measureable disease is defined as bidimensionally contrast -enhancing or enhancing lesions 
with clearl y defined margins by [CONTACT_9252] (MRI) scan, with two 
perpendicular diameters of at least [ADDRESS_923329] be assessed using the same techniques as at 
baseline.
Complete response (CR): Requires all of the following:
complete disappearance of all enhancing measurable and non-measurable disease 
sustained for at least 4 weeks
no new lesions
stable or improved non-enhancing (T2/FLAIR [fluid attenuated inversion recovery ]) 
lesions
subjects must be off corticosteroids (or on ph ysiologic replacement do ses only)
stable or improved clinically .
Note: Subjects with non
-measurable disease onl ycannot have a CR; the best response
possible is stable disease (SD).
Partial response (PR): Requires all of the following:
  50% decrease compared with baseline, inthe sum of products of perpendicular 
diameters of all measurable enhancing lesions sustained for at least 4 weeks
no progression of non- measurable disease; no new lesions
stable or improved non-enhancing (T2/FLAI R) lesions on same or lower dose of
corticosteroids compared with baseline scan
[COMPANY_001] Confidential Page 198
Amended Protocol Version 11           Protocol No. CDRB436X2201
corticosteroid dose at the time of the scan evaluation should be no greater than the 
dose at time of baseline scan
stable or improved clinically .
Note: Subjects with non- measurable disease onl ycannot have a PR; the best response
possible is SD.
Stable disease (SD): Requires allofthefollowing:
does not qualify for CR, PR, or progression
stable non- enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids 
compared with baseline scan.
In the event that the corticosteroid dose was increased for new s ymptoms and signs without 
confirmation of disease progression (PD) on neuro- imaging, and subsequent follow -up 
imaging shows that this increase in corticosteroids was required because of PD, the last scan 
considered to show SD will be the scan obtained when the corticosteroid dose was equivalent 
to the baseline dose.
NOTE: Stable doses of corticosteroids include subjects not on corticosteroids.
Disease progression (PD): Disease progression (PD) is defined by[CONTACT_422956]:
  25% increase in sum of the products of perpendicular diameters of enhancing 
lesions compared with the smallest tumor measurement obtained either at baseline 
(if no decrease) or best response, on stable or increasing doses of corticosteroids
significant increase in T2/FLAIR non-enhancing lesion on stable or increasing
doses of corticosteroids compared with baseline scan or best response after initiation 
of therap ynot caused by[CONTACT_3252]-morbid events (e.g., radiation therap y,demy elination, 
ischemic injury , infection, seizures, post-operative changes, orother treatment 
effects)
anynew lesion; clear clinical deterioration not attributable to other causes apart from 
the tumor (e.g., seizures, medication adverse effects, complication s of therap y, 
cerebrovascular events, infection) or changes in corticosteroid dose
failure to return for evaluation as a result of death or deteriorating condition
[COMPANY_001] Confidential Page 199
Amended Protocol Version 11           Protocol No. CDRB436X2201
clear progression of non -measurable disease.
Summary ofRANO Response Criteria
Criterion CR PR SD PD
T1gadolinium -
enhancing diseaseNone 50% decrease <50% decrease but
<25% increase25% increase1
T2/FLAIR Stable ordecrease Stable ordecreasing Stable ordecrease Increase
New Lesion None None None Present
Corticosteroids None Stable ordecreasing dose Stable orDecreasing
doseNA2
Clinical Status Stable orincrease Stable orincrease Stable orincrease Decrease
Requirement for
ResponseAll All All Any
Abbreviations: CR=complete response; FLAIR =fluid- attenuated inversion recovery; NA=not applicable; PD=
progressive disease; PR=partial response; RANO =Response Assessment inNeuro- Oncology: SD=stable disease
Progression occurs when thiscriterion ispresent.
Increase incorticosteroids alone willnot be taken intoaccount indetermining progression intheabsence ofpersistent
clinical deterioration.
References:
Wen PY. Updated Response Assessment Criteria for High -Grade Gliomas: Response
Assessment in Neuro -Oncology Working Group. JClin Oncol . 2010;28(11):1963 -1972.
[COMPANY_001] Confidential Page 200
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.15 Appendix 15:Consensus Recommendations fortheUniform
Reporting ofClinical Trials
Report of the International Myeloma Workshop Consensu sPanel
International Myeloma Workshop Consensus (IMWC) Response Criteria: 
Stringent Complete Response (sCR):
Complete response (CR) as defined below plus:
normal free light chain (FLC) ratio and
absence of clonal cells in bone marrow (BM) b yimmunohistochemistry (IHC) or 2 to 
4 color flow cy tometry
Complete Response (CR):
Negative serum and urine immunofixation, and
Disappearance of anysoft tissue plasmacy tomas, and
≤5% plasma cells in BM
Very Good Partial R esponse (VGPR):
Serum and urine M-component detectable by[CONTACT_681927]
90% or greater reduction in serum M-component plus urine M-component <100 mg 
per 24 hrs
Partial R esponse (PR):
≥50% reduction of serum M-protein and reduction in 24-hr urinary M -protein by ≥90% 
or to <200 mg per 24 hrs
AND
[COMPANY_001] Confidential Page 201
Amended Protocol Version 11           Protocol No. CDRB436X2201
If the serum and urine M-protein are not measurable, a ≥50% decrease in the difference 
between involved and uninvolved FLC levels is required in place of the M-protein 
criteria. If serum and urine M-protein are not measurable, andserum FLC assay is also 
not measurable, ≥50% reduction in BM plasma cells is required in place of M -protein, 
provided baseline BM plasma cell percentage was ≥30%, and in the size of the soft 
tissue plasmacy tomas is also required.
Minimal R esponse (MR):
≥25% but ≤49% reduction of serum M-protein and reduction in 24-hr urinary M -
protein by 50% to 89%
AND
If present at baseline, 25% to 49% reduction in the size of soft tissue plasmacy tomas 
is also required.
No increase in size or number of lytic bone lesions (development of compression
fracture does not exclude response).
Stable D isease (SD):
Not meeting criteria for CR, VGPR, PR, MR or PD
Progressive D isease (PD):
Requires an increase of ≥25% from lowest response value in anyone or more of the
following:
•serum M -component (absolute increase must be≥0.5 g/dL), or
•urine M -component (absolute increase must be ≥200 mg/24 hr), or
•the difference between involved and uninvolved FLC levels (absolute increase 
must be >10 mg/dL): only for subjects without measurable serum and urine M-
protein levels, or
•bone marrow plasma cell percentage (the absolute % must be ≥10%) –only for 
subjects without measurable serum and urine M-protein levels and without 
measurable disease by[CONTACT_681928] 202
Amended Protocol Version 11           Protocol No. CDRB436X2201
•definite development of new bone lesions or soft tissue plasmacy tomas or definite 
increase in the size of existing bone lesions or soft tissue plasmacytomas
•development of hy percalcemia (corrected calcium >11.5 mg/dL or 2.65 mmol/L) 
that can be attributed solely to the plasma cell proliferative disorder
a.All response categories (CR, sCR, VGPR, PR, MR and PD) require 2 consecutive assessments 
made at anytime before the institution of anynew therapy ; CR, sCR, VGPR, PR, MR, and 
SD categories also require no known evidence of progressive or new bone lesions if 
radiographic studies were performed. VGPR and CR categories require serum and urine 
studies regardless of whether disease at baseline was measurable on serum, urine, both, or 
neither. Radiographic studies are not required to satisfy these response requi rements. Bone 
marrow assessments need not be confirmed. For PD, serum M -component increases of more 
than or equal to 1 g/dL are sufficient to define relapse ifstarting M -component is ≥5 g/dL.
b.Clarifications to IMWG criteria for coding CR and VGPR in subjects in whom theonly
measurable disease is by [CONTACT_128758]: CR in such subjects indicates a normal FLC ratio 
of 0.26 to 1.65 in addition to CR criteria listed above. VGPR in such subjects requires a >90% 
decrease in the difference between involved an d uninvolved FL C levels.
c.Clarifications to IMWG criteria for coding PD: Bone marrow criteria for PD are to be used 
only in subjects without measurable disease byM protein and by [CONTACT_64391]; “25% increase” 
refers to M protein, FLC, and BM results, and does not refer to bone lesions, soft tissue 
plasmacy tomas, or hypercalcemia and the “lowest response value” does not need to be a 
confirmed value.
References:
Durie BGM, Harousseau J- L, Miguel JS, et. al. International uniform response criteria for
multiple myeloma. Leukemia. 2006:20:1467-73.
Rajkumar SV, Harousseau JL,Durie B, et al. Consensus recommendations for the uniform 
reporting of clinical trials: Report of the International My eloma Workshop Consensus Panel 
1. Blood. 2011;117:4691-4695.
[COMPANY_001] Confidential Page 203
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.16 Appendix 16:Imaging Guidelines forWHO Grade IorIIGlioma
Basic MRI protocol:
Axial FLAIR(canthomeatal alignment): 3 to 5 mm sections, 1 mm interslice gaps, 
slice registration preserved as much as possible between sequential studies
Axial T2: 5 mm sections, 1 mm interslice gap
Coronal T1: 5 mm sections, 1 mm interslice gap
Post-gadolinium chelate (contrast agent per local clinical practice): cornoal T1,axial 
T1
Alternativel ypre-gadolinium and post -gadolinium volumetric T1 may replace axial and
coronal T1-weighted sequences.
Supplementary imaging methods:
Two-dimensional or 3 -dimensional spectroscopic imaging (MR spectroscopy )
Perfusion imaging (DSC -MRI )
Diffusion- weighted imaging ( -B=0, B=1000)
PET imaging:
For 11C-MET and 18F-FET PET:
Subject must fast for 4 hrs prior to imaging
Images must be obtained in a supi[INVESTIGATOR_2547]
[ADDRESS_923330] be done prior to tracer application
C-MET or F-FET administered intravenously as a bolus injection of 740 MBq (20 
mCi; MET) or 370 MBq (10 mCi; FET)
[COMPANY_001] Confidential Page 204
Amended Protocol Version 11           Protocol No. CDRB436X2201
Accumulation of tracer will be recorded over 60 min in 47 transaxial slices ofentire 
brain
Spatial resolution of C- MET PET and F -FET PET: 6 mm or better in all dimensions
SUV, T/B ratios and uptake kinetics: calculated in tumor and corresponding mirror 
regions
Abbreviations: DSC, dynamic susceptibility contrast; FET, 18F-fluoroethy ltyrosine; FLA IR, 
fluid attenuation inversion recovery ; MET, 11C-methionine; PET, positron emission 
tomograph y; SUV, standard upta ke value; T/B, tumor background ratio
Reference s:
van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro- oncology (a 
report of the RANO group): assessment of outcome in trials of diffuse low grade gliomas. 
The Lancet. 2011;12:583-593.
[COMPANY_001] Confidential Page 205
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.17 Appendix 17:Volumes ofCollected Blood Samples
Assuming a subject remains on treatment for a period of 6 months, the total blood volume 
collected is estimated to be 306 mL (excluding any unpredictable events that would require 
additional blood samples to be obtained 
).
Reason for
Blood SampleScreening Day 1Day 15 Week 4 Week 8 Week 12 Week 16 Trmt
Disc
PK Analysis N/A N/A N/A 4mL 2mL 2mL N/A 2mL
BRAF V600E
(HCL andMM
cohorts only)3mL N/A N/A N/A N/A N/A N/A N/A
PD and
Biomarker
Analyses21mL N/A 18mL N/A N/A N/A N/A 18mL
Clinical 
Laboratory
Assessments17mL 17mL N/A 17mL 17mL 17mL 17mL 17mL
TOTAL
Volume38mL 23mL 18mL 21mL 19mL 19mL 17mL 37mL
Abbreviations: HCL =Hairy CellLeukemia; MM=Multiple Myeloma; PD=pharmacodynamics;
;PK=pharmacokinetics; Trmt Disc =treatment discontinuation

[COMPANY_001] Confidential Page 206
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.18 Appendix 18:LiverSafet y Drug Restart orRechallenge
Guidelines
If subject meets liver chemistry stoppi[INVESTIGATOR_90549]/rechallenge subject with
study treatment unless:
[COMPANY_001] Medical Governance approval is granted (as described below),
Independent Ethics Committee (IEC) and/or institutional review board (IRB) 
approval is obtained, if required, and
Separate consent for treatment restart/rechallenge is signed by[CONTACT_681929]/rechallenge subject with study
treatment
is not granted , then subject must permanentl y discontinue study treatment and may
continue in the study for protocol -specified follow -up assessments.
1.Rechallenge Following Liver Stoppi[INVESTIGATOR_681813]-induced liver injury (DILI), drug rechallenge is associated with a 13%
mortality across all drugs in prospective studies [Andrade ,2009] Clinical outcomes vary
by[CONTACT_9934], with nearly 50% fatality  with halothane readministered within 1month ofinitial 
injury .However, some drugs seldom result in recurrent liver injury or fatality.
Risk factors for a fatal drug rechallenge outcome include:
hypersensitivity1with initial liver injury (e.g. fever, rash, eosinophilia)
jaundice or bilirubin >2xULN with initial liver injury (direct bilirubin
>35% of total)
subject currentl yexhibits severe liver injury defined by:[CONTACT_42386] 3xULN,
bilirubin 2xUL N (direct bilirubin >35% of total), or INR1.5
serious adverse event or fatalit yhas earlier been observed with drug 
rechallenges [ Papay , 2009; Hunt , 2010]
[COMPANY_001] Confidential Page 207
Amended Protocol Version 11           Protocol No. CDRB436X2201
evidence of drug-related preclinical liability (e.g. reactive metabolites;
mitochondrial impairment) [ Hunt , 2010]
Recha llenge refers to resuming study treatment following DILI.  Because of the risks 
associated with rechallenge after DILI this should only be considered for a subject for
whom there is compelling evidence of benefit from a critical or life -saving medicine, there 
is no alternative approved medicine available, and a benefit:risk assessment of rechallenge 
is considered to be favorable .
Approval by [CONTACT_681930]:
Investigator requests consideration of rechallenge with study treatment for a subject 
who is receiving compelling benefit with study treatment that exceeds risk, and no
effective alternative therapy is available.
EC or IRBapproval for rechallenge with study treatment must be obtained, asrequired.
If the rechallenge is approved by[CONTACT_681931], the subject 
must be provided with a clear description of the possible benefits and risks of study 
treatment administration, including the possibility of recurrent, more severe liver injury
or death.
The subject must also provide signed informed consent specifically for the rechallenge 
with study treatment.  Documentation of informed consent must be recorded in the study
chart.
Study treatment must be administered at the dose specified b ythe sponsor.
Subjects approved by[CONTACT_681932] a week for liver chemistry tests until stable
liver chemistries have been demonstrated and then standard l aboratory monitoring ma y
resume as per protocol.
If after study treatment rechallenge, subject meets protocol -defined liver chemistry
stoppi[INVESTIGATOR_3418], study treatment should be permanently discontinued.
Medical Lead , and the IEC orIRB as required, must be informed of the subject’s
outcome following stud y treatment rechallenge.
The sponsor to be notified of anyAEs, as per Section 11.
2.Restart Following Transient
Resolving Liver Stoppi[INVESTIGATOR_681814] 208
Amended Protocol Version 11           Protocol No. CDRB436X2201
Restart refers to resuming stud y treatment following liver stoppi[INVESTIGATOR_53057] 
a clear underl ying cause (other than DILI) of the liver event (e.g. biliary obstruction,
pancreatic events, hy potension, acute viral hepatitis). Furthermore, there should be no
evidence of alcoholic hepatitis or hy persensitivity, and the study treatment should not be
associated with HLA markers of liver injury.
Approval by [CONTACT_681933] d where:
Investigator requests consideration for study  treatment restart if liver chemistries have 
a clear underl ying cause (e.g., biliary obstruction, hypotension and liver chemistries 
have improved to normal or are within 1.5x baseline and ALT <3xUL N).
Restart risk factors (e.g. fever, rash, eosinophilia, or hypersensitivity , alcoholic hepatitis, 
possible study treatment -induced liver injury orstudy treatment has anHLA genetic 
marker associated with liver injury (e.g. lapatinib, abacavir, amoxicillin/clavulanate) 
are reviewed and excluded.
IECorIRB approval of study treatment restart must be obtained, as required.
If restart of study treatment is approved by[CONTACT_681931], 
thesubject must be provided with a clear description of the possible benefits and risks 
of study treatment administration, including the possibility of recurrent, more severe 
liver injury or death.
The subject must also provide signed informed consent specifically  for the study
treatment restart.  Documentation of informed consent must be recorded in the study  
chart.
Study treatment must be administered at the dose specified by [CONTACT_456].
Subjects approved by[CONTACT_681934] a week for liver chemistry  tests until stable liver chemistries 
have been demonstrated and then laboratory monitoring may resume as per protocol.
Ifafter study treatment re-start, subject meets protocol -defined liver chemistry stoppi[INVESTIGATOR_31732], follow usual stoppi[INVESTIGATOR_53058].
Medical Lead , and the IEC orIRB as required, must be informed of the subject’s
outcome following stud ytreatment restart.
The sponsor to be notified of anyAEs, as per Section 11.
[COMPANY_001] Confidential Page 209
Amended Protocol Version 11           Protocol No. CDRB436X2201
References:
Andrade RJ, Robles M, Lucena MI. Rechallenge in drug -induced liver injury : the
attractive hazard. Expert Opin Drug Saf. 2009;8:709 -714.
Hunt, CM.  Mitochondrial and immunoallergic injury increase risk of positive drug
rechallenge after drug -induced liver injury : A s ystematic review.  Hepatol. 2010;52:2216-
2222.
Papay JI,Clines D, Rafi R, et al.  Drug -induced liver injury following positive drug
rechallenge. Regul Tox Pharm . 2009;54:84 -90
[COMPANY_001] Confidential Page 210
Amended Protocol Version 11           Protocol No. CDRB436X2201
21.19 Appendix 19:Protocol Amendment Changes
AMENDMENT [ADDRESS_923331] details for Medical 
Monitor, to implement reference to new Investigator’s Brochure (v7), to update list of 
abbreviation, to update risk assessment for dabrafenib + trametinib combination therap y,to 
change in time window for radiotherap y in Glioma Grade 1- [ADDRESS_923332] discrepancies between T&E Table and text, to
implementing “Tissue Sample for Histology Confirmation” for ATC and WHO Grade 1- [ADDRESS_923333] timelines for re- escalation of toxicity induced dose reduction, to clarify
instructio ns for prohibited medications and non -drug therapi[INVESTIGATOR_014], to add additional analysis 
populations that are planned for the interim analyses, to add an expansion cohort to allow 
enrollment of patients if a given cohort{ is stopped earl y for efficacy, to add the language 
to refer to the RAP for the response confirmation criteria for each histological cohort, to 
update Table 
[ADDRESS_923334]/NGGCT cohort, to clarify the 
definition for Duration of Response to include all response categories as defined in Table 
[ADDRESS_923335]/NGGCT, WHO Grades [ADDRESS_923336] of Specific Changes
Section Sponsor/Medical Monitor Infor mation 
Page: REVISED TEXT
Role Name [CONTACT_681952] -hours
Phone/Cell/
Pager
NumberFaxNumber [COMPANY_001] Address
[COMPANY_001] Pharmaceuticals
Corporation One Health Plaza East
MD,PhD Hanover, NJ07936 -1080
[LOCATION_003]
[COMPANY_001] Pharmaceuticals

[COMPANY_001] Confidential Page 212
Amended Protocol Version 11           Protocol No. CDRB436X2201
The safety profile for dabrafenib + trametinib combination therapy has been 
established and is well-characterized in subjects with unresectable/metastatic
melanoma, with consistent results across tworandomized Phase IIIstudy. The safety 
profile of the combination of dabrafenib and trametinib generally reflect AEs of the 
individual agents; some notable exceptions are described below.
Cutaneous Squamous cell carcinoma (cuSCC):  Invitro experiments have demonstrated a
paradoxical activation of MAPK signalling in kerationcy tes and potentially other cells
harboring a wild -type BRAF kinase but a mutated RAS kinase upon exposure to a BRAFi.  
This paradoxical MAPK pathway activation is potentially associated with a higher risk for 
the development of cuSCC induction. Cases of cuSCC (which include those classified as 
keratoacanthoma or mixed keratoacanthoma subt ypes) have been reported in subjects 
treated with dabrafenib + trametinib.
Skin examination should be performed prior to initiation of dabrafenib or dabrafenib +
trametinib treatment and while receiving therap y.Dermatologic examinations should be
perform ed following discontinuation of dabrafenib monotherap y or in combination with
trametinib, or until initiation of another anti -neoplastic therap y (see Section 7.1, Time and 
Events Table for schedule of assessments). Cases of cuSCC should be managed by
[CONTACT_681837]; dabrafenib and trametinib treatment should be continued
without any dose adjustment . A brief dermatological exam should be performed every 4 
weeks (±7 days) forthefirst 6months after discontinuation ofstudy treatments to
monitor for new cutaneous malignancies.
Pyrexia has been reported in clinical trials with dabrafenib monotherapy and in
combination with trametinib.  Indabrafenib monotherap y studies, p yrexia was one of the
most frequently occurring AEs in up to 27% of subjects across all dabrafenib studies.
Most of the py rexia events (64%) were considered treatment -
related.  The incidence and
severit yof py rexia are increased when dabrafenib is used in combination with trame tinib.
In subjects who received the combination dose of dabrafenib 150 mg twice daily (BID) and 
trametinib [ADDRESS_923337] of
the subjects who experienced p yrexia had 3 or more events. Pyrexia may beaccompanied 
by[CONTACT_681935]/rigors, dehy dration and hy potension which in some cases can lead to acute 
renal insufficiency .
Subjects should be instructed on the importance of immediately reporting febrile epi[INVESTIGATOR_1841].
Therap y with dabrafenib should be interrupted if the patient’s temperature is
≥38.5ºC or 101.3°F but trametinib should be continued at the same dose. Inthe event of 
a fever, the subject should be instr ucted to take anti -pyretics (i.e., ibuprofen or
acetaminophen/paracetamol) as appropriate to control fever.  The use of oral corticosteroids 
should be considered in those instances in which anti- pyretics are insufficient. Monitor 
serum creatinine and other evidence of renal function during and following severe events of 
pyrexia.  (See Section 8.2.3 for additional details.)
[COMPANY_001] Confidential Page 213
Amended Protocol Version 11           Protocol No. CDRB436X2201
Decreased left ventricular ejection fraction (LVEF): Left ventricular dy sfunction has
been reported with trametinib as well as with oth er MEKi in clinical development. In the
2 Phase III studies decreased ejection fraction occurred in 7% of subjects receiving 
combination therapy and the majority of the LVEF decreases that met interruption 
criteria were asymptomatic and resolved.  Most sub jects who were re- challenged
were able to continue on treatment without further dose modification. Subjects 
enrolled instudies with dabrafenib incombination with trametinib undergo regular 
cardiac assessments with echocardiograms (ECHOs).  Guidelines for clinical
management of treatment -related LVE F decreases have been provided in Section [IP_ADDRESS].
Hemorrhage : Hemorrhagic events, including major hemorrhagic events defined as
symptomatic bleeding inacritical area or organ, and fatal intracranial hemorrhages , 
have occurred in patients taking dabrafenib in combination with trametinib. The
majority ofbleeding events were mild. Three of 209 subjects (1%) receiving 
trametinib in combination with dabrafenib in a phase III trial had fatal intracranial 
hemorrhagic events. The management of hemorrhagic events may require treatment 
interruption, dose reduction, or treatment discontinuation….
Hypergl ycemia: Hypergly cemia requiring an increase in the dose of, or initiation of,
insulin or oral therapy can occur with dabrafenib or dabrafenib in combination with
trametinib .  Monitor serum glucose levels as clinically appropriate during treatment with
dabrafenib in subjects with pre -existing diabetes or hy pergl ycemia. Advise subject s to
report s ymptoms of severe hy pergl ycemia such as excessive thirst or any increase in the
volume or frequency of urination.
Pancreatitis:  Subjects receiving dabrafenib or dabrafenib in combination with 
trametinib have reported AEs of acute pancreatiti s or pancreatitis. Insome cases,
serious adverse events (SAEs) of Grade 4 pancreatitis were reported as treatment -related
by[CONTACT_093]. The time to onset of pancreatitis ranged from stud yDay 21 to 292 
(median 138 day s)with dabrafenib monotherapy, and from Study Day 24 to 312
(median 50days) with combination therapy . Discontinuation of study treatment due to
pancreatitis was not deemed necessary in anyof the cases by[CONTACT_473]. For AEs
of abdominal pain or suspected pancreatitis, amylaseand lipase laboratory samples
should be monitored locally .  Subjects should be closely monitored when re-starting
dabrafenib after an epi[INVESTIGATOR_28547].
Use during Pregnancy andLactation
Fertility :  There is no information on the effect of dabraf enib or trametinib on human
fertility .  Animal studies with dabrafenib monotherapy or in combination with trametinib 
have shown reproductive toxicity which may impair fertility in humans. In dogs, rats and 
mice given dabrafenib and in dogs given dabrafenib in combination with trametinib, male
reproductive effects, including testicular degeneration/depletion with secondary  epi[INVESTIGATOR_681815], have occurred without clear evidence of reversibility .Male subjects should 
be informed of the potential risk fo r impaired spermatogenesis, which may be irreversible. 
Trametinib may impair fertility in humans.
[COMPANY_001] Confidential Page 214
Amended Protocol Version 11           Protocol No. CDRB436X2201
Pregnancy :  No adequate and well -controlled studies of dabrafenib or trametinib in
pregnant women have been conducted. Animal studies with trametinib and dabrafenib
have shown embry ofetal developmental toxicities, including teratogenic effects.
Dabrafenib or trametinib should not be administered to pregnant women or nursing 
mothers. Women of childbearing potential should use effective methods of contracepti on
during therap y and for 4 months following discontinuation of trametinib when taken in
combination with dabrafenib, or for 4 weeks following discontinuation of dabrafenib.
Dabrafenib may decrease the efficacy of hormonal contraceptives; therefore, an alternative 
method of contraception such as barrier methods should be used. If dabrafenib or trametinib 
is used during pregnancy, or if the subject becomes pregnant while taking dabrafenib or 
trametinib, the subject should be informed of the potential hazard to the fetus.
Section 1.5.6 Cohort 6: Non- Seminomatous/Non -Germinomatous Germ Cell Tumors 
(NSGCT/NGGCT): 2ndparagraph
REVISED TEXT
Non-seminomatous GCTs (NSGCTs) tend to be more clinicall y aggressive and grow
quicker than the seminoma- type of GCT.  If untreated, NSGCTs can spread to the lungs,
liver, ly mph nodes, or bones. Common risk factors include being male, under the age of 20 
and having Klinefelter s yndrome [Nichols, 1987].  Chest pain and difficult ybreathing are 
early signs of NSGCT. Other s ymptoms include: cough, fever, headache, and change in 
bowel habits, fatigue, difficulty  walking and visual problems (difficulty  seeing or moving 
eyes). Testicular GCTs present with a painless, solid testicular mass and often discomfort 
or swelling; persistent conditions warrant further evaluation.
Section 2.1 Rationale for the Combination of Dabrafenib and Trametinib: 
REVISED TEXT
Pre-
clinical studies have demonstrated that the combination of dabrafenib and trametinib is
synergistic and/or enhances cell grow th inhibition in majority of the BRAF V600E mutant 
melanoma, colon, th yroid, and lung cancer cells.  The combination delayed dabrafenib 
resistance and reduced hyperproliferation skin adverse effect in pre -clinical models.  The 
scientific rationale suggesti ng MEK- mediated re -activation of the MAPK pathway as a 
prominent mechanism of resistance to BRAFi single- agent therap y supports the 
combination study of trametinib with BRAFi in cancer [Alcala, 2012; Greger, 2012]. 
Because BRAF V600E mutated tumors have been shown to develop resistance to BRAF
inhibitors, the combination of a BRAFi and MEKi provides a rational approach for dual 
vertical inhibition within the MAPK pathway to address such drug resistance [Johannessen, 
2010]. Both have demonstrated substanti al clinical activity with ORR between 28 to 53% 
and PFS ranging between 4.8 to 5.1 months. Further, the combination of both dabrafenib 
and trametinib indicated increased efficacy over both monotherapi[INVESTIGATOR_681735] 63% and 
an increase of PFS to approximate ly10 to 11 months for the 150 mg BID dabrafenib and 2 
mg once dail y trametinib dose cohort [Flahert y, 2012; Hauschild, 2012; Weber, 2012].
Furthermore, the combination of dabrafenib and rametinib has demonstrated overall 
survival of a median of  more than [ADDRESS_923338] 
[COMPANY_001] Confidential Page 215
Amended Protocol Version 11           Protocol No. CDRB436X2201
survival data for the combination is further supported by [CONTACT_681936] >11 months, overall response rates of about 64 -
69% (13 -16% ofpatients achieving a complete response) with duration of response of 
12.9-13.8 months and a disease control rate of 94% across two randomized Phase -III 
studies ( Long GV ,2015; Robert C et al, 2015).
Section 2.3 Dose Rational: 
REVISED TEXT
Administration of dabrafenib + trametinib in the ongoing study BRF113220 indicates that
dabrafenib does not have a clinically relevant effect on trametinib PK [GlaxoSmithKline
Document Number CM2010/0010/05 ].  Cross -study comparisons indicate that exposure 
to dabrafenib may be greater after repeat -dose administration of dabrafenib in combination 
with trametinib relative to administration of dabrafenib alone at 150 mg BID. The 
combination was relatively well tolerated in study BRF113220 and study MEK115306 , 
with toxicities manageable with appr opriate intervention.
In this stud y, dabrafenib will be administered at the dose of 150 mg BID continuously that 
demonstrated significant benefit in PFS in a Phase III trial [Hauschild, 2012].
Trametinib administered at adose of 2mg once daily has demonstrated significant benefit 
in PFS (hazard ratio [HR] = 0.45), a confirmed response rate (22% vs. 8%), and OS (HR =
0.54) relative to chemotherapy  [Flaherty , 2012]. As determined in Phase III studies, the 
safety profile of the combination of dabrafenib and trametinib generally reflects the 
well established safety profiles of the individual approved agents, with toxicities that 
are manageable with appropriate intervention.
Section 4 Study Design: 4thparagraph
REVISED TEXT
This is a Phase II, open -label, non-randomized, multi -center study of oral dabrafenib in
combination with oral trametinib in subjects with rare cancers with the BRAF V600E 
mutation. The following histologies will be included in this study :ATC, BTC, GI ST,
WHO Grade 1 or 2 glioma, WHO Gra de 3 or 4 (high -grade) glioma, NSGCT/NGGCT, 
ASI, HCL and MM (Cohorts 1 to 9, respectivel y). This study is designed to determine the
ORR of dabrafenib in combination with trametinib in subjects with rare BRAF V600E 
mutated cancers.  Further supporting secon dary objectives include the evaluation of 
duration of response, PFS, OS, and safet y of the combination treatment. For each cohort,
up to 25 evaluable subjects will be enrolled in the primary analysis cohort as defined in 
Section 5.2. If a given cohort is s topped early for efficacy, a histology specific
expansion cohort may be opened to allow for additional patient enrollment (see
Section 5.3). Only subjects with histologically orcytologicall yconfirmed advanced disease 
with no available treatment options as determined by [CONTACT_144935] y or regionall y available 
standards of care and by[CONTACT_20467]’s discretion will be eligible for enrollment. 
Subjects may  be enrolled based on local BRAF V600E mutation results and mutation status 
will be confirmed bya central reference laboratory. …
[COMPANY_001] Confidential Page 216
Amended Protocol Version 11           Protocol No. CDRB436X2201
…Subjects will receive dabrafenib [ADDRESS_923339] 8 weeks of treatment. …
Section 5.2 Primary analysis cohorts 
New Section
5.1. Primary analysis cohorts
The “primary analysis cohort” will be comprised of those patients enrolled within a 
histology -specific group prior to cappi[INVESTIGATOR_25577] 25 patients per cohort or prior to early
stoppi[INVESTIGATOR_582413]. The primary analysis cohort will form the basis of 
the Bayesian modelling.
Section 5.2 Expansion cohorts 
New Section
5.2. Expansion cohorts
If a cohort closes early at an interim analysis because it meets the rules for early
stoppi[INVESTIGATOR_34303], an expansion cohort may be opened to allow additional patient 
enrollment for that particular histology. The patients in the expansion cohort will 
provide supportive efficacy data and will NOT contribute to the Bayesian modeling. 
The expansion cohort(s) will enroll subjects for the duration of trial enrollment.
The same general and histology specific eligibility criteria and T&E tables and 
biomarker/histology confirmation analyses will apply to patients in the expansion 
cohort.
Section 5.3Number ofSubjects: 1stparagraph
REVISED TEXT
Section 5.[ADDRESS_923340] been enrolled, 
the histology cohort will be closed to further enrollment. See Section 18.2 for sample size 
assumptions.
Section 5.4Eligibility: 1stparagraph
[COMPANY_001] Confidential Page 217
Amended Protocol Version 11           Protocol No. CDRB436X2201
REVISED TEXT
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on the study treatment(s) that may impact subject eligibility is
provided in the IB for dabrafenib + trametinib combination [GlaxoSmithKline Document 
Number CM2010/[ZIP_CODE]/05 ].
Section 5.4.1 Inclusion Criteria: 5thTable [ADDRESS_923341]/NGGCT, ASI1.2109/L
MM 1109/L
Hemoglobin3 ATC, BTC, GIST, WHO
Grade 1-[ADDRESS_923342]/NGGCT, ASI9g/dL
Platelets3 ATC, BTC, GIST,
NSGCT/NGGCT, ASI75109/L
MM 50109/L
WHO Grade 1 -4 Glioma 100109/L
PT,PTT, INR2, [ADDRESS_923343]/NGGCT, ASI, HCL,
MM1.[ADDRESS_923344]/NGGCT, ASI, HCL,
MM2.5 g/dL
Total Bilirubin4 ATC 1.[ADDRESS_923345]
BTC 3times ULN if stable for
[ADDRESS_923346]/NGGCT, MM2times ULN
HCL <[ADDRESS_923347]
ASI 2times ULN OR3times
ULN if stable for [ADDRESS_923348]/NGGCT 2times ULN without liver
metastases 2.[ADDRESS_923349]
if documented liver
metastases
BTC, ASI, MM 3times ULN without liver
metastases [ADDRESS_923350] if
documented liver
metastases
[COMPANY_001] Confidential Page 218
Amended Protocol Version 11           Protocol No. CDRB436X2201
HCL <[ADDRESS_923351]
WHO Grade 1, 2, 3or 4Glioma 3times ULN
Renal Creatinine ATC, BTC, GIST, WHO
Grade 1-[ADDRESS_923352]/NGGCT, ASI, HCL,
MM1.5 mg/dL
OR
Calculated Creatinine
Clearance6or [ADDRESS_923353]/NGGCT, ASI, HCL,
MM50mL/min
Cardiac LVEF ATC, BTC, GIST, WHO
Grade 1-[ADDRESS_923354]/NGGCT, ASI, HCL,
MMLLN7by [CONTACT_681860]: ALT, alanine aminotransferase; ANC, absolute neutrophil count; ASI, adenocarcinoma ofsmall
intestine AST, aspartate aminotransferase; CBC, complete blood count; ECHO, echocardiogram; HCL, hairy cell
leukemia; hr,hour; INR, international normalization nratio; LLN, lower limitofnormal; LVEF, leftventricular
ejection fraction; PT,prothrombin time; PTT, partial thromboplastin time; ULN, upper limitofnormal
1. Laboratory values areobtained within 14days prior tofirstdose ofstudy treatment.
2. PTT andPT/INR >1.[ADDRESS_923355] willbeacceptable incase ofsubjects receiving therapeutic
anticoagulants such aswarfarin aslong asINRismonitored during thestudy according toclinical
practice.
3. HCL: Nominimum CBC criteria ifthecytopenias areduetodisease under study.
4. HCL: Subjects willbeallowed toenroll withindirect hyperbilirubinemia; however, thiscondition must
beconfirmed duetohemolysis, hypersplenism ordirect bilirubin ratio <35% ,andrequires approval
from theMedical Monitor.
5. HCL: Subjects willbeallowed toenrol withelevated ALT/AST values upto5times ULN; however
thiscondition must beconfirmed duetohemolysis and/or hypersplenism and not associated with
hepatic dysfunction and required approval from theMedical Monitor.
6. Calculated by[CONTACT_36575] -Gault formula (see Appendix 3).
7. IfLLN isnotdefined foragiven institution, then ejection fraction must be≥50% .
NOTE: Subjects withAST, ALT ortotal bilirubin values outside therange(s) inTable 3duetoGilbert's syndrome or
asymptomatic gallstones arenotexcluded. Laboratory results obtained during Screening should beused to
determine eligibility criteria. Insituations where laboratory results areoutside thepermitted range, theinvestigator
may opttoretest thesubject andthesubsequent within -range screening result may beused toconfirm eligibility.
Section 5.4.2 Exclusion Criteria: 3rdbulletpoint
REVISED TEXT
Prior radiotherap yless than [ADDRESS_923356] resolved prior to enrollment.
For WHO Grades 1, 2, 3, or 4 Glioma ONLY: Radiotherap y is not permitted within 3 
months prior to enrollment (extended period of time of >3 months needed to prevent 
subjects with pseudo -progression from radiotherapy from being enrolled in the study ).
Subjects may be 2weeks from radiotherapy  if a new lesion relative to the pre-
radiat ion MRI develops outside the primary radiation field. Treatment -related AEs must
have resolved prior to enrollment.
[COMPANY_001] Confidential Page 219
Amended Protocol Version 11           Protocol No. CDRB436X2201
For ATC Only: Radiotherap y is not permitted within 7 daysprior to enrollment.
Treatment -related AE(s) must have resolved prior to enrollmen t.
Section [IP_ADDRESS].3 WHO Grade 1, 2, 3 or 4 Glioma: Note 
REVISED TEXT
1. Prior treatment with enzyme- inducing anticonvulsants within 14 day sprior to enrollment.
2. Radiotherap y treatment within 3 months prior to enrollment.
NOTE:  Extended period of time (>3 months) needed to prevent subjects with pseudo -
progression from radiotherapy being enrolled in the study .Subjects may be ≥[ADDRESS_923357] resolved prior to
enrollment.
[COMPANY_001] Confidential Page 224
Amended Protocol Version 11                                                                                            Protocol No. CDRB436X2201
ScreeningTreatment5 Follow -upVisit55 Extended
Follow -
up58
Day15,7 Day15
(1day)Every
4weeks
(3days)Every
8weeks
(3days)Every
12weeks
(3days)Every
16weeks
(3days)Treatment orStudy
WithdrawalEvery
3months
(14days)
except
when
noted
Dispensation ofstudy
treatmentsX54 X
Dabrafenib Dosing Continuous Twice Daily Dosing
Trametinib Dosing Continuous Once Daily Dosing
Compliance Assessment X X
Abbreviations: AFP, alpha -fetoprotein; ANC, absolute neutrophil count; AP,anteroposterior; ASI, adenocarcinoma ofsmall intestine; -HCG, beta-human chorionic gonadotropin;
BM, bone marrow ;CBC, complete blood count; CR,complete response; CRP, C-reactive protein; CT,computed tomography; ECG, electrocardiogram; ECHO, echocardiogram;
ECOG, Eastern Cooperative Oncology Group; ;FFPE, formalin- fixed,
paraffin -embedded; FISH, fluorescence insituhybridization; FLC, freelightchain; H/E, Hematoxylin andeosin; hr(s), hour(s); ICF, informed consent form; IHC,
immunohistochemistry; INR, international normalization ratio; PD,pharmacodynamic; ; PK, pharmacokinetics; PT,prothrombin time; PTT, partial
thromboplastin time; SPEP, serum protein electrophoresis; TSH, thyroid stimulating hormone; UPEP, urine protein electrophoresis
1. ICF: Informed consent should beobtained prior toperforming anystudy -related procedure(s).
2. MEDICAL HISTORY: Medical History willinclude past andcurrent medical conditions, including cardiovascular medical history andriskfactors
3. DISEASE CHARACTERISTICS: Disease characteristics willinclude date ofinitial diagnosis, primary tumor type, histology, stage, etc.
4. MUTATION TESTING: Subjects may beenrolled based onlocal determination ofBRAF V600E mutation status. Asubject may betested for the BRAF V600E mutation greater
than 28days prior toenrollment. (Any past results oflocal BRAF V600E mutation testing may beused todetermine eligibility regardless ofwhen theresults were obtained.) To
enroll asubject, theresult ofmutation testing from asponsor designated central reference laboratory isnotrequired; however, ifthesubject does not have alocal result
available, thesponsor designated central reference laboratory mutation testresult willberequired todetermine eligibility forenrollment. NOTE: For subjects with asolid tumor:
Anarchived orfresh tumor tissue sample must be available tosend toasponsor designated central reference laboratory forconfirmation testing. NOTE: For subjects with HCL
orMM: A  fresh BMaspi[INVESTIGATOR_681816]. IfaBMaspi[INVESTIGATOR_681817],please contact [CONTACT_681937]. Intheevent ofadrytap,fresh orarchived tumor tissues such aslymph node or plasmacytoma
biopsies   may beacceptable pending medical monitor approval. Anarchived tissue sample (such as FFPE tissue sample from aBMbiopsy), BMcore samples andBMclot
samples cannot beused. Thesame BMaspi[INVESTIGATOR_681818], thebaseline assessment
5. Dose interruptions should notalter theassessment schedule.

[COMPANY_001] Confidential Page 226
Amended Protocol Version 11                                                                                            Protocol No. CDRB436X2201
26. DISEASE ASSESSMENTS (Solid Tumor Cohorts only): Baseline disease assessments must beperformed within 28days prior toenrollment (orwithin 35days ifMRI isused for
disease assessment).
27. DISEASE ASSESSMENTS (Solid Tumor Cohorts only): Disease assessments areevery 8weeks during thefirst48weeks ofstudy treatment, then every 12 weeks thereafter
unless otherwise noted, and at theFollow -upVisit. Confirmatory scan(s) aretobeperformed ≥28days after documented CRorPR. Ifsubject discontinues treatment forreasons
other than disease progression, disease assessments should continue every [ADDRESS_923358] withdrawal of
consent, ordeath.
28.HISTOLOGY CONFIRMATION :(ATC andWHO grade 1-4cohorts only) Atissue specimen forpossible retrospective histology confirmation should beobtained and
submitted toa[COMPANY_001] designated central reference laboratory . Please refer totheSPM for the requirements ofthetissue specimen that isrequired for the histology
confirmation.
29. NSGCT/NGGCT ONLY: AFP, B-HCG andLDH arethedisease assessment markers for the NSGCT/NGGCT cohort. LDH result obtained from clinical chemistry panel can  
beused asatumor marker result. Regardless ofbaseline values ofAFP,-HCG andLDH, ablood sample willbedrawn every 4weeks forfirst48weeks ofstudy treatment, then
every 8to12weeks thereafter, and at thetime ofdisease progression. Synchronize thecollection oftheblood sample withtheimaging schedule.
30. BTC/ASI ONLY: Ablood sample willbedrawn toassess CEA andCA19-9 every 4weeks forfirst48weeks ofstudy treatment, then every 8to12weeks thereafter, and at the
time ofdisease progression. Synchronize thecollection oftheblood sample withtheimaging schedule.
31. HCL ONLY: Allrequired disease assessments necessary forapost- baseline response determination should beperformed every 4weeks +/- 3days. Aresponse isto
bedetermined every 4 weeks based ontheresponse criteria (please consult Appendix 12)using data collected from thescheduled disease assessments.
32. HCL ONLY :BMbiopsy andaspi[INVESTIGATOR_85878] H/Estain andIHCwillbeperformed when blood counts areconsistent with CRorPRfor4weeks (please consult Appendix
12).Ifapatient hasaCR,andthen blood counts become consistent with aCRfor4weeks, arepeat BMaspi[INVESTIGATOR_681748].
Following best response, abone marrow biopsy andaspi[INVESTIGATOR_681749] 6 months fortwotime intervals, then after ayear fortwotime intervals, then
every twoyears.
33. HCL ONLY: Recommend thatflowcytometry panel consists ofCD19, CD20, CD22, SmIg, CD11c, CD25, CD103 andCD123. Flow cytometry ofthebone marrow aspi[INVESTIGATOR_681819]4weeks (please consult Appendix 12).Ifapatient hasaCR,andthen blood counts
become consistent with aCRfor4weeks, arepeat flow cytometry oftheBMaspi[INVESTIGATOR_681751].Following best response, aflow
cytometry ofthebone marrow aspi[INVESTIGATOR_681749] 6 months fortwotime intervals, then after ayear fortwotime intervals, then every twoyears .
34. HCL ONLY: BMbiopsy (with H/Estain andIHC), BMaspi[INVESTIGATOR_337] (with flow cytometry) andperipheral blood sample (with flow cytometry) willbeassessed within 28days
prior toenrollment.
35. HCL ONLY :Achest CTscan and an abdominal CTscan withcontrast willbeperformed within 28days prior toenrollment .Ifanabdominal CTscan withcontrast cannot be
performed, then aMRI may beperformed within 35days prior toenrollment .If lymph nodes or spleen areenlarged atbaseline, then theabnormal organ needs tobefollowed
onpost- baseline assessments using thesame modality ofimaging.
36. MMONLY: Askeletal survey should beperformed within 28days prior toenrollment. Ifmyeloma associated bony lesions arepresent atbaseline, skeletal surveys should be
performed every [ADDRESS_923359] oflateral
radiographs oftheskull, APandlateral views ofthespi[INVESTIGATOR_050], andAPviews ofthehumeri, ribs, pelvis, andfemurs.
37. MMONLY: Each patient should beclinically examined forsoft tissue plasmacytomas/extramedullary disease at each visit forresponse assessment .Ifextramedullary
disease ispresent at baseline, then Chest/Abdominal/Pelvis CTscan withcontrast should beperformed toconfirm andtodetermine size andlocation ofthesoft tissue
plasmacytoma. Ifnodisease isidentified atbaseline, then subsequent scans areonly required ifclinically indicated. Alternative imaging modality (i.e., MRI) may beused if it is
better toassess thelesion andapproved by[CONTACT_681938]. Thesame imaging modality should beused forallsubsequent assessments.
38. MMONLY: BMaspi[INVESTIGATOR_681752], flowcytometry, FISH and cytogenetics within 90days prior enrollment .
[COMPANY_001] Confidential Page 228
Amended Protocol Version 11                                                                                            Protocol No. CDRB436X2201
55. FOLLOW -UPVISIT: TheFollow -upVisit should take place within 28days (+7days) ofthelastdose ofstudy treatments. Ifthesubject isunable toreturn toclinic dueto
hospi[INVESTIGATOR_059], sitestaff isencouraged tocallsubject forassessment ofAEs.
56. FOLLOW -UPVISIT: Allsafety andlaboratory assessments should beperformed unless theassessments were performed within 4weeks prior totheFollow -upVisit.
57. FOLLOW -UPVISIT: Ifthelastcardiac assessment was>12weeks prior totheFollow -upVisit, anECHO should beperformed.
58. EXTENDED FOLLOW -UP: Subjects should becontact[CONTACT_457] 4weeks (7days) for the first6months andthen every 3months (14days) until death, withdrawal ofconsent,
orsubject islosttofollow -up.Contact [CONTACT_681939], atelephone contact, ane-mail or by [CONTACT_2319]. Theinitiation of any new anti-cancer treatment(s) anddate oflast
contact [CONTACT_681940].
[COMPANY_001] Confidential Page [ADDRESS_923360] be performed within 28 daysof enrollment except
where indicated differently in the T&E table (Section 7.1). Guidance onbaseline 
documentation of target and non -target lesions will be provided in the SPM.
Section 7.4.2 Dermatological Examinations; 1stparagraph
REVISED TEXT
Dermatological examinations will be performed by [CONTACT_681941], atthediscretion oftheinvestigator. A complete or full body 
dermatological examination will be performed at the time points indicated in the
Time and Event Table (Section 7.1)to identify any abnormal skin lesions. All
abnormal findings (i.e., suspi[INVESTIGATOR_681820]) willbeidentified and 
photographed during the Screening examination. Brief dermatological examinations
should be performed every 4weeks or more frequently if clinically indicated while on 
study treatment and every 4 weeks ( 7days)for the first [ADDRESS_923361] should be
conducted if clinically indicated.
Section 7.4.3 Ophthalmic Examinations; 1stparagraph
REVISED TEXT
Subjects are required to have a standard ophthalmology exam performed by [CONTACT_681942] (Section 
7.1).  The exam will include best corrected visual acuity ,tonometry ,slit lamp
biomicroscopic examination, visual field examination, anddilated indirect fundoscopy
with special attention toretinal abnormalities. Optical coherence tomography isstrongl y
recomme nded at scheduled visits, and if retinal abnormalities are suspected. Other types
of ancillary testing including color fundus photography and fluorescein angiography are
also recommended if clinically indicated. Refer to Section 8.2.7 for additional details on 
management of visual changes.
Section 7.4.3 Echocardiogram; 1stparagraph
REVISED TEXT
Echocardiograms (ECHOs) will be performed to assess cardiac ejection fraction and
cardiac valve abnormalities. ECHOs will be performed at the time points ind icated in
the Time and Event Table (Section 7.1). The evaluation by [CONTACT_681943]-sided valvular lesions.
The procedure (ECHO) to document the subject’s baseline LVEF status must be used
[COMPANY_001] Confidential Page 230
Amended Protocol Version 11             Protocol No. CDRB436X2201
consistently throughout the study .  If possible, it is also preferred that interpretation of LVEF 
status be performed consistently by[CONTACT_681879].
Section 7.4.8 Clinical Laboratory Assessments; Table 3 
REVISED TEXT
Hematology
RBC Count RBC Indices (atScreening andifhemoglobin decreases
2g/dL compared tobaseline):Automated WBC
Differential:
Platelets  MCV
 MCH
 MCHC
 Reticulocyte Count Lymphocytes
 Monocytes
 Eosinophils
 BasophilsWBC Count (absolute)
Hemoglobin
Hematocrit
Absolute neutrophil
count (ANC)
Clinical Chemistry
BUN Potassium Total Protein Total anddirect bilirubin1
Creatinine3 Chloride2 Phosphorus AST
Glucose UricAcid2 Magnesium ALT
Sodium Calcium LDH Alkaline Phosphatase
Albumin HbA1c GGT
Coagulation
PT
PTT
INR
Urinalysis4
Color Specific gravity Ketones Urobilinogen
Appearance Glucose Blood
pH Protein5 Leukocyte esterase
Other Tests
Amylase andlipase [monitor vialocal laboratory when clinically indicated toevaluate certain AEs (i.e.,
abdominal pain, pancreatitis, etc.)
Serum orurine-hCG6
Forsubjects withahistory ofchronic HBV and/or HCV, thefollowing tests willbeperformed atScreening:
 Viral hepatitis serology;
 Hepatitis Bsurface antigen andHepatitis Bcore antibody (IgM); and/or
 Hepatitis CRNA
Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; -
hCG, Beta-human chorionic gonadotropin; BUN, blood urea nitrogen; GGT, gamma glutamyl transferase; INR,
international normalization ratio; HbA1C, hemoglobin A1C; HBV, hepatitis Bvirus; HCV, hepatitis Cvirus; LDH, lactate
dehydrogenase; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular
hemoglobulin concentration; PT,prothrombin time; PTT, partial thromboplastin time; RBC, redblood cells; TSH, thyroid
stimulating hormone; ULN, upper limitofnormal; WBC, white blood cells
1. Direct bilirubin isrequired only ifthetotal bilirubin iselevated (2times theULN)
2. Chemistry evaluation ofchloride oruricacid isnotrequired where there arelogistical constraints.
3. Ifserum creatinine is>2.0 mg/dL, calculate creatinine clearance using standard Cockcroft- Gault method
(Appendix 3).
4. Ifurine protein result isnotavailable, urine albumin result may beused.
[COMPANY_001] Confidential Page [ADDRESS_923362] 1year prior toScreening.
Section [IP_ADDRESS] Additional Histology Specific Assessments and Histology Confirmation; 
Headline
REVISED Header
Additional Histology Specific Assessments and Histology Confirmation
Section [IP_ADDRESS] Additional Histology Specific Assessments and Histology Confirmation; 
new paragraph (4th)
REVISED TEXT
Histology Confirmation for ATC and WHO Grade 1-4 Glioma Cohorts ONLY:
A tissue specimen from the biopsy of
a primary or metastatic site must be
submitted toa[COMPANY_004] designated central reference laboratory as soon as possible
after enrollment for possible retrospective confirmation of histologic type. Refer
to the SPM and the Lab Manual for details regarding sample submission.
Section 7.4.9 Monitoring for Non- Cutaneous Secondary/Recurrent Malignancy; 2nd
paragraph
REVISED TEXT
Abnormal findings should be managed according to standard clinical practice.
Section 7.5.1 Disease Assessments for Solid Tumor Histologies; Tables 
REVISED TEXT
Histology Area(s) of
AssessmentImaging tobe
PerformedAlternative Imaging Methods if
Contraindications are Present
ATC1 Brain MRI with
contrast1stalternative: MRI without contrast
2ndalternative: CTscan with contrast
Neck CT scan with
contrast1stalternative: aMRI with contrast 2nd
alternative: CT scan without contrast
(if1stalternative is contraindicated)
Chest/Abdomen
(including liver and
adrenal glands)CTscan2
[COMPANY_001] Confidential Page 232
Amended Protocol Version 11          Protocol No. CDRB436X2201
BTC/ASI Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the
Chest and MRI with contrast of
Abdomen/Pelvis
Histology Area(s) of
AssessmentImaging tobe
PerformedAlternative Imaging Methods if
Contraindications are Present
NSGCT/NGGCT Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the
Chest and MRI with contrast of
Abdomen/Pelvis
GIST Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the
Chest and MRI with contrast of
Abdomen/Pelvis
ATC1
BTC
GIST
NSGCT/NGGCT
ASI
WHO Grade [ADDRESS_923363] scan, MRI,
orbone scan
asappropriate
WHO Grade 1-4
GliomaBrain MRI with
contrast3N/A
NSGCT/NGGCT4 Brain (for pi[INVESTIGATOR_681755])MRI with
contrast1stalternative: MRI without contrast
2ndalternative: CTscan with contrast
Abbreviations: ASI, adenocarcinoma ofsmall intestine; ATC, anaplastic thyroid carcinoma; BTC, biliary tract
carcinoma; CNS, central nervous system; CR,complete response; CT,computed tomography; GCT, germ celltumor;
GIST, gastrointestinal stromal tumor; MRI, magnetic resonance imaging; NGGCT, non-geminomatous germ celltumor;
NSGCT, non-seminomatous germ celltumor; PET, positron emission tomography; SPM, Study Procedures Manual;
WHO, World Health Organization
1. ForATC subjects without CNS andneck disease atbaseline, subsequent brain andneck imaging should
onlybeperformed asclinically indicated.
2. Optional: Whole body PET/CT scan
3. MRI ofthebrain withcontrast ismandated inthiscohort; CTscan isnotpermitted. Please refer toimaging
details intheSPM.
4. ForNSGCT/NGGCT subjects without CNS disease atbaseline, subsequent MRI ofthebrain withcontrast
should only beperformed asclinically indicated (e.g., symptoms suggestive ofCNS progression). For
subjects withCNS disease atbaseline, aMRI ofthebrain withcontrast isrequired every 4to8weeks or as
clinically indicated. In addition, inorder toconfirm aCR in asubject withbrain disease atbaseline, aMRI of
thebrain withcontrast must beperformed 1week prior tothefirstsetofimages showing CRto4weeks after
thenext protocol specified assessment.
Post-Baseline Assessments: All post -baseline assessments require imaging of disease sites 
identified by [CONTACT_301196].  The same imaging modality  used at baseline should be utilized 
for all post -baseline assessments. If subject discontinues treatment prior to
Week 48 for reasons other than disease progression, disease assessments (imagin g)should 
continue every 12 weeks until a new treatment is initiated.
Histology Area(s) of
AssessmentImaging tobe
PerformedAlternative Imaging Methods if
Contraindications are Present
[COMPANY_001] Confidential Page [ADDRESS_923364]/Abdomen
(including liverand
adrenal glands)CTscan1
BTC, ASI Chest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the Chest
and MRI with contrast of
Abdomen/Pelvis
WHO Grade 1 -4
GliomaBrain MRI with
contrast2N/A
NSGCT/NGGCT,
GISTChest/Abdomen/Pelvis CT scan with
contrastCT scan without contrast of the Chest
and MRI with contrast of
Abdomen/Pelvis
Abbreviations: ASI, adenocarcinoma ofsmall intestine; ATC, anaplastic thyroid carcinoma; BTC, biliary tract
carcinoma; CT,computed tomography; GIST, gastrointestinal stromal tumor; MRI, magnetic resonance imaging;
NGGCT, non-geminomatous germ celltumor; NSGCT, non-seminomatous germ celltumor; SPM, Study Procedures
Manual; WHO, World Health Organization
1. Optional: Whole body PET/CT scan
2. MRI withcontrast ismandated inthiscohort; CTscan isnotpermitted. Please refer toimaging details in
SPM.
Section [IP_ADDRESS] Laboratory and Disease Assessments: HCL
REVISED TEXT
Baseline Assessments:  The following baseline disease assessments are will
beperformed at the time points indicated in the Time and Event Table (Section 7.1):
Complete blood count
Routine stain of peripheral blood sample
BM aspi[INVESTIGATOR_681756] H/E stain and IHC
Flow cy tometry on BM aspi[INVESTIGATOR_681757]
Chest CT scan and abdominal CT scan with contrast
NOTE: MRI of the abdomen may be performed if abdominal CT cannot be performed.
The method used to document baseline status is used consistently throughout the study to 
facilitate comparison of resul ts.
If lymph nodes and spleen were enlarged at baseline, they must be followed by [CONTACT_447]-baseline 
assessments using a consistent imaging modality .
Post-Baseline Assessments :A response is to be determined every 4 weeks based on the 
HCL response criteria (please consult Appendix 12) using data collected from the 
scheduled disease assessments.
Complete blood count
[COMPANY_001] Confidential Page 234
Amended Protocol Version 11          Protocol No. CDRB436X2201
Routine stain of peripheral blood sample
BM aspi[INVESTIGATOR_681756] H/E stain and IHC
Flow cytometry on BM aspi[INVESTIGATOR_681759] (Section 7.1).
Flow cytometry on peripheral blood sample will be performed as indicated in the Time 
and Event Table (Section 7.1)
If lymph nodes and/orspleen were enlarged at baseline, they must be followed by[CONTACT_447]-
baseline assessments using a consistent imaging modality as indicated in the Time and 
Event Table (Section 7.1).
Section [IP_ADDRESS] Laboratory and Disease Assessments: MM 
REVISED TEXT
Baseline Assessments:  The following baseline disease assessments will be performed at 
the time points indicated in the Time and Event Table (Section 7.1):
Skeletal survey s
Extramedullary disease assessment
NOTE: An alternative imaging modality  (i.e., MRI) may be used to assess extramedullary
disease if the investigator considers the other modality to be better in assessing the lesion 
and if approval is received from a Medical Monitor. The same t ype of imaging should be 
used for all subsequent assessments.
BM aspi[INVESTIGATOR_681821]: Samples will be asses sed by[CONTACT_4658], flow cytometry ,
fluorescence in situ hybridization (FI SH)andcytogenetics.
UPEP : to be performed using a 24 -hr urine collection
SPEP
CRP, -2 microglobulin, serum FLC assay , levels of immunoglobulin (Ig)G, IgA, and 
IgM
Post-baseline Assessment s:  All post -baseline assessments require imaging of disease sites 
identified by [CONTACT_301196].  The same imaging modality  used at baseline should be utilized 
for all post -baseline assessments.
BM aspi[INVESTIGATOR_681822] (Section 7.1)
Laboratory tests (SPEP, UPE P, CRP, -2microglobulin, serum FLC assay , levels of 
IgG,
IgA, and IgM will be performed as indicated in the Time and Event Table (Section 7.1).
Skeletal survey s:  Post-baseline assessments only need to be performed if disease is
noted on the baseline assessment. If no disease is identified at baseline, then subsequent 
skeletal survey s are onl y required if clinically  indicated.
[COMPANY_001] Confidential Page 235
Amended Protocol Version 11          Protocol No. CDRB436X2201
Extramedullary disease assessment:  Post-baseline assessments only need to be
performed if disease is noted on the baseline assessment. Ifno disease is identified at 
baseline, then subsequent assessments are onl y required if clinicall yindicated.
Section 8.1 Dose Modification; 2ndand 3rdparagraph
REVISED TEXT
If a dose reduction of trametinib is required, but the toxicity resolves and no additional
toxicities are seen after one treatment cy cles(4 weeks) , the dose of trametinib may be re -
escalated but should not exceed 2 mg once daily .
If a dose reduction of dabrafenib is required, but the toxicity resolves and no additional 
toxicities are seen after one treatment cycle (4 weeks), the dose of dabrafenib may be re -
escalated but should not exceed 150 mg BID daily.
Section [IP_ADDRESS].2 Managem ent of Hypertension; Table 14 
REVISED TEXT
Hypertension Action and Dose Modification
(A). Asymptomatic and
persistent1SBP of 140mmHg
and <160 mmHg, or DBP
90mmHg and <100 mmHg, or
aclinically significant increase in
DBP of 20 mmHg (but still
<100 mmHg). Continue study treatments at the current dose
 Adjust current or initiate new antihypertensive medication(s)
 Titrate antihypertensive medication(s) during the next 2
weeks as indicated to achieve well -controlled2BP
 If BP is not well controlled within 2weeks, consider 
referral to aspecialist and go to scenario (B).
(B). Asymptomatic SBP
160mmHg, or
DBP 100 mmHg, or failure to
achieve well -controlled BP within
2weeks in scenario (A). Interrupt study treatments if clinically indicated
 Adjust current or initiate new antihypertensive medication(s)
 Titrate antihypertensive medication(s) during the next 2
weeks as indicated to achieve well -controlled BP
 Once BP is well controlled2, restart study treatments 
reduced by [CONTACT_100699]3
(C).Symptomatic4hypertension
or persistent SBP 160 mmHg,
or DBP 100mmHg, despi[INVESTIGATOR_681770](s)
and dose reduction of study Interrupt study treatments
 Adjust current or initiate new antihypertensive medication(s)
 Titrate antihypertensive medication(s) during the next 2
weeks as indicated to achieve well -controlled BP
 Referral to aspecialist for further evaluation and follow -up is
Hypertension Action and Dose Modification
[COMPANY_001] Confidential Page 236
Amended Protocol Version 11          Protocol No. CDRB436X2201
treatment recommended
 Once BP is well controlled2, restart study treatments 
reduced by [CONTACT_100699]3
(D). Refractory hypertension
unresponsive to above
interventions or hypertensive
crisis Permanently discontinue study treatments
 Continue follow -up per protocol.
Abbreviations: BP,blood pressure; DBP, diastolic blood pressure; mmHg, millimeters ofmercury; SBP, systolic blood
pressure
1. Hypertension detected in2separate readings during upto3consecutive visits
2. Well- controlled BPdefined asSBP140mmHg andDBP90mmHg in2separate readings during upto
3consecutive visits
3. Escalation toprevious dose level canbeconsidered ifBPremains well-controlled for4weeks after
restarting. Approval from theMedical Monitor isrequired.
4. Symptomatic hypertension defined ashypertension aggravated by[CONTACT_23805] (e.g. headache,
lightheadedness, vertigo, tinnitus, epi[INVESTIGATOR_681771]) thatresolve after the BPi[INVESTIGATOR_681772].
Section 8.1.2 Pancreatitis; 1stparagraph
REVISED TEXT
In the event of abdominal pain or suspected pancreatitis, amy lase and lipase laboratory
samples should be collected for confirmation of the diagnosis. Subjects should be closely  
monitored when re -starting study treatment after an epi[INVESTIGATOR_28547].
Section [IP_ADDRESS] Palmar
-plantar Erythrodysesthesia
NEW TEXT
Palmar- plantar erythrodysesthesia (PPE) syndrome: Measures for PPE syndrome
should include lifestyle modification (avoidance of hot water, traumatic activity, 
constrictive footwear, or excessive friction on the skin and the use of thick cotton 
socks and gloves, and shoes with padded insoles) and symptomatic treatments.
Apply moisturizing creams frequently, topi[INVESTIGATOR_477365] (e.g., urea 20 to 40%
cream, salicylic acid 6%, tazarotene 0.1% cream, fluorouracil 5%cream),
clobetasol propi[INVESTIGATOR_16847] 0.05% ointment for erythematous areas, topi[INVESTIGATOR_24242] 2%, 
and/or systemic pain medication such as nonsteroidal anti-inflammatory drugs,
codeine, and pregabalin for pain.  Dose modification may also be required.
Section [IP_ADDRESS] Cutaneous squa mous cell carcinoma (cuSCC); 1stparagraph
REVISED TEXT
[COMPANY_001] Confidential Page 238
Amended Protocol Version 11          Protocol No. CDRB436X2201
restart dabrafenib reduced by [CONTACT_30560]. No dose modification of trametinib is 
required when taken in combination with dabrafenib.
Section 10.2 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_681823] 28 days or 5 half- lives,
whichever is shorter, prior to start of treatment will not be allowed:
Antiretroviral drugs
Herbal remedies (e.g., St. John’s wort)
Drugs that are strong inhibitors or inducers of CYP2C8 or
CYP3A4 (Table 27):
The use of certain medications and illicit drugs within 28 daysor 5 half -lives, whichever is 
shorter, prior to randomization and for the duration of the study will not be allowed.
The following medications or non-drug therapi[INVESTIGATOR_014] (excluding topi[INVESTIGATOR_29899]) are also 
prohibited while on treatment in this study :
Other anti -
cancer therapi[INVESTIGATOR_014]
Other investigational drugs
Antiretroviral drugs
Herbal remedies (e.g., St. John’s wort)
For MM cohort only: non -steroidal anti -inflammatory drugs (NSAIDS)
NOT E:Use of NSAIDS by [CONTACT_681889] .
Drugs that are strong inhibitors or inducers of CYP2C8 or CYP3A4 (Table 27):
NOTE:  Dabrafenib is metabolized primarily by [CONTACT_097]2C8 and CYP3A4.  Co- administration 
of dabrafenib with ketoconazole, a CYP3A4 inhibitor, or gemfibrozil, a CYP2C8 inhibitor, 
increased the area under the concentration
-time curve (AUC) of dabrafenib by71% and 47%, 
respectivel y.  Drugs that are strong inhibitors or inducers of CYP2C8 or CYP3A4 are likel y
to increase or decrease, respectivel y, dabrafenib concentrations.  Strong inhibitors or 
inducers should only be used under special circumstances (e.g., as a single use for a 
procedure) while stud y treatment is interrupted as they may alter dabrafenib concentrations; 
consider therapeutic substitutions for these medications.  Approval from the Medical Monitor 
is required in these situations.
Section 10.3 Medications to b e used with Caution; 2ndbullet point
REVISED TEXT
[COMPANY_001] Confidential Page 239
Amended Protocol Version 11          Protocol No. CDRB436X2201
•Dabrafenib has been s hown to induce CYP3A4 and CYP2C9 in vivo using midazolam 
(CYP3A4 substrate) and S -warfarin (CYP2C9 substrate).  Dabrafenib is an in vitro inducer of 
CYP2B6 and may affect other enzymes such as CYP2C8, CYP2C19, UDP -glucuron yl 
transferases, and transporters.  Co -administration of dabrafenib and medicinal products which 
are affected b ythe induction of these enzy mes such as hormonal contraceptives, warfarin, 
dexamethasone, antiretroviral agents, or immunosuppressants may result in decreased 
concentrations and loss of effectiveness.  Where possible consider substitutions of these 
medicinal products if therapeutic effects cannot be monitored.
Section 11.2 Definition of Serious Adverse Event; point h. Protocol -specific SAEs: first 
bullet point
REVISED TEXT
h. Protocol -specific SAEs:
•cuSCC (Section [IP_ADDRESS]), new primary melanomas (Section [IP_ADDRESS]) and non -
cutaneous malignancies (Section [IP_ADDRESS]) with the exception of basal cell carcinoma
(BCC). BCC should bereported as
anAEorSAE based onthediscretion ofthe 
investigator.
Section 18.1 Hypotheses and Treatment Comparisons; 3rdparagraph 
REVISED TEXT
jis the true response rate for histology j, where j = 1,…, [ADDRESS_923365] a high 
clinically meaningful response rate and is based on the hierarchical model assessment 
of whether there is sufficiently high probabilit y that jexceeds Cj.The posterior 
probability that the ORR for a given histology is greater than Cjwill be computed 
according to the following comparison:
Section 18.2.1 Sample Size Assumption
REVISED TEXT
Each cohort of BRAF V600E mutation -positive tumor typeof a given histology will
enroll a maximum of 25 subjects in the primary analysis c ohort as defined in Section
5.1.If all histologies enroll the maximum of 25 subjects, this will result in no more than
225subjects in the primary analysis 
cohort .
Enrollment into specific histology cohorts may be halted earl y based on results from interim 
analyses incorporating emerging response data.  Response data from a minimum of 5 subjects 
will be required in a histologic cohort before it may discontinue enroll ment for futility and 
[COMPANY_001] Confidential Page 240
Amended Protocol Version 11          Protocol No. CDRB436X2201
response data from a minimum of 10 subjects will be required before discontinuing a 
histologic cohort for efficacy . If a cohort closes early for efficacy at an interim analysis, a 
histology specific expansion cohort (see Section 5.2) may be opened to allow additional 
enrollment. At 
the final anal ysis and after the study has been closed, a minimum of [ADDRESS_923366] based on the timing of the
analysis for both efficacy and safety; accompanying definitions are provided 
beneath the table.
Table 30 Definition of Population for specific analysis
Analysis Period
Analysis Intent Interim Analyses Final Analysis
Efficacy Primary ITT/Evaluable BRAF V600E
Supportive BRAF
V600/EvaluableITTHistology -
specific cohortsa
Safety Primary ATS ATS
aSubset of the BRAF V600E population that include histologically similar subjects 
forcohorts that were stopped forpromising efficacy; includes those from the 
primary analysis cohort and those from the expansion cohort, as defined in Section 
5.1and Section 5.2.
The BRAF V600E Population is defined as all enrolled subjects regardless of whether or 
nottreatment wasadministered, who obtain positive verification oftheBRAF V600E 
mutation from a certified central reference laboratory .
The Intent-to-Treat (ITT) population is defined as all enrolled subjects regardless of
whether or not treatment was administered. 
The All -Treated Subjects (ATS) population isdefined asallsubjects who receive atleast
one dose of dabrafenib ([COMPANY_004]2118436) or trametinib ([COMPANY_004]1120212).
[COMPANY_001] Confidential Page 241
Amended Protocol Version 11          Protocol No. CDRB436X2201
The Intent -to-Treat (ITT)/Evaluable population is defined as all ITT subjects in the
primary analysis cohort who are also evaluable according to the evaluability defined in 
the interim analysis RAP.
The BRAF V600E /Evaluable Population is defined as all BRAF V600E subjects in 
the primary analysis cohort who are also evaluable according to the evaluability
defined intheinterim analysis RAP.
Section 18.3.[ADDRESS_923367]. Secondary efficacy endpoints will likely not be mature at this time, 
but will still be reported. Subsequent analy ses for secondary endpoints will occur as follows:
Duration of response, PFS and OS when 70% of subjects have reached a PFS event 
(progressed or died)
OS when 70% of subjects have died
Safety will be updated once the last subject has discontinued and been off all study
treatment for 30 day s.
These latter anal yses will provide mature estimates/incidence for duration of response, PFS, 
OS, and safet y.
Section [IP_ADDRESS] Safety Analysis 
REVISED TEXT
Safety data w ill be presented in tabular and/or graphical format and summarized descriptively  
according to [COMPANY_004]’s IDSL standards.
The ATS population will be used for the anal ysis of safet y data. In general, safet ydata will be 
summarized by [CONTACT_681944].
Complete details of the safet y analyses will be provided in the RAP.
Section [IP_ADDRESS].3 Other Safety Measures 
REVISED TEXT
[COMPANY_001] Confidential Page 242
Amended Protocol Version 11          Protocol No. CDRB436X2201
The results of scheduled assessments of vital signs, 12- lead ECG, ECHO andECOG 
performance status will be summarized. Summa ries will include data from scheduled 
assessments only .  All data will be reported according to the nominal visit date for which it 
was recorded; no visit windows will be applied.  All data will be listed.
Section [IP_ADDRESS] Efficacy Analysis 
REVISED TEXT
ORR will be analy zedusing an integrated anal ysis with the hierarchical model as well as 
analy zedindependentl yfor each histology.
Section [IP_ADDRESS] Efficacy Analysis; Table 31 Response Subcategories Define as 
‘Response’ by H istology
REVISED TEXT
Histol ogy Response CriteriaResponse Subcategories
defined as‘Response’
ATC, BTC, GIST, Small
Intestine AdenocarcinomaRECIST 1.[ADDRESS_923368]/NGGCTRECIST 1.1.
Tumor Markers: -HCG andAFPMarker -Negative CR,
Marker -Positive CR,
Marker -Negative PR,
Marker -Positive PR
MM IMWG Uniform Response Criteria forMM sCR, CR,PR,VGPR
HCLAdapted from NCCN guidelines, Consensus
Resolution Criteria andprevious studies definitionCR±MRD, PR
WHO Grade 1and2GliomasResponse Assessment Criteria forWHO Grade 1or
2Gliomas: RANO Working GroupCR,PR,MR
WHO Grade 3and4GliomasUpdated Response Assessment Criteria forWHO
Grade 3or4Gliomas: RANO Working GroupCR,PR
Abbreviations: AFP, alpha -fetoprotein; ATC, anaplastic thyroid cancer; -hCG, beta-human chorionic
gonadotropin; BTC, biliary tract cancer; CR,complete response; GIST, gastrointestinal stromal tumor; HCL,
hairy cellleukemia; IMWG, International Myeloma Working Group; MM, multiple myeloma; MR,minor
response; NCCN, National Comprehensive Cancer Network; NGGCT, non- geminomatous germ celltumor;
NSGCT, non- seminomatous germ celltumor; PR,partial response; RANO, Response Assessment forNeuro-
Oncology; RECIST, Response Evaluation Criteria inSolid Tumors; sCR, stringent complete response; VGPR,
very good partial response; WHO, World Health Organization
Further details on response confirmation criteria for each histological cohort will be 
provided in the RAP.
Bayesian inference based on summary statistics from the posterior distributions of each ORR 
will be reported. The posterior mean and posterior 2.5% and 97.5% percentiles of the ORR 
will be calculated for each histology .Inaddition, the posterior probability thatthe ORR 
exceeds its corresponding historical con trol will be reported for each histology .
[COMPANY_001] Confidential Page [ADDRESS_923369] a confirmed response (as 
defined in Table 31), as the time from first documented evidence of response until the first 
documented sign of disease progression or death. Duration of response will be summarized 
descriptivel yfor each histology , if data warrant, using Kaplan -Meier medians and quartiles.  
Details on rules for censoring will be provided in the RAP.
Section 18.4.[ADDRESS_923370] been conducted todevelop andunderstand theperformance of 
the adaptive design; the hierarchical model including clustering mechanism, interim
monitoring, and decision criteria. Subject enrollments into the expansio n cohorts as
defined in Section 5.2 are not taken into consideration in the simulations presented 
in this section.
Section 20 References
REVISED TEXT
GlaxoSmithKline Document Number CM2010/[ZIP_CODE]/05. Dabrafenib Investigator’s 
Brochure. Version 07. Report dated [ADDRESS_923371]-2015.
Long GV et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600
BRAF- mutant melanoma: a multicentre, double -blind, phase 3randomised
controlled trial. Lancet. 2015; 386(9992): 444-51
Robert Cetal.Improved overall survival in melanoma with combined dabrafenib 
and trametinib. N Engl J Med. 2015; 372(1): 30 
– 9
AMENDMENT 07
This amendment applies to all study  sites. Bolded text indicates revised text and strike 
through indicates deleted text.
Amendment Summary  of Main Changes:
Section(s) Change Rationale
Sponsor signatory Change of sponsor signatory Change in study sponsor from [COMPANY_004] to [COMPANY_001]
Multiple Delete or replace references 
to GlaxoSmithKline or its To align with the change of sponsorship from 
[COMPANY_004] to [COMPANY_001].
[COMPANY_001] Confidential Page 244
Amended Protocol Version 11          Protocol No. CDRB436X2201
Section(s) Change Rationale
staff with that of [COMPANY_001] and 
its authorized agents
Multiples Change “medical monitor” to 
“Medical Lead”To align with [COMPANY_001] processes
Multiple Make administrative changes To align with the change of sponsorship from 
[COMPANY_004] to [COMPANY_001].
Amendment Details:
Section: Title Page: 
Text changed:
The title page replaced as per [COMPANY_001] requirements. 
Reason for change:
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: Sponsor Information Page
Text changed:
The[COMPANY_004] contact [CONTACT_681945].
The term medical monitor has been replaced b y Medical Lead and the email for Medical Lead 
provided.
Reason for change:
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
LIST OF ABBREVIATIONS
Text changed:
CRO Clinical Research Organization
GCPH Global Clinical Program Head
HA Health Authority
Reason for change: 
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: [IP_ADDRESS]. Pregnancy  Reporting
[COMPANY_001] Confidential Page 245
Amended Protocol Version 11          Protocol No. CDRB436X2201
Text changed:
To ensure subject safet y, each pregnancy  must be reported to the sponsor within 24hours of 
learning of its occurrence.
Reason for change: 
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: [IP_ADDRESS]. Action to be taken if pregnancy  occurs in a female partner of 
a male study  subject
Text changed:
The investigator will record pregnancy  information on the appropriate form and submit it to 
the sponsor within 24hours of learning of the partner’s pregnancy .
Reason for change: 
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: 11.7. Time Period and Frequency  of Detecting AEs and SA Es
Text changed:
Reason for change: 
Change in stud y sponsorship and to bring into l ine with [COMPANY_001] processes.
Section: 11.13. Regulatory  Reporting Requirements for SA Es
Text changed:
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) fro m the sponsor will file it 
with the IB and will notify  the IRB/IEC , if appropriate according to local requirements.
Reason for change: 
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: 17. DATA MANAGEMENT
Text changed:
Adverse events (AEs) and concomitant medications terms will be coded using Medical 
Dictionary  for Regulatory  Activities (MedDRA) and a custom drug dictionary .
[COMPANY_001] Confidential Page 246
Amended Protocol Version 11          Protocol No. CDRB436X2201
Reason for change: 
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: 19.4. Quality  Control (Study Monitoring)
Text changed:
In accordance with applicable regulations, GCP, and [COMPANY_001] procedures, [COMPANY_001] 
personnel (or designated Clinical Research Organization [CRO]) will contact [CONTACT_681946], study requirements, and 
their responsibilities to satisfy  regulatory , ethical, and the sponsor’s requirements.
Reason for change:
Change in stud y sponsorship and to bring into line with Novar tis processes.
Section: 
19.6. Study and Site Closure
Text changed:
Upon completion or termination of the study , [COMPANY_001] personnel (or designated CRO)
will conduct site closure activities with the investigator or site staff (as appropriate), in 
accordanc e with applicable regulations, ICH GCP, and [COMPANY_001] Standard Operating 
Procedures.
Reason for change:
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: 19.7. Records Retention
Text changed:
Essential documents (written and electronic) should be retained for a period of not less 
than fifteen (15) years from the completion of the Clinical Trial unless the Sponsor 
provides written permission to dispose of them or, requires their retention for an 
additional period of time be cause of applicable laws, regulations and/or guidelines.
Reason for change:
Change in stud y sponsorship and to bring into line with [COMPANY_001] processes.
Section: 19.8. Provision of Study Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers and Publication
Text changed:
[COMPANY_001] Confidential Page [ADDRESS_923372] a results summary to the [COMPANY_001] Clinical Trial Results website 
(www.novartisclinicaltrials.com) and other publicly available registers no later than 
twelve (12) months after the last subject’s last visit (LSLV). In addition, upon study 
completion and finalization of study report, [COMPANY_001] aims to submit results of the study 
for publication.
When publication is not feasible, please refer to the [COMPANY_001] Clinical Trial Res ults 
website (www.novartisclinicaltrials.com) for a summary of the trial results .